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ABSTRACT OF DISSERTATION 
LACTONE-CARBOXYLATE NTERCONVERSION AS A DETERMINANT OF THE 
CLEARANCE AND ORAL BIOAVAILABILTY OF THE LIPOPHILIC 
CAMPTOTHECIN ANALOG AR-67 
The third generation camptothecin analog, AR-67, is undergoing early phase clinical 
trials as a chemotherapeutic agent. Like all camptothecins it undergoes pH dependent 
reversible hydrolysis between the lipophilic lactone and the hydrophilic carboxylate. The 
physicochemical differences between the lactone and carboxylate could potentially give 
rise to differences in transport across and/or entry into cells. In vitro studies indicated 
reduced intracellular accumulation and/or apical to basolateral transport of AR-67 lactone 
in P-gp and/or BCRP overexpressing MDCKII cells and increased cellular uptake of 
carboxylate in OATP1B1 and OATP1B3 overexpressing HeLa-pIRESneo cells. 
Pharmacokinetic studies were conducted in rats to study the disposition and oral 
bioavailability of the lactone and carboxylate and to evaluate the extent of the interaction 
with uptake and efflux transporters. A pharmacokinetic model accounting for 
interconversion in the plasma was developed and its performance evaluated through 
simulations and in vivo transporter inhibition studies using GF120918 and rifampin. The 
model predicted well the likely scenarios to be encountered clinically from 
pharmacogenetic differences in transporter proteins, drug-drug interactions and organ 
function alterations. Oral bioavailability studies showed similarity following lactone and 
carboxylate administration and indicated the significant role ABC transporters play in 
limiting the oral bioavailability.  
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CHAPTER 1  
BACKGROUND 
1-1. Camptothecins 
Camptothecin is a naturally occurring compound with anticancer properties. 
Since its isolation from the bark of Camptotheca accuminata by Wall and Wani in 1966, 
only two analogues, topotecan and irinotecan, have been approved by the Food and 
Drug Administration (FDA) for clinical use. However, recently there have been several 
other analogues that have entered preclinical and clinical development. The antitumor 
activity of camptothecins stems from their reversible interaction with the nuclear protein 
topoisomerase I (topo I) during cell replication. Topo I is an enzyme that facilitates 
DNA transcription by unwinding supercoiled DNA. During this process, topo I 
introduces a single strand DNA break allowing the DNA helix to rotate and relieve the 
torsional strain (1-3).  Once the DNA helix unwinds, these single strand DNA breaks are 
religated and the enzyme repeats its action in the next coiled DNA segment. However, 
in the presence of a camptothecin, the enzyme–DNA complex is stabilized through weak 
non-covalent interactions between the camptothecin and topo I, leading to double strand 
breaks, and consequently, apoptosis and cell death (4, 5).  
Camptothecin molecules depend on the E-ring lactone pharmacophore group for 
their pharmacological activity (6). Figure 1-1 depicts the chemical structure and ring 
numbering of camptothecin as it undergoes a pH dependent, but reversible hydrolysis, 
between the labile lactone and ring open carboxylate forms. At acidic pH, the lactone 
form predominates, while at physiological pH and above, the carboxylate prevails (7). 
The presence of lipid bilayers protects the lactone (8).  For camptothecin and some of 
the first generation analogues, such as 9-aminocamptothecin and 9-nitrocamptothecin, 
the stability of the lactone form is further compromised in vivo (9-12) due to the strong 
binding of the carboxylate to human serum albumin (13). The hydrolysis of 
camptothecins is purported to limit their clinical use because of presumed toxicity and 
lack of antitumor activity of the carboxylate (14).  
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Figure 1-1. Chemical structure and ring numbering system of camptothecin and 
its pH dependent reversible hydrolysis from the lactone to the carboxylate.  
The poor aqueous solubility of the parent compound camptothecin (2-3 µg/mL) 
(15) hinders its administration (16) and therefore its clinical utility. Efforts to increase the 
aqueous solubility of camptothecin by substitution of chemical groups on rings A and/or 
B have yielded second generation compounds with enhanced water solubility and 
stability. Topotecan, obtained by substitution of -CH2N(CH3)2 at position 9 and an -OH 
group at position 10, is the first FDA approved water soluble analogue (17). The other 
camptothecin analog in clinical use, irinotecan, is a water soluble pro-drug of 7-ethyl-10-
hydroxycamptothecin (SN-38). 
 Table 1-1 lists some camptothecin analogs in various stages of drug development 
while Figure 1-2 presents their chemical structures. Efforts to further stabilize the lactone 
moiety of camptothecin have resulted in third generation camptothecin analogs (AR-67, 
gimatecan, chimmitecan, etc) that are highly lipophilic. It is likely that some of these 
analogs might advance to clinical use in the near future, although their poor aqueous 
solubility presents a challenge to administration through the oral or intravenous routes.  
Among these analogues, 7-t-butyldimethylsilyl-10-hydroxycamptothecin (AR-67 
or DB-67) displays elevated lactone levels in blood as a result of the weak binding of its 
carboxylate form to plasma proteins and the strong binding to lipid membranes and 
partitioning into red blood cells of the lactone form (11). Substitution of a tert-butylsilyl 
(-Si(CH3)2C(CH3)3) group at position 7 increases its lipophilicity and membrane 
partitioning, while the substitution of a hydroxyl (-OH) group at position 10 reduces the 
binding of the carboxylate with human serum albumin (11). Figure 1-3 presents a 
comparison of the percent lactone concentrations at equilibrium of some camptothecin 
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analogues and AR-67 in whole blood (11). As the figure illustrates, percent lactone in 
whole blood is higher for AR-67 than for camptothecin or topotecan. In other studies, 
lipid membrane partitioning of AR-67 markedly decreased lactone hydrolysis and 
carboxylate formation (18, 19). The relatively higher percent lactone in blood makes AR-
67 an attractive drug molecule since pharmacological activity is believed to be due to the 
lactone moiety. 
 Table 1-1. Camptothecin analogues in development or clinical use‡. 
Analogue Status Route and indications 
Topotecan  FDA approved  IV infusion in metastatic ovarian cancer 
(second line); SCLC (second line) 
Irinotecan FDA approved IV infusion in metastatic colorectal cancer 
(first line with 5-FU/leucovorin) 
Rubitecan (9-NC) Phase II/III Oral in pancreatic cancer (converted to 9-AC) 
IDEC-132 (9-AC) Phase II IV infusion/oral/intraperitoneal in ovarian 
cancer  
Exatecan  Phase II/III IV infusion in various carcinomas 
Lurtotecan  Phase II IV infusion (liposomal) in ovarian and other 
carcinomas 
Gimatecan  Phase I/II Oral in glioblastoma, SCLC, solid tumors 
PEG-camptothecin Phase II IV infusion (PEGylated) NSCLC and other 
solid tumors 
Karenitecin  Phase II Oral in glioblastomas, melanomas and 
NSCLC 
Belotecan Phase I/II IV infusion in advanced SCLC, ovarian 
cancer, cervical cancer  
Silatecan (AR-67) Phase I IV infusion in colorectal carcinoma, lung 
cancer 
‡Adapted from references (20-22). NSCLC: non-small cell lung cancer; SCLC: 
small cell lung cancer; PEG: polyethylene glycol; IV: intravenous: 5-FU: 5-fluorouracil. 
9-NC: 9-nitrocamptothecin 
9-AC; 9-aminocamptothecin 
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9-aminocamptothecin 9-nitrocamptothecin Topotecan Irinotecan
SN-38 Belotecan Chimmitecan Lurtotecan
Exatecan Gimatecan AR-67 Karenitecin  
Figure 1-2. Chemical structures of camptothecins in development or clinical use. 
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Figure 1-3. Percent lactone of camptothecin (CPT), topotecan (TPT) and AR-67 at 
equilibrium in human whole blood at pH 7.4 and 37oC (Mean ± Standard deviation of 
n≥3 determinations). Adapted from references (9, 11). 
AR-67 was further investigated for its antitumor effects in preclinical studies due 
to its improved lactone stabilityin the presence of lipid membranes (23). Table 1-2 
presents the median effective concentrations of camptothecin analogues for inhibition of 
proliferation in five glioma cell lines (23). As summarized in the table, AR-67 exerted 
potent antiproliferative effects at nanomolar concentrations and at ED50 values that were 
much lower than other camptothecin analogues considered in the study.  
In U87 xenograft tumor bearing mice, a 5-day treatment with a 3 mg/kg 
subcutaneous dose of AR-67 resulted in a 61% reduction in tumor volume on day 28. 
Similar treatment with 10 mg/kg dose resulted in 73% reduction in tumor volume on day 
28; however, continuation with 10 mg/kg dose for three cycles (1 cycle = 5 day 
treatment/21 days) arrested tumor progression for greater than 90 days. These data 
demonstrated that AR-67 exerted a dose and treatment duration-dependent 
antiproliferative effect (23). Similar results were obtained in our lab the details of which 
are presented in the appendix. Briefly, nude mice were first treated with different doses of 
AR-67 (0, 2, 5, 7.5, 10 and 15 mg/kg) via the intravenous or oral routes to determine the 
maximum tolerated dose. Weight was recorded everyday during treatment and every 
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other day following cessation of treatment.  Blood counts were done on days 8, 11 and 21 
after the first treatment. Our results indicated that the maximum tolerated dose was 37.5 
mg/kg following the intravenous route whereas the oral route of administration was well 
tolerated, as no obvious signs of toxicity were noted. Subsequently, nude mice were 
implanted with H460 NSCLC tumor xenografts. Our results indicated that administration 
of the maximum tolerated dose (MTD) over a prolonged period of time was more 
efficacious in prolonging survival and delaying tumor growth than administration of the 
same dose over a shorter duration (Appendix II). Our toxicity and efficacy results favor 
the clinical use of AR-67.  
Table 1-2. Comparison of the antiproliferative effect of AR-67, 9-AC, topotecan, and 
SN-38 in glioma cell lines‡. 
Camptothecin analogue ED50 (ng/mL) in glioma cell lines 
U87 A172 SG388 LN-Z308 T98G 
9-AC 300 300 1000 200 30 
Topotecan 30 60 100 100 300 
SN-38 30 20 100 20 100 
AR-67 2 30 3 40 6 
‡Adapted from reference (23).  Cell proliferation was measured in five glioma 
cell lines (n= 2x104 cells ), which were plated and grown for 12 h before being treated for 
4 days with various concentrations of each agent. 
1-2.  In vivo interconversion of camptothecins 
Scott et al. (24) were the first to study the pharmacokinetics of the lactone and 
carboxylate forms of camptothecin. The lactone or the carboxylate forms of camptothecin 
were intravenously administered to anesthetized rats and their disposition characterized 
using a four compartment interconversion model (Figure 1-4) also proposed for 
hormones undergoing reversible biotransformation (25). The reversible and irreversible 
clearance parameters were obtained from areas under the plasma concentration versus 
time curves (AUC) of the parent (lactone) and metabolite (carboxylate) as indicated 
below by equations 1.1-1.4.  
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Systemic clearance of the metabolite (carboxylate) 
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Parent to metabolite conversion clearance 
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12     Equation 1.3   
Metabolite to parent conversion clearance 
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**
*
21     Equation 1.4   
In the above equations the subscripts denote the compound that is measured 
(parent/metabolite) while the superscripts denote the compound that was administered 
(parent/metabolite), p denotes parent drug and m denotes the metabolite. 
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Figure 1-4. Four compartment model of reversible biotransformation from 
reference (25). VCp & VCm-Central volumes of distribution of parent and metabolite 
respectively.VTp & VTm-Peripheral volumes of distribution of parent and metabolite 
respectively. Cldp and Cldm-Distribution clearances of the parent and metabolite The 
studies indicated that the carboxylate form of camptothecin predominates in plasma 
following the administration of either the lactone or the carboxylate. However, exposure 
to one compound versus the other, i.e., lactone or carboxylate, depends on the 
compound administered despite the interconversion. Administration of camptothecin 
lactone provided a threefold higher lactone AUC compared to that provided by the same 
dose of camptothecin carboxylate. Lactone AUC represented 36.1% of the total AUC 
following camptothecin lactone administration and 6% following camptothecin 
carboxylate administration. Moreover, as illustrated in Table 1-3, lactone clearance 
(Cl10) was fivefold higher than that of the carboxylate (Cl20) while lactone to carboxylate 
conversion (Cl12) was threefold higher than the reverse process (Cl21) (24). 
respectively. Cl12, Cl21, Cl10 and Cl20 are as described in the text. 
The rapid lactone clearance and conversion to carboxylate coupled with the slow 
carboxylate clearance and conversion to the lactone may be responsible for the 
predominance of the carboxylate in plasma in vivo. In an in vivo open system, 
irreversible elimination, which occurs at different rates for the lactone and carboxylate 
forms, decreases the lactone and carboxylate concentrations in the body available for the 
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competing process, i.e, lactone to carboxylate interconversion. Biliary and urinary 
clearances of total camptothecin were three and 2.4 fold higher, respectively, after 
carboxylate administration than after lactone administration (26).  
Similarly, the fastest clearance pathway of the second generation camptothecin 
analog,  topotecan in dogs was the systemic clearance of the lactone (Table 1-3), which 
was 4.4 fold higher than that of the carboxylate (27). Clearance of lactone conversion to 
the carboxylate was about 3 fold higher than the reverse process suggesting that the 
driving forces in the disposition of topotecan are the rate of lactone elimination and 
lactone to carboxylate steady state concentration ratios.  
Table 1-3. Clearances of the lactone (Cl10, Cl12) and carboxylate forms (Cl20, 
Cl21) of camptothecin (in rats) and topotecan (in dogs)‡.  
 Lactone 
(ml/min) 
Mean (SD) Carboxylate 
(ml/min) 
Mean (SD) Ratio* 
Camptothecin CL10 47.8 (5.52) Cl20 9.5 (3.3) 5 
 Cl12 31.4 (4.18) Cl21 10.4 (0.86) 3 
      
 Lactone 
(ml/min) 
Mean  
(SD) 
Carboxylate 
(ml/min) 
Mean (SD)  
Topotecan CL10 176 (40.6) Cl20 40.2 (9.00) 4.3 
 Cl12 118 (48.0) Cl21 60.2 (23.2) 2 
‡Adapted from reference (24) (camptothecin data) and reference (27) (topotecan). 
*Ratio values are (CL10/CL20) or (CL12/CL21). 
As was seen with camptothecin, the form of topotecan administered determines 
the magnitude of exposure to the lactone and carboxylate forms (27). Administration of 
the lactone provided 47.4% lactone AUC and 1.6 fold higher lactone AUC than 
administration of the same dose of carboxylate, which provided 16.6% lactone AUC and 
2.8 fold higher carboxylate AUC  (27).  
Irinotecan (CPT-11), another camptothecin analog in clinical use, is a water 
soluble pro-drug, which is acted upon by carboxylesterases primarily in the liver (28, 
29) but also in other tissues such as the intestine (30) to irreversibly form 7-ethyl-10-
hydroxycamptothecin (SN-38). As shown in Figure 1-5, in addition to lactone-
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carboxylate interconversion, CPT-11 and SN-38 also undergo complex 
biotransformation mediated by cytochrome P450 (CYP450) and UDP-glucuronosyl- 
transferase (UGT) enzymes, respectively. Hence, exposure to irinotecan and its active 
metabolite, SN-38, is complicated not only by lactone hydrolysis, but also by multiple 
metabolism and transport pathways (31, 32) (33).  
Conversion of CPT-11 to SN-38 is not complete and varies among species due to 
the differences in the presence and activity of their respective carboxylesterases (34-37). 
In mice, it was shown that the conversion of CPT-11 to SN-38 was saturable (36). As 
shown in Figure 1-5, CPT-11 conversion to SN-38 is also limited by CYP450 mediated 
biotransformation to two inactive metabolites. Although in-vitro studies demonstrate 
that the metabolites 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] 
carbonyloxycamptothecin (APC) and 7-ethyl-10-[4-(1-piperidino)-1-amino]-
carbonyloxycamptothecin (NPC) can be hydrolyzed to SN-38 by carboxylesterases (38), 
the catalytic efficiency is poor especially for the APC metabolite. 
UGT1A1 
UGT1A9
CE 
CYP3A4
CYP3A5
CPT-11 Lactone CPT-11 Carboxylate
NPC, APC
SN-38 Lactone
SN-38 Lactone
Glucuronide
SN-38 Carboxylate
SN-38 Carboxylate
Glucuronide
CE 
pH
pH
pH
pH
pH
pH
UGT1A1 
UGT1A9
  
Figure 1-5. Metabolism and pH dependent interconversion of irinotecan (CPT-11) and its 
metabolite, SN-38. (Abbreviations used are CPT-11:-irinotecan; APC:-7-ethyl-10-[4-N-
(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin; NPC:- 7-ethyl-10-[4-
(1-piperidino)-1-amino]-carbonyloxycamptothecin; CE:--carboxylesterase enzyme). 
Adapted from references (39, 40). 
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SN-38 is good substrate for hepatic phase-II enzymes, which mediate its 
glucuronidation, most likely at the phenolic hydroxyl at position 10 (see Figure 1-1). As 
shown in  
Figure 1-6, the hydrophilic SN-38 glucuronide (SN-38-G) is then effluxed by 
Multidrug Resistance Protein 2 (MRP2) into the bile (33). The formation of glucuronide 
is thus the most important step in the detoxification process and individuals with genetic 
mutations, mainly in the UGT1A1 gene, are unable to efficiently glucuronidate SN-38 
and therefore are more prone to toxicity following treatment with irinotecan (41, 42). 
Once in the gastrointestinal tract, SN-38 glucuronide is subject to enzymatic 
hydrolysis and reconversion to SN-38 by bacterial β-glucuronidases (43, 44). Although 
the newly generated SN-38 has poor solubility and is a substrate for efflux transporters 
expressed in the gastrointestinal epithelium (43), some is likely to diffuse into these 
rapidly dividing cells causing cell death. This in turn manifests as the severe diarrhea 
associated with CPT-11 use (45). Although conversion to SN-38 represents a small 
fraction of the total CPT-11, antitumor activity and toxicity of CPT-11 is linked to the 
SN-38 generated. Therefore, understanding of factors affecting the disposition of SN-38 
is essential from a pharmacological as well as a toxicological point of view. The third 
generation camptothecin analog, AR-67 shares structural similarities with SN-38 and 
may therefore share biotransformation and elimination pathways (Figure 1-2). The 
available literature indicates the presence of both the lactone and carboxylate forms in 
vivo in plasma, with the lactone form representing the majority of AR-67 (46). 
However, extensive studies on the disposition of the lactone and carboxylate forms of 
AR-67 and/or on the role of transporters in its disposition are lacking. 
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Figure 1-6. Carboxylestrase (CE)-mediated conversion of irionotecn (CPT-11) to SN-38 
and the glucuronidation and biliary excretion of SN-38 and SN-38 Glucuronide (SN-
38G) into the intestine (Redrawn and modified from (33). 
1-3. Major transporters involved in the cellular uptake and efflux of 
camptothecins  
As the target of camptothecins is the nuclear enzyme topo I, passage through the 
cell membrane could be seen as a prerequisite for cellular accumulation and 
pharmacological effect. One of the factors that affects the cellular accumulation and/or 
transport of camptothecins is interaction with uptake and efflux transporters. Interaction 
with uptake transporters likely facilitates cellular entry while interaction with efflux 
transporters will likely limit it. In general, camptothecins have been shown to interact 
with the ATP Binding Cassette (ABC) efflux transporters, P-gp, BCRP/Bcrp, and MRPs 
(47-50) as well as with the organic anion uptake transporter polypeptide OATP1B1 (51, 
52). An extensive review of efflux and uptake transporters is available in the literature 
(53-56). A brief summary of major transporters relevant in cellular uptake and efflux of 
camptothecins is presented below.  
1-3.1. ABC efflux transporters 
ATP binding cassette (ABC) transporter proteins are expressed in nearly all 
organisms. The human genome encodes 49 ABC proteins, which are grouped into seven 
subfamilies (A, B, C, D, E, F and G). Common features of the architecture of ABC 
transporters are the presence of ATP binding subunits (also known as nucleotide binding 
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domains, NBDs) in the cytoplasm, and transmembrane domains (TMD), which are 
composed of six membrane spanning helices and embedded in the lipid bilayer (57). All 
ABC transporters contain at least two conserved cytoplasmic NBDs and at least two 
TMDs (57). The ATP binding subunits can bind and hydrolyze ATP, while the two 
transmembrane domains (TMDs) form a central cavity in the lipid bilayer and are 
believed to be sites for interaction with substrates (55, 58, 59). Secondary structures of 
ABC transporters are presented in Figure 1-7.  
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Figure 1-7. Representative secondary structures of ABC transporter proteins (A) MRP1, 
MRP2 & MRP3, (B) P-gp, (C) BCRP redrawn from references (54, 55, 58-60). 
Abbreviations used are TMD-Transmembrane Domain; NBD-Nucleotide Binding 
Domain.  
P-glycoprotein (ABCB1) 
P-gycoprotein is a 170 kDa ABC transporter protein that limits the intracellular 
accumulation of lipophilic substrates (61). It effluxes its substrates against a 
concentration gradient using the energy generated from the hydrolysis of ATP (62) and is 
believed to contribute to the development of multidrug resistance (61). It is widely 
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expressed in the endothelium and epithelium of most tissues, including the 
gastrointestinal tract, liver, kidney, brain, and placenta (63-65). Its expression in the 
apical face of gastrointestinal epithelium is associated with decreased oral bioavailability 
of substrates (66, 67). Expression in the liver and kidney contributes to the clearance of 
substrate drugs through biliary and renal pathways, respectively (68-71). Expression of P-
gp at the blood-brain barrier limits the entry of substrates into the brain (72). Depending 
on the desired pharmacological outcome, the exclusion of drugs from the brain could be 
protective or undesirable (73, 74). Although P-gp physiological substrates have not been 
identified, P-gp transports several lipophilic and amphiphilic compounds. These 
compounds have widely varying structures and include many highly utilized clinical 
agents such as antiarrhythmics (e.g., quinidine, amiodarone), anti-retrovirals (e.g., 
saquinavir, ritonavir) and chemotherapeutic agents (e.g. doxorubicin, paclitaxel) (53, 58, 
75, 76). Camptothecins have also been shown to be substrates of P-gp. For instance, P-gp 
contributed to the vectorial transport of camptothecin in MDCKII cell monolayersover 
expressing P-gp. In these cells, the efflux ratio, which is a the ratio of flux from the 
basolateral to the apical side to that of flux from the apical to the basolaateral side in  was 
found to be 3.36.  P-gp inhibition with GF120918 decreased the efflux ratio to 1.49 (47). 
In another study, P-gp overexpressing MDCKII cell lines were found to be 143 times 
more resistant to topotecan compared to control cells (48). 
Multidrug resistance proteins (MRPs) 
The multidrug resistant protein sub-family of ABC transporters has 12 members 
(MRP1-MRP12). MRPs 1-9 are transporters while MRP10 (ABCC7, CFTR) is a chloride 
channel. MRP11 (ABCC8, SUR1) and MRP12 (ABCC9, SUR2) are sulfonylurea 
receptors (54). Based on available data and relevance to the cellular efflux of 
camptothecins, a brief summary will be subsequently provided for MRP1, MRP2, MRP3, 
MRP4 and MRP5.   
MRP1 (ABCC1) 
MRP1 was the first member of MRPs to be identified in small cell lung cancer 
cell lines selected with doxorubicin (HL60/ADR) (77). It is a 190 kDa membrane 
glycoprotein (78-80) with three transmembrane domains (TMD0, TMD1 and TMD2) 
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and two ATP binding domains (NBD1 and NBD2). TMD0 possesses five 
transmembrane helices unlike TMD1 and TMD2, which possess six transmembrane 
helices (60, 81) (Figure 1-7).  
MRP1 is expressed ubiquitously on the basolateral membrane of barrier forming 
epithelial cells and in the basolateral face of blood-brain barrier endothelium. Much like 
P-gp, MRP1 substrates vary in their structure, but are generally more hydrophilic and 
include several physiologically important molecules. The endogenous substrates include 
glutathione (GSH), oxidized glutathione (GSSG), glutathione conjugates of leukotrienes 
(LTC4, LTD4, LTE4) and prostaglandins (PGA2), glucuronide conjugates of bilirubin 
and estradiol, and sulfate conjugates of estrone and taurocholate. It also transports a 
variety of drugs mostly as glutathione, glucuronide and sulfate conjugates (54). Some of 
the substrate drugs are methotrexate, doxorubicin, etoposide (glucuronide) and 
camptothecins (49). Thus, MRP1 appears to be an important efflux transporter that 
limits the intracellular accumulation of substrates and facilitates the efflux of 
endogenous and xenobiotic molecules that have been biotransformed. 
MRP2 (ABCC2) 
MRP2 is similar in size, membrane topology and substrate specificity to MRP1 
(Figure 1-7). Unlike MRP1, however, MRP2 is expressed on the apical membrane of 
epithelial cells (60, 82) in the liver (83), kidney (84) and intestine (85). MRP2 transports 
leukotrienes (LTC4, LTD4 and LTE4), glutathione conjugates of prostaglandin A1 and 
heavy metal ions, glucuronide and sulfate conjugates of endogenous substances (e.g., 
bilirubin, estriadiol, cholate, lithocholate) and xenobiotics (59). As such, it plays an 
important role the biliary secretion of drug metabolites into the bile (54, 60). CPT-11 and 
SN-38 glucuronide have been shown to be transported by MRP2 (33, 86). In humans, 
mutations in the MRP2 gene cause the Dubin-Johnson syndrome, an inherited 
hyperbilirubinemia in which the glucuronide conjugate of bilirubin is not secreted into 
bile (87). 
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MRP3 (ABCC3) 
The secondary structure of MRP3 is similar to MRP1 and MRP2, but it is more 
closely related to MRP1 in terms of amino acid sequence, substrate specificity, and 
basolateral expression. It is found in liver, kidney, intestine, adrenal cortex, gall bladder 
and pancreas (88-90) and transports bile acids, glucuronide conjugates of bile acids and 
glutathione and glucuronide conjugates of xenobiotics (88, 89). A recent study showed 
that the mouse Mrp3 could transport SN-38 glucuronide (50), and given its basolateral 
expression in the liver, it may contribute to the high SN-38 glucuronide concentrations 
that are typically found in the blood following CPT-11 dosing.  
MRP4 (ABCC4) and MRP5 (ABCC5) 
Unlike MRP1-3, MRP4 and MRP5 lack one transmembrane domain (TMD0) and 
consist of two transmembrane domains and two nucleotide binding domains. This 
secondary structure is similar to P-gp. MRP4 expression could be apical or basolateral in 
different epithelial cells. It is expressed apically in the kidney (91) and in endothelial 
cells of brain capillaries (92, 93) and basolaterally in the prostate (94), choroid plexus 
(93) and hepatocytes (91). The substrates of MRP4 and MRP5 overlap and include cyclic 
and acyclic nucleotides (95). MRP4 prefers methylated thionucleotides, while MRP5 
prefers unmethylated thionucleotides (96). MRP4 has been shown to confer resistance to 
topotecan and irinotecan (92, 93). At this time, no data on the interaction of MRP5 with 
camptothecins are available. 
BCRP (ABCG2) 
The Breast Cancer Resistance Protein (BCRP, ABCG2, MXR) was first cloned 
from MCF-7/AdrVp breast cancer cells rendered resistant to the P-gp inhibitor verapamil 
(97). Later on it was isolated from human placenta (98) and from mitoxantrone-resistant 
human colon carcinoma cell lines (99). As shown in Figure 1-7, BCRP is a 72-kDa half-
transporter with one ATP binding domain and one transmembrane domain (TMD) 
consisting of six membrane spanning helices (59). It is believed to function after 
homodimerization of two monomers through disulfide bond formation (100). Studies also 
suggest that it can form a homotetramer (101) In contrast to other ABC transporters, its 
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ATP binding domain is at the N-terminus (97, 99). BCRP serves a protective purpose 
against xenobiotics/toxins in the gut (102), brain (103, 104), testis (104), and the placenta 
(102). It is also expressed at sites of reduced oxygen tension, liver and mammary gland 
(105-107). It transports a variety of substrates and their sulfate, glutathione and 
glucuronic acid conjugates. Some BCRP substrates include anthracyclines (e.g., 
doxorubicin, daunorubicin), anti-retrovirals (e.g., zidovudine, lamivudine) and proton 
pump inhibitors (e.g., pantoprazole) (39)(59). Several studies have indicated 
camptothecins to be BCRP substrates (48, 108, 109). BCRP overexpression decreased 
cellular accumulation and conferred resistance to 9-AC, but not to 9-NC. However, no 
differences were observed in the cytotoxicity of both 9-AC and 9-NC between control 
cells and cells that overexpress P-gp, MRP1 or MRP2. The authors suggested that the 
presence of a polar group at position 9 or 10 of camptothecin enhances interaction with 
BCRP (48).  
Table 1-4 summarizes the 1 hour intracellular accumulation of the hydrophilic 
topotecan and the lipophilic gimatecan in sensitive (HT29) and resistant (Bcrp 
overexpressing HT29/MIT) colon carcinoma cells (110). HT29/MIT cells had 
significantly lower intracellular concentration of topotecan compared to HT29 cells. In 
contrast, cellular accumulation of the lipophilic gimatecan was similar in both HT29 and 
HT29/MIT cells. When compared to accumulation following incubation with the same 
concentration of topotecan (2 µg/ml), there was up to a 100 fold higher accumulation of 
gimatecan in both HT29 and HT29/MIT cells.The authors suggest that BCRP may not 
recongnize gimatecan. In another study the intracellular accumulation of topotecan in 
resistant T8 and MX3 ovarian cancer cells that overexpress BCRP was significantly 
lower than in non-BCRP expressing parental IGROV1 cell lines (109). The difference in 
accumulation was abolished by co-incubation with the efflux inhibitor GF120918. T8 
cells were 111 and 259 times more resistant to topotecan and SN-38, respectively, 
compared to parental control cells. MX3 cells on the other hand, were 30 and 54 times 
more resistant to topotecan and to SN-38, respectively, compared to parental control 
cells. In the presence of GF120918, resistance to topotecan and SN-38 was diminished 
in T8 and MX3 cell lines (109). Moreover, the tyrosine kinase inhibitor imatinib 
reversed BCRP mediated resistance of Saos2 cells to topotecan and SN-38 (108). 
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Imatinib competes with ATP binding and is thus a functional inhibitor of BCRP. 
Reversal of resistance with imatinib could have resulted from the increased intracellular 
accumulation of topotecan observed (108). These results indicate the prominent role 
BCRP plays in limiting intracellular accumulation and/or in contributing to resistance to 
the cytotoxic effect of camptothecins. Therefore, it is expected it could play similar roles 
on AR-67. 
Table 1-4. Intracellular accumulation of topotecan or gimatecan‡. 
Camptothecin 
analogue 
Concentration 
(µg/ml) 
Mean drug content (ng/107 cells), (SD) 
HT29 HT29/MIT 
Topotecan 2 9 (5) 4 (3) 
20 195 (20) 80 (25) 
Gimatecan 0.2 22 (4) 34 (3) 
2 250 (22) 390 (18) 
‡Adapted From reference (110). Cells were incubated for 1 h with either 
topotecan or gimatecan. Values were obtained from quadruplicate determinations  
1-3.2. Organic anion transporting polypeptides (OATPs) 
Unlike ABC transporter proteins, OATPs do not require ATP for their function. 
As their name implies, their substrates are primarily organic anions and most importantly 
they function as uptake transporters with the potential for bidirectional transport (49, 111) 
. Given that the carboxylate forms of camptothecin analogues meet the physicochemical 
criteria of OATP substrates, interaction between carboxylate and OATPs has been the 
subject of investigation. The organic anion transporting polypeptides (OATPs-humans, 
Oatps-rodents) are members of solute carrier organic anion transporter family (SLCO) 
and are membrane transporters expressed in different species (e.g., humans, rats, mice, 
cows, quail, zebrafish) (40).  
Eleven human OATPs have been identified and are categorized into six families, 
OATP1-6 with each family subdivided into subfamilies (56, 112). OATP1, which is the 
largest family, has three sub-families, OATP1A, OATP1B and OATP1C (47, 103). 
OATPs are predicted to have 12 membrane spanning domains (Figure 1-8) (56, 112). 
Uptake of substrates is sensitive to extracellular pH and is believed to be coupled with 
exchange of anions such as HCO3-. The transport, however, is independent of sodium 
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(111). Among the OATPs, OATP1B1 (MW 84 kDa) and OATP1B3 (MW, 120 kDa) and 
the rodent homolog Oatp1b2 (MW ≈77 kDa) are believed to be liver-specific and are 
expressed basolaterally (111, 113-115). OATP1B1 and OATP1B3 share similar substrate 
specificity and are involved in the hepatic uptake of several endogenous compounds (e.g., 
bilirubin, estradiol 17-β-glucronide, LTC4) and drugs (e.g., statins, rifampin, SN-38, 
valsartan) (51, 56, 116, 117). OATP1B1 and/or OATP1B3-mediated hepatic uptake 
impacts drug concentration in the liver and contributes to the elimination of substrates 
either by metabolism or hepatobiliary efflux (115).  
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Figure 1-8. Predicted secondary structure of OATPs redrawn from reference (118). 
The organic anion transporters OATP1B1 and/or OATP1B3 may play a role in 
the disposition of camptothecins as shown for irinotecan and SN-38 (51). Both irinotecan 
and SN-38 significantly inhibited OATP1B1-mediated uptake of the OATP1B1 substrate, 
[3H]estrone-3-sulfate. Moreover, SN-38 displayed increased transport in HEK293 cells 
expressing OATP1B1 (51). The lipophilic camptothecin analogues gimatecan and 
BNP1350 were also transported by OATP1B1 in vitro as evidenced by trancellular 
studies in which basolateral to apical flux of gimatecan and BNP1350 in MDCKII-
OATP1B1 cells was 2.7 fold higher than the apical to basolateral transport (52). 
Although these studies did not specifically assess the transport of the lactone or 
carboxylate forms, it is likely that the carboxylate forms of camptothecins, which are 
hydrophilic, are OATP substrates. 
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The hydrolysis of the lactone form to the carboxylate in the extracellular culture 
medium could also play a role in limiting intracellular accumulation in vitro (119). In 
IGROV-1, VERO and WIDR cell types, incubation of 9-AC carboxylate resulted in more 
than 18 fold lower intracellular accumulation than that done with the same concentration 
of 9-AC lactone (1.5-1.8 ng/mg protein with carboxylate vs. 22.3-32.5 ng/mg protein 
with lactone) (10). It is likely that the lipophilicity of the lactone allows enhanced 
intracellular accumulation by passive diffusion whereas the hydrophilicity or charge on 
the carboxylate limits it. Differential interactions with efflux and uptake transporters were 
noted for the lactone and carboxylate forms of statins (120), which like camptothecins 
undergo reversible lactone-carboxylate hydrolysis (120, 121). Thus, it is likely that such 
interactions would also be relevant for camptothecins in vitro and in vivo. 
1-4. In vivo interaction of camptothecins with transporters 
1-4.1. Disposition  
The interconversion between lactone and carboxylate forms of camptothecins 
becomes important in their overall disposition as the lactone and carboxylate forms may 
differentially interact with efflux and uptake transporters. Thus, pharmacogenetic 
differences in transporters, changes in organ function, or drug-drug interactions may 
affect one or both types of transporters leading to changes in the predominant clearance 
pathway of the lactone and/or the carboxylate forms. In vitro studies have demonstrated 
that camptothecins are substrates of OATP and ABC efflux transporters (52, 109, 110). 
Moreover, this interaction has been shown to be relevant in the clearance, distribution 
and oral bioavailability of camptothecins using either chemical inhibitors or genetic 
knockout animals (122-124). 
With the parent compound camptothecin, it has been shown that P-gp inhibition 
results in an almost two fold increase in brain exposure (122). The implication of a 
change in the MRP2-mediated clearance pathway of SN-38, i.e, biliary efflux of SN-38 
glucuronide was illustrated in EHBR rats, which do not express MRP2. After intravenous 
administration of 10 mg/kg CPT-11 in EHBR rats, plasma AUC of SN-38 lactone 
glucuronide was 4 fold higher and the amount in the bile was about 7 fold lower 
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compared to wild type Sprague Dawley rats that received the same dose of CPT-11 (125). 
Another study showed that in the presence of the P-gp and MRP2 inhibitor cyclosporin, 
plasma concentration of irinotecan carboxylate, SN-38 lactone and SN-38 carboxylate 
were elevated in rats. It was also noted that biliary, intestinal exsorption and ‘apparent’ 
systemic clearance of CPT-11 lactone, CPT-11 carboxylate, SN-38 lactone and SN-38 
carboxylate decreased significantly in the presence of cyclosporin (123). It appears 
therefore, that both P-gp and MRP2 are involved in the active efflux of ininotecan and 
SN-38 glucuronide. 
Studies in Bcrp and/or mdr1 knockout animals also show the importance of ABC 
transporters in the clearance of topotecan (124). Topotecan clearance in Bcrp knockout 
animals was 73% of the value in wild type animals (15.4 ± 1.6 (SE) vs. 11.3± 2.2 
L/hr/m2, p<0.05). The clearance decreased to 54% of control values in the presence of the 
Bcrp transporter modulator gefitinib (15.4 ± 1.6 (SE) in wild type vs. 8.3 ± 2.5 L/hr/m2 in 
Bcrp knockouts, p<0.05). Similarly in mdr1a/b knockout animals, topotecan clearance 
was 79% of that in wild type animals (15.5 ± 0.97 (SE) in wild type vs. 12.2 ± 1.5 
L/hr/m2 in knockout animals) and gefitinib decreased it to 65.8% of control values (124). 
Given that the lactone and carboxylate forms of camptothecins may be eliminated 
differently due to differential interaction with uptake and efflux transporters, alteration of 
the clearance of one but not of the other could take place. This was illustrated by 
probenecid, an organic anion transporter inhibitor, which predominantly decreased the 
clearance of the carboxylate in mice when co-administered with topotecan (126). 
Although in this study interconversion between the lactone and carboxylate forms was 
not taken into consideration during the estimation of pharmacokinetic parameters, 
“lactone” systemic clearance decreased 16.5% (16.3 without vs. 13.6 L/hr/m2 with 
probenecid) while total drug systemic clearance decreased 31% in the presence of 
probenecid (10.9 without vs. 7.5 L/hr/m2 with probenecid). Moreover, probenecid led to 
1.2 and 2.2 fold increases in lactone and carboxylate AUCs, respectively, following 
administration of the lactone form. On the other hand, following carboxylate 
administration, probenecid led to 2.0 and 3.7 fold increase in lactone and carboxylate 
AUCs, respectively. Using equations 1-1 to 1-4 and areas under the plasma concentration 
versus time curve (AUC) of the lactone and carboxylate systemic and conversion 
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clearances of the lactone and carboxylate were calculated and are presented in Table 1-5. 
As shown in the table, probenecid appears to selectively decrease the clearance of the 
carboxylate (four fold reduction in carboxylate clearance). Although both lactone to 
carboxylate and carboxylate to lactone clearances decreased with probenecid, the ratios 
with respect to each other did not appreciably change.  
 
Table 1-5. Effect of probenecid on the clearance of topotecan in mice‡.  
Clearance  
(L/hr/m2) 
Without  
probenecid  
With 
probenecid  
Fold 
change 
Lactone systemic clearance 
(Cl10) 
3.33 3.09 1.06 
Carboxylate systemic clearance 
(Cl20) 
2.46 0.59 4.21 
Lactone to carboxylate 
conversion (Cl12) 
1.47 0.70 2.10 
Carboxylate to lactone 
conversion (Cl21) 
0.51 0.23 2.25 
‡ Adapted from reference (126). Probenicid (600 mg/kg) was administered by 
oral gavage 30 minutes before and 3 h after administration of  topotecan (1.25 mg/kg) by 
the intravenous route. 
1-4.2. Oral bioavailability of camptothecins and role of efflux transporters  
As shown in Table 1-6, the oral bioavailability of camptothecins is incomplete 
(127-131). For some, it can in part be attributed to their poor aqueous solubility. 
However, limited bioavailability is also a feature of more soluble analogs such as 
topotecan. Thus, interaction with ABC efflux transporters located in the gastrointestinal 
(GI) tract or metabolism in the GI epithelium are likely factors influencing the 
bioavailability of camptothecins. The oral bioavailability of camptothecins is reduced by 
ABC efflux transporters located in the gastrointestinal tract, while inhibition or absence 
of these transporters improves oral bioavailability (102, 124, 132, 133). Although it is 
likely that efflux transporters might also reduce the oral bioavailability of AR-67, the 
extent remains to be determined. Moreover, there is a scarcity of data with regard to the 
contribution of first pass metabolism in the intestine and/or the liver in reducing the 
bioavailability of camptothecins. Therefore, studies assessing first pass metabolism of 
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AR-67 are deemed necessary not only for AR-67 but potentially also for other 
camptothecins.  
Table 1-6. The oral bioavailability (F%) of some camptothecin analogs. 
Analogue 
% 
Species Remark Reference 
9-NC 14.6 Rat A solution of 9-NC in DMSO was diluted 
with a vehicle containing PEG-400 and 
sterile water (1:1, v:v) and acidified with 
phosphoric acid (pH 3.0-3.5) 
(127) 
Irinotecan 25% Mice Diluted in normal saline (132) 
Topotecan 30 Mice Dissolved in water (129) 
50 Dog Dissolved in 0.9% saline (pH 3) and 
administered in size 12 gelatin capsules 
(27) 
29.7 Rat Dissolved in saline containing 5% d-
glucose 
(130) 
42 Humans Administered as gelatin capsules 
containing anhydrous free base 
(topotecan) 
(131) 
Karenitecin 67 Mice Solubilizer composed of  N-
methylpyrrolidone, PEG-300, Tween 80, 
ethanol and citric acid 
(128) 
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1-5. Summary 
AR-67 is a relatively lactone stable camptothecin analog undergoing early phase 
clinical trials as a chemotherapeutic agent. Its pH dependent interconversion allows the 
existence of the lactone and carboxylate forms in equilibrium. While the carboxylate 
prevails at physiological pH in vitro, it is the lactone that prevails in vivo. The reasons for 
this apparent discrepancy remain to be understood. The interaction of camptothecins with 
ABC efflux and OATP uptake transporters affects cellular accumulation, cytotoxcity and 
transcellular transport in vitro. On the other hand, ABC efflux transporters and OATPs 
have been shown to affect disposition and/or oral bioavailability. Because of their 
physicochemical differences, the lactone and carboxylate forms may preferentially 
interact with efflux and uptake transporters, and may therefore follow different 
elimination pathways in vivo. SNPs in transporter proteins, drug-drug interactions, and 
alterations in organ functions have the potential to alter pharmacokinetics and as a 
consequence the pharmacodynamics of the lactone and carboxylate forms. It is therefore 
essential to study the pharmacokinetics of the lactone and carboxylate forms. The 
reversibility of lactone and carboxylate conversion means that the study of the 
pharmacokinetics of camptothecins in general and of AR-67 in particular requires the 
separate administration and quantification of the lactone and carboxylate forms. 
Estimation of clearances that uniquely describe the disposition of the lactone and 
carboxylate forms of AR-67 as well as their interconversion will allow the identification 
of the driving force in AR-67 disposition and the prediction of likely outcomes of 
clearance changes.  
Efficacy of protracted dosing of AR-67 in tumor bearing mice via the intravenous 
route and minimal signs of toxicity via the oral route make AR-67 a good candidate as an 
oral chemotherapeutic agent. However, its lipophilicity as well as its potential interaction 
with efflux transporters located in the gastrointestinal tract could limit its bioavailability. 
Studies are therefore required to investigate factors that affect the oral bioavailability of 
AR-67. 
Copyright © Eyob Debebe Adane 2010 
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CHAPTER 2 
HYPOTHESIS AND SPECIFIC AIMS 
 
AR-67 is a potent third generation camptothecin analog that undergoes pH 
dependent but reversible hydrolysis between its lipophilic lactone and hydrophilic 
carboxylate forms. AR-67, like all camptothecin analogues exerts its effect through 
interaction with the nuclear enzyme Topoisomerase I (topo I). Therefore, it is essential 
that AR-67 enters the cell to exert its pharmacological action. The distinct 
physicochemical properties of the lactone and carboxylate forms could lead to differences 
in cellular accumulation and/or transport as a result of their differential interaction with 
uptake and efflux transporter proteins in vitro and in vivo. In this dissertation, the effect 
of ABC efflux transporters P-gp and BCRP and organic anion transporting polypeptides, 
OATP1B1 and OATP1B3, on cellular accumulation and transcellular transport of AR-67 
was determined in vitro. The findings of in vitro studies were extended to the in vivo 
situation by studying the disposition and oral bioavailability of the lactone and 
carboxylate forms in the presence and absence of transporter inhibitors. The overall 
hypothesis is that interconversion between the lactone and carboxylate forms of AR-67 
leads to differences in cellular accumulation and/or transport, systemic disposition and 
oral bioavailability. 
Specific Aim 1 
To determine the role of major efflux and uptake transporters on cellular efflux 
and uptake of AR-67. (Addressed in CHAPTER 3). 
The lipophilic lactone and the hydrophilic carboxylate are expected to display 
differences in interaction with uptake (OATP1B1 and OATP1B3) and efflux transporters 
(P-gp and BCRP) in-vitro. 
Rationale: Camptothecin analogues are substrates of P-gp and BCRP, which are 
ABC efflux transporters that facilitate drug removal from the cell. Due to the abundant 
expression of these two efflux pumps in organs primarily responsible for drug disposition 
(i.e., intestine, liver and kidney), these transporters have been shown to affect 
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elimination, distribution and oral bioavailability of various camptothecin analogues (102, 
124, 134). On the other hand, there are studies that indicate the interaction of 
camptothecins such as irinotecan, SN-38 and gimatecan with the organic anion uptake 
transporter OATP1B1 (51, 52). OATP1B1 and OATP1B3 are organic anion uptake 
transporters that are preferentially expressed in hepatocytes and play an important role in 
drug elimination (56, 112). As a result of the labile nature of AR-67, both the lactone and 
carboxylate forms exist at physiological pH in vivo. It is likely that the more lipophilic 
AR-67 is a substrate of ABC efflux transporters, which may mediate its oral 
bioavailability, tissue distribution and systemic clearance in vivo. Conversely, the 
hydrophilic and charged carboxylate is more likely to be a substrate of the liver specific 
uptake transporters OATP1B1 and/or OATP1B3, which may mediate its hepatic uptake 
and biliary clearance. 
Aim 1.1. 
To determine the effect of P-gp and BCRP on intracellular accumulation of AR-
67 lactone.  
In this aim the intracellular accumulation of AR-67 was measured in control and 
P-gp or BCRP overexpressing cells. The effect of P-gp and BCRP inhibition on 
intracellular accumulation of AR-67 using GF120918 was also assessed.  
Aim 1.2.  
To determine the vectorial transport of AR-67 lactone by BCRP.  
In this aim the apical to basolateral and basolateral to apical transport of AR-67 
lactone was determined in control and BCRP overexpressing cells grown in transwell cell 
culture plates. Transport experiments were also carried out in the presence and absence of 
GF120918 and rifampin to assess effect of efflux transporter inhibition. 
Aim 1.3. 
To determine organic anion uptake transporter (OATP1B1 and/or OATP1B3) 
mediated-uptake of AR-67 lactone or carboxylate. 
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In this aim the intracellular accumulation of AR-67 lactone and carboxylate was 
measured in control and OATP1B1 or OATP1B3 overexpressing cell lines. The 
intracellular accumulation of AR-67 carboxylate was also measured in the presence and 
absence of known ABC efflux and/or uptake inhibitors, GF120918, bromosulphopthalein, 
and rifampin. 
Specific Aim 2  
To determine the in vivo disposition of the lactone and carboxylate forms of AR-
67 in the presence and absence of efflux or uptake transporter inhibitors. (Addressed in 
CHAPTER 4). 
Based on in vitro studies addressed in Aim 1, it was e hypothesized that ABC 
efflux transporters, P-gp and/or Bcrp likely affect the clearance of the lactone while 
Oatps likely affect the clearance of the carboxylate. It was hypothesized that inhibition of 
the predominant clearance term in the disposition of AR-67 wouldl lead to enhanced 
exposure to AR-67. 
Rationale: Like all camptothecins, AR-67 undergoes a pH dependent reversible 
hydrolysis. Although it displays improved lactone stability in in blood, compared to other 
camptothecins, about 70% exists in the carboxylate form at physiological pH (11). 
However, in vivo the predominant species is the lactone. This discrepancy may be related 
to differences in the interconversion rate observed in vivo and may be compounded by 
the differential interaction of AR-67 lactone and carboxylate with efflux and uptake 
transporters, which could uniquely affect their respective clearances. Similar observations 
regarding differences in transporter interaction have previously been demonstrated with 
lactone and carboxylate forms of statin analogues(120, 121). Given that AR-67 displays 
reversible hydrolysis between the lactone and carboxylate, the potential for drug-drug 
interactions is increased. Furthermore, previous studies with statins and camptothecin 
analogues have shown that single nucleotide polymorphisms in OATP1B1 and BCRP 
transporters can significantly affect drug clearance. Therefore, using pharmacologic 
inhibitors the significance of efflux transporters (BCRP and P-gp) as well as OATPs on 
the pharmacokinetics of AR-67 was assessed.  
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Through the use of modeling and simulation and transporter inhibition studies in 
vivo, attempts are made to explain the apparent lactone stability of AR-67 and propose 
possible driving factor(s) in AR-67 disposition.    
Aim 2.1.  
To determine the pharmacokinetics of AR-67 lactone and carboxylate following 
intravenous administration of each form.  
In this aim the lactone and carboxylate forms of AR-67 were separately 
administered to rats by the intravenous route. A 4-compartmental model allowing for 
interconversion between lactone and carboxylate was used to estimate lactone and 
carboxylate clearances by simultaneously fitting the plasma concentrations of the lactone 
and carboxylate forms following the administration of each form.  
Aim 2.2.  
To determine how clearance changes of either the lactone or carboxylate forms 
affect the disposition of AR-67.  
In this aim the pharmacologic inhibitors GF120918 and rifampin to were used to 
decrease the clearance of the lactone and carboxylate forms, respectively. Modeling and 
simulation were also used to determine the effect of each inhibitor on the clearance of 
lactone and carboxylate.  
Specific Aim 3 
To determine the effect of efflux transporters P-gp and Bcrp on oral 
bioavailability of AR-67. (Addressed in CHAPTER 5). 
Rationale:  In vitro data from Aim 1 showed the dependence of intracellular 
accumulation and/or transcellular transport of AR-67 lactone on efflux transporters, P-gp 
and BCRP, and its independence on uptake transporters (OATP1B1 and OATP1B3). 
Furthermore, in vivo data from Aim 2 extended these findings and indicated the 
dependence of lactone clearance on efflux transport. However, the significance of 
gastrointestinal efflux transporters on oral bioavailability of AR-67 has not been studied.  
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The interconversion between the lactone and carboxylate forms of AR-67 in the 
gastrointestinal tract, the pH of which varies along its length, and the possible selective 
uptake of the carboxylate form into the liver by organic anion transporter protein 
mediated processes make the gastrointestinal absorption of AR-67 complex. Therefore, to 
fit the data from oral administration of AR-67 lactone and carboxylate and estimate oral 
bioavailability, a flexible input function was incorporated into the four compartment 
model used to fift the intravenous data.  
Aim 3.1. To estimate oral bioavailability following lactone or carboxylate 
administration.  
In this aim incremental doses of AR-67 lactone or carboxylate by were 
administered by the oral route to estimate bioavailability and its dependence on dose and 
form of AR-67 administered The 4-compartment pharmacokinetic model used in aim 2 
was coupled with an inverse Gaussian input function to estimate the pharmacokinetic 
parameters of AR-67 following oral administration of either the lactone or carboxylate 
forms. 
Aim 3.2. To determine the effect of efflux transporters P-gp and Bcrp on oral 
bioavailability. 
In this aim animals were pretreated with the selective P-gp inhibitor zosuquidar 
and the dual P-gp and Bcrp inhibitor GF120918 prior to the administration of AR-67 in 
order to determine the effect of efflux transporters on oral bioavailability.  
 
 
 
 
 
Copyright © Eyob Debebe Adane 2010
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CHAPTER 3 
INTERACTION OF THE LACTONE AND CARBOXYLATE FORMS OF AR-67 
WITH ABC EFFLUX AND ORGANIC ANION TRANSPORTING 
POLYPEPTIDES (OATPS) 
3-1. Introduction 
Camptothecin analogs are substrates of ABC efflux transporters such as P-gp and 
BCRP (47, 102, 135). However, their interaction with organic anion transporting 
polypeptides (OATPs) was only recently recognized (51, 52). Whereas ABC efflux 
transporters have been implicated in development of resistance to the cytotoxic effect of 
camptothecins in vitro (109, 135, 136), in vivo studies have not yet clearly demonstrated 
this. However, oral bioavailability of camptothecins such as topotecan and irinotecan is 
reduced by P-gp and/or BCRP (105, 132), which pump substrates back into the lumen of 
the gastrointestinal tract. Studies conducted using ABC efflux transporter inhibitors 
and/or genetic knock-out animals further demonstrate the importance of ABC 
transporters in determining oral bioavailability (102, 132). Furthermore, ABC efflux 
transporters expressed in the biliary canalicular membrane pump substrate drugs into the 
bile and therefore contribute to the clearance of camptothecins through the biliary route 
(68, 69, 125, 137). On the other hand, organic anion transporting polypeptides, 
OATP1B1 and OATP1B3 are preferentially expressed in the liver (56). OATP-mediated 
uptake into the liver may represent a pathway for the elimination of hydrophilic 
compounds, which could be metabolized and/or effluxed into the bile once inside the 
hepatocyte (138). Therefore, ABC efflux and OATP transporters alone or in concert 
could affect pharmacokinetic and pharmacodynamic properties of camptothecins. 
 
The camptothecin class of anticancer compounds undergo pH dependent 
reversible hydrolysis of the lactone moiety to a carboxylic acid (7). In vitro and at 
physiological pH, the carboxylate form predominates (11), while in vivo, the 
predominance of one or the other form depends on the analogue under consideration. For 
instance, the parent camptothecin (139) and first generation analogues such as 9-
aminocamptothecin (140) are mainly in the form of the carboxylate while lipophilic 
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analogs, such as gimatecan (141), karenitecin (BNP1350) (142) and AR-67 (143) are 
mainly in the form of the lactone. Since the pharmacological activity of camptothecins is 
attributed to the lactone form (14), interconversion between the lactone and carboxylate 
forms is likely to impact pharmacological activity and cytotoxicity. Moreover, the 
existence of the lipophilic lactone and the hydrophilic carboxylate forms of 
camptothecins in equilibrium at physiological pH suggests that these two compounds 
could interact with uptake and efflux transporters differentially. This differential 
interaction could in turn lead to differences in the pharmacokinetic and 
pharmacodynamic properties of camptothecins. The third generation camptothecin 
analog, AR-67, is used in this study as a model compound to assess the role of efflux (P-
gp & BCRP) and uptake transporters (OATP1B1 & OATP1B3) on cellular accumulation 
and transcellular transport of the lactone and carboxylate forms. The hypothesis is that 
AR-67 lactone is a substrate for P-gp and BCRP while the hydrophilic carboxylate but 
not the lipophilic lactone depends on OATP-mediated uptake for intracellular 
accumulation. The outcomes of these studies would serve as a basis for designing in vivo 
studies that will in turn assess the effect of these transporters on AR-67 disposition and/or 
oral bioavailability.  
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3-2. Methods 
3-2.1. Chemicals 
AR-67 was obtained from Novartis (East Hanover, NJ) and rifampin was 
purchased from Fisher Scientific (Fair Lawn, NJ). H3 mannitol and BSP were from 
Perkin Elmer (Hebron, KY) Sigma Aldrich (St. Louis, MO) ?, respectively. GF120918 
was a gift from GlaxoSmithKline (Research Triangle Park, NC). Minimum Essential 
Medium Eagle (MEM), Dulbeco’s Modified Eagle Medium (DMEM) and reduced serum 
medium (Opti-MEM) and Fetal Bovine Serum (FBS) were from Invitrogen (Carlsbad, 
CA).  
3-2.2. Intracellular accumulation of AR-67  
Preparation of working solutions 
A stock solution of AR-67 lactone in DMSO (1 mg/ml) was used for preparation 
of working solutions. For lactone accumulation studies, the stock solution was further 
diluted to 25, 50, 75 and 100 M with DMSO. 10 L of working solutions were added to 
1 ml of incubation medium as described below for a final concentration of 0.25, 0.5, 0.75 
and 1 µM. Working solutions for carboxylate uptake studies were prepared by dilution of 
DMSO stock solution with 0.005 N NaOH. For intracellular accumulation studies, a 
stock solution of GF120918 (10 mM) was prepared by dissolving 51 mg GF120918 in 10 
ml of DMSO. This stock solution was further diluted to make a working solution (500 
M) by adding 6 L of 10 mM stock solution to 114 L in DMSO. For inhibition of 
MDR1 or BCRP , 10 µL of working GF120918 solution (500 µM) was added to 1 m of 
incubation medium. For trancellular flux studies. 10.1 mg of GF120918 was dissolved in 
25 ml of DMSO to prepare ≈600 µM solution. This was further diluted in Opti-MEM 
(1:100). 
Efflux studies  
To examine the effect of human ABC efflux transporters on intracellular 
accumulation of AR-67, L-MDR1, MDCKII-BCRP or their respective vector transfected 
cells (4x105) were seeded in six well plates 24 hours before the experiment. MDCKII-
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BCRP cells were grown in MEM containing 5% FBS while L-LCPK1 and L-MDR1 cells 
were grown in DMEM containing 10% FBS. On the day of the experiment cell culture 
medium was replaced with DMEM. Cells were incubated with 0.25, 0.5, 0.75 and 1 µM 
AR-67 lactone for 20 minutes. For ABC efflux transport inhibition studies, cells were 
preincubated with 5 µM GF120918 or control l solvent (10 µL DMSO) 10 minutes prior 
to the addition of 1 µM AR-67 lactone. At the end of 20 minutes the all the incubation 
medium was aspirated & discarded. Cells were then washed twice with ice cold 10% FBS 
in PBS (pH=7.4). Cells were then lysed with 200 µL of 0.5 N NaOH and placed on a 
rocker at 4oC. Protein precipitation was carried out by adding 100 µL cell lysate to 400 
µL of dry ice-cold methanol. The mixture was vortexed and centrifuged at 13x103 g for 
10 minutes. The resulting supernatant was poured into amber vials and stored at -80oC 
until analysis by HPLC. The remainder of the cell lysate was used for protein 
quantification. Protein concentrations were determined with BCA reagents (Pierce, 
Rockford, IL) according to the manufacturer’s instruction. For ABC efflux transport 
inhibition studies, cells were preincubated with 5 µM GF120918 prepared as above or 
control solvent 10 minutes prior to the addition of 1 µM AR-67 lactone.  
Uptake studies 
To measure the cellular uptake of AR-67 lactone or carboxylate, HeLa-pIRESneo control 
or cells expressing human organic anion transporting polypeptides (OATP1B1 or 
OATP1B3) were grown in six well plates (2 ml/well)  in DMEM with 5% FBS. In order 
to minimize interconversion between the lactone and carboxylate forms of AR-67, the 
incubation medium (DMEM) was maintained at pH 7.4 for lactone uptake experiments 
and pH 8 for carboxylate uptake experiments. In addition, separate experiments were 
conducted to monitor hydrolysis of lactone at pH 7.2 and conversion of carboxylate to 
lactone at pH 8. Concentration dependence studies were conducted at 0.5, 1 & 5 µM AR-
67 lactone (pH 7.2) or carboxylate  (pH 8) for 10 minutes. 
Carboxylate uptake inhibition studies were conducted at pH 7.4 medium (Opti-
MEM) using the inhibitors GF120918 (5 µM), rifampin (100 µM) or 
bromosulfophthalein (50 µM) for 5 minutes. At the end of 5 minutes the incubation 
medium was aspirated and cells were washed twice with ice cold Opti-MEM. Cells were 
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then lysed with 200 µL of 0.5 N NaOH and placed on a rocker at 4oC. Extraction was 
carried out by adding 100 µL cell lysate to 400 µL of dry ice cold MeOH.  
3-2.3. Transcellular flux of AR-67  
MDCKII-pcDNA3 and MDCKII-BCRP cells were grown for 5-7 days in Corning 
Transwell 3414 membrane inserts (3.0-μm pore size, 24-mm diameter; Corning Glass 
works, Corning, NY) until the TEER was above 200 ·cm2s. On the day of the 
experiment medium was aspirated and replaced with 1.8 ml of Opti-MEM with or 
without ≈5 µM GF120918 or ≈100 µM rifampin on the apical and basolateral sides. The 
cells were incubated at 37oC in humidified 5% CO2 incubator for 1 hour. At the end of 1 
hour, 0.2 ml of 50 µM AR-67 lactone prepared by dilution of a DMSO stock solution (1 
mg/ml) in Opti-MEM immediately before the experiment was added to each well on 
either the apical or basolateral side (donor sides) to give a final concentration of 5 µM. 
An equal volume of control medium was added to the receiver side. The plates were then 
placed on a rocker and incubated at 37oC and 5% CO2. 50 µL of sample was taken from 
the receiver and donor sides at 12 min, 24 min, 36 min and 48 min and added to 200 µL 
of dry-ice cold methanol and then centrifuged at 8.5x103 g for 3 minutes. The supernatant 
was transferred to empty amber vials and kept at -80oC until analysis by HPLC. Apparent 
permeability surface area product (PS) and other membrane flux parameters were 
calculated as described in the literature (47, 144) and as shown below.  
dt
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0
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dt
dX
dt
dX
ER BCRP
BA
BCRP
AB


      Equation 3.2 
dt
dX
dt
dX
ER pcDNA
AB
BCRP
AB
A 3


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35 
 
dt
dX
dt
dX
ER BCRP
BA
pcDNA
BA
B



3
     Equation 3.4 
where PSapp is the apparent permeability surface area product (both passive and 
transporter mediated), V is the volume of the receiver side, A is the surface area of the 
membrane, C0 is the initial donor concentration and dX/dt, which is equal to V*dC/dt, is 
the slope of the plot of cumulative amount in the receiver side as a function of time. ERα 
is asymmetry ratio, ERA is apical efflux ratio and ERB is basolateral efflux ratio. H3 
labeled mannitol was added on either the apical or basolateral side and was used to assess 
the integrity of the cell monolayers. Data from wells with <1% H3 mannitol transfer per 
hour from the donor to the receiver side were considered for analysis. Fluxes in the A>B 
direction were compared with fluxes in the B>A direction analyzed using one-way 
ANOVA followed by a Bonerroni post-hoc t-test. A p-value <0.05 was considered a 
significant difference.  
3-2.4. HPLC analysis 
AR-67 concentrations in experimental samples from the receiver side were 
measured by HPLC as described in the literature (145). Concentrations of AR-67 lactone 
and carboxylate were summed to give total drug concentration. The concentration was 
normalized to protein content for samples obtained from cell lysates.  
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3-3. Results 
3-3.1. Efflux of AR-67 lactone by BCRP and P-gp 
Intracellular accumulation 
To examine if AR-67 is a substrate of BCRP or MDR1, intracellular accumulation 
of AR-67 was studied in mock transfected cells and in cells that overexpress BCRP or 
MDR1. To measure differences in intracellular accumulation, we performed linear 
regression of the intracellular concentration of AR-67 as a function of the extracellular 
concentration. The slope of the regression line for L-LCPK cells was 2.6 fold higher than 
that of L-MDR cells (95% CI, 118.8 - 148.2 vs. 41.4 - 55.1). Similarly, the slope of the 
regression line for pCDNA3 cells was 7.6 fold higher than that of BCRP cells (95% CI, 
106.1 - 166.0 vs.  9.1 - 26.9). These results indicate that at the range of extracellular 
AR-67 lactone concentrations studied (0.25, 0.5, 0.75 and 1 µM) efflux transporter 
overexpressing cells had significantly lower intracellular AR-67 concentration than their 
controls (Figure 3-1). To examine if decreased accumulation of AR-67 in transporter 
overexpressing cells was due to efflux by BCRP or P-gp, the intracellular accumulation 
of 1 µM AR-67 was measured in control and transporter overexpressing cells in the 
presence of the dual P-gp and BCRP inhibitor GF120918. In both BCRP and MDR1 
overexpressing cells, preincubation with GF120918 resulted in significantly higher drug 
accumulation (Figure 3-1). Incubation with GF120918 abolished the difference in 
intracellular concentration between L-LCPK and L-MDR (unpaired two-tailed t-test, 
p=0.21) and between pCNDA3 and BCRP cells (unpaired two tailed t-test, p=0.41). 
37 
 
0.0 0.2 0.4 0.6 0.8 1.0
50
150
250
350
LLC-PK1
L-MDR1
LLC-PK1 + GF
L-MDR1 + GF
1.0
Extracellular AR-67 (M)
In
tr
ac
el
lu
la
r A
R-
67
(n
g/
m
g 
pr
ot
ei
n)
0.0 0.2 0.4 0.6 0.8 1.0
0
50
100
150
200
pcDNA3
BCRP
pcDNA3 + GF
BCRP + GF
1.0
Extracellular AR-67 (M)
In
tr
ac
el
lu
la
r A
R-
67
 (n
g/
m
g 
pr
ot
ei
n)
A
B
 
Figure 3-1. Efflux transporters (A) MDR1 and (B) BCRP limit the intracellular 
accumulation AR-67 lactone compared to control cells following 20 min incubation 
(open symbols). Pretreatment with 5 µM GF120918 reverses the effect of BCRP and 
MDR1 in cells incubated with 1 µM AR-67 lactone (closed symbols).  
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Transcellular transport of AR-67  lactone across cell monolayers 
Based on the results of intracellular accumulation studies, which showed the 
interaction of AR-67 with P-gp and BCRP, vectorial transport of 5 μM AR-67 was 
assessed in MDCKII-pcDNA3 and MDCKII-BCRP cells. In MDCKII wild-type cells, 
apparent permeability surface area product (PS (ml*sec-1X10-5) of AR-67 from B to A 
(secretory transport) was slightly higher than from A to B direction (absorptive transport) 
(PSB>A 12.90 ± 0.57 vs. PSA>B 9.85 ± 1.17) (Table 3-1 and Figure 3-2A and Figure 3-2B). 
This difference was not statistically different in the presence or absence of transporter 
inhibitors. On the other hand, in BCRP-transfected cells, permeability surface area 
product (PS) was several fold higher (p<0.05) in the B to A direction compared with the 
A to B direction (PSA>B 0.34 ± 0.08 vs. PSB>A 31.02 ± 23.35; ERα 90.82 ± 23.35) (Table 
3-1 and Figure 3-2C and Figure 3-2D). GF120918 increased A to B transport and reduced 
B to A transport as shown by reduced efflux ratios (Table 3-1). However, it inhibited but 
did not completely abolish BCRP mediated efflux since A>B and B>A fluxes were still 
statistically different (p<0.05). Similar to GF120918, although not to the same extent, 
treatment with rifampin also reduced (p<0.05) BCRP mediated efflux as shown by 
reduced efflux ratios (Table 3-1). 
3-3.2. Uptake of AR-67 lactone and AR-67 carboxylate by OATP1B1 and 
OATP1B3 
To test the hypothesis that the hydrophilic carboxylate but not the lipophilic 
lactone requires uptake by OATP1B1 or OATP1B3 for entry into cells, we performed 
intracellular accumulation experiments in transporter overexpressing cells and in their 
controls. Our data show that interconversion was minimal for the duration of the 
experiments (Figure 3-3A.). For AR-67 lactone uptake studies, linear regression of the 
intracellular concentration as a function of the extracellular concentration showed no 
significant difference between the slopes of control and OATP1B1 or 1B3 
overexpressing cells (95% confidence interval, 56.0 - 72.0 control vs. 54.0 - 67.0 
OATP1B1 vs. 47.0 – 64.0 OATP1B3). These results suggest that lactone uptake is more 
likely dependent on diffusion than on uptake by OATPs (Figure 3-4). For carboxylate 
uptake studies, the relationship between intracellular concentration and extracellular 
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concentration was not linear for OATP expressing cells. Carboxylate uptake was higher 
in OATP1B1 and OATP1B3 cells compared to control cells (Figure 3-4). OATP-
mediated carboxylate uptake was confirmed using 50 µM BSP, 5 µM GF120918, and 
100 µM rifampin, which inhibited carboxylate uptake in OATP1B1 and OATP1B3 cells 
to control (pIRESneo) levels (Figure 3-5).  
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Figure 3-2. Apical to basolateral (A, B) and basolateral to apical (C, D) transport of 5 
µM AR-67 lactone in pcDNA3 (A, C) and BCRP cells (B, D). Transport experiments 
were carried out in the presence and absence of 100 µM rifampin or 5 µM GF120918 as 
denoted in the figure. Data represent values obtained from n=3 wells. 
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Table 3-1. Permeability surface area product (PS) and efflux ratios of AR-67 lactone in the presence and absence of various 
transport inhibitors.  
PS  
(ml/sec x 10-5) 
MDCKII-pcDNA3 MDCKII-BCRP 
Control  
Mean (SD) 
Rifampin 
Mean (SD) 
GF 
Mean (SD) 
Control 
Mean (SD) 
Rifampin 
Mean (SD) 
GF 
Mean (SD) 
A>B  9.85 (1.17) 6.29 (1.19) 6.01 (0.30) 0.34 (0.08) 2.44 (0.82) 6.55 (0.27) 
B>A  12.90 (0.57) 8.11 (1.16) 5.93 (0.45) 31.02 
(23.35)* 
24.78 
(2.30)* 
14.85 (3.99)* 
Efflux ratios 
 Formula Control Rifampin GF 
ERα (Asymmetry Efflux Ratio) 
dt
dX
dt
dX
BCRP
BA
BCRP
AB


 
 
90.82 (23.35) 
 
10.15 (3.53) 
 
2.27 (0.62) 
ERA (Apical Efflux Ratio) 
dt
dX
dt
dX
pcDNA
AB
BCRP
AB
3


 
 
2.41 (0.27) 
 
3.06 (0.52) 
 
2.50 (0.70) 
ERB (Basolateral Efflux Ratio) 
dt
dC
dt
dX
BCRP
BA
pcDNA
BA


3
 
 
28.84 (7.62) 
 
2.58 (0.99) 
 
0.92 (0.06) 
*In MDCKII-BCRP cells, A>B fluxes in control, rifampin and GF groups were significantly different from their respective 
B>A fluxes (p<0.05). In MDCKII-pcDNA3 cells A>B fluxes were not found to be significantly different from their respective 
B>A fluxes.  
 
41 
 
 
Time, hr
0 2 4 6 8
La
ct
on
e 
hy
dr
ol
ys
is
/
C
ar
bo
xy
la
te
 fo
rm
at
io
n 
(%
)
0
20
40
60
80
100
Lactone
Carboxylate
Time, min
0 2 4 6 8 10 12
0
20
40
60
80
100
pH 8.0pH 7.2
Figure 3-3. In vitro stability of (A) AR-67 lactone (pH 7.4) and (B) AR-67 carboxylate 
(pH 8) in transport medium.  
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Figure 3-4. Uptake of AR-67 (A) lactone (1 µM) and (B) carboxylate (1 µM) after a 10 
minute incubation in OATP1B1 and OATP1B3 transiently transfected HeLa cells.  
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Figure 3-5. Inhibition of OAT1B1 and OAT1B3-mediated 5 minute carboxylate uptake in 
stably transfected HeLa cells with 50 µM BSP, 5 µM GF120918 (GF) or 100 µM 
Rifampin (Rif). 
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3-4. Discussion 
In the current study, the effect of efflux (MDR1 and BCRP) and uptake 
(OATP1B1 and OATP1B3) transporters on cellular accumulation and/or transcellular 
transport of the lactone and carboxylate forms of AR-67 was measured. Cell lines 
overexpressing MDR1 or BCRP had markedly reduced intracellular accumulation 
following incubation with AR-67 lactone. The decreased intracellular accumulation in 
MDR1 or BCRP overepressing cells and increased accumulation in the presence of the 
dual MDR and BCRP inhibitor, GF120918 indicates that the decreased accumulation was 
due to efflux by these transporters. In transcellular flux studies, BCRP was found to limit 
the apical to basolateral transport (absorptive transport) and enhance the basolateral to 
apical transport of AR-67 further demonstrating the role of BCRP in the transport of AR-
67. Consistent with efflux transporter inhibition, GF120918 and rifampin increased 
permeability in the apical to basolateral direction and reduced permeability in the 
basolateral to apical direction. These results are in agreement with the works of others. In 
a study that assessed the intracellular accumulation of topotecan in ovarian 
adenocarcinoma cells (IGROV1 and IGROV1-derived resistant T8 and MX3 cells), there 
was a threefold lower accumulation in resistant cell lines overexpressing BCRP which, 
upon co-incubation with GF120918, increased to levels observed in non-resistant cells 
(109). 
The prominent role Bcrp plays in the transport of the water soluble topotecan was 
shown in LLC-PK1 and L-Bcrp cell lines (20). The apical to basolateral and basolateral 
to apical transport did not differ in the parental cell line (LLC-PK1) when residual P-gp 
activity was abolished with the specific P-gp inhibitor valspodar (PSC 833, 10 µM). The 
basolateral to apical transport was much more than in the apical to basolateral direction in 
Bcrp overexpressing cells under similar conditions. However, in the presence of the dual 
MDR and Bcrp inhibitor, GF120918 (10 µM), the difference in apical to basolateral and 
basalolateral to apical transport of topotecan was abolished (102).  
The lipophilic camptothecin analog, gimatecan, shares similarities with AR-67 
due to a bulky substitution at position 7 but differs from AR-67 by lack of an –OH group 
at position 10. According to Perego et al. (110) the cellular accumulation of gimatecan 
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was not affected by BCRP expression. In contrast, accumulation of topotecan was about 
two fold lower in BCRP overexpressing HT29/MIT (resistant) cell lines than in HT29 
(sensitive) cell lines (110). Furthermore, Gounder et al. (146) showed that BCRP 
expression neither lowered the intracellular accumulation nor altered cytotoxicity of 
gimatecan. These findings suggested that enhanced lipophilicity might circumvent 
interaction with BCRP (110). However, a follow up study by Marchetti et al. (134) 
assessed the transport of gimatecan by Bcrp. The transcelluar transport of gimatecan 
across cell monolayers was more in the B to A than in the A to B direction in MDCKII-
Bcrp1 cell lines but was similar in parental cell lines (Efflux ratio, B>A/A>B 3.1 in Bcrp 
vs. 0.94 in parental cell lines). This was observed after excluding the effect of P-gp with 
the selective P-gp inhibitor zosuquidar (5 µM). Differences in A to B and B to A 
transport of gimatecan in MDCKII-Bcrp1 cells were abolished by pantoprazole (500 µM) 
and GF120198 (5 µM) (134). This study demonstrated that gimatecan is a substrate for 
Bcrp. According to another study by Bates et al. (147), the parent compound 
camptothecin is a poorer substrate for BCRP than SN-38. Furthermore, based on efflux of 
homocamptothecins by BCRP, the authors propose that substitutions on A- and B-rings 
and stabilized E-ring contribute to recognition of camptothecins by BCRP. The latter 
raises the question of whether or not the carboxylate forms of camptothecins in general 
and that of AR-67 in particular are substrates of ABC efflux transporters. Further studies 
are needed to elucidate the mechanism of cellular exit for the carboxylate. 
 Enhanced uptake of AR-67 carboxylate in OATP1B1 and OATP1B3 
overexpressing cells and its reversal by BSP and rifampin indicates OATP mediated 
uptake of the carboxylate. In addition, reversal of AR-67 carboxylate uptake by 
GF120918 indicates that GF120918 also inhibits OATPs as well as ABC transporters, 
MDR1 and BCRP. Both rifampin (10 µM) and GF120918 (5 µM) were recently shown to 
inhibit OATP mediated in vitro uptake of 17β estradiol 17β-D-glucuronide (E2G), and the 
camptothecins gimatecan and BNP1350. Compared to the carboxylate form, AR-67 
lactone accumulated much more but its accumulation was not affected by the expression 
of OATP1B1. This is likely related to diffusion of the lipophilic lactone (148). In one 
study, initial rate of uptake of irinotecan and SN-38 in isolated intestinal cells at pH 6.2 
was more than threefold higher than at pH 8, where the carboxylate form would 
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predominate (148). Nozawa et al. (51) examined the cellular uptake of irinotecan, SN-38 
and SN-38 glucuronide by OATP1B1 at pH 7.4 for up to 40 minutes. It was found that 
HEK293 cells expressing OATP1B1 accumulated more SN-38 than mock transfected 
cells. In this study,  the drug solutions for the uptake studies were prepared in 50 mM 
phosphate buffer (pH 9.0) and left overnight before dilution with pH 7.4 uptake medium  
In PBS (pH 7.4) only 13% of irinotecan and SN-38 were found to exist as the lactone 
(149). It can be argued, therefore, that at pH 9.0, irinotecan, SN-38 and SN-38 
glucuronide were predominantly in their carboxylate forms. Although dilution with a pH 
7.4 uptake medium could favor the reformation of the lactone forms, the uptake measured 
could not necessarily be that of the lactone but also of the carboxylate. The study, 
nevertheless, demonstrates that an OATP1B1 mediated uptake process is involved in the 
intracellular accumulation of SN-38 (carboxylate).  
In conclusion, these in vitro studies indicate that the lactone and carboxylate 
forms of AR-67 interact with uptake and efflux transporters. It is expected that such 
interactions will affect the pharmacokinetics and/or oral bioavailability of the lactone and 
carboxylate forms. 
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CHAPTER 4 
FACTORS AFFECTING THE IN VIVO LACTONE STABILITY AND 
SYSTEMIC CLEARANCE OF THE LIPOPHILIC CAMPTOTHECIN 
ANALOGUE AR-67 
4-1. Introduction 
AR-67 (DB-67) is a highly lipophilic and potent third generation camptothecin 
analogue (11, 23) currently in early phase clinical trials as an anticancer agent (150). 
Previous in vitro experiments assessing percent lactone in whole blood, showed that 
equilibrium favors the carboxylate form of AR-67 as well as other camptothecin 
analogues. Nonetheless,  percent lactone of AR-67 lactone is relatively hihger compared 
to other camptothecin analogues (11). This molecule was selected for further 
development among several analogues designed to have higher lactone fraction in the 
blood. Camptothecins owe their pharmacologic activity to their α-hydroxy-δ-lactone 
pharmacophore, which hydrolyses to the open ring or carboxylate form in a pH 
dependent, but reversible manner (2, 3, 7). Lower pH favors the lactone form, while 
plasma and alkaline pH favors the carboxylate (7). For many camptothecin analogues, the 
pH dependent lactone hydrolysis is strongly facilitated in plasma by carboxylate binding 
to serum proteins. As a result of the avid binding, sink conditions are established and the 
equilibrium shifts towards carboxylate formation (151). Thus, lactone concentrations 
reach lower levels than carboxylate in plasma at steady state (152), which is of concern 
because the latter is considered inactive. However, due to its capacity to revert to the 
lactone form in acidic environments, the carboxylate has also been associated with the 
increased toxicities observed in early camptothecin trials and with some 2nd generation 
analogues (153, 154). Comparatively, AR-67 was chosen for development based on its 
decreased interaction with albumin and its increased lipophilicity that facilitated 
partitioning in lipid membranes. Collectively, these physicochemical characteristics were 
believed to “protect” the lactone and minimize hydrolysis.  
As compared to most drugs, cytotoxic anticancer agents have a fairly narrow 
efficacy-toxicity window and a good understanding of factors contributing to their 
disposition is essential for ensuring patient safety. The disposition of the lactone and 
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carboxylate forms of AR-67 is expected to vary due to differences in aqueous solubility, 
interaction with transporters and enzymes and distribution into tissues. Several studies 
have demonstrated that camptothecins are substrates of uptake and efflux transporters 
(47, 51, 134, 155). As would be expected from the physicochemical differences between 
lactone and carboxylate, we recently demonstrated that AR-67 lactone is a substrate for 
efflux transporters P-gp and BCRP, while the carboxylate is a substrate for the organic 
anion uptake transporters OATP1B1 and OATP1B3 in vitro (156). Although the overall 
drug disposition depends collectively on many factors, dissimilar transporter interactions 
will potentially lead to differences in lactone and carboxylate systemic clearances. The 
unique physicochemical properties of each camptothecin analogue also add an additional 
layer of complexity in estimating the reversible hydrolysis kinetic parameters and the 
lactone and carboxylate systemic clearances. 
Although the in vitro interaction of camptothecins with transporters and the in 
vivo disposition of lactone and carboxylate forms of camptothecin (24, 26),  topotecan 
(27) and irinotecan (157) have been studied, the pharmacokinetics of AR-67 have not 
been examined in detail. To accurately estimate lactone and carboxylate pharmacokinetic 
parameters, administration of both species is required (158, 159). In this study we used 
pharmacokinetic modeling and simulations to assess how clearance changes of either the 
lactone or carboxylate forms could affect overall drug disposition. A primary objective 
was to estimate the systemic and interconversion clearances of the lactone and 
carboxylate forms of AR-67. Furthermore, through simulation and in vivo pharmacologic 
inhibition of transporters, we examined the influence of AR-67 lactone clearance changes 
on drug disposition.   
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4-2. Methods 
4-2.1. Chemicals 
Ammonium acetate (Mallinckrodt Baker, Phillipsburg, NJ), HPLC grade 
acetonitrile and methanol (Burdick and Jackson, Muskegon, MI) were purchased from 
VWR (West Chester, PA). Tetrabutylammonium dihydrogen phosphate (TBAP; 1.0 M 
aq. solution), Tween-80 and PEG-300 were obtained from Sigma-Aldrich (St. Louis, 
MO). Dimethylsulfoxide (≥ 99.7% DMSO) and glacial acetic acid came from Fisher 
Scientific (Fair Lawn, NJ). Blank rat plasma, used in the preparation of calibrators and 
quality control solutions, was from Innovative Research (Novi, Michigan). Siliconized 
pipette tips were obtained from Cole-Parmer (Vernon Hills, IL) and amber and 
transparent siliconized microcentrifuge tubes were from Crystalgen Inc. (Plainview, NY) 
and Fisher Scientific (Fair Lawn, NJ) respectively. Magnesium- and calcium-free 
Dulbecco’s phosphate buffered saline (PBS) was from Gibco Invitrogen (Carlsbad, CA). 
AR-67 was obtained from Novartis (East Hanover, NJ). Sulfobutylether-β-cyclodextrin 
(Captisol®) was received as a gift from CyDex, Inc. (Overland Park, KS). Rifampin for 
injection (USP) and diluent (5% dextrose in water, D5W) were from Baxter Healthcare 
Corporation (Deerfiled, IL) while GF120918 was a gift from GlaxoSmithKline (Research 
Triangle Park, NC).  
4-2.2. Animal study design 
Female Harlan Sprague-Dawley rats weighing between 240-270 g were used for 
the efflux inhibition studies. Animals were fasted during the experiment, but had free 
access to water. This was a four-week randomized crossover study. Treatment was 
allocated in a randomized scheme to each animal (n=6) such that each animal received 
the following four treatments: a) oral pretreatment with control vehicle (10% Tween-80, 
40% PEG-300 in D5W) 5 minutes before intravenous AR-67 lactone (2.5 mg/kg), b) oral 
pretreatment with GF120918 (2.5 mg/kg solubilized in control vehicle) 5 minutes before 
intravenous AR-67 lactone (2.5 mg/kg), c) oral pretreatment with control vehicle 5 
minutes before intravenous AR-67 carboxylate (at 2.5 mg/kg), d) oral pretreatment with 
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GF120918 (2.5 mg/kg solubilized in control vehicle) 5 minutes before intravenous AR-67 
carboxylate (2.5 mg/kg).  
The effect of uptake transporter inhibition on the pharmacokinetics of AR-67 was 
assessed in rats weighing 250-280 g using rifampin. Rifampin powder for intravenous 
administration (600 mg) was reconstituted with 10 ml of 5% dextrose in water. Animals 
were then pretreated with 50 mg/kg rifampin orally 1 h before the the intravenous 
administration of 2.5 mg/kg lactone or carboxylate solutions. AR-67 was administered 
through injection in the lateral tail vein. Following drug administration, about 100 µL of 
blood was collected from the saphenous vein at 5 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, and 
12 h using heparinized hematocrit capillary tubes and was then transferred to heparinized 
microcentrifuge tubes. 
4-2.3. HPLC analysis 
Plasma was separated from blood cells by centrifugation at 8500 g for 3 minutes 
at room temperature. The plasma was extracted (1:4, v/v) with dry ice cold methanol (-
80°C). The extracts were kept frozen at -80°C until analysis by HPLC with fluorescence 
detection for both AR-67 carboxylate and lactone forms as described previously (145). 
Assay accuracy and precision were validated in rat plasma and were found acceptable. 
Three quality control samples in the range of 2.5-250 ng/mL for carboxylate and 5-300 
ng/mL for lactone demonstrated accuracy within 15% (85-115%) of nominal AR-67 
concentrations. The relative standard deviation (RSD) was <6%. System suitability 
criteria were met prior to sample batch analysis. Samples were placed in an autoinjector 
(4°C) and injected within 6 hours to prevent lactone-carboxylate interconversion. 
4-2.4. Pharmacokinetic analysis 
Pharmacokinetic analysis was carried out using two approaches. The first utilized 
ADAPT-II to fit lactone-carboxylate interconversion (Figure 4-1A) and the in vivo 
disposition of each form using a 4 compartment model depicted in Figure 4-1B. The 
model was built using eight differential equations, four each for the lactone and 
carboxylate administration. Each set of four equations shared the same kinetic 
parameters, which were simultaneously fitted to the data obtained from the lactone and 
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carboxylate bolus doses using the maximum likelihood method (160). Micro-rate 
constants used in the model fitting process were converted into clearances using the 
volumes of the respective compartments. The alternate noncompartmental approach 
(NCA) utilized a method described in the literature for reversible biotransformation 
systems (161). This method was used as a basis for comparison of parameter estimates of 
the compartmental approach. In this analysis, areas under plasma concentration (AUC0-
inf) versus time curves of both the lactone and the carboxylate following administration of 
the lactone or the carboxylate were estimated with WinNonlin v.5.2. The elimination and 
apparent distribution half-lives of the lactone and carboxylate were calculated from the 
micro-rate constants estimated with ADAPT-II as described in the literature (162).  
4-2.5. Simulations 
The model depicted in Figure 4-1B was built in Stella® (High Performance 
System, Inc., Lyme, NH). Simulations were conducted to assess the clinical significance 
of clearance changes as they relate to alteration of exposure to either form of AR-67. In 
these simulations we estimated plasma concentrations while varying either the lactone or 
carboxylate clearance parameters that were estimated using compartmental modeling in 
ADAPT-II under control conditions (Table 4-1). 
4-2.6. Statistical analysis  
Differences between clearance parameters in the presence or absence of inhibitors 
were assessed using a paired two sample t-test (cross-over studies) and comparison of 
95% confidence estimates of the parameters. The level of significance was p<0.05. 
4-3. Results 
4-3.1. Plasma pharmacokinetics of AR-67 lactone and carboxylate 
The plasma pharmacokinetics of AR-67 were assessed in female Sprague Dawley 
rats following an intravenous bolus dose of 2.5 mg/kg. To obtain better estimates of the 
lactone –carboxylate interconversion kinetics, we administered AR-67 lactone and AR-67 
carboxylate, separately, and measured the plasma concentration of both forms during the 
individual experiments. As shown in Figure 4-1A, the lactone and carboxylate 
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interconversion involves the hydrolysis of the lactone ring, but this reaction is reversible. 
To elucidate the role of each moiety in the overall drug disposition, we sought to 
selectively perturb the clearance of each AR-67 form. In previous studies we determined 
that AR-67 lactone is a substrate of BCRP and to lesser extent P-gp, while the 
carboxylate is a substrate of OATP1B1 (156). Therefore, the BCRP and P-gp 
pharmacologic inhibitor, GF120918, was used to decrease the lactone clearance and the 
OATP1B1 inhibitor, rifampin, was used to impair the carboxylate clearance. GF120918 
and rifampin were administered orally 5 minutes and 1 hour, respectively, prior to the 
administration of the AR-67 intravenous bolus doses. Experiments with animals (six per 
group) receiving AR-67 alone (lactone or carboxylate) or AR-67 following GF120918 
consisted of a four period randomized crossover design. In studies with animals receiving 
rifampin, each animal was only used once to avoid rifampin experimental artifacts via 
rifampin mediated metabolism and transporter induction (i.e., CYP450 and P-gp). Each 
animal was sampled at indicated time points via venipuncture of the saphenous vein. 
Pharmacokinetic analyses were carried out with ADAPT-II (160) following the 
implementation of the model depicted in Figure 4-1B. The data sets for lactone and 
carboxylate doses were analyzed simultaneously. The pharmacokinetic parameter 
estimates are presented in Table 4-1 and the pharmacokinetic profiles are depicted in 
Figure 4-2. (A, B, C &D). When the lactone form was administered, the lactone 
concentrations (Figure 4-2.A) were much higher than the carboxylate (Figure 4-2.B). 
Interestingly, when the carboxylate dose was administered the carboxylate declined 
rapidly, and within 30 minutes the lactone reached similar concentration levels as the 
carboxylate (Figure 4-2.C and Figure 4-2.D). As expected, the administration of 
GF120918 prior to AR-67 lactone administration had a significant effect on the clearance 
of the lactone form, which decreased to approximately 60% of the clearance estimates 
obtained in animals not receiving the inhibitor prior to AR-67.  
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Figure 4-1. (A) AR-67 undergoes a pH dependent hydrolysis of the lactone and 
carboxylate moieties of AR-67. (B) A pharmacokinetic model allowing for AR-67 
interconversion was used to fit the data. 
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Figure 4-2. Plasma pharmacokinetics of AR-67 lactone (A, C) and carboxylate (B, D) 
following intravenous administration of 2.5 mg/kg lactone (A, B) or carboxylate (C, D). 
Each experiment represents mean ± standard deviation of 6 rats. Animals receiving AR-
67 only (Control) or AR-67 following GF120918 pretreatment were used in a 4 period 
crossover experimental design. Animals receiving rifampin pretreatment were only used 
once. Lines represent the unweighted model estimated fits.  
 
Although, the carboxylate concentrations were higher in the group receiving 
GF120918, the model predicted that the carboxylate clearance was unchanged and the 
higher concentrations were a result of the increased lactone concentrations. Rifampin pre-
administration had significant effects on the clearance of the carboxylate, but notably it 
also had a significant effect on the clearance of the lactone, which decreased by 
approximately 60% and 45%, respectively, as compared to animals not receiving a 
pharmacologic inhibitor. In the case of the rifampin pre-treated animals, the model also 
predicted a significant decrease in the peripheral compartment distributional clearance of 
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the lactone, but not of the carboxylate. The central compartment volume estimate for the 
lactone (1.4 L/kg) was higher than the carboxylate moiety (0.5 L/kg) and there were no 
significant differences in its magnitude among the three experimental groups. Although 
differences were not statistically significant, the model predicted higher carboxylate 
volume when animals were pretreated with GF120918 and a lower volume when 
pretreated with rifampin (Table 4-1).  
The apparent lactone stability of AR-67 in plasma is evident in Figure 4-3. Panels 
A and B depict the model predicted lactone to carboxylate ratios following administration 
of the lactone or carboxylate forms of AR-67, respectively. In all cases, following lactone 
administration, there was rapid conversion of the lactone to the carboxylate within the 
first 30-60 minutes. However, a second phase of slower conversion was observed at later 
time points with the ratio ranging between 2-fold and 4-fold (i.e., approximately 67-80% 
of AR-67 was in the lactone form) (Figure 4-3A). A similar rapid conversion was 
observed within 30 minutes after the carboxylate dose was administered followed by a 
steady state phase where the lactone and carboxylate concentrations were either 
equivalent or the lactone concentrations were higher, as was the case when GF120918 
was administered (Figure 4-3D).  
The effect of each inhibitor on the exposure to AR-67 is shown in Figure 4-3C 
and Figure 4-3D for the lactone and carboxylate dosages, respectively. When the lactone 
was administered, 84% of the total AUC was contributed by the lactone and pretreatment 
with GF120918 or rifampin significantly increased exposure to both forms (Figure 4-3C). 
Animals receiving GF120918 and rifampin pretreatment had 81% and 76%, respectively, 
of the total AUC in the lactone form. The slight decrease in lactone exposure (or 
increased carboxylate exposure) in the later group is consistent with the effect of rifampin 
in decreasing carboxylate clearance.  
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Table 4-1. Pharmacokinetic parameter estimates in rats gavaged with either the control vehicle or GF120918 prior to 
intravenous AR-67 administration. Parameters were estimated by fitting the model presented in Figure 4-1 to the data or from 
areas under the plasma concentration versus time curves (NCA model) as previously described (24). 
*Clearances are in L/hr/kg; half-lives are in minutes; volumes are in L/kg. **Parameter estimates were significantly different 
from the respective values obtained under control pretreatment conditions
 Control GF120918 Rifampin
 
PK Parameter* 
Estimate (95% CI) Estimate (95% CI) Estimate (95% CI)
ADAPT
model
NCA model ADAPT 
model
NCA 
model
ADAPT 
model
NCA model
Lactone systemic clearance 
(Cl10) 
1.8
(1.4-2.1)
1.7 
(1.3-2.1)
0.7**
(0.4-1.1)
1.1  
(0.8-1.5)
1.0**
(0.8-1.2)
0.8
(0.5-1.1)
Carboxylate systemic 
clearance (Cl20) 
6.3
(4.9-7.6)
4.9 
(4.0-5.8)
6.1 
(4.8-7.4)
3.5  
(2.8-4.3)
2.6**
(2.0-3.2)
2.7
(2.2-3.2)
Lactone to carboxylate 
conversion clearance (Cl12) 
1.4
(1.0-1.8)
1.1
(0.8-1.2)
2.2
(1.6-2.9)
1.4 
 (1.2-1.6)
1.0
(0.7-1.3)
0.9
(0.7-1.1)
Carboxylate to lactone 
conversion clearance (Cl21) 
0.9
(0.6-1.2)
1.3
(0.8-1.9)
3.6**
(2.4-4.7)
3.5 
 (2.8-4.3)
0.6 
(0.1-1.4)
0.5
(0.4-0.7)
Lactone distributional 
clearance (CLD-L) 
5.2 
(4.5-5.9) -- 
4.7
(1.2-8.2) -- 
0.8 
(0.1-1.7)
--
Carboxylate distributional 
clearance (CLD-C) 
2.4
(1.4-3.5) -- 
3.2 
(1.7-4.7) -- 
1.9 
(0.4-4.0)
--
Lactone central volume 
(V1) 
1.4 
(1.2-1.5) -- 
1.6 
(1.0-2.2) -- 
1.4 
(1.1-1.7)
--
Carboxylate central volume 
(V2) 
0.5 
(0.2-0.8) -- 
1.4 
(0.8-1.9) -- 
0.20 
(0.1-0.3)
--
Apparent lactone 
elimination half life (t ½ L)  
-- 82.3
(71.7-92.8)
-- 194.0 
(111.3-276.7)
-- 100.3
(66.7-133.9)
Apparent carboxylate  
elimination  half-life (t ½ C) 
-- 109.3 
(50.6-167.9) 
-- 223.7 
(182.5-264.9) 
-- 223.8
(113.3-
334.2)
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Figure 4-3. AR-67 exists primarily in the lactone form in the plasma of rats following lactone 
administration. The lactone to carboxylate concentration ratios were calculated based on the 
model fits to the experimental pharmacokinetic data following AR-67 lactone (A) or AR-67 
carboxylate (B) administration alone or following the administration of GF120918 or rifampin. 
The area under plasma concentration versus time (AUC0-24hr) for the lactone and carboxylate 
forms observed following administration AR-67 lactone (C) and AR-67 carboxylate 
intravenously (D). 
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In experiments where the carboxylate was administered, 22% of the total AUC 
was contributed by the lactone and again, pretreatment with GF120918 or rifampin 
significantly increased exposure to both forms (Figure 4-3D). Animals receiving 
GF120918 and rifampin pretreatment had 55% and 22%, respectively, of the total AUC 
in the lactone form.  
4-3.2. Simulations assessing the effect of clearance changes on AR-67 
exposure 
The pharmacokinetic model fitted to the data obtained from the separate lactone 
and carboxylate administration suggests that the relative increases in the lactone and 
carboxylate concentrations in the GF120918 pretreated groups are consistent only with 
inhibition of the lactone clearance. In contrast, the model estimated that the observed 
increases in plasma concentrations of both lactone and carboxylate in the rifampin 
pretreated groups were due to the inhibition of both the lactone and carboxylate 
clearance. To better understand these results, we simulated the effects of decreasing 
lactone (Figure 4-4A, Figure 4-4B) or carboxylate (Figure 4-4C, Figure 4-4D) clearance 
on their respective AUC following lactone administration. The estimated AUCs are 
presented for clearance values ranging from 1-100% of the experimentally estimated 
clearance values. Thus, the axis was normalized between 0.01 and 1. The estimated AUC 
values are presented as the absolute estimates (Figure 4-4A, Figure 4-4C) or normalized 
to the AUC estimates obtained when there was no clearance inhibition (Figure 4-4B, 
Figure 4-4D). Simulations predicted that selective decrease in the lactone clearance 
would result in the increase of both the lactone and carboxylate AUC. The absolute 
magnitude of the increased exposure (Figure 4-4A) would be greater for the lactone, but 
the relative increase (Figure 4-4B) would be the same for either form. The selective 
decrease in the carboxylate clearance demonstrated that the magnitude of the AUC would 
increase for either form but the clearance has to decrease by more than 90% in order for 
the carboxylate AUC to be higher than the lactone one (Figure 4-4C). The relative 
increase, however, is more pronounced for the carboxylate resulting in a more rapid 
increase in carboxylate exposure with decreased carboxylate clearance (Figure 4-4D). 
Further analysis demonstrated that a decrease in the lactone or carboxylate clearance by 
58 
 
about 90% would yield similar increases in the overall exposure to AR-67 (Figure 4-5A). 
However, inhibition of the carboxylate clearance would also result in a significantly 
higher increase in carboxylate exposure (Figure 4-5B).  
 
Figure 4-4. Simulations depicting the effect of lactone (A, B) or carboxylate (C, D) 
clearance inhibition following the intravenous bolus administration of AR-67 lactone.  
 
Figure 4-5. Simulation results depicting the effect of lactone (Cl10) or carboxylate 
clearance (Cl20) inhibition on total AR-67 AUC (A) and on the % carboxylate plasma 
AUC (B) following intravenous bolus administration of AR-67 lactone. 
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4-4. Discussion 
In the current study we estimated the systemic and interconversion clearances of 
AR-67 by separately administering the lactone and carboxylate forms. According to our 
results, the predominant clearance term in AR-67 disposition was the systemic clearance 
of the carboxylate, which was more than threefold higher than the clearance of the 
lactone. Through transporter inhibition studies and simulations, we showed that 
decreased clearances of the lactone and carboxylate both led to elevated lactone and 
carboxylate plasma concentrations. Inhibition of carboxylate clearance led to a relatively 
enhanced carboxylate exposure.  
The results of the compartmental modeling were corroborated by non-
compartmental analyses (NCA) previously presented by Cheng and Jusko for metabolites 
undergoing interconversion (161). The NCA analyses estimated the systemic and 
interconversion clearances based on areas under the time-concentration curves, which 
were obtained by the trapezoidal rule method. Some differences were noted in the 
parameter estimates obtained by the two different analyses. In all cases but one, there was 
an overlap in the 95% confidence intervals around the parameter estimates (Table 4-1). 
In the case of the carboxylate clearance the means and 95% confidence intervals were 
different, but the relationship between the lactone and carboxylate clearances were 
similar for both methods (i.e., the carboxylate clearance was higher). Thus the parameter 
estimates from both methods lead us to the same conclusions. An advantage of the NCA 
analysis is its simplicity as it only requires the estimation of areas under the curve in the 
sampling compartment for parameter estimation (161). No assumption is required as to 
how many compartments are needed to fit the data. Furthermore, the NCA analysis can 
provide good initial parameter estimates for a more robust compartmental model analysis 
required to perform modeling and simulation of concentration-time profiles.  
The pronounced difference in the systemic clearances of the lactone and the 
carboxylate suggest that the two moieties are eliminated via different pathways. 
Following lactone administration, the predominant form of AR-67 is the lactone as 
shown by a greater than 80% lactone AUC. This is most likely due to the lower systemic 
and interconversion clearance of the lactone compared to the systemic clearance of the 
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carboxylate. The carboxylate that is converted from the lactone is likely to be eliminated 
before it gets converted back to the lactone. Moreover, the effect of higher carboxylate 
clearance is more evident following the carboxylate dosing; the carboxylate rapidly 
declines from the plasma. In contrast, the pharmacokinetics of camptothecin and the 
camptothecin analog, topotecan, seem to be driven by the systemic clearance of the 
lactone and the lactone to carboxylate conversion clearance (24, 27). For camptothecin, 
the systemic clearance of the lactone was 5 fold higher than that of the carboxylate while 
lactone to carboxylate conversion clearance was three fold higher than the reverse 
process. Although the magnitudes of the various clearance parameters were different, a 
similar finding was also observed in the pharmacokinetics of topotecan. The systemic 
clearance of topotecan lactone was more than fourfold higher than the systemic clearance 
of the carboxylate and the conversion of the lactone to carboxylate was about threefold 
higher than the reverse process. Thus, rapid lactone clearance coupled with rapid lactone 
to carboxylate conversion and slow carboxylate elimination likely explains the fact that 
the predominant form of camptothecin and that of topotecan is the carboxylate. In 
addition to physiological pH, the strong binding of the carboxylate form to plasma 
proteins facilitates the hydrolysis of camptothecin and first generation analogs. (7) (163). 
In contrast, hydrolysis of AR-67 in blood in vitro occurred at a slower rate than SN-38 
and camptothecin (11). In addition, the AR-67 lactone fraction at equilibrium was 
approximately 30% in whole blood as compared to 19.5% and 5% for SN-38 and 
camptothecin, respectively (11). Thus, it was hypothesized that the relatively higher AR-
67 percent lactone in blood in vitro was a function of increased membrane partitioning in 
red blood cell membranes and decreased affinity of the carboxylate form for human 
serum albumin (11). The results in this chapter demonstrate that an additional 
mechanism, the relatively higher carboxylate clearance, contributes to the apparent in-
vivo stability of AR-67 lactone. 
The use of efflux and uptake transporter inhibitors allowed us to examine the 
effect of selective clearance changes on plasma concentration and overall exposure to 
AR-67. In the current study, the dual P-gp and BCRP/bcrp inhibitor GF120918 
significantly decreased systemic clearance of the lactone, but not that of the carboxylate 
and led to elevated lactone and carboxylate concentrations. The effect of GF120918 on 
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lactone plasma concentration was quite pronounced following carboxylate 
administration, where lactone AUC increased 3.7 fold compared to that in control 
pretreated animals. The results indicate that lactone clearance depends on efflux by P-gp 
and Bcrp, consistent with our in vitro studies, which showed that the lactone is a substrate 
of P-gp and BCRP (156). GF120918 is widely used to assess the effect of P-gp and 
BCRP/Bcrp on drug disposition in vitro and in vivo. In both preclinical and clinical 
studies, pretreatment with GF120918 significantly increased the oral bioavailability of 
topotecan as a result of efflux inhibition leading to decreased clearance and increased 
gastrointestinal absorption (102, 133, 164) . In mice, pretreatment with GF120918 
decreased plasma clearance and hepatobiliary excretion and increased fetal penetration 
and intestinal absorption of topotecan (102, 133, 164). Similarly, in clinical studies co-
administration of GF120918 increased the apparent oral bioavailability of topotecan from 
40% to 97% (133). In addition to inhibition of ABC transporters, P-gp and BCRP/Bcrp, 
GF1290918 was shown to inhibit the uptake of OATP substrates in vitro (165). The 
clearance of AR-67 carboxylate, which is a substrate of OATPs, did not significantly 
differ between control and GF120918 pretreatments. Nonetheless, it is possible that 
GF120918 could inhibit the OATP/Oatp-mediated hepatic uptake and subsequent biliary 
efflux of substrate drugs in vivo.      
Our studies suggest that the increased AR-67 lactone and carboxylate exposure 
observed with rifampin pretreatment was related to a decrease in the clearance of both the 
lactone and the carboxylate. Thus, the inhibition of carboxylate clearance by rifampin is 
most likely due to inhibition of the hepatic uptake of the hydrophilic carboxylate, while 
inhibition of lactone clearance could have happened as a result of ABC transporter 
inhibition. There is literature evidence to support the effect of rifampin on both 
OATPs/Oatps and P-gp. Rifampin inhibited OATP1B1-mediated transcellular transport 
and intracellular accumulation of substrate drugs resulting in a 60% reduction in the 
intracellular accumulation of 17β-estradiol-17-(β-D-glucuronide) (E2G) and a significant 
reduction in the OATP1B1 mediated basolateral to apical transport of E2G, gimatecan 
and BNP1350 (52). In rats it was shown that rifampin pretreatment increased atorvastatin 
plasma concentration as a result of decreased Oatp-mediated hepatic uptake and 
metabolism by the liver. Decreased hepatic uptake in the presence of a single dose of 
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rifampin also led to decreased first-pass effect by the liver and therefore, increased oral 
bioavailability of atorvastatin from 5% to 14% (166). On the other hand, inhibition of P-
gp by a single dose of rifampin was shown to lead to increased penetration of verapamil 
across the mouse blood-brain barrier (BBB) (167). This is consistent with previously 
discussed in-vitro results (Chapter 3), which demonstrated the carboxylate to be a 
substrate for uptake transporters OATP1B1 and OATP1B3, while the lactone form was 
transported by BCRP and to lesser extent by P-gp (156). The effect of rifampin on BCRP 
is currently under investigation. 
Changes in clearance are likely to occur in clinical practice and may have 
implications in the clinical use and toxicity of camptothecin analogues. These changes 
could arise from pharmacogenetic differences in transporters between individuals and 
have been reported to lead to pharmacokinetic differences. In one study, plasma 
concentration of diflomotecan in 5 patients heterozygous for the ABCG2 421C>A allele, 
was 2.9 fold higher than that of 15 patients with wild-type alleles (168). Similarly an 
association was shown between high plasma pravastatin concentration and single 
nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 
(OATP1B1) (169). Lau et al have shown the major role organic anion uptake transporters 
play for the clearance of atorvastatin and its active metabolites by the hepatobiliary 
system and concluded that inhibition of hepatic uptake may have consequences on 
efficacy and toxicity of drugs mainly eliminated by the hepatobiliary system (116, 166).  
In conclusion, lactone to carboxylate ratio of AR-67 is much higher in vivo than 
in vitro. This discrepancy can be explained by the fact that the in vivo system is not 
closed. The interconversion and the irreversible elimination of both lactone and 
carboxylate affect the plasma concentration of the lactone and carboxylate at any given 
moment. In addition, the carboxylate concentration is formation rate limited and the 
carboxylate moiety is eliminated as fast as it is formed. Because the lactone systemic 
clearance and the carboxylate to lactone conversion clearance is slower than the 
carboxylate systemic clearance, the lactone prevails. In summary, we studied the 
pharmacokinetics of the lactone and carboxylate forms of AR-67 and assessed through 
clearance inhibition studies and simulations the effect of clearance changes on plasma 
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concentrations and AUCs of AR-67. Our findings demonstrate that the carboxylate 
clearance is the predominant factor affecting the disposition of AR-67 and that lactone 
and carboxylate clearances are dependent on efflux and uptake processes respectively.  
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                                                   CHAPTER 5 
ORAL BIOAVAILABILITY STUDIES OF THE LACTONE AND 
CARBOXYLATE FORMS OF AR-67 
5-1. Introduction 
AR-67 is a third generation camptothecin analogue with potent antitumor activity 
and enhanced lactone stability (18) that is currently undergoing early phase clinical trials 
in patients with solid tumors (150). Camptothecins are a class of anticancer molecules 
that elicit their effect through interactions with topoisomerase I. This nuclear enzyme is 
typically expressed in all cells and performs its function during cell replication. As a 
direct consequence of this requisite interaction with topoisomerase I during cell 
replication, it has become apparent that camptothecin dosing schedules should be 
protracted. This ensures that drug exposure is achieved and potential for antitumor 
activity increased when different fractions of the tumor cell population enter the 
replication stage of their cell-cycle. Currently, there are only two camptothecin 
analogues, topotecan (Hycamtin®) and irinotecan (Camptosar®), available on the market 
while several others, including AR-67, are in various stages of drug development (21, 
150, 170). In both rodents and humans, low dose protracted treatment by the intravenous 
route with topotecan or irinotecan was shown to be better tolerated and to be more 
efficacious than shorter and more intense therapies (171-173).  
Although the intravenous route is the typical administration modality, an oral 
formulation may be more desirable for protracted dosing regimens. In addition, an oral 
formulation could reduce treatment cost while allowing for greater dosing flexibility 
(174). Oral topotecan has been shown to be as effective as intravenous docetaxel in 
patients with unresectable non-small-cell lung cancer (NSCLC) (175) and ovarian 
cancers (176). Similarly, in patients with solid tumors, oral irinotecan was well tolerated 
and was advantageous in terms of enhanced exposure to the active agent, SN-38, due to 
carboxylesterase-mediated presystemic conversion from irinotecan (177-179).  
A common feature of all camptothecins is the pH dependent reversible hydrolysis 
of the lipophilic lactone to the hydrophilic carboxylate (18, 180). Following oral 
administration, the relative concentration of the lactone and carboxylate in the 
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gastrointestinal tract is likely to be influenced by the local pH. Gastrointestinal regions 
with acidic pH are expected to maintain the lactone whereas those with physiological or 
alkaline pH should promote carboxylate formation. Since dissolution in the 
gastrointestinal tract influences absorption of orally administered drugs, differences in the 
aqueous solubility of the lactone and the carboxylate may in turn give rise to differences 
in oral bioavailability. Overall, the poor aqueous solubility of the AR-67 lactone (0.11 
µg/mL) (181) is expected to limit its oral bioavailability but improvement of AR-67 
lactone solubility, through the use of excipients, could potentially overcome this 
limitation. A sulfobutylether-β-cyclodextrin based formulation of AR-67 has previously 
been developed and sustains a supersaturated lactone solution (1-2 mg/mL) (181) and 
allows the oral and intravenous administration of AR-67. On the other hand, the 
carboxylate form may provide enhanced bioavailability due to its higher aqueous 
solubility and may therefore serve as an alternative formulation to the lactone, provided 
that it yields adequate bioavailability in the systemic circulation. 
In addition to dissolution, efflux by ABC transporter proteins, such as P-gp and/or 
BCRP/Bcrp, located on the luminal side of gastrointestinal tract is known to limit oral 
bioavailability of camptothecins (102, 182). Published data on camptothecins (102, 124) 
and  previous in vitro studies in this laboratory  indicated that AR-67 is a substrate of P-
gp and BCRP (183). This interaction is likely to affect the oral bioavailability of AR-67. 
Therefore, the objectives of the current study were 1) to estimate the oral bioavailability 
of AR-67 lactone and carboxylate and 2) to test the hypothesis that the efflux 
transporters, P-gp and Bcrp, limit the oral bioavailability of AR-67 by using 
pharmacological efflux transport inhibitors. 
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5-2. Methods 
5-2.1. Chemicals 
Ammonium acetate (Mallinckrodt Baker, Phillipsburg, NJ), HPLC grade acetonitrile and 
methanol (Burdick and Jackson, Muskegon, MI) were purchased from VWR (West 
Chester, PA). Alamethicin, uridine 5’-diphosphoglucuronic acid (UDPGA), NADP+, 
glucose-6-phosphate, glucose-6-phosphate dehydrogenase were from BD Biosciences 
(Woburn, MA). Siliconized pipette tips were from Cole-Parmer (Vernon Hills, IL). 
Amber microcentrifuge tubes were from Crystalgen Inc. (Plainview, NY). Transparent 
siliconized microcentrifuge tubes, dimethylsulfoxide (≥ 99.7 % DMSO) and glacial acetic 
acid were from Fisher Scientific (Fair Lawn, NJ). Magnesium- and calcium-free 
Dulbecco’s phosphate buffered saline (PBS) was from Gibco Invitrogen (Carlsbad, CA). 
5% Dextrose in water (D5W) was from Baxter Healthcare Corporation (Deerfiled, IL). 
Tween-80 and PEG-300 were from Sigma-Aldrich (St. Louis, MO). Sulfobutylether-β-
cyclodextrin (SBE-β-CD, Captisol®) was from CyDex, Inc. (Overland Park, KS). AR-67 
was provided from Novartis (East Hanover, NJ). AR-67 lactone or carboxylate solutions 
(1-2 mg/mL) were prepared in SBE-β-CD either by reconstituting a lyophilized SBE-β-
CD based formulation of AR-67 lactone (181) or carboxylate or from AR-67 powder. 
GF120918 (Elacridar) was a gift from GlaxoSmithKline (Research Triangle Park, NC) 
and was solubilized in 10% Tween-80 and 40% PEG-300 in distilled water (184). 
Zosuquidar was synthesized at the University of Kentucky following published 
procedures (185) and was dissolved with slight modification of the published procedure 
in an aqueous solution of 20% SBE-β-CD (186).  
5-2.2. Pharmacokinetic studies 
Female Harlan Sprague-Dawley rats weighing between 220-300 g were used for 
these studies (n=3-6). To assess the dose dependence of oral bioavailability, animals 
received 2.5, 5, 10, 15 or 20 mg/kg of either AR-67 lactone or carboxylate by oral 
gavage. For estimation of absolute bioavailability, separate groups of animals (n=3-6) 
were also treated with 2.5 mg/kg doses of either the lactone or carboxylate intravenously. 
For all the studies the SBE-β-CD formulation of AR-67 was used (181). To determine the 
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effect of P-gp inhibition on oral bioavailability, rats were orally pretreated with 
zosuquidar (20 mg/kg, 7.5 mL/kg (dosing volume)) 5 minutes before the oral or IV 
administration of AR-67 lactone (2.5 mg/kg, 2.5 mL/kg). To measure the effect of dual 
inhibition of P-gp and Bcrp on oral bioavailability, GF120918 (0.25, 1, 2.5 or 20 mg/kg , 
7.5 mL/kg dosing volume)  prepared as described in the methods section were separately 
administered by oral gavage 5 minutes before the oral administration of AR-67 lactone or 
carboxylate (2.5 mg/kg, 2.5 mL/kg). Different doses of GF120918 were used to select a 
dose of GF120918 that provides maximal efflux inhibition. This dose of GF120918 was 
then used to measure its effect on systemic clearance following intravenous 
administration of either AR-67 lactone or carboxylate. In order to assess contribution of 
possible factors affecting oral bioavailability of AR-67, we estimated the hepatic 
extraction ratio (EH) and the theoretical maximum oral bioavailability (F) as shown 
below. 
                                                  Equation 5.1 (187)  
                                                     Equation 5.2 (187) 
Cliv is the plasma clearance of AR-67 lactone , which is 1800 ml/hr/kg (188). QH is 
hepatic blood flow, which is 13.8 ml/min for a 250 g rat (189). CB/CP is the blood to 
plasma concentration ratio of AR-67. 
Following AR-67 administration, blood (100 µL) was collected from the 
saphenous vein at 5-15 min, 30 min and at 1, 2, 4, 6, 8 and 12 hr with heparinized 
hematocrit tubes and transferred into heparinized microcentrifuge tubes. Plasma was 
separated by centrifugation of blood at 8,500 g and extracted 1:4 (v:v) with cold (-80°C) 
methanol (145). Samples were stored at -80°C until analysis by HPLC. 
A separate group of animals (n≤3) receiving an oral dose of 2.5 mg/kg AR-67 
lactone were euthanized at designated time points to examine the presence of metabolites 
and unabsorbed drug in the gastrointestinal tract. Different segments of the 
gastrointestinal tract were excised after ligations were made with sutures between the 
lower esophageal and pyloric sphincters (for the stomach), at 20 cm length from the 
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stomach (for the duodenum) and at 20 cm length proximal to the ileocecal junction (for 
the ileum). The region between the duodenum and the ileum was cut in half and was 
designated as the proximal and distal jejunum. The region beyond the ileo-cecal junction 
was designated the colon. The stomach and intestinal contents were gently squeezed out 
and washed off with 10-20 mL of 20% human plasma in water and transferred into 50 
mL screw cap conical tubes. The mixture was vortexed for 30 seconds and centrifuged 
for 10 minutes at 1200 rpm. The supernatant was extracted 1:4 (v:v) with -80°C 
methanol. Samples were kept at -80°C until HPLC analysis.  
5-2.3. AR-67 liver and intestinal metabolism 
 Microsome preparation 
Intestinal and liver microsomes from non-fasting Sprague Dawley rats were 
prepared as described in the literature with minor modifications (190). Briefly, rats were 
euthanized with CO2 and their left ventricle was perfused with 30 mL ice-cold saline. The 
duodenum, jejunum, ileum and the liver were excised. The intestinal segments were cut 
open longitudinally and washed with ice cold 1.15% KCl with gentle swirling. The 
mucosal layer was then gently scraped off with glass cover-slips. The liver was cut into 
small pieces and washed similarly to the intestinal segments. The samples obtained were 
immediately homogenized in 3 volumes of ice-cold homogenization buffer (50 mM Tris-
HCl, 150 mM KCl, 1 mM EDTA, 20% (v/v) glycerol, trypsin and protease inhibitors) 
with a motor-driven Teflon pestle. The homogenate was centrifuged at 9,000 g for 20 
minutes at 4°C. The supernatant was then centrifuged at 105,000 g for 60 min in 
Beckman L-90 K ultracentrifuge at 4°C. The supernatant was discarded and the pellet 
(microsome) was suspended in 3 mL of homogenization buffer. Protein contents of the 
samples were measured using modified Lowry protein assay kit according to the 
manufacturer’s instructions (Pierce, Rockford, IL).   
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Microsomal incubation  
Glucuronidation: Rat liver microsomes (RLM) and rat intestinal microsomes 
(RIM) reaction mixtures consisted of MgCl2 (8 mM), alamethicin (63.6 μM), microsomal 
protein (1 mg/mL), and AR-67 (1 μM lactone) in 0.5 M Tris-HCl buffer (pH 7.5) 
containing 5 % DMSO. Incubation mixtures were prepared on ice, pre-incubated at 37°C 
for 2 min, and reactions were initiated by the addition of uridine 5’-diphosphoglucuronic 
acid (UDPGA, final concentration 2 mM).  
Oxidation: Oxidative reaction incubations contained MgCl2 (3.3 mM), NADP+ 
(1.3 mM), glucose-6-phosphate (3.3 mM), AR-67 (1 μM lactone) and microsomal protein 
(1 mg/mL) in 100 mM potassium phosphate buffer (pH 7.4). Mixtures were prepared on 
ice, pre-incubated at 37°C for 2 min, and reactions were initiated by the addition of 
glucose-6-phosphate dehydrogenase (final concentration 0.4 U/mL).  
Reaction quenching and workup: RLM and RIM reactions were stopped at 0 and 
60 min with methanol as outlined above for sample workup. Methanolic supernatants 
were analyzed by gradient HPLC methods as described below. 
5-2.4. HPLC analyses 
Lactone and carboxylate plasma concentrations were simultaneously quantified 
by HPLC using fluorescence detection at excitation wavelength of 380 nm and emission 
wavelength of 560 nm based on a previously published method for analysis of AR-67 in 
mouse plasma (145). A partial assay validation using rat plasma as the matrix was carried 
out. The assay was linear in the range of 2.5-250 ng/mL for the carboxylate and 5-300 
ng/mL for the lactone. Accuracy for both analytes was within 15% of expected values at 
the low end of the calibration curve (7 ng/mL) and within 10% of expected values at 
middle (150 ng/mL) and high (250 ng/mL) concentrations. Assay precision (% relative 
standard deviation) was <6% across the calibration range. Both analytes were stable at 
4°C for 6 hr in the methanol extract when mixed with mobile phase buffer. This ensured 
stability during automated HPLC analyses. Extracted samples were stable at -80°C for 14 
days. The lower limit of quantitation was 2.5 ng/mL for carboxylate and 5.0 ng/mL for 
lactone. Sample analysis was completed within 14 days after collection. 
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A separate HPLC assay method using a mobile phase gradient was used for 
separation of AR-67 metabolites. Given the qualitatative purposes of the metabolite 
analyses and the lack of metabolite reference standards, a formal validation protocol was 
not performed. The mobile phase flow rate was 1 mL/min and was comprised by varying 
ratios of Solvent A (0.15 M ammonium acetate buffer containing 10 mM TBAP adjusted 
to pH 6.5) and Solvent B (acetonitrile). The initial A:B solvent ratio was set at 83:17 and 
was linearly ramped to 71:29 over the first 10 min. A 10 min linear ramp to 65:35 A:B 
immediately followed, dropping in a linear fashion to 60:40 A:B over the next 2 min. The 
ratio was increased to the initial 83:17 solvent ratio over 1 min, then held constant for 5 
min. 
5-2.5. Pharmacokinetic and statistical analysis 
Non-compartmental pharmacokinetic analyses of the lactone and carboxylate 
plasma data were done with WinNonlin v5.2 (Pharsight, Mountain View, CA). A 
compartmental model previously developed for the intravenous administration of AR-67 
lactone and carboxylate (143) served as the basis for the compartmental model used to 
estimate pharmacokinetic parameters following oral administration of each AR-67 form. 
Linear regression of dose-normalized AUC values was performed with GraphPad Prism 
V5.02 for Windows (GraphPad Software, San Diego, California).  Compartmental 
pharmacokinetic modeling was also performed using algorithms implemented in ADAPT 
5. Parameter estimates were obtained by simultaneously fitting the lactone and 
carboxylate plasma concentrations resulting from the oral and intravenous administration 
of AR-67. The lactone and carboxylate forms were administered separately by each route. 
Population pharmacokinetic modeling was performed using the Iterated Two Stage (ITS) 
algorithm implemented in ADAPT 5 assuming log-normal parameter distribution (191). 
The model building was performed at several stages with increasing levels of complexity. 
A reduction of the negative log-likelihood by 3.84 (p = 0.05, χ2 distribution, one degree 
of freedom) was used to discriminate between models. Statistical analyses on areas under 
the plasma concentration versus time curve (AUC) were compared with ANOVA 
followed by Bonferroni two-tailed post-hoc t-test using GraphPad Prism V5.02 for 
Windows. A p-value of less than 0.05 was considered significant.  
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5-3. Results 
Non-compartmental analyses 
Female Sprague Dawley rats were dosed orally with AR-67 lactone or AR-67 
carboxylate formulated in SBE-β-CD. Plasma samples were analyzed for AR-67 lactone 
and carboxylate. In order to assess if there were a dose-dependent increase in oral 
bioavailability due to saturation of efflux transporters and/or metabolizing enzymes, 
increasing doses of the lactone or carboxylate were administered. Pharmacokinetic 
parameters were assessed following administration of 2.5, 5, 10, 15, and 20 mg/kg doses 
to groups of 3-6 animals. Multiple plasma samples were collected from each animal over 
12 hours. Plasma AR-67 concentrations were primarily in the lactone form, irrespective 
of the AR-67 form being administered, and lactone AUC ranged between 80 and 95% of 
the total AUC (i.e., lactone + carboxylate). Maximum plasma concentration (Cmax) was 
achieved within 30 minutes at most dosage levels. Time to reach maximum concentration 
in the plasma (Tmax) did not differ between the lactone and carboxylate dosing. The 
results of oral bioavailability studies at different dose levels analyzed by non-
compartmental methods are summarized in Table 5-1. The plasma concentrations and 
AUCs of the predominant lactone form were dose normalized and are presented in Figure 
5-1. For clarity the minor carboxylate AUC is not shown but it follows a similar pattern 
as the lactone. A trend towards an increase in dose normalized AUC with an increase in 
dose was observed following lactone administration and suggests some degree of 
saturation of efflux transporters and/or metabolizing enzymes at the high dose levels 
(Figure 5-1A-B). On the other hand, oral carboxylate administration did not show such a 
trend (Figure 5-1C-D). Linear regression of the dosed normalized AUC values obtained 
following the administration of multiple lactone dosage levels (Figure 5-1B) 
demonstrates that the slope of the fitted line deviated significantly from zero (p=0.0001). 
In contrast, the dose normalized lactone AUCs obtained following increasing doses of 
carboxylate (Figure 5-1D) were variable and no significant deviation from zero could be 
ascertained.
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Table 5-1. Pharmacokinetic parameters obtained from noncompartmental analysis of plasma data in animals that received oral 
doses of the lactone or carboxylate. 
 
Compound  
administered 
 
Dose, mg/kg 
 
Tmax, min# 
 
Cmax, ng/mL# 
(SD) 
AUC0-inf, ng*hr/mL (SD) 
 
 
 
% Lactone  
AUC 
Lactone Carboxylate 
 
 
 
Lactone 
2.5 30-60 19.3 (11.3) 61.8 (22.3) 3.2 (2.5) 95.5 (2.5)  
5 30 79.0 (32.0) 145.4 (32.1) 34.8 (7.8) 81.7 (1.1) 
10 30 120.9 (12.1) 370.2 (40.2) 71.5 (15.5) 81.1 (2.9) 
15 30 263.8 (53.5) 680.8 (129.2) 216.6 (32.7) 82.3 (14.6) 
20 30-120 272.0 (24.4) 966.8 (259.1) 232.2 (38.1) 80.4 (1.4) 
 
 
 
Carboxylate 
2.5 30 25.2 (9.3) 72.7 (21.3) 13.4 (7.7) 88.1 (6.2)  
5 30-60 58.6 (25.4) 152.9 (30.1) 34.6 (15.2) 86.0 (3.4) 
10 30 116.3 (20.2) 279.5 (35.5) 60.8 (6.3) 82.2 (2.9) 
15 30 380.99 (184.5) 956.7 (248.8) 233.8 (69.1) 80.0 (1.1) 
20 60 121.6 (83.4) 752.5(490.8) 67.1 (47.9) 91.5 (4.5)  
#denotes value obtained for the predominant lactone form. 
SD, standard deviation (n=3) 
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Figure 5-1. Assessment of dose-dependent increase in plasma concentration or AUC 
following oral administration of increasing doses of AR-67 lactone or carboxylate. Panels 
A & B represent plasma concentrations and AUCs normalized by dose of lactone while C 
& D represent similar data for the carboxylate dose. P-values indicate the significance of 
the slope’s deviation from zero as obtained by linear regression (n=3). 
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Compartmental analyses 
The positive slope of the line fitting the dose normalized AUCs obtained from 
increasing lactone AR-67 dosages suggested that increasing drug concentrations in the 
gastrointestinal tract saturate one or more of the processes that limit oral bioavailability. 
Thus, we sought to develop a pharmacokinetic model that would allow us to examine the 
effect of dose on oral bioavailability and clearance. The pharmacokinetic model would 
also allow the use of covariate models on the parameter estimates and a more robust 
statistical analysis when comparing the pharmacokinetic parameters obtained following 
pharmacologic inhibition of efflux transporters. First order absorption models were 
initially constructed to simultaneously model oral and intravenous data but did not 
adequately fit the data. Moreover, when the oral carboxylate dose input was into the 
carboxylate central compartment, the model fits were not satisfactory. Visual inspection 
of the lactone and carboxylate plasma concentrations over time suggested that AR-67 was 
mainly in the lactone form, irrespective of which form was orally administered. 
Therefore, based on this observation, a simplifying assumption was made to allow all oral 
inputs to be applied into the central lactone compartment (Figure 5-2). First order 
absorption models did not provide adequate fits. Therefore, a flexible input function was 
used instead to accommodate the apparently complex absorption processes. The data 
were modeled by incorporating an inverse Gaussian input (192, 193) into a four 
compartment disposition model which was previously used to model intravenously 
administered AR-67 lactone and carboxylate (143). Following extravascular 
administration, the model allows the estimation of absorption kinetic parameters for 
drugs with complex absorption behavior by decomposing the plasma concentration-time 
curve into input (absorption) and output (disposition) processes (192, 193). The inverse 
Gaussian input function IG(t) is described by: 
]
**2
)(exp[
*2
**)( 2
2
32 tMITCVI
MITt
tCVI
MITFDosetIG   , 
where F is oral bioavailability, MIT is the mean input time and CVI2 is the variance or 
the relative dispersion of absorption times. Population data modeling was performed 
using the Iterated Two Stage (ITS) algorithm implemented in ADAPT 5 assuming a log-
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normal parameter distribution (191). To estimate oral bioavailability of AR-67 at 
different dose levels, data from oral and intravenous inputs were simultaneously modeled 
using dose level and form administered orally, i.e. lactone or carboxylate, as covariates 
on F, MIT and CVI2. To model the effect of efflux transporter inhibition with GF120918 
on oral bioavailability and clearance, a similar modeling approach as above was 
followed. Oral and intravenous AR-67 data obtained from animals that were pretreated 
with either the control vehicle or the efflux inhibitor GF120918 were modeled using the 
presence of GF120918 and the form of AR-67 administered orally as covariates on 
clearance, F, MIT and CVI2. The performance of alternative methods was judged by 
convergence of parameters, reduction in the negative log-likelihood, improvement in the 
error estimates of parameters and diagnostic plots. A reduction of the negative log-
likelihood by 3.84 (p = 0.05, χ2 distribution, one degree of freedom) was used as a 
criterion to include a covariate in the model. 
Oral data at different dose levels (from this study) and intravenous data (from this 
and our previous study (143) were simultaneously analyzed using the Iterated Two Stage 
population algorithm in ADAPT 5 (191). This algorithm allows modeling of sparse and 
noisy population data (191) and was found appropriate for modeling our oral and 
intravenous data. 
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Figure 5-2. Schematic representation of the inverse Gaussian oral input of AR-67 linked 
to a four compartment disposition model with elimination occurring from the central 
lactone and carboxylate compartments. 
 We tested several models using dose level and AR-67 form administered, i.e., 
lactone or carboxylate, as covariates. The plasma concentrations of AR-67 lactone and 
carboxylate with all oral doses of AR-67 were much less than the concentrations from the 
intravenous dose of AR-67 lactone (2.5mg/kg) and carboxylate (2.5mg/kg) and are not 
likely to lead to saturation of clearance processes. Therefore, the clearances of AR-67 
lactone and carboxylate were assumed to be the same for all oral doses of AR-67. Of the 
models tested, the model that allowed F, MIT and CVI2 to be estimated uniquely at each 
dose level of lactone or carboxylate performed best based on convergence of iterations 
(finding of global minimum), decrease in negative log-likelihood and diagnostic plots. 
Plots of experimental and model fitted AR-67 plasma concentration as a function of time 
are shown in Figure 5-3 (lactone dose) and Figure 5-4 (carboxylate dose) while 
diagnostic plots are presented in Figure 5-5. As depicted in the figures, the model 
adequately predicted the observed data. Pharmacokinetic parameters are presented in 
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Table 5-2. Following the oral administration of lactone, bioavailability ranged between 
5.8 and 10.4%. The highest bioavailability obtained was 10.4% at 15 mg/kg dose. The 
mean input time (MIT) ranged between 66.6 and 259.0 minutes while the dimensionless 
shape factor CVI2 ranged between 1.9 and 8.8. Following carboxylate administration 
bioavailability ranged between 5.5 and 16.6%, MIT ranged between 141 and 200 minutes 
and CVI2 ranged between 1.8 and 5.3. The 15 mg/kg carboxylate dose showed the 
highest bioavailability (F=16.6%).  
 Based on literature data on other camptothecin analogs (102, 124) and on oral 
bioavailability estimates of AR-67 of the current study, which increased with increasing 
dose, we speculated that intestinal efflux transporters, (i.e., P-gp and/or Bcrp may limit 
oral bioavailability of AR-67. In order to assess role of these efflux transporters, we used 
the selective P-gp inhibitor zosuquidar (194) and the dual P-gp and Bcrp inhibitor 
GF120918 (109, 195). Intravenous administration of 20 mg/kg zosuquidar was previously 
shown to effectively inhibit the function of P-gp at the blood-brain barrier as manifested 
by increased nelfinavir concentrations in the brain (185). Assuming that the same dose 
would provide much higher local concentrations in the GI and would effectively abolish 
P-gp function, we pretreated rats orally 5 minutes prior to AR-67 dosing. We observed 
that pretreatment with zosuquidar resulted in a statistically significant (p<0.05) threefold 
increase in lactone AUC (61.8±22.3 with 5% dextrose in water vs. 183.7±61.3 ng-hr/mL 
with zosuquidar). In the same animals, the carboxylate AUC increased nine-fold but these 
results were highly variable and given the sample size, this increase was not statistically 
significant (3.2±2.5 without vs. 28.0±13.0 ng-hr/mL with zosuquidar) (Figure 5-6A). 
Zosuquidar slightly increased the lactone AUC of intravenously administered AR-67 (1.2 
fold, p<0.05) indicating that, at the dose administered, it exerted minimal but statistically 
significant effect on systemic clearance of AR-67 (Figure 5-6B).  
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Figure 5-3. Plasma concentration of AR-67 lactone ( ○ ) and carboxylate ( □ ) following 
oral doses of (A) 2.5, (B) 5, (C) 10, (D) 15 and (E) 20 mg/kg AR-67 lactone. The solid 
and dashed lines represent simulated population estimated lactone and carboxylate 
concentrations, respectively, which were generated by simulation using the mean 
population parameter estimates. 
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Figure 5-4. Plasma concentration of AR-67 lactone (○) and carboxylate ( □ ) following 
oral doses of (A) 2.5, (B) 5, (C) 10, (D) 15 and (E) 20 mg/kg AR-67 carboxylate. The 
solid and dashed lines are the fitted lactone and carboxylate concentrations, respectively, 
which were generated by simulation using the mean population parameter estimates. 
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Figure 5-5. Goodness-of-fit and residual plots of the final covariate model. (A) 
Individual predicted versus observed concentrations, (B) population predicated vs. 
observed concentrations, (C) standardized residuals versus population predictions, D) 
standardized residuals vs. time. The solid line is the line of unity. 
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Table 5-2. Pharmacokinetic parameter estimates obtained by compartmental analysis of plasma data using the inverse 
Gaussian input. 
              Parameter  Lactone dose (mg/kg) Carboxylate dose (mg/kg)         
% CV2.5 5 10 15 20 2.5 5 10 15 20 
F %  5.8 9.6 7.9 10.4 9.9 9.5 7.8 8.1 16.6 5.5 20 
MIT (min) 111.0 87.0 259.0 66.6 128.0 100.0 141.0 200.0 174.0 153.0 42.5 
CVI2 4.4 2.4 8.8 1.9 4.2 3.1 3.4 5.3 4.4 1.8 53.4 
ClLact (L/hr/kg) 1.53 54.0 
ClCarb (L/hr/kg) 5.53 10.8 
ClLact→Carb (L/hr/kg) 1.39 12.0 
ClCarb→Lact (L/hr/kg) 0.98 19.4 
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Figure 5-6. The effect of zosuquidar (ZSQ) (20 mg/kg PO) or control (5% dextrose in 
water) pretreatment on lactone AUCs following the oral (A) and intravenous (B) 
administration  of 2.5 mg/kg AR-67 lactone.  
To examine the effect of dual P-gp and Bcrp inhibition, we administered AR-67 
lactone or carboxylate following pretreatment with different oral doses of GF120918 (0, 
0.25, 1, 2.5 or 20 mg/kg). Due to poor aqueous solubility, GF120918 was formulated in 
10% Tween-80 and 40% PEG-300 in distilled water, which allows the oral administration 
of GF120918 (184). The solution of 10% Tween 80 and 40% PEG-300 served as control 
for GF120918. As shown in Figure 5-7A, the 2.5 mg/kg dose of GF120918 yielded the 
highest increase in plasma AUC value. The increase was statistically significant (p<0.05) 
compared to control AUC values but not when compared to 1 mg/kg and 20 mg/kg 
GF120918 pretreatment doses. Pretreatment with 2.5 mg/kg oral dose of GF120918 five 
minutes before the oral administration of AR-67 lactone, resulted in a 5.5 fold increase in 
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lactone AUC (ng*hr/mL) (141.5±57.1 (Mean±SD) with control vs. 779.6±163.3 
(Mean±SD) with GF120918) and about eleven fold increase in carboxylate AUC 
(13.2±5.6 (Mean±SD) with control vs. 142.4 ± 29.6 (Mean±SD) with GF120918). The 
increases in lactone and carboxylate AUCs were statistically significant (p<0.05). 
Similarly, pretreatment with 2.5 mg/kg oral dose of GF120918 five minutes before the 
oral administration of AR-67 carboxylate increased lactone AUC 4.2 fold (108.9±21.9 
(Mean ± SD) with control vs. 457.7±96.1 (Mean±SD) with GF120918) and carboxylate 
AUC 5.2 fold (17.6±10.7 (Mean±SD) with control vs. 92.7±15.6 (Mean±SD). The 
increases in lactone and carboxylate AUCs were statistically significant (p<0.05). As was 
the case in the studies without an inhibitor (Figure 5-3 and Figure 5-4), following 
pretreatment with GF120918, the majority of AR-67 was in the form of the lactone, 
irrespective of which form of AR-67 was administered (percent lactone AUC 83-91%).   
To assess if the increase in lactone and carboxylate AUCs due to pretreatment 
with GF120918 was also related to decrease in clearance, animals were pretreated with 
2.5 mg/kg oral dose of GF120918 prior to the administration of 2.5 mg/kg AR-67 lactone 
or carboxylate intravenously. In agreement with our previous studies (143), GF120918 
significantly increased lactone AUC (1.7 fold, p<0.05) and but not carboxylate AUCs 
(1.4 fold) following intravenous administration of AR-67 lactone (Figure 5-7B). 
Similarly, GF120918 significantly increased lactone AUC (≈3 fold, p<0.05) but not 
carboxylate AUC following intravenous administration of AR-67 carboxylate.   
84 
 
A
B
0 0.25 1 2.5 20
0
200
400
600
800
1000
Lact dose
Carb dose
GF dose (mg/kg)
La
ct
on
e 
AU
C
(0
-in
f)
(n
g*
hr
/m
L)
0 2.5
0
1000
2000
3000
4000
Carb dose
Lact dose
GF dose (mg/kg)
La
ct
on
e 
AU
C
(0
-in
f)
(n
g*
hr
/m
L)
 
Figure 5-7. The effect of pretreatment with GF120918 (GF) or control vehicle on lactone 
AUCs following the oral (A) or intravenous (B) administration of 2.5 mg/kg AR-67. 
Unfilled bars and filled bars indicate lactone and carboxylate, respectively, as the 
administered forms. 
Lactone and carboxylate plasma data from GF120918 inhibition studies were also 
fitted with the models outlined above. Models were constructed by including presence of 
GF120918 as a covariate on clearance, bioavailability, MIT and/or CVI2. Model selection 
was based on convergence of iterations, decrease in negative log-likelihood and 
diagnostic plots.  Incorporating GF120918 as a covariate on bioavailability and lactone 
clearance resulted in better model fits. Experimental data and simulated concentrations 
are shown in Figure 5-8 and pharmacokinetic parameters are presented in Table 5-3. The 
model was able to adequately fit the plasma concentrations of the lactone and 
carboxylate. The modeling results show that pretreatment with the dual P-gp and Bcrp 
85 
 
inhibitor GF120918 led to a threefold increase in bioavailability after taking the decrease 
in clearance into consideration (9.4±4.1% without GF120198 vs. 29.8±13.0% with 
GF120918 for the lactone dose and 9.1±3.9% without GF120198 vs. 27.4±11.9% with 
GF120918 for the carboxylate dose). 
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Figure 5-8. Plasma concentration of AR-67 lactone (A, B) or carboxylate (C, D) in the 
presence or absence of GF120918 (GF). (A) and (C) are the lactone and carboxylate 
concentrations, respectively, following lactone administration while (B) and (D) are the 
lactone and carboxylate concentrations, respectively, following carboxylate 
administration. The solid and dashed lines represent simulated concentrations obtained 
using the point estimates of the population pharmacokinetic parameters in the presence or 
absence of GF120918, respectively. 
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Table 5-3. AR-67 pharmacokinetic parameter estimates in rats orally pretreated with 
vehicle or 2.5 mg/kg GF120918 (GF) before the oral or intravenous administration of 2.5 
mg/kg AR-67 lactone or carboxylate. 
 
#Presence of inhibitor was used as a covariate on these parameters. 
Pretreatment of animals with the vehicle used to solubilize GF129018 (10% 
Tween-80 and 40% PEG-300 in distilled water) resulted in higher plasma AUC compared 
to animals pretreated with D5W (mean lactone AUC (ng*hr/mL) 141.5 with vehicle vs. 
61.8 with D5W) indicating that excipients in the vehicle could also increase oral 
bioavailability. However, this excipient factor was taken into consideration by using the 
vehicle as a control when analyzing the GF120918 results.    
Using equations 5.1 and 5.2, we calculated the hepatic extraction ratio (EH) and 
the theoretical maximum oral bioavailability of AR-67 in order to assess the contribution 
of factors that would limit oral bioavailability. The hepatic extraction ratio (EH) and 
bioavailability (F) were 0.54 and 0.46 respectively. These values are based on the 
minimum value of blood to plasma ratio of AR-67 (CB/CP=1), based on literature data 
that show AR-67 partitions into red blood cells (11). As was presented earlier, efflux 
transporter inhibition increased oral bioavailability to about 30%. Since the theoretical 
minimum bioavailability is 46%, we considered limited gastrointestinal solubility and/or 
metabolism as additional factors that would limit the oral bioavailability of AR-67.  
In order examine the fate of the drug in the gastrointestinal tract and the presence 
of metabolites we dosed rats orally with 2.5 mg/kg AR-67 lactone. The % of AR-67 dose 
recovered in the washing fluid (20% human plasma) from contents ofthe stomach, small 
Parameter (Units) Without GF With GF 
Mean (SD) Mean (SD) 
ClLactone (L/hr*kg)# 1.23 (0.93) 0.82 (0.50) 
ClCarboxylate (L/hr*kg) 4.60 (3.15) 4.60 (3.15) 
ClLact→Carb (L/hr*kg) 1.41 (0.53) 1.41 (0.53) 
ClCarb→Lact (L/hr*kg) 1.87 (1.33) 1.87 (1.33) 
FLact dose (%)# 9.4% (4.1) 29.8% (13.0) 
FCarb dose (%)# 9.1% (3.9) 27.4% (11.9) 
MIT (min) 152.0 (50.7) 152.0 (50.7) 
CVI2 1.2 (0.7) 1.2 (0.7) 
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intestine, colon as well as the cumulative % remaining in the GI tract is presented in 
Figure 5-9. The estimated half-life in the stomach was approximately 4.7 hours while in 
the small intestine the estimated half-life was approximately 1 hr. The total recovery at 
the initial time points was approximately 50% which suggests that the extraction 
efficiency of the washing buffer was limited and these values represent a potential 2-fold 
underestimation of the actual amount remaining in the gastrointestinal tract. Thus, it is 
possible that 5-10% of the dose still remained in the stomach at the 12 hr time point, 
while ~20-40% of the dose could be present in the GI tract between 6-12 hr after oral 
dosing. 
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Figure 5-9. Total AR-67 recovered, as % of orally administered dose, from contents of 
(A) stomach, (B) small intestine, (C) colon and (D) the total dose recovered in the 
gastrointestinal tract (GI) following an oral dose of 2.5 mg/kg AR-67 lactone. Dotted 
lines represent the data fit with a monexponential decay model to estimate the half-life in 
the stomach and small intestine. (n=2-3 rats per time point). 
In addition to assaying for AR-67, we also analyzed the gastrointestinal contents for the 
presence of oxidative and glucuronidation metabolites. To determine metabolite 
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formation we prepared rat liver and rat intestinal microsomes and demonstrated that they 
were functional by their capacity to degrade irinotecan and SN-38, which are known 
substrates of phase-I (i.e., CYP450s) and phase-II (i.e., UDP glucuronosyltransferases)  
metabolizing enzymes, respectively (data not shown). Samples were analyzed by gradient 
HPLC with fluorescence detection and early eluting peaks were considered metabolites 
given that their biotransformation would have rendered them relatively more hydrophilic 
than AR-67. Following AR-67 incubation with intestinal microsomes there was no 
evidence of significant oxidative or glucuronidation metabolite formation. However, 
following incubation of AR-67 lactone in rat liver microsomes under conditions that 
would promote glucuronidation revealed that AR-67 is glucuronidated and two additional 
hydrophilic peaks appeared in the chromatogram (Figure 5-10), which were considered as 
the carboxylate-glucuronide and lactone-glucuronide. The structures of these metabolites 
have not yet been characterized. In contrast, several additional peaks appeared in the 
chromatogram (Figure 5-10) following incubation with rat liver microsomes under 
conditions that would promote oxidative metabolism.  
Figure 5-10 also shows a comparison of metabolites obtained in a sample from the 
jejunum at 2 h. These results indicate the presence of oxidative, glucuronide and other 
unidentified metabolites in intestinal contents, which could have arisen from 
gastrointestinal and liver metabolism. 
Lack of metabolite reference standards did not allow us to make quantitative 
assessments of the metabolite concentrations but qualitative assessment based on relative 
peak heights demonstrated that although present, the metabolites were of low abundance 
in the GI contents as compared to the parent compound. As illustrated in Figure 5-11, 
both oxidative and glucuronide metabolites were observed in all segments considered.  
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Figure 5-10. AR-67 and its metabolites in rat liver microsomes (RLM) and jejunum 
samples. Top and middle chromatograms show the presence of glucuronide and oxidative 
metabolites, respectively. Samples in the jejunum (bottom) indicate the presence of 
glucuronide, oxidative and other unidentified metabolites. C-G:-carboxylate glucuronide; 
L-G:-lactone glucuronide; C:-carboxylate; L:-lactone; *oxidative metabolites; # 
unidentified metabolites. 
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Figure 5-11. Amount of metabolites ( ○ ) and parent AR-67 ( □ ) recovered (in nanogram 
(ng) equivalents§) from the gastrointestinal tract after an oral dose of 2.5 mg/kg AR-67 
lactone. § Nanogram equivalents were calculated from the slopes and intercepts of AR-67 
lactone and carboxylate standard curve and the volume of washing fluid used to empty 
the contents. Each time point in the graph above represents data from one animal. 
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5-4. Discussion 
In this in vivo study the bioavailability of AR-67 following increasing doses of 
the lactone or carboxylate was compared. Furthermore, the effect of ABC efflux 
transporters P-gp and Bcrp on oral bioavailability was examined. Bioavailability 
estimates ranged between 4-17% and did not differ between lactone and carboxylate 
doses. The lactone form predominated in the plasma following lactone or carboxylate 
dosing (>83% lactone AUC). In contrast,  it was shown in Chapter 4 that 84% of the 
plasma AUC was due to the lactone following intravenous lactone administration while 
following intravenous carboxylate administration, the lactone AUC accounted for only 
22% (143). Percent lactone AUCs are therefore similar following the oral and 
intravenous administration of the lactone. A possible explanation for this discrepancy in 
percent lactone AUC between oral and intravenous carboxylate administration could be 
that only the lipophilic lactone form was absorbed from the gastrointestinal tract. In a 
study by Scott et al. (26) less than 1% of the administered dose was absorbed following 
intraduodenal administration of sodium camptothecin (carboxylate) dissolved in bile 
suggesting that carboxylate absorption is minimal. The carboxylate form is a substrate of 
the liver specific organic anion uptake transporters OATP1B1 and OATP1B3 (183). 
Therefore, the predominance of the lactone in the plasma could be also be related to the 
selective uptake of the carboxylate into the liver by these uptake transporters. Thus, if 
carboxylate is absorbed it would have been rapidly cleared by the liver and very little 
would have been available for conversion to carboxylate. This is consistent with the 
results in Chapter 4 that indicated that the carboxylate clearance is more than 5-fold 
higher than the carboxylate to lactone conversion clearance (5.5±0.6 vs. 0.98±0.19 
L/hr/kg). Moreover, since the plasma exposure following lactone and carboxylate was 
practically identical, carboxylate to lactone conversion in the gut and subsequent lactone 
absorption is the most likely explanation for this observation across several doses, which 
spanned an order of magnitude (i.e., 2.5 mg/kg – 20 mg/kg). 
Limited dissolution of lipophilic drugs in the gastrointestinal tract is known to 
limit bioavailability of orally administered drugs (196). The aqueous solubility of AR-67 
is 0.11 µg/mL at pH 5.2 and ≈18 mg/mL at pH 10.2 (181). At pH 5.2 AR-67 is primarily 
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in the lactone form whereas at pH 10.2 it is predominantly in the carboxylate form (181). 
Based on aqueous solubility and membrane permeability alone, AR-67 lactone and 
carboxylate would belong to two different classes. Under the Biopharmaceutics Drug 
Disposition Classification (BCS) System, the lactone would be classified as a Class II 
drug given its low aqueous solubility and high membrane permeability and the 
carboxylate as a class III drug based on its high aqueous solubility and low membrane 
permeability (197). This means that under conditions that favor the predominance of the 
lactone in the gastrointestinal tract, bioavailability would be amenable to improvement by 
use of formulations that enhance dissolution. In this study, the formulation of Xiang & 
Anderson (181) that provides a supersaturated lactone solution was employed. While this 
formulation was able to maintain supersaturation in vitro, it may not have done so in 
vivo. This formulation is made through a pH regulated chemical conversion of the 
carboxylate in the presence of a sulfobutylether-β-cyclodextrin (SBE-β-CD). AR-67 
lactone forms a predominantly 1:1 complex with SBE-β-CD, which involves inclusion of 
7-t-butyldimethylsilyl residue in the SBE-β-CD core (181). The carboxylate also forms a 
1:1 complex, the formation of which is an order of magnitude less than that of the lactone 
complex (181). It is highly likely that absorption AR-67 from this bulky complex occurs 
after dissociation form the complex. Therefore, the stability of the complex will have an 
effect on oral bioavailability. More studies are, however, needed to examine if and how 
much complexation affects the oral bioavailability of AR-67. If the charged carboxylate 
predominates in the gastrointestinal tract, formulation factors that enhance conversion to 
lactone may be relevant in improving bioavailability. Examination of luminal contents 
showed the presence of a significant portion of AR-67 in the stomach and in the colon. 
This could have resulted from efflux by ABC transporters and/or from the limited 
gastrointestinal solubility of AR-67. The contents also showed the presence of oxidized, 
glucuronidated and other unidentified metabolites. Taken together, these data indicate 
that ABC efflux limits the bioavailabilty of AR-67. The presence of metabolites and a 
significant portion of the administered dose unabsorbed in the gastrointestinal tract point 
that first pass metabolism and limited in vivo solubility could also reduce bioavailability 
of AR-67. However, CYP450 and UGT inhibition studies using oral grapefruit juice and 
valproic acid administration did not afford any improvement in oral bioavailability of 
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AR-67 (pilot studies, data not shown). More work is needed to quantify the contribution 
of intestinal metabolism on the oral bioavailability of AR-67.  
Due to their apical expression in the lumen of the gastrointestinal tract, ABC 
efflux transporters P-gp and BCRP/Bcrp limit oral bioavailability of camptothecin 
analogs and their inhibition has been shown to increase oral bioavailability (102, 182). 
The threefold increase in oral bioavailability of AR-67 above the control vehicle with 
GF120918 demonstrates the involvement of efflux transporters P-gp and Bcrp in limiting 
the oral bioavailability of AR-67. Since we have previously demonstrated the lactone to 
be a substrate of P-gp and BCRP in vitro (183), the increase in bioavailability upon 
lactone administration in the presence of inhibitors is likely to be due to inhibition of P-
gp and BCRP. On the other hand, the increase in bioavailability in the presence of 
GF120918 following carboxylate administration could have resulted from inhibition of 
lactone efflux and/or carboxylate efflux (provided the carboxylate is substrate of efflux 
transporters). Whether or not the carboxylate is also a substrate of P-gp and/or Bcrp has 
not yet been established and more work needs to be done in this regard.  
Poor gut solubility might play a role and could magnify the effect of efflux 
transporter(s) in that enterocyte concentrations coming from the gut lumen will not be 
enough to saturate efflux transporters (198) partly explaining the increase in 
bioavailability we observed with efflux inhibition. The results of ABC transporter 
inhibition studies are in line with other studies demonstrating that oral bioavailability of 
camptothecin analogues is limited by ABC transporters and that inhibition of transporter 
function leads to improvement in oral bioavailability. Co-administration of topotecan and 
GF120918 by the oral route, increased plasma AUC of total topotecan more than six fold 
in P-gp knockout mice and greater than nine fold in wild-type mice compared with the 
wild type and P-gp knockout control mice (102). This increase is not only due to 
gastrointestinal efflux inhibition but also due to decreased systemic clearance (102). 
Similarly, in cancer patients GF120918 increased the bioavailability of topotecan 2.4 fold 
(40 to 97%) (133). The study, however, did not consider the effect of GF120918 on the 
clearance of topotecan. Therefore, the increase in bioavailability is likely to be due to 
decreased gastrointestinal efflux as well as decreased systemic clearance of topotecan. An 
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animal study using gefitinib as the ABC transporter inhibitor showed that a single dose of 
100 mg/kg led to a 3.5 fold increase in the oral bioavailability of irinotecan in mice (25 in 
control versus 87% with gefitinib) (132). In another study, gefitinib (100 mg/kg) 
increased the bioavailability of topotecan in Bcrp knockout mice about 2.1 fold compared 
to wild-type animals (22 to 47%). Similarly, the same dose of gefitinib increased 
bioavailability about 1.7 fold (30 to 50%) in Mdr1 knockout animals compared to Mdr1 
wild-type animals. The increase in bioavailability was related to both gastrointestinal 
efflux transporter inhibition and reduced systemic clearance (124). GF120918 was 
solubilized in an aqueous solution of 10% Tween 80 and 40% PEG-300.  Both Tween 80 
and PEG-300 increase oral bioavailability of lipophilic drugs through improved 
solubilization and/or inhibition of efflux transporters located in the gastrointestinal tract 
(8, 28, 29). However, as mentioned earlier in the results section, this excipient factor was 
taken into consideration by using the vehicle as a control when analyzing the GF120918 
results.    
The increase in oral lactone and carboxylate AUCs that was observed with 
GF120918 pretreatment (Table 5-3) was not solely due to the effect of the inhibitor. It is 
possible GF120918 formulation excipients may have improved in vivo solubility of AR-
67, delayed its gastric emptying and inhibited Bcrp as was previously demonstrated in 
mice receiving topotecan (199). Inhibition of transport was found to be responsible for 
this increase as Tween-20 had little effect on oral AUC of topotecan in Bcrp knockout 
animals or on AUC of intravenously administered topotecan (199). 
HPLC analysis of gastrointestinal contents indicated the presence of unabsorbed 
drug in the gastrointestinal tract long after drug administration. The presence of 
unabsorbed drug in the stomach long after drug administration is unlikely to have 
resulted from efflux by ABC transporters as the stomach is not believed to be a major site 
of drug absorption nor has it been shown to express ABC efflux transporters. More 
studies are needed to investigate the reason for the presence of unabsorbed drug in the 
stomach. First pass metabolism could also be responsible for limiting oral bioavailability 
of AR-67 as suggested by the presence of oxidative, glucuronide and other unidentified 
metabolites in the intestinal contents. Further studies are, however, required to quantify 
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the extent of first pass metabolism. Furthermore, we propose that pretreatment with an 
Oatp inhibitor prior to the oral administration of the carboxylate could help rule out the 
contribution of carboxylate uptake by Oatp as a reason for the predominance of the 
lactone form following oral administration of the carboxylate.  
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CHAPTER 6 
SUMMARY AND FUTURE DIRECTIONS 
The camptothecins represent an essential class of anticancer compounds that 
inhibit DNA replication by poisoning the nuclear enzyme Topoisomerase I (1-3). 
Camptothecins undergo pH dependent reversible hydrolysis from the lipophilic lactone to 
the hydrophilic carboxylate, which is favored at physiological and basic pH (7). The 
pharmacological activity of camptothecins is thought to be due to the ring-closed lactone 
form (6) although the ring-opened carboxylate also has the potential to interact with topo 
I (5). While the lipophilic nature of the lactone facilitates its diffusion through the plasma 
membrane, the hydrophilic nature of the carboxylate could limit its access to its site of 
action, i.e., the nucleus and may, therefore, be one reason for the reported lack of activity 
of the carboxylate. The poor aqueous solubility of camptothecin (15) and the rapid 
conversion of the lactone to carboxylate at physiological pH, especially in the presence of 
human serum albumin (9, 151), spurred research on water soluble and lactone stable 
analogues. First generation analogues still suffer from rapid lactone hydrolysis (9, 12) 
while second generation analogues, topotecan and irinotecan, possess improved water 
solubility and lactone stability and are currently in clinical use (200). Several third 
generation analogues are currently at various stages of preclinical and/or clinical 
investigation (20). Although these new generation analogues have improved lactone 
stability (11, 134), their poor aqueous solubility is a limiting factor for clinical use.  
ABC efflux transporters and organic anion transporting polypeptides 
(OATPs/Oatps) play an essential role in the pharmacokinetics of substrate drugs in 
general and camptothecins in particular by regulating drug absorption, distribution and 
elimination (102, 116, 201-203). The existence of the lactone and carboxylate forms of 
camptothecins in equilibrium at physiological pH and the differences in their 
physicochemical properties (7) could contribute to differences in interaction with efflux 
and uptake transporters. This could in turn give rise to differences in cellular 
accumulation and/or transport in vitro and ultimately in pharmacokinetics. AR-67 is a 
third generation lactone stable camptothecin analog currently undergoing early phase 
clinical trials as a chemotherapeutic agent. AR-67 was chosen as a model compound for 
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this project based on its enhanced lactone stability and promising antiproliferative effects. 
Using this relatively lactone stable third generation camptothecin analog, the following 
hypotheses were tested:-1) Is the intracellular accumulation of AR-67 lactone reduced by 
ABC transporters P-gp and BCRP? and 2) Does AR-67 carboxylate or AR-67 lactone 
depend on uptake transporters, OATP1B1 or OATP1B3, for intracellular accumulation? 
It was speculated that these in vitro studies would provide essential information for the 
design of in vivo studies that will characterize the pharmacokinetics of the lactone and 
carboxylate forms as well as examine the role efflux and uptake transporters play in the 
disposition and oral bioavailability of AR-67 lactone and AR-67 carboxylate. In order to 
test the hypotheses stated above intracellular accumulation experiments were carried out 
in cell lines overexpressing ABC efflux (P-gp or BCRP) or uptake transporters 
(OATP1B1 or OATP1B3) using AR-67 lactone or AR-67 carboxylate. Transcellular 
transport experiments that assess the vectorial transport of AR-67 lactone across cell 
monolayers were also conducted in the presence or absence of efflux transporter 
inhibitors GF120918 and rifampin to examine the role of BCRP on the vectorial transport 
of AR-67 lactone. The results indicated that efflux by P-gp and BCRP decrease 
intracellular accumulation of AR-67 lactone. BCRP was shown to contribute to the 
vectorial transport of AR-67 by decreasing apical to basolateral transport and enhancing 
basolateral to apical transport across cell monolayers. Moreover, inhibition of P-gp 
and/or BCRP mediated efflux increased intracellular accumulation and reduced the 
vectorial transport of AR-67. OATP-mediated uptake was found to be responsible for the 
increased carboxylate uptake observed in OATP overexpressing cells. The wide 
expression of efflux transporters, P-gp and BCRP in organs involved in drug absorption, 
distribution, elimination (202) and the interaction of AR-67 lactone with these 
transporters indicates that the oral bioavailability, tissue distribution and systemic 
clearance of AR-67 is likely to be impacted by them. On the other hand, liver-specific 
uptake transporters, OATP1B1 or OATP1B3 (56) may represent a pathway for the 
elimination of the hydrophilic carboxylate. The interaction of the lactone with ABC 
efflux transporters and that of the carboxylate with organic anion transporting 
polypeptides (OATPs/Oatps) could lead to differences in the in vivo disposition of the 
lactone and carboxylate forms.Based on the results of in vitro studies the disposition of 
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the lactone and carboxylate forms of AR-67 were determined and the role of uptake and 
efflux transporters in the pharmacokinetics of AR-67 lactone and carboxylate was 
examined in rats (143). Single intravenous bolus doses of 2.5 mg/kg AR-67 lactone or 
carboxylate were given with or without oral transporter inhibitor pretreatment (GF120918 
or rifampin). The results indicated that the majority of AR-67 was in the form of the 
lactone (% lactone AUC=84%) following lactone administration but in the form of the 
carboxylate following carboxylate administration (% carboxylate AUC=78%). 
Pharmacokinetic modeling and simulation was carried out to estimate reversible and 
irreversible (systemic) lactone and carboxylate clearances and assess the impact of 
clearance changes on overall AR-67 exposure. It was found that carboxylate systemic 
clearance was 3.5-fold higher than that of the lactone. Pretreatment with the dual P-gp 
and BCRP/Bcrp inhibitor, GF120918 decreased lactone clearance only, while 
pretreatment with rifampin decreased both lactone and carboxylate clearances. 
Simulations showed that decreasing carboxylate clearance significantly increases AR-67 
exposure and suggested that the apparent in vivo blood stability of AR-67 is partly 
dependent on the increased carboxylate clearance. As the hydrophilic carboxylate is a 
substrate for OATPs, its clearance in vivo is likely to be mediated by these transporters. 
Changes in transporter function resulting from single nucleotide polymorphisms that 
impair the function of uptake transporter genes (e.g., SLCO1B1) or from drug-drug 
interactions could lead to altered exposure to AR-67 and lead to altered exposure to AR-
67. 
Several studies have indicated that the camptothecin class of anticancer 
compounds are better tolerated and more efficacious when administered at smaller but 
more frequent dosing schedules in what is known as protracted dosing (171-173). 
Previous preclinical studies in this lab have also demonstrated the efficacy of the third 
generation camptothecin analog, AR-67, when administered over a protracted schedule 
(Leggas lab unpublished data). Such dosing could easily be achieved using an oral dosage 
form as the oral route of administration offers many advantages ranging from flexibility 
of dosing regimen to minimization of cost. However, optimum bioavailability is a 
prerequisite to achieving the desired anticancer effects. It is therefore essential to study 
Implementation of the  
 
99 
 
factors that could potentially limit the oral bioavailability of AR-67 before advocating the 
clinical use of AR-67 via the oral route. The literature indicates that camptothecins are 
substrates of ABC efflux transporters and that their oral bioavailability is limited by P-gp 
and BCRP/Bcrp (47, 102, 124). First pass metabolism could also limit the amount of 
substrate drug reaching the systemic circulation following oral administration (204). 
Moreover, it has now been recognized that gastrointestinal efflux transporters and drug 
metabolizing enzymes could work in concert to limit the oral bioavailability of substrate 
drugs (198). In the case of most lactone stable camptothecins, such as AR-67, another 
limiting factor to bioavailability is their high lipophilicity. In these studies, the 
bioavailabilities of the lipophilic lactone and the hydrophilic carboxylate forms of AR-67 
were determined. In addition, a pharmacokinetic model for the oral absorption of AR-67 
was developed and the effect of efflux transporters P-gp and Bcrp on oral bioavailability 
was investigated, using the selective P-gp inhibitor, zosuquidar and the dual P-gp and 
BCRP/Bcrp inhibitor, GF120918. The presence of AR-67 metabolites and unabsorbed 
AR-67 in the gastrointestinal tract was also examined. Metabolism of AR-67 by intestinal 
and liver microsomes was also assessed to examine if first pass metabolism could impact 
oral bioavailability of AR-67.  
The results of these studies indicated that the majority of AR-67 in the plasma 
was in the form of the lactone as represented by percent lactone AUCs ranging from 80-
95% irrespective of whether the lactone or the carboxylate was orally administered. Dose 
normalized AUCs tended to increase with lactone dose suggesting the involvement of 
efflux transporters and/or metabolizing enzymes and saturation of either one or both of 
these processes at high doses of AR-67 lactone. Simultaneous modeling of the oral 
absorption of AR-67 following lactone and carboxylate inputs using the inverse Gaussian 
function and ITS algorithm in ADAPT5 provided estimates of bioavailability ranging 
from 6-17%. The pharmacokinetic model was able to adequately predict the plasma 
concentrations of lactone and carboxylate. Inhibition of P-gp with the selective P-gp 
inhibitor, zosuquidar, resulted in three fold increase in bioavailability over control (5% 
dextrose in water, D5W) pretreated animals. The increase resulted from GI efflux 
inhibition and minimal decrease in systemic clearance. On the other hand, pretreatment 
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with the dual P-gp and BCRP/Bcrp inhibitor, GF120918, led to increased bioavailability 
resulting from decreased gastrointestinal efflux and decreased systemic clearance. The 
modeling results indicated that inhibition of gastrointestinal efflux accounted for a 
threefold increase in bioavailability (F≈30) clearly indicating that both P-gp and Bcrp 
reduce the bioavailability of AR-67. However, based on the estimate of AR-67 extraction 
ratio, the oral bioavailability of AR-67 could be 46% suggesting efflux alone is not 
responsible for limiting bioavailability.  
Examination of gastrointestinal contents indicated the presence of unabsorbed 
drug in the gastrointestinal tract, which could have resulted from the poor gastrointestinal 
tract (GI) dissolution of AR-67 and/or efflux by ABC transporters. Measurement of 
gastrointestinal contents in animals pretreated with ABC efflux inhibitors will with the 
accurate estimation of the contribution of poor GI dissolution in limiting oral 
bioavailability. At least 5% of the drug remained in the stomach at 12 h. The stomach is 
not believed to be a major site of drug absorption nor has it been shown to express ABC 
efflux transporters. Therefore, the presence of unabsorbed drug in the stomach long after 
drug administration is unlikely to have resulted from efflux by ABC transporters. More 
studies are needed to investigate the reason for the presence of unabsorbed drug in the 
stomach. Measurement of AR-67 in the feces and urine in addition to gastrointestinal 
contents will help with accurate estimation of the loss of AR-67 through the 
gastrointestinal tract or the urine. Intestinal and hepatic first pass metabolism could also 
be responsible for limiting oral BA of AR-67 as suggested by the presence of oxidative, 
glucuronide and other unidentified metabolites in the intestinal contents. It should be 
noted that the presence of metabolites in the gastrointestinal tract does not necessarily 
prove intestinal metabolism but provides an indication that first pass metabolism could 
limit oral bioavailability of AR-67. Incubation of AR-67 lactone with liver microsomes 
also suggests that AR-67 could be metabolized. Further studies are, however, required to 
quantify the extent of first pass metabolism as well as delineate if metabolism is either 
hepatic or intestinal.  
The predominance of the lactone following oral administration of the lactone is in 
line with previous intravenous studies which also showed similar results (143). However, 
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the predominance of the lactone following oral administration of the carboxylate raised 
the question of which of the two forms is absorbed from the gastrointestinal tract. One 
explanation is that AR-67 is absorbed as the lactone form. Another explanation is that 
both could be absorbed from the gastrointestinal tract with selective uptake of the 
carboxylate into the liver by organic anion transporting polypeptides (Oatps). This 
however needs to be further studied. Pretreatment with an Oatp inhibitor prior to the oral 
administration of the carboxylate could help rule out the contribution of carboxylate 
uptake by Oatp as a reason for the predominance of the lactone form following oral 
administration of the carboxylate. In conclusion, the in vivo disposition of AR-67 and 
role of transporters in the clearance of the lactone and carboxylat forms is presented in 
Figure 6- 1. 
 
Figure 6- 1. AR 67 undergoes interconversion between lactone (L) and carboxylate forms 
in the blood and other tissues in vivo. The lipophilicity of the lactone is likely to favor its 
passive diffusion into the liver. The lactone is a substrate of efflux transporters BCRP and 
MDR1. Following its diffusion into the liver, the lactone could be 1) converted into the 
carboxylate, 2) metabolized by cytochrome P450 (CYP450) and/or UGT enzymes, or 3) 
effluxed by BCRP, MDR1 and possibly MRP2 into the bile. On the other hand, the 
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hydrophilic carboxylate is a substrate of OATPs and is likely taken up by OATP1B1 
and/or OATP1B3 into the liver. Once inside the liver the carboxylate is reversibly 
converted to the lactone. It is possible that it could also be metabolized by CYP450s 
and/or UGTs and/or effluxed into the bile. The biliary contents are released into the 
gastrointestinal tract, from which the lipophilic AR-67 lactone could primarily be 
absorbed. It is possible that the carboxylate could also be absorbed through an uptake 
process (OATP2B1). Before AR-67 reaches the systemic circulation it is acted upon by 
efflux transporters MDR1, BCRP and possibly MRP2 and CYP450 and UGT enzymes.  
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APPENDIX I 
 
PARTIAL VALIDATION OF AN HPLC METHOD FOR THE DETERMINATION OF 
THE LACTONE AND CARBOXYLATE FORMS OF AR-67 IN RAT PLASMA 
I. Standards 
AR-67 containing samples were prepared and/or stored in amber siliconized 
tubes. Aqueous solutions were kept on ice while all methanolic extracts were kept on dry 
ice. Measurements were made with siliconzed pipette tips. Extracts were kept frozen at -
80C. 
A. AR-67 stock solution 
A stock solution of AR-67 lactone was prepared using the analytical grade 
crystalline drug from Dr. Brad Anderson’s lab (TOX LOT).  A 1 mg/mL AR-67 stock 
solution was prepared by dissolving 10 mg of AR-67 powder with dimethylsulfoxide 
(DMSO) in a 10 ml volumetric flask. This stock was aliquoted in 40 l volumes into 
amber siliconized microcentrifuge tubes and kept at –80C. 
 
B. Working standard solutions 
Working AR-67 lactone and carboxylate solutions were prepared from the stock 1 
mg/ml lactone solution as described in the literature for mouse data (REF) and outlined in 
Table 1. Lactone working solutions were prepared in 0.005 N HCl kept on ice while 
carboxylate solutions were prepared in 0.005 N NaOH kept on ice (Table 1).  Working 
solutions were kept on ice for 1 h.  
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Table 1. Preparation of AR-67 lactone or carboxylate working solutions. 
 
C. Calibration and quality control standards 
Lactone and carboxylate calibrators and quality control samples were prepared as 
outlined in Table 2 below. The concentrations of calibrators were 2.5, 5, 10, 20, 50, 100, 
200 and 300 ng/mL. Samples were vortexed for 10 seconds after preparation and were 
extracted with cold methanol (-80oC) (1:4, v/v). Mixtures were then vortexed for 10 
seconds and centrifuged for 2 mins at 13,000 rpm (4ºC). The supernatant was poured into 
siliconized amber microcentrifuge tubes, and stored at -80°C. Three quality control 
samples:- a low (7 ng/mL), a medium (150 ng/mL) and a high (250 ng/mL)- were 
separately prepared, extracted and stored as described above for calibrators. Each quality 
control sample contained designated concentrations of both the lactone and carboxylate 
(Table 2).  
From solution  Aliquot  0.005 N HCl for lactone or 0.005 N 
NaOH for carboxylate (µL) 
Final  
concentration  
1000 µg/mL (stock 
solution) 
10 µL 990 µL 10 µg/mL 
1000 µg/mL (stock 
solution) 
10 µL QS to 10 mL 1 µg/mL 
1000 µg/mL (stock 
solution) 
10 µL QS to 100 mL 0.1 µg/mL 
1000 µg/mL (stock 
solution) 
10 µL 990 10 µg/mL 
10 µg/mL 100 µL 900 1 µg/mL 
1 µg/mL 100 µL 900 0.1 µg/mL 
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Table 2. AR-67 standard curve and quality control sample preparation in rat plasma.  
 
D. Short term matrix and extract stability   
Short term stability of AR-67 quality control samples containing both lactone and 
carboxylate was determined in the matrix (rat plasma) or in the extract. The results of 
these studies are presented in Tables 3-5. For matrix stability studies plasma samples 
containing AR-67 lactone and carboxylate were kept on ice while for extract stability 
studies extracts were diluted with an equal volume of the mobile phase buffer and kept in 
the HPLC autoinjector chamber at 4oC. AR-67 was found to be stable in the matrix for 
less than 3 hrs indicating that extraction should be performed immediately. The extract, 
on the other hand was stable for up to 6 hrs after mixing with the mobile phase buffer. 
Calibrator 
/Quality 
control  
AR-67 carb & 
lact. Conc 
(ng/mL) 
From AR-67 
carb & lact 
working 
solutions 
Aliquot from 
working solution 
PBS (pH 7.4)/ 
 plasma (µL) 
1 2.5 0.1 25 (carb)/25 (lact) 10/940 
2 5 1 5 50/940 
3 10 1 10 40/940 
4 20 1 20 20/940 
5 50 10 5 50/940 
6 100 10 10 40/940 
7 200 10 20 20/940 
8 300 10 30 0 
QC1 7 1 7 46/940 
QC3 150 10 15 30/940 
QC4 250 10 25 10/940 
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Table 3. Short term matrix stability-QC4. 
 
Table 4a. Short term extract stability of AR-67 –QC1 trial 1. 
 
 
 
 
 
250 ng/mL 
Time 
 (hr) 
Carboxylate (% initial) Lactone (% initial) 
1 2 3 Average SD RSD 1 2 3 Average SD RSD 
0 100.0 100.0 100.0 100.0 0 0 100.0 100.0 100.0 100.0 0 0 
1 113.0 103.5 114.5 110.3 6.0 5.4 89.1 81.6 90.4 87.0 4.8 5.5 
3 126.6 120.7 127.2 124.8 3.6 2.9 64.4 62.7 63.7 63.6 0.9 1.4 
6 126.6 120.7 127.3 124.8 3.6 2.9 44.4 42.3 47.0 44.5 2.3 5.2 
7 ng/mL 
Time 
(hr) 
Carboxylate (% initial) Lactone (% initial) 
1 2 3 Average SD RSD 1 2 3 Average SD RSD 
0 100.0 100.0 100.0 100.0 0 0 100.0 100.0 100.0 100.0 0 0 
1 93.7 90 103.1 95.6 6.8 7.1 99.9 96.1 103.1 99.7 3.5 3.5 
3 86.4 85.6 87.7 86.7 0.9 1.1 102.8 103.5 97.4 101.3 3.3 3.3 
6 85.0 86.7 82.2 84.6 2.3 2.7 109.0 118.0 112.0 113.0 4.6 4.0 
24 87.1 79.3 72.1 79.5 7.5 9.4 165.4 150.6 135.9 150.6 14.7 9.8 
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Table 4b. Short term extract stability of AR-67- QC1 trial 2. 
 
 
 
 
 
Table 5a. Short term extract stability of AR-67-QC4.  
 
 
7 ng/mL 
Time 
(hr) 
Carboxylate (% initial) Lactone (% initial) 
1 2 3 Average SD RSD 1 2 3 Average SD RSD 
0 100 100 100 100 0 0 100 100 100 100 0 100 
1 93.4 94.7 94.4 94.2 0.7 0.7 99.7 97.8 98.8 98.8 1.0 1.0 
3 85.8 90.2 87.2 87.7 2.3 2.6 102.9 105.9 97.3 102.0 4.4 4.3 
6 84.4 86.0 81.2 83.9 2.4 2.8 109.2 118.8 112.4 113.4 4.9 4.3 
24 100.9 86.8 81.2 89.6 10.1 11.3 163.0 144.2 141.1 149.4 11.9 7.9 
250 ng/mL 
Time 
 (hr) 
Carboxylate (% initial) Lactone (% initial) 
1 2 3 Average SD RSD 1 2 3 Average SD RSD 
0 100.0 100.0 100.0 100.0 0 0 100.0 100.0 100.0 100.0 0 0 
1 86.4 94.4 99.0 93.3 6.4 6.8 98.9 99.6 100.9 99.8 1.0 1.0 
3 79.9 93.3 97.1 90.1 9.0 10.0 99.8 105.7 104.0 103.2 3.0 2.9 
6 78.5 81.5 86.2 82.0 3.9 4.7 111.1 110.7 104.1 108.7 3.9 3.6 
24 85.0 96.4 87.5 89.6 6.0 6.7 141.3 147.3 137.3 142.0 5.0 3.5 
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E. Long term matrix and extract stability studies 
To determine the long term stability of AR-67 in the matrix and in methanolic extracts unextracted samples or extracted 
samples were kept at -80oC for 0, 7 14 and 21 days before HPLC analysis. The results of these studies are shown in Tables 6 
and 7. AR-67 lactone concentration in the matrix was less than 85% of the initial concentration by day 7 for both QC1 and 
QC4. Similarly, AR-67 carboxylate concentration was less than 85% of its initial concentration by day 21 for QC1. The 
carboxylate concentration of AR-67 in the maxtrix appears not to have changed for QC4. On the hand, the lactone 
concentration declined to ≤ 80% of the nominal concentration in the matrix within 7 days for both QC1 and QC4. In contrast, 
the extract was stable for up to 14 days (Tables 8 &9). 
Table 6. Long term matrix stability of AR-67-QC1. 
 7 ng/mL
Day Carboxylate (% initial) Lactone (% initial)
1 2 3 Average SD RSD 1 2 3 Average SD RSD
0 100.0 100.0 100.0 0 0 0 100.0 100.0 100.0 100.0 0 0
7 93.7 99.0 98.9 97.2 3.1 3.1 75.9 80.9 82.7 79.8 3.5 4.1
14 81.8 101.8 96.4 93.3 10.4 11.1 65.1 80.5 78.0 74.5 8.2 11.0
21 75.9 88.6 86.4 83.7 6.8 8.1 72.1 85.9 87.1 81.7 8.3 10.2
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Table 7. Long term matrix stability of AR-67-QC4. 
250 ng/mL
Day Carboxylate (% initial) Lactone (% initial)
1 2 Average SD RSD 1 2 Average SD RSD
0 100.0 100.0 100.0 0 0 100.0 100.0 100.0 0 0
7 110.8 106.1 108.4 3.3 3.1 78.0 75.5 76.7 1.8 2.3
14 105.2 91.5 98.4 9.7 9.8 63.6 72.8 68.2 6.5 9.5
21 103.9 109.4 106.6 3.9 3.6 88.9 95.6 92.2 4.8 5.2
 
Table 8. Long term extract stability-QC1. 
7 ng/mL 
Day Carboxylate (% initial) Lactone (% initial) 
1 2 3 Average SD RSD 1 2 3 Average SD RSD
0 100 100 100 100 0 0 100 100 100 100 0 0 
7 103.8 103.4 108.3 105.1 2.7 2.6 111.8 89.8 95.6 99.1 11.4 11.5 
14 85.9 83.7 84.5 84.7 1.1 1.3 95.9 93.1 98.5 95.8 2.7 2.8 
 
Table 9. Long term extract stability-QC4. 
QC4 (250 ng/mL): Long term extract stability  
Day Carboxylate (% initial) Lactone (% initial)
1 2 Average SD RSD 1 2 Average SD RSD
0 100.0 100.0 100.0 0 0 100.0 100.0 100.0 0 0
7 106.3 103.8 105.1 1.7 1.6 85.3 82.3 83.8 2.1 2.5
14 96.3 88.8 92.5 5.3 5.8 102.4 93.9 98.1 6.0 6.1
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II. HPLC system and assay 
A. Instrumentation and chromatographic conditions 
Shimadzu HPLC system (Shimadzu Inc., Atlanta, GA)  
Class-VP integrating software (Ver. 7.2.1.) 
In-line degasser (DGU-14A) 
LC-10ADVP pump 
Refrigerated autoinjector (SIL-10ADVP) (rack temperature at 4°C) 
Fluorescence detector (set at high sensitivity): excitation-380 nm and emission-560 nm  
Reversed-phase C18 analytical column (Waters Nova-Pak C18 4μ; 3.9 x 150 mm)  
Mobile phase buffer:  0.15 M ammonium acetate containing 10 mM tetrabutylammonium 
dihydrogen phosphate (TBAP; pH 6.5).  
Mobile phase: 65% mobile phase buffer and 35% acetonitrile. 
Flow rate: 1 mL/min  
Retention times: carboxylate- ≈ 3 min and lactone- ≈ 9 mins. 
B. Extract preparation and injection 
Extracts were diluted with an equal volume of ice cold mobile-phase buffer and 
were briefly vortexed. Air bubbles were removed by gentle tapping on the walls of the 
vials and 50 μL injection was made.  
C. Simultaneous calibration curves 
Simultaneous carboxylate and lactone calibration curves were prepared as 
described above (Table 1). A list of the curves prepared and the parameters describing the 
curve are shown in Table 10.  The parameters were generated by linear regression of peak 
lactone and carboxylate heights (x-axis) and analyte concentrations (y-axis). 
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Table 10. Simultaneous carboxylate and lactone calibration curves in rat plasma. 
Carboxylate Linear Regression Parameters 
Curve Slope y-intercept R2 Weighing 
1a 0.0003639 0.00000 0.99933 1/Response 
1b 0.0004327 -1.06019 0.99985 None 
1c 0.0004493 -0.19637 0.99864 1/Amount 
2 0.0004175 0.01005 0.98889 1/Response 
3a 0.0003858 -0.53943 0.99990 None 
3b 0.0003528 0.20519 0.99973 None 
3c 0.0003654 -0.15301 0.99797 None 
4 0.0003775 0.00000 0.98967 None 
3d 0.0003303 -0.21542 0.99812 None 
3e 0.0002982 -0.38162 0.99963 None 
4a 0.0002445 0.29259 0.99911 1/Response 
4b 0.0002792 -0.21435 0.99099 1/Response2 
5a 0.0003314 -0.25858 0.99967 1/Response 
5b 0.0002414 -0.31928 0.99796 1/Response2 
6a 0.0003501 -0.26273 0.99993 1/Response 
6b 0.0002447 0.01827 0.99966 None 
6c 0.0002740 -0.18674 0.99990 1/Response 
7a 0.0003806 -0.0523507 0.999082 None 
7b 0.0003454 -0.221892 0.999226 None 
7c 0.0004053 0.16872 0.99871 None 
7d 0.0002683 -0.343719 0.983075 1/Response 
7e 0.0002603 0.368477 0.998514 1/Amount 
7f 0.0002312 0.167203 0.991336 1/Response2 
7g 0.0002589 -0.359501 0.997235 None 
8a 0.0001986 -0.789946 0.999287 None 
AVG 0.0003435 -0.1683572 0.9977976 
SD 0.0000629 0.2928403 0.0035012 
RSD 18.3082031 -173.9399113 0.3508967 
Table 10 Ctd 
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Table 10 Ctd 
Lactone Linear Regression Parameters 
Curve Slope y-intercept R2 Weighing 
1a 0.0005915 0.78068 0.99808 1/Response 
1b 0.0007784 1.78870 0.99737 None 
1c 0.0006923 0.82613 0.99579 1/Amount 
2 0.0008396 -0.61582 0.98028 1/Response 
3a 0.0006500 -0.09537 0.99614 1/Response 
3b 0.0008215 -0.34830 0.99845 1/Response 
3c 0.0008375 -0.63140 0.99615 1/Response 
4 0.0007551 -0.31251 0.99905 1/Amount 
3d 0.0006096 0.00013 0.99538 1/Response 
3e 0.0004798 0.46941 0.99660 1/Response 
4a 0.0004501 0.28835 0.99574 1/Response 
4b 0.0004357 -0.16735 0.99856 1/Response 
5a 0.0004784 0.31671 0.99853 1/Amount 
5b 0.0003908 0.47596 0.99707 1/Amount 
6a 0.0005673 0.31824 0.99892 1/Response 
6b 0.0004577 0.21205 0.99839 1/Response 
6c 0.0006683 0.19528 0.99869 1/Response 
7a 0.0008204 -0.69046 0.99655 1/Amount^2 
7b 0.0007718 -1.92884 0.99863 None 
7c 0.0007676 -1.85451 0.99832 1/Response 
7d 0.0005796 -0.85303 0.99880 1/Response 
7e 0.0005647 -0.99484 0.99912 1/Response 
7f 0.0005293 -0.78830 0.99825 1/Response 
7g 0.0005498 -1.50909 0.99842 1/Amount 
8a 0.0004234 -0.40877 0.99926 1/Response 
AVG 0.0006432 -0.0486453 0.9966340 
SD 0.0001534 0.8562193 0.0040368 
RSD 23.8549161 -1760.1285629 0.4050393 
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III. Accuracy and precision  
A. Intraday precision.  
Ten injections of QC3 and QC4 extracts were made in the same day to determine 
intraday precision of the assay. Table 11 shows the results of these studies. The CV 
values for both analytes in the QCs were < 15%. 
Table 11. Intraday variability and accuracy. 
 
  
Replicate QC-3 (150 ng/mL) QC-4 (250 ng/mL) 
 
Carboxylate 
(ng/mL) 
Lactone 
(ng/mL) 
Carboxylate 
(ng/mL) 
Lactone 
(ng/mL) 
1 148.53 135.45 246.18 245.55 
2 156.38 144.09 248.53 248.66 
3 152.18 141.47 244.52 250.6 
4 140.56 129.26 246.97 255.86 
5 149.17 138.67 242.06 255.65 
6 143.36 136.3 234.16 244.25 
7 143.68 139.47 246.69 253.71 
8 141.23 139.34 254.54 267.4 
9 136.89 136.61 260.17 267.46 
10 141.05 142.05 270.38 273.51 
AVG 145.30 138.27 249.42 256.27 
SD 6.05 4.18 10.09 10.02 
CV 4.2 3.0 4.0 3.9 
Accuracy (%) 96.9 92.9 99.08 102.5 
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B. Interday precision 
The interday precision was determined as the %CV of average analyte values of 
5-10 injections on four different days (Table 12). all CV values are < 15 %. 
Table 12. Interday precision. 
 
IV.  Lower limit of quantification (LLOQ) 
The lower limit of quantification was determined from the AR-57 lactone and 
carboxylate calibration curves by comparison of the baseline (noise) and the peak signal 
of AR-67 lactone/carboxylate at 2.5 and 5 ng/mL concentrations (Table 13). The LLOQ 
defined as the concentration for which  
1) S/N >= 5, 
2) a mean estimated analyte concentration within 20 % of nominal, and 
3) a RSD <= 20 %.  
Day of Validation 
QC-1 (7 ng/mL) QC-3 (150 ng/mL) QC-4 (250 ng/mL) 
Avg. % of Nominal Avg. % of Nominal Avg. % of Nominal 
Carb. Lactone Carb. Lactone Carb. Lactone 
Day 1  
108.23 
(n=5)  
97.77 
(n=5) 
100.97 
(n=5) 
92.8 
(n=5) 
98.54 
(n=5) 
101.13 
(n=5) 
Day 2 
110.57 
(n=5) 
96.49 
(n=5) 
96.87 
(n=10) 
92.5v 
(n=10) 
93.41 
(n=5) 
98.33 
(n=5) 
Day 3 
113.06 
(n=5) 
97.60 
(n=5) 
106.41 
(n=5) 
95.10 
(n=5)  
99.77 
(n=10) 
104.51 
(n=10) 
Day 4 
117.77 
(n=5) 
99.94 
(n=5) 
111.00 
(n=5) 
96.97 
(n=5) 
105.14 
(n=5) 
105.27 
(n=5) 
Accuracy AVG 112.41 97.95 103.81 94.34 99.22 102.31 
SD 4.1 1.4 6.2 2.1 4.8 3.2 
CV% 3.6 1.5 6.0 2.2 4.9 3.1 
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Table 13. Lower limit of quantification of AR-67 in rat plasma. 
 
The lower limit of quantitation is 2.5 ng/mL for the carboxylate analyte and 5 ng/mL for 
the lactone analyte.  
Curve 
Conc 
 (ng/mL) 
Carboxylate  
Height  
(Signal, mm) 
Baseline  
Height 
 (noise, mm)  
Lactone 
Height  
(Signal, mm) 
Carboxylate 
 S/N ratio 
Lactone  
S/N ratio 
2/21/2009 
2.50 
9.87 1.04 4.28 9.48 4.12 
3/25/2009 8.66 0.69 4.16 12.52   6.01  
 Average 11.0 5.97 
SD 2.15 1.34 
% RSD 19.5 22.4 
3/25/2009 
5.00 
14.57 0.44 6.06 32.88  13.67  
2/21/2009 17.97 0.66 9.62 24.43 14.69 
 Average 28.7 12.05 
SD 5.97 0.72 
% RSD 20.9 6.0 
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Raw-data: short term matrix stability. 
Data file name Sample ID Carb.  
(ng/mL) 
Lact 
(ng/mL) 
Carb. 
(% initial) 
Lactone  
(% initial) 
20AC-031608-Short term 
matrix & long term extact 
stability 005.dat 
QC4a matrix -
0h-031608 
260.76 248.27 100.0% 100.0% 
20AC-031608-Short term 
matrix & long term extact 
stability 006.dat 
QC4b matrix -
0h-031608 
273.55 263.02 100.0% 100.0% 
20AC-031608-Short term 
matrix & long term extact 
stability 007.dat 
QC4c matrix -
0h-031608 
259.41 252.52 100.0% 100.0% 
20AC-031608-Short term 
matrix & long term extact 
stability 008.dat 
QC4a matrix -
1h-031608 
294.55 221.15 113.0% 89.1% 
20AC-031608-Short term 
matrix & long term extact 
stability 009.dat 
QC4b matrix -
1h-031608 
283.07 214.61 103.5% 81.6% 
20AC-031608-Short term 
matrix & long term extact 
stability 010.dat 
QC4c matrix -
1h-031608 
296.96 228.33 114.5% 90.4% 
20AC-031608-Short term 
matrix & long term extact 
stability 011.dat 
QC4a matrix -
3h-031608 
330.08 159.84 126.6% 64.4% 
20AC-031608-Short term 
matrix & long term extact 
stability 012.dat 
QC4b matrix -
3h-031608 
330.11 164.83 120.7% 62.7% 
20AC-031608-Short term 
matrix & long term extact 
stability 013.dat 
QC4c matrix -
3h-031608 
329.91 160.88 127.2% 63.7% 
20AC-031608-Short term 
matrix & long term extact 
stability 014.dat 
QC4a matrix -
6h-031608 
330.09 110.21 126.6% 44.4% 
20AC-031608-Short term 
matrix & long term extact 
stability 015.dat 
QC4b matrix -
6h-031608 
330.15 111.25 120.7% 42.3% 
20AC-031608-Short term 
matrix & long term extact 
stability 016.dat 
QC4c matrix -
6h-031608 
330.15 118.57 127.3% 47.0% 
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Raw data: Short term extract stability    
Data Filename Sample ID Carb. 
(ng/mL) 
Lact 
(ng/mL) 
Carb.  
(% initial) 
Lact. 
(%initial) 
10AD-030108-Rat plasma 
short term extract stability 
001.dat 
QC1a-0h 
(prep 021308 
Reext 030108) 
8 6.97 100.0% 100.0% 
10AD-030108-Rat plasma 
short term extract stability 
002.dat 
QC1b-0h 
(prep 021408 
Reext 030108) 
7.56 6.82 100.0% 100.0% 
10AD-030108-Rat plasma 
short term extract stability 
003.dat 
QC1c-0h 
(prep 021408 
Reext 030108) 
7.88 7.28 100.0% 100.0% 
10AD-030108-Rat plasma 
short term extract stability 
004.dat 
QC1a-1h 
(prep 021308 
Reext 030108) 
7.47 6.95 93.4% 99.7% 
10AD-030108-Rat plasma 
short term extract stability 
005.dat 
QC1b-1h 
(prep 021408 
Reext 030108) 
7.16 6.67 94.7% 97.8% 
10AD-030108-Rat plasma 
short term extract stability 
006.dat 
QC1c-1h 
(prep 021408 
Reext 030108) 
7.44 7.19 94.4% 98.8% 
10AD-030108-Rat plasma 
short term extract stability 
007.dat 
QC1a-3h 
(prep 021308 
Reext 030108) 
6.86 7.17 85.8% 102.9% 
10AD-030108-Rat plasma 
short term extract stability 
008.dat 
QC1b-3h 
(prep 021408 
Reext 030108) 
6.82 7.22 90.2% 105.9% 
10AD-030108-Rat plasma 
short term extract stability 
009.dat 
QC1c-3h 
(prep 021408 
Reext 030108) 
6.87 7.08 87.2% 97.3% 
10AD-030108-Rat plasma 
short term extract stability 
010.dat 
QC1a-6h 
(prep 021308 
Reext 030108) 
6.75 7.61 84.4% 109.2% 
10AD-030108-Rat plasma 
short term extract stability 
011.dat 
QC1b-6h 
(prep 021408 
Reext 030108) 
6.5 8.1 86.0% 118.8% 
10AD-030108-Rat plasma 
short term extract stability 
012.dat 
QC1c-6h 
(prep 021408 
Reext 030108) 
6.41 8.18 81.3% 112.4% 
10AD-030108-Rat plasma 
short term extract stability 
013.dat 
QC1a-24h 
(prep 021308 
Reext 030108) 
6.92 11.69 100.9% 163.0% 
10AD-030108-Rat plasma 
short term extract stability 
014.dat 
QC1b-24h 
(prep 021408 
Reext 030108) 
5.92 10.41 86.8% 144.2% 
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10AD-030108-Rat plasma 
short term extract stability 
015.dat 
QC1c-24h 
(prep 021408 
Reext 030108) 
5.58 9.99 81.2% 141.1% 
10AD-021508-Rat plasma 
short term extract stability 
002.dat 
QC4a-0h-
021508 
248.85 238.81 100% 100% 
10AD-021508-Rat plasma 
short term extract stability 
003.dat 
QC4b-0h-
021508 
239.31 228.35 100% 100% 
10AD-021508-Rat plasma 
short term extract stability 
004.dat 
QC4c-0h-
021508 
265.1 255.58 100% 100% 
10AD-021508-Rat plasma 
short term extract stability 
005.dat 
QC4a-1h-
021508 
215.07 236.14 86% 99% 
10AD-021508-Rat plasma 
short term extract stability 
006.dat 
QC4b-1h-
021508 
225.8 227.37 94% 100% 
10AD-021508-Rat plasma 
short term extract stability 
007.dat 
QC4c-1h-
021508 
262.41 257.81 99% 101% 
10AD-021508-Rat plasma 
short term extract stability 
008.dat 
QC4a-3h-
021508 
198.94 238.38 80% 100% 
10AD-021508-Rat plasma 
short term extract stability 
009.dat 
QC4b-3h-
021508 
223.19 241.35 93% 106% 
10AD-021508-Rat plasma 
short term extract stability 
010.dat 
QC4c-3h-
021508 
257.54 265.72 97% 104% 
10AD-021508-Rat plasma 
short term extract stability 
011.dat 
QC4a-6h-
021508 
195.34 265.41 78% 111% 
10AD-021508-Rat plasma 
short term extract stability 
012.dat 
QC4b-6h-
021508 
195.01 252.86 81% 111% 
10AD-021508-Rat plasma 
short term extract stability 
013.dat 
QC4c-6h-
021508 
228.42 266.15 86% 104% 
10AD-021608-Rat plasma 
short  term extract stability 
003 
QC4a-24h-
021608 
211.44 337.54 85% 141% 
10AD-021608-Rat plasma 
short  term extract stability 004 
QC4b-24h-
021608 
230.68 336.31 96% 147% 
10AD-021608-Rat plasma 
short  term extract stability 005 
QC4c-24h-
021608 
232.01 350.89 88% 137% 
 
 145 
 
Raw data: Long term extract stability 
Data file name 
 
Sample ID 
Carb.  
(ng/mL) 
Lact. 
(ng/mL) 
Carb. 
 % initial  
Lact.  
% initial 
Day 1 
20AC-041108-Rat PK 
Expt 111 & 112 056.dat QC1a-day0-long term 7.73 7.14 100% 100% 
20AC-041108-Rat PK 
Expt 111 & 112 057.dat QC1b-day0-long term 7.35 8.65 100% 100% 
20AC-041108-Rat PK 
Expt 111 & 112 058.dat QC1c-day0-long term 7.01 7.22 100% 100% 
day 7 
20AC-041808-Rat 
plasma matrix & extract 
stability 001.dat 
QC1a-extract-day 7-
041808 8.02 7.98 103.8% 111.8% 
20AC-041808-Rat 
plasma matrix & extract 
stability 002.dat 
QC1b-extract-day 7-
041808 7.6 7.77 103.4% 89.8% 
20AC-041808-Rat 
plasma matrix & extract 
stability 003.dat 
QC1c-extract-day 7-
041808 7.59 6.9 108.3% 95.6% 
Day 14 
20AC-extract matrix 
stability-042508-002.dat 
QC1a-Extract 
(041108) 6.64 6.85 85.9% 95.9% 
20AC-extract matrix 
stability-042508-003.dat 
QC1b-Extract 
(041108) 6.15 8.05 83.7% 93.1% 
20AC-extract matrix 
stability-042508-004.dat 
QC1c-Extract 
(041108) 5.92 7.11 84.5% 98.5% 
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Long term matrix stability 
Data file 
 
Sample ID 
Carb  
(ng/mL) 
Lact  
(ng/mL) 
Carb  
% initial  
Lact  
% initial  
Day 1 
20AC-041108-Rat PK 
Expt 111 & 112 059.dat 
QC4a-day0-long 
term 262.58 261.12 100% 100% 
20AC-041108-Rat PK 
Expt 111 & 112 061.dat 
QC4c-day0-long 
term 272.44 279.4 100% 100% 
Day 7 
20AC-041808-Rat 
plasma matrix & extract 
stability 009.dat 
QC4a-matrix-day 7-
041808 290.91 203.6 110.8% 78.0% 
20AC-041808-Rat 
plasma matrix & extract 
stability 010.dat 
QC4b-matrix-day 7-
041808 265.37 199.65 
20AC-041808-Rat 
plasma matrix & extract 
stability 011.dat 
QC4c-matrix-day 7-
041808 289.1 210.9 106.1% 75.5% 
Day 14 
20AC-extract matrix 
stability-042508-014.dat 
QC4a-matrix 
(041108) 276.29 166.08 105.2% 63.6% 
20AC-extract matrix 
stability-042508-015.dat 
QC4b-matrix 
(041108) 330.01 202.5 
20AC-extract matrix 
stability-042508-016.dat 
QC4c-matrix 
(041108) 249.37 203.44 91.5% 72.8% 
Day 21 
20AC-050208-Rat PK 
Expt 122 & 124 040.dat QC4a-day 21-matrix 272.83 232.05 103.9% 88.9% 
20AC-050208-Rat PK 
Expt 122 & 124 041.dat QC4c-day 21-matrix 297.96 267.16 109.4% 95.6% 
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Inter and intraday variability and accuracy of Quality controls    
Day 1 QC-1 ( 7 ng/mL) QC-3 (150 ng/mL) QC-4 (250 ng/mL) 
  
  
  
  
  
  
Carb. Lact. Carb. Lact. Carb. Lact. 
109.14 100.14 99.51 90.33 95.29 97.16 
107.43 95.43 98.80 90.37 102.22 103.76 
108.86 97.43 100.37 92.55 97.47 100.08 
109.00 100.14 101.92 94.29 98.53 101.58 
106.71 95.71 104.23 96.47 99.20 103.08 
Average 108.23 97.77 100.97 92.80 98.54 101.13 
SD 1.09 2.30 2.16 2.63 2.53 2.64 
RSD 1.01 2.35 2.14 2.84 2.57 2.61 
Day 2 
QC-1  
(7 ng/mL) QC-3 (150 ng/mL) QC-4 (250 ng/mL) 
  
  
  
  
  
  
  
  
  
  
  
Carb. Lact. Carb. Lact. Carb. Lact. 
116 98.57 99.02 90.30 95.19 100.00 
110.5714 95 104.25 96.06 91.21 96.56 
108.2857 94.45 101.45 94.31 93.40 98.67 
109.1429 96.71 93.71 86.17 92.16 96.33 
108.8571 97.71 99.45 92.45 95.07 100.07 
95.57 90.87   
95.79 92.98   
94.15 92.89   
91.26 91.07   
94.03 94.70   
Average 110.57 96.49 96.87 92.50 93.41 98.33 
SD 3.15 1.76 4.04 1.58 1.76 1.81 
RSD 2.85 1.82 4.17 1.70 1.88 1.84 
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Day 3 
QC-1 
 ( 7 ng/mL) 
QC-3 ( 150 
ng/mL) 
QC-4 ( 250 
ng/mL) 
  
  
  
  
  
  
  
  
  
  
  
Carb. Lact. Carb. Lact. Carb. Lact. 
121 103.1429 105.78 89.94 98.47 98.22 
115.5714 100.5714 106.84 95.54 99.41 99.46 
108 92.28571 106.21 96.13 97.81 100.24 
114 97.71429 105.97 95.91 98.79 102.34 
106.7143 94.28571 107.23 97.97 96.82 102.26 
93.66 97.70 
98.68 101.48 
101.82 106.96 
104.07 106.98 
108.15 109.40 
Average 113.06 97.60 106.41 95.10 99.77 104.51 
SD 5.83 4.44 0.61 3.03 4.04 4.79 
RSD 5.16 4.55 0.57 3.19 4.05 4.58 
Day 4 QC-1 ( 7 ng/mL) 
QC-3 ( 150 
ng/mL) 
QC-4 ( 250 
ng/mL) 
  Carb. Lact. Carb. Lact. Carb. Lact. 
  126.2857 102 110.91 96.00 107.44 104.27 
  122.8571 101.8571 110.61 96.39 106.77 106.96 
  111.7143 95 109.70 96.02 105.25 105.07 
  112.4286 96 111.15 97.30 106.50 107.10 
  115.5714 104.8571 112.65 99.15 99.75 102.94 
Average 117.77 99.94 111.00 96.97 105.14 105.27 
SD 6.49 4.24 1.07 1.33 3.12 1.78 
RSD 5.51 4.25 0.96 1.37 2.96 1.69 
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Intraday accuracy and precision. 
 
 
 
 
 
 
 
 
 
 
 QC-3 ( 150 
ng/mL) 
QC-4 ( 250 
ng/mL) 
Carb. Lact. Carb. Lact. 
99.02 90.30 98.47 98.22 
104.25 96.06 99.41 99.46 
101.45 94.31 97.81 100.24 
93.71 86.17 98.79 102.34 
99.45 92.45 96.82 102.26 
95.57 90.87 93.66 97.70 
95.79 92.98 98.68 101.48 
94.15 92.89 101.82 106.96 
91.26 91.07 104.07 106.98 
94.03 94.70 108.15 109.40 
Average 96.87 92.50 99.77 104.51 
SD 4.04 1.58 4.04 4.79 
RSD 4.17 1.70 4.05 4.58 
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APPENDIX II.   
MAXIMUM TOLERATED DOSE (MTD) FINDING EXPERIMENTS AND 
XENOGRAFT STUDIES IN FEMALE ATHYMIC NUDE MICE (NU/NU) 
Maximum Ttolerated dose (MTD)  
Animals were administered with D5W, 5 mg/kg, 7.5 mg/kg, 10 mg/kg and 15 
mg/kg either orally or intravenously for five days (n=3/treatment, total n=30). Weight 
was recorded everyday during treatment and every other day following cessation of 
treatment. Blood counts were done on days 8, 11 and 21 after the first treatment. (The 
day treatment started was taken as day 0). Blood was withdrawn from the submandibular 
vein using lancets and the blood collected in hematocrit tubes. The count was made with 
Heska Vet Blood analyzer.  
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Figure A2- 1. Weights (gm) of nude mice treated with control (5% dextrose, D5W), 5, 
7.5, 10 or 15 mg/kg AR-67 lactone A) intravenously and B) orally for five days. AR-67 
was well tolerated following both oral and intravenous routes of administration.  
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Figure A2- 2. Figure A2.2. Complete Blood counts (CBC x103) on day 8 in animals 
treated with control (D5W), 5, 7.5, 10 or 15 mg/kg AR-67 lactone either orally or 
intravenously for five days. Intravenous doses of AR-67 ≥ 7.5 mg/kg resulted in reduced 
CBC counts to below normal levels.  
a) Xenograft studies 
Non-small cell lung cancer (H460) tumor was implanted in the flank region of 
nu/nu mice (body weight 20-25 g). When tumors were palpable, mice (n=7 per treatment 
group) were randomized to four treatment groups and received  
a). Control (5% dextrose in water (D5W) intravenously, b). 7.5 mg/kg/day intravenously 
for 5 days per cycle (1 cycle=21 days), c). 3.75 mg/kg/day intravenously for 10 days per 
cycle or d). 2.5 mg/kg/day intravenously for 15 days per cycle 
The width and length of the tumors were measured using a caliper every other day 
for the duration of the study. Tumor volume was calculated using the following formula:  
6
**
2baPIV  ; V- is tumor volume in mm3, PI=3.1416, a=size of the longest 
side in millimeters, b=size of the shortest side in millimeters. Mice were euthanized when 
their tumor volume reached 1500 mm3 for humane reasons. Comparison between the 
median survivals of different treatment groups was done using Kaplan-Meir survival 
analysis.  
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Figure A2- 3. Tumor volumes (mm3) in animals nude mice treated with control or AR-67 
intravenously (7.5 mg/kg for five days, 3.75 mg/kg for 10 days or 2.5 mg/kg for 15 
mg/kg).  
0 10 20 30 40
0.0
0.2
0.4
0.6
0.8
1.0 Control
7.5 mg/kg (Dx5)
3.75 mg/kg (Dx5x2)
2.5 mg/kg (Dx5x3)
Time, days
Su
rv
iv
in
g 
Fr
ac
tio
n
 
Figure A2- 4. Survival of H460 tumor bearing animals treated with control or AR-67 
intravenously (7.5 mg/kg for five days, 3.75 mg/kg for 10 days or 2.5 mg/kg for 15 
mg/kg). Median survival of mice receiving 3.75 mg/kg x10 days or 2.5 mg/kg x15 days 
was significantly longer than those receiving 7.5 mg/kg x5 days or control (5% dextrose 
in water). 
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APPENDIX III 
ANIMAL EXPERIMENTS DATA 
 
These studies were designed to assess 1) the effect of transporters on the AR-67oral 
bioavailability, 2) establish in-vivo/in-vitro correlations that would enable rapid screening 
of formulations in-vitro and allow for selection and further screening of formulations 
with potentially increased bioavailability, 3) to determine the bioavailability of selected 
formulations in capsule form. The studies were intended to be carried out in rats due to 
experimental limitations associated with administering capsules to mice. Initial studies in 
rats focused on the effect of transporters on the oral bioavailability of AR-67 and on 
establishing in-vivo/in-vitro correlations. 
A. The effect of transporters on the oral bioavailability of AR-67 lactone and 
AR-67 carboxylate 
Pharmacologic inhibition of efflux transporter proteins in the intestine was 
accomplished with GF120918 (N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-
isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide). 
This experimental agent has previously been shown to be an inhibitor of P-glycoprotein 
and BCRP. These proteins represent the two major efflux pumps expressed on the apical 
face of the intestinal epithelium and are known to transport xenobiotics, including other 
camptothecin analogs.  
A1. Experimental design 
To determine the effect of GF120918 (formulated in 40% PEG-300, 10% Tween-
80 in D5W) on the oral bioavailability of AR-67 we administered the lactone or 
carboxylate forms formulated in SBE-β-CD (200:1, excipient: drug (w/w)). The dose of 
GF120918 was chosen following studies that determined the oral GF120918 dose 
required to obtain maximum area under the time-concentration curve (AUC) of total 
(lactone + carboxylate) AR-67 when AR-67 was administered orally as the lactone form.  
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To account for the increased liquid volume administered orally when animals 
were pretreated with GF120918, animals in control experiments received an equivalent 
volume of 5% dextrose in water (D5W) prior to receiving the drug. In addition, the 
effects of the vehicle/excipients used to solubilize GF120918 were assessed in separate 
studies administering the vehicle prior to AR-67. For proper assessment of 
bioavailability, the effect of GF120918 and its vehicle on the AUC was assessed 
following oral and intravenous administration of AR-67 as the lactone or carboxylate 
form.  
Some additional experiments were carried out to determine the role of individual 
transporters and enzymes on the oral AUC of AR-67 lactone. Zosuquidar was used as an 
inhibitor of P-glycoprotein and novobiocin as an inhibitor of BCRP. Grapefruit juice and 
valproic acid pretreatment were used to assess the effects of CYP450 and UGT enzymes, 
respectively, on the oral AR-67 AUC. 
The descriptions of the above experiments are listed in  
Table 1. The experiment number can be used as a reference for experimental 
details and raw data.   
 
A2. Summary of methods for pharmacokinetic experiments and sample 
analysis  
All experiments were carried out in female Sprague-Dawley rats weighing 
approximately 300 grams. Each experiment was done in 3-6 rats. Drugs were 
administered via oral gavage or as an intravenous bolus injection in the tail vein. Blood 
samples (100-200 µL) were collected using saphenous vein bleeding and animals did not 
require anesthetization. Samples were collected at multiple time points from each animal 
and the concentration of AR-67 lactone and AR-67 carboxylate was assessed by HPLC 
after the system suitability criteria were met (i.e., three quality control standard solutions 
spanning a range of 2.5 – 300 ng/mL were prepared in plasma and analyzed. System 
suitability was met when their concentration was within 15% of the theoretical value).. 
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Table 1. Description of experiments designed to assess the effects of efflux transporters 
on oral bioavailability of AR-67 lactone and carboxylate in Sprague-Dawley rats (Table 1 
continues on following page). 
Exp# Title/Objective N  Notes 
102 
The effects of D5W (7.5 mL/kg) PO on oral bioavailability 
of SBE-β-CD (200:1 E/D ratio) based AR-67 lactone (2.5 
mg/kg) PO in female SD rats  
 
100 
The effects of GF120918 vehicle (40% PEG-300, 10% 
Tween-80 in D5W) PO pretreatment on bioavailability of 
SBE-β-CD (200:1 E/D ratio) based AR-67 lactone PO (2.5 
mg/kg) in female SD rats 
6   
101a 
The effects of GF120918 vehicle (7.5 mL/kg) PO on oral 
bioavailability of SBE-β-CD (200:1 E/D ratio) based AR-
67 lactone (2.5 mg/kg) PO in rats  
Repeat 
of exp 
100 
106 
Study on the effects of GF120918 (0.25 mg/kg) on the oral 
bioavailability of SBE-β-CD (200:1 E/D ratio) based AR-
67 lactone (2.5 mg/kg) PO in female SD rats 
 
127 
Study on effects of GF120918 (0.25 mg/kg) on PK of SBE-
β-CD based (200:1 E/D ratio) AR-67 lactone (2.5 mg/kg) 
PO in female SD rats 
Repeat 
of exp 
106 
105 
Study on the effects of GF (1.0 mg/kg) on the oral 
bioavailability of SBE-β-CD (200:1 E/D ratio) based AR-
67 lactone (2.5 mg/kg) PO in female SD rats 
 
101b 
The effects of GF120918 (2.5 mg/kg) PO on oral 
bioavailability of SBE-β-CD (200:1 E/D ratio) based AR-  
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67 lactone (2.5 mg/kg) PO in female SD rats 
103a 
The effects of GF120918 (2.5 mg/kg) PO on oral 
bioavailability of SBE-β-CD (200:1 E/D ratio) based AR-
67 lactone (2.5 mg/kg) PO in female SD rats 
Repeat 
of exp 
101b 
104b 
Study the effects GF120918 (2.5 mg/kg)  PO on PK profile 
following IV administration of SBE-β-CD (200:1 E/D 
ratio) based AR-67 lactone (2.5 mg/kg) in female SD rats  
 
103b 
Study the effects of GF120918 (20.0 mg/kg) PO on oral 
bioavailability of SBE-β-CD (200:1 E/D ratio) based AR-
67 lactone (20 mg/kg) PO in female SD rats 
 
104a 
Study the effects of GF120918 vehicle (7.5 mL/kg) PO on 
PK profile following IV administration of SBE-β-CD 
(200:1 E/D ratio) based AR-67 lactone (2.5 mg/kg) in 
female SD rats  
 
107a 
Study the effects of GF120918 vehicle (7.5 mL/kg) PO on 
PK profile following IV administration of SBE-β-CD 
(200:1 E/D ratio) based AR-67 lactone (2.5 mg/kg) in 
female SD rats  
 
107b 
Study the effects GF120918 PO (2.5mg/kg) on PK profile 
following IV administration of SBE-β-CD (200:1 E/D 
ratio) based AR-67 lactone (2.5 mg/kg) in female SD rats  
 
Table 1 continued 
108 
Study the effects of D5W (7.5 mL/kg) PO on PK profile 
following IV administration of SBE-β-CD (200:1 E/D 
ratio) based AR-67 lactone (2.5 mg/kg) in female SD rats  
 
131 
Study on effects of GF120918 in 10% PEG-300 (2.5 
mg/kg) on PK of SBE-β-CD based (200:1 E/D ratio) AR-
67 lactone (2.5 mg/kg) PO in female SD rats 
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135 
Study on effects of GF120918 (2.5 mg/kg) IV on PK of 
SBE-β-CD based (200:1 E/D ratio) AR-67 lactone (2.5 
mg/kg) PO in female SD rats 
 
152 
Study on the effects of GF120918 (8.25 mg/kg) IV on oral 
bioavailability of SBE-β-CD (200:1 E/D ratio) based AR-
67 lactone (2.5 mg/kg) in female SD rats 
 
     
113 
Study on oral bioavailability of buffered SBE-β-CD (200:1, 
E:D) based AR-67 carboxylate (2.5 mg/kg) in female SD 
rats 
 
114 
Study on oral bioavailability of unbuffered SBE-β-CD 
(200:1, E:D) based AR-67 carboxylate (2.5 mg/kg) in 
female SD rats 
 
119 
The effect of GF120918 vehicle (7.5 mL/kg) PO on SBE-β-
CD  (200:1 E/D ratio) AR-67 carboxylate (2.5 mg/kg ) PO 
in female SD rats 
 
125 
The effect of GF120918 vehicle (7.5 mL/kg) PO on SBE-β-
CD  (200:1 E/D ratio) AR-67 carboxylate (2.5 mg/kg ) PO 
in female SD rats 
Repeat 
of exp 
119 
120 
The effect of GF120918 vehicle (7.5 mL/kg) PO on SBE-β-
CD  (200:1 E/D ratio) AR-67 carboxylate (2.5 mg/kg ) IV 
in female SD rats 
 
126 
The effect of GF120918 vehicle (7.5 mL/kg) PO on SBE-β-
CD  (200:1 E/D ratio) AR-67 carboxylate (2.5 mg/kg ) IV 
in female SD rats 
Repeat 
of exp 
120 
117 
Study on the effect of GF120918 (2.5 mg/kg) PO on 
bioavailability of SBE-β-CD based AR-67 carboxylate (2.5 
mg/kg) PO in female SD rats 
 
128 
Study on the effect of GF120918 (2.5 mg/kg) PO on 
bioavailability of SBE-β-CD based AR-67 carboxylate (2.5 
mg/kg) PO in female SD rats 
Repeat 
of exp 
117 
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118 
Study on effects of GF120918 (2.5 mg/kg) PO on PK of 
SBE-β-CD based (200:1 E/D ratio) AR-67 carboxylate (2.5 
mg/kg) IV in female SD rats 
 
129 
Study on effects of GF120918 (2.5 mg/kg) PO on PK of 
SBE-β-CD based (200:1 E/D ratio) AR-67 carboxylate (2.5 
mg/kg) IV in female SD rats 
Repeat 
of 
exp118
121 
Study the effect of the selective P-gp inhibitor zosuquidar 
(20 mg/kg) PO on bioavailability of SBE-β-CD based AR-
67 lactone (2.5 mg/kg) PO in female SD rats 
 
122 
Study the effect of the selective P-gp inhibitor zosuquidar 
(20 mg/kg) PO on the kinetics of SBE-β-CD based AR-67 
lactone (2.5 mg/kg) IV in female SD rats 
 
123 
Study the effect of the selective Bcrp inhibitor novobiocin 
(50 mg/kg) PO on bioavailability of SBE-β-CD based AR-
67 lactone (2.5 mg/kg) PO in female SD rats  
 
124 
Study the effect of the selective Bcrp inhibitor novobiocin 
(50 mg/kg) PO on the kinetics of SBE-β-CD based AR-67 
lactone (2.5 mg/kg) IV in female SD rats 
 
132 
Study on effects of grapefruit juice double strength (10 
mL/kg) on PK of SBE-β-CD based (200:1 E/D ratio) AR-
67 lactone (2.5 mg/kg) PO in female SD rats 
 
134 
Study on effects of UGT inhibition by valproic acid (200 
mg/kg) on PK of SBE-β-CD based (200:1 E/D ratio) AR-
67 lactone (2.5 mg/kg) PO in female SD rats 
 
 
A3. Data Analysis 
Data were analyzed using non-compartmental analysis methods with WinNonlin 
v5.2 and GraphPad Prism 5.02. The area under the time-concentration curve was used to 
compare different formulations. Statistical analyses using t-test or ANOVA were carried 
out when appropriate. 
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A4. Results (effect of transporters on lactone and carboxylate) 
In all cases the plasma concentration of AR-67 was primarily in the lactone form. 
A representative profile of AR-67 lactone and carboxylate pharmacokinetics is presented 
in  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. A summary of the treatment and resulting AUC and bioavailability is 
presented in  
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Table 1 and Table 2.  
The oral bioavailability of AR-67 prepared in SBE-β-CD (200:1, E:D) was low in 
the rat (3.72% (±1.22%)). A dose dependent increase in the total AR-67 AUC was 
observed with increasing dose of GF120918. However, there was no significant 
difference in the oral AR-67 AUC between groups pretreated with 2.5 mg/kg and 20 
mg/kg of GF120918 (886.72 (±155.95) vs. 1149.13 (±202.20 hr-ng/mL)). Inhibition of 
transporters with 2.5 mg/kg GF120918 significantly increased the total AR-67 
bioavailability to 32.45% (±8.82%). However, some of that increase was a result of the 
GF120918 formulation, which alone increased the AR-67 bioavailability from 3.72% to 
7.36% (±2.23%).  
Given that GF120918 inhibits both P-glycoprotein and BCRP, some preliminary 
studies were conducted to assess the effect of single transporters. Zosuquidar (20 mg/kg) 
was used as an inhibitor of P-glycoprotein and novobiocin (50 mg/kg) as an inhibitor of 
BCRP. Zosuquidar treatment resulted in an increase of total AR-67 AUC, but its effect 
was relatively minor and resulted in an insignificant bioavailability increase of 6.70% 
(±2.41%) as compared to the control. The effect of novobiocin was also insignificant and 
pretreatment resulted in no apparent increase in the AUC.  
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Figure 1. Typical AR-67pharmacokinetic profiles in plasma following (A, B) oral and (C, 
D) intravenous administration of (A, C) lactone and (B, D) carboxylate forms of AR-67. 
 
Based on the low overall bioavailability, we also explored the potential 
contribution of metabolizing enzymes on the disposition of AR-67. Pretreatment with 
grapefruit juice is known to inhibit metabolizing enzymes of the CYP450 family while 
valproic acid has been shown to inhibit the effect of conjugating enzymes such as those 
of the UGT family. In these preliminary studies the effects of both inhibitors were minor. 
The effect of transporter inhibition on AR-67 disposition following carboxylate 
administration was also assessed. The experimental treatments and the resulting AUC and 
bioavailability estimates are presented in Table 3. Carboxylate was administered in SBE-
β-CD (200:1, E:D) and was either unbuffered or buffered with 0.5M sodium bicarbonate 
to sustain the carboxylate form in the rat stomach. The volume and buffer strength were 
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chosen based on preliminary studies that demonstrated that the stomach pH could be 
maintained ~pH 7 for 30-45 minutes (data not shown). The total bioavailability of oral 
carboxylate was 3.23% (±1.09%) when the carboxylate formulation was buffered with 
sodium bicarbonate to sustain the carboxylate form after oral administration vs. 4.33% 
(±1.29%) when the carboxylate solution was unbuffered. These bioavailability estimates 
were calculated using the intravenous lactone dose of AR-67. As with the lactone form, 
pretreatment with GF120918 (2.5 mg/kg) PO increased the oral bioavailability of total 
AR-67 to 36.48% (±5.15%) when bioavailability was estimated using the intravenous 
carboxylate dose (exp 118, 129) and 16.42% (±3.82%) when compared to intravenous 
lactone following GF120918 pretreatment. The latter is a rational comparison given that 
following oral administration of carboxylate the primary form measured in plasma was 
the lactone form (see  
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Figure 1and Figure 2, panel B). 
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Figure 2. Typical lactone fraction profiles following (A, B) oral and (C, D) intravenous 
administration of (A, C) lactone and (B, D) carboxylate forms of AR-67. 
A5. Conclusions  
We conclude that AR-67 bioavailability in rats is low. AR-67 lactone is the major 
species observed in plasma after intravenous and oral administration. Following 
administration of the carboxylate form intravenously there is a rapid conversion to the 
lactone form within 2 hours. Although further work is needed to confirm this observation, 
it is likely that only the converted lactone is being absorbed after oral administration of 
carboxylate.  
Pharmacologic inhibition of transporters increases the AUC when AR-67 is 
administered orally or intravenously. Although the bioavailability increases, it is only 
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~32%. This suggests that other unknown factors are more important contributors to the 
low bioavailability observed in the rat. Further studies are needed to determine the 
importance of BCRP and P-glycoprotein, but the minimal effect of zosuquidar, a 
validated P-glycoprotein inhibitor, suggests that P-glycoprotein may not be a major factor 
in the efflux of AR-67. An obvious implication for this result is the potential for 
increased partition in the brain, which is typically protected from xenobiotic entry via the 
action of P-glycoprotein expressed at the blood-brain barrier. This result along with the 
role of BCRP and intestinal metabolizing enzymes will have to be explored further in 
order to draw more definitive conclusions. 
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Table 2. The effect of transporter and metabolizing enzyme modulators on AR-67 lactone bioavailability. 
Exp# Pretreatment  Pretreatment Route 
AR-67  
Route 
Average AUC  
(hr-ng/mL) SE F SE 
F 
estimated 
using 
exp# 
102 D5W PO PO 68.64 21.61 3.72% 1.22% 108 
108 D5W PO IV 1845.77 177.79    
100 , 
101a 
GF120918 
vehicle PO PO 127.84 32.35 7.36% 2.23% 104a/107a 
106, 
127 
GF120918 – 
0.25 mg/kg PO PO 248.67 63.94    
105 GF120918 – 1.0 mg/kg PO PO 646.93 105.61    
101b, 
103a 
GF120918 – 
2.5 mg/kg PO PO 886.72 155.95 32.45% 8.82% 104b/107b
103b GF120918 – 20  mg/kg PO PO 1149.13 202.20    
         
104a, 
107a 
GF120918 
vehicle PO IV 1736.02 288.80    
104b, 
107b 
GF120918 – 
2.5 mg/kg PO IV 2732.88 566.53    
131 
GF120918 
(10% PEG-
300) 
PO PO 289.01 28.67    
135 GF120918 – 2.5 mg/kg IV PO 244.14 57.99    
152 GF120918 – 8.25 mg/kg IV PO 324.85 63.32    
121 Zosuquidar – 20 mg/kg PO PO 155.68 55.95 6.70% 2.41% 122 
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122 Zosuquidar – 20 mg/kg PO IV 2323.42 49.04    
123 Novobiocin – 50 mg/kg PO PO 65.71 31.84 3.68% 1.94% 124 
124 Novobiocin – 50 mg/kg PO IV 1784.77 373.85    
132 
Grapefruit 
juice – 10 
mL/kg 
PO PO 112.60 15.09 6.10% 1.01% 108 
134 Valproic acid – 200 mg/kg PO PO 90.70 5.15 4.91% 0.55% 108 
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Table 3. The effect of transporter modulator GF120918 on AR-67 carboxylate bioavailability. 
Exp# Pretreatment  Pretreatment Route AR-67 Route 
Average  
AUC             
(hr-ng/mL) 
SE F SE 
F 
estimated  
using exp# 
       
113 None NA PO (buffered) 59.67 19.31 3.23% 1.09% 108 
114 None NA PO (unbuffered) 79.89 22.59 4.33% 1.29% 108 
119, 
125 GF120918 vehicle PO PO 104.14 12.31    
120, 
126 GF120918 vehicle PO IV 833.48 120.44    
117, 
128 GF120918  PO PO 448.61 47.71 
36.48% 5.15% 118, 129 
16.42% 3.82% 104b, 107b 
118, 
129 GF120918 PO IV 1229.78 114.15    
        
 
 
  
B. Pharmacokinetic experiments to establish vitro/in-vivo correlations (IVIVC) 
in rats 
Several formulations were prepared by Dr. Anderson’s laboratory in order to test 
the capacity of different excipients to maintain supersaturation in-vitro by measuring the 
extent of AR-67 precipitation and relate that to oral bioavailability. All formulations were 
prepared by Dr. Anderson’s lab and were provided on the day of the experiment. 
  
B1. Experimental design 
The descriptions of the above experiments are listed in Table 4. The experiment 
number can be used as a reference for experimental details and raw dataSeveral 
formulations were prepared in . order to achieve AR-67 supersaturation and maintain a 
solution.  The extent of precipitation was to be compared with the bioavailability of each 
formulation. For animal experiments, the excipients were dissolved in simulated gastric 
fluid. Based on the results of the in-vitro studies the excipient concentrations were chosen 
to be 28:1 (E/D) as though to minimize the excipient that may be required to prepare 
capsules or tablets. A solution of AR-67 carboxylate was prepared in a basic solution and 
was mixed with simulated gastric fluid just prior to the gavage. Under these conditions, 
the carboxylate converts to the lactone and depending on the excipient it either stays in 
solution or precipitates. All animals received a dose of 2.5 mg/kg AR-67 lactone by oral 
gavage. Based on the results of experiments 109-112, the experiments with the best and 
worst excipient, in terms of maintaining supersaturation in-vitro, were repeated in male 
rats (exp 146 (Vitamin E-TPGS) and exp 147 (PEG-6000)). 
Given the overall poor bioavailability, we also explored the potential for dose 
dependent bioavailability of the lactone and carboxylate forms. These experiments were 
performed using the SBE-β-CD (200:1 E/D ratio) formulation and the experiment 
number and descriptions are given in Table 5. The potential for using carboxylate as a 
means to prepare a spray-dried formulation was also explored by administering AR-67 
carboxylate in Vit E-TPGS (28:1,E/D). As shown in Table 6 buffered and unbuffered 
  
formulations of carboxylate in Vit E-TPGS were prepared. The buffer was included in an 
effort to maintain the carboxylate form once administered in the stomach via gavage. 
 
B2. Summary of animal experiments and sample analysis  
All experiments were carried out in Sprague-Dawley rats weighing approximately 
300 grams. Please refer to section A2 for additional details. 
 
B3. Data Analysis 
Data were analyzed using non-compartmental analysis methods with WinNonlin 
v5.2 and GraphPad Prism 5.02. The area under the time-concentration curve was used to 
compare different formulations. Statistical analyses using t-test or ANOVA were carried 
out when appropriate. 
Table 4. Description of experiments designed to establish in-vitro/in-vivo correlation 
(IVIVC) between degree of supersaturation/precipitation and oral bioavailability. 
Exp# Title/Objective  Notes 
109 Study the oral bioavailability of PEG-6000 (28:1, E:D) based AR-67 lactone at 2.5 mg/kg in female SD rats  
110 Study the oral bioavailability of HP-CD (28:1, E:D) based AR-67 lactone at 2.5 mg/kg in female SD rats 3   
111 Study the oral bioavailability of SBE-β-CD (28:1, E:D) based AR-67 lactone at 2.5 mg/kg in female SD rats 3   
112 Study the oral bioavailability of vitamin E-TPGS (28:1, E:D) based AR-67 lactone at 2.5 mg/kg in female SD rats 3   
146 Study the oral bioavailability of E-TPGS (28:1 E/D ratio) based AR-67 lactone in male SD rats (2.5 mg/kg) PO  3 
Repeat 
of 
exp112  
47 
Study the oral bioavailability of PEG-6000 (28:1 E/D ratio) based 
AR-67 lactone in male SD rats (2.5 mg/kg) PO 3 
Repeat 
of 
exp109  
 
  
Table 5. Effect of lactone or carboxylate dose on total AR-67 AUC. 
Exp
# Title/Objective  Notes 
151 Study the oral bioavailability of SBE-β-CD (200:1 E/D ratio) based AR-67 carboxylate (2.5 mg/kg) PO in female SD rats 3 
Carboxylate 
dose 
dependence 
141 Study the oral bioavailability of SBE-β-CD (200:1 E/D ratio) based AR-67 carboxylate (5 mg/kg) PO in female SD rats 3 
Carboxylate 
dose 
dependence 
138 Study the oral bioavailability of SBE-β-CD (200:1 E/D ratio) based AR-67 carboxylate (10 mg/kg) PO in female SD rats 3 
Carboxylate 
dose 
dependence 
140 Study the oral bioavailability of SBE-β-CD (200:1 E/D ratio) based AR-67 lactone (5 mg/kg) PO in female SD rats 3 
Lactone dose 
dependence  
137 Study the oral bioavailability of SBE-β-CD (200:1 E/D ratio) based AR-67 lactone (10 mg/kg) PO in female SD rats 3 
Lactone dose 
dependence  
Note: Experiment 102 was used as the 2.5 mg/kg lactone dose. 
Table 6. Effect of Vitamin E-TPGS on the bioavailability of AR-67 carboxylate. 
Exp# Title/Objective  Notes 
115 Study the oral bioavailability of buffered Vitamin E-TPGS (28:1, E:D) based AR-67 carboxylate (2.5 mg/kg)   
116 Study the oral bioavailability of unbuffered Vitamin E-TPGS (28:1, E:D) based AR-67 carboxylate (2.5 mg/kg)   
 
B4. Results (IVIVC) 
All formulations yielded low AUCs and consequently low oral bioavailability 
ranging from 2.38%-3.88% (see Table 7). Although there were some differences between 
the worst performing and best performing formulations (ranked from in-vitro results), 
these were minor and not as dramatic as would be expected based on the in-vitro 
behavior.  
The potential for differential pharmacokinetics by gender was also explored 
because female rats have increased expression of some CYP450 enzyme isoforms. 
However, there was no significant difference in the oral bioavailability between male and 
  
female rats administered the PEG-6000 and the Vitamin E-TPGS based formulations. 
The oral bioavailability in male rats was 3.04% for PEG-6000 and 3.52% for Vit E-TPGS 
based formulations. 
The effect of dose on oral bioavailability was also examined (Table 8) but there 
was no significant difference with increasing dose of either the lactone or the carboxylate 
forms administered orally as determined by linear regression analysis of the 
bioavailability data ( 
 
 and Figure 3).  
The vitamin E-TPGS based carboxylate formulations (Table 10) yielded AUCs 
that were equivalent to the lactone formulation (exp 102) and the resulting bioavailability 
was 4.03% (±1.15%) for the unbuffered formulation and 3.63% (±0.59%) for the 
buffered one. 
 
Table 7. Results of pharmacokinetic studies designed to establish in-vitro/in-vivo 
correlations. All excipients were in 28:1 (E/D) ratio. 
Exp# Excipient Rat gender 
Average 
AUC            
(hr-ng/mL) 
SE F SE F estimated using exp# 
       
109 PEG-6000 Female 43.93 8.34 2.38% 0.51% 
108 (AR-67 
administered 
IV in SBE- β-
CD, 200:1, 
[E/D]) 
110 HP-CD Female 46.34 6.42 2.51% 0.42% 
111 SBE-β-CD Female 52.46 11.11 2.84% 0.66% 
112 Vit E-TPGS Female 71.69 7.47 3.88% 0.55% 
146 Vit E-TPGS Male 64.91 5.58 3.52% 0.45% 
147 PEG-6000 Male 56.09 3.71 3.04% 0.36% 
        
 
  
Table 8. The effect of dose on AR-67 carboxylate and lactone bioavailability. 
Exp# AR-67 form/dose  (mg/kg)  
Average 
AUC     
(hr-ng/mL) 
SE F SE F estimated using exp# 
     
151 Carboxylate (2.5) 135.57 39.49 7.34% 2.25% 
108 
(AR-67 
administered 
IV in SBE- 
β-CD, 
200:1, 
[E/D]) 
141 Carboxylate (5) 146.48 46.26 3.97% 1.31% 
138 Carboxylate (10) 323.11 39.66 4.38% 0.68% 
102 Lactone (2.5) 68.64 21.61 3.72% 1.22% 
140 Lactone (5) 183.97 41.78 4.98% 1.23% 
137 Lactone (10) 358.37 50.23 4.85% 0.83% 
       
 
  
 
 
 
 
 
 
 
Figure 3. Effect of AR-67 dose on oral bioavailability. Lines represent linear regression 
(see  
 
). 
Table 9. Linear regression analysis of bioavailability data presented in Table 8. 
Best-fit values Lactone  Carboxylate 
Slope 0.1254 ± 0.1311 -0.3266 ± 0.3538 
Y-intercept when X=0.0 3.785 ± 0.8674 7.135 ± 2.340 
X-intercept when Y=0.0 -30.18 21.85 
1/slope 7.973 -3.062 
95% Confidence Intervals     
Slope -1.541 to 1.792 -4.822 to 4.169 
Y-intercept when X=0.0 -7.236 to 14.81 -22.60 to 36.87 
X-intercept when Y=0.0 -inf to +inf -inf to +inf 
Goodness of Fit     
R square 0.4777 0.4600 
Sy.x 0.7082 1.911 
Is slope significantly non-
zero? 
    
F 0.9148 0.8518 
DFn, DFd 1.000, 1.000 1.000, 1.000 
P value 0.5142 0.5255 
Deviation from zero? Not Significant Not Significant 
Data     
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Number of X values 3 3 
Max number of Y replicates 1 1 
Total number of values 3 3 
Number of missing values 0 0 
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Table 10. Bioavailability of AR-67 carboxylate formulated in Vitamin E-TPGS. 
Exp# AR-67 form/dose  (mg/kg) 
Average AUC  
(hr-ng/mL) SE F SE 
F  
estimated  
using exp# 
      
115 Carboxylate  buffered 74.46 20.07 4.03% 1.15% 
108 
(AR-67 
administered 
IV in SBE- 
β-CD, 
200:1, 
[E/D]) 
116 Carboxylate unbuffered 67.03 8.71 3.63% 0.59% 
       
 
B5. Conclusions  
The oral bioavailability of all formulations was extremely low. Establishing IV/IV 
correlations would be very difficult based on the narrow range of observed bioavailability 
among the different formulations. Interestingly, the Vit E-TPGS (28:1, E/D) formulation 
(exp 112) performed equivalently to the SBE-β-CD (200:1, E/D) formulation (exp 112).   
There was no significant difference in the oral bioavailability between male and 
female rats administered the PEG-6000 and the Vitamin E-TPGS based formulations. 
There was no dose effect on the bioavailability in the doses tested (2.5 – 10 mg/kg).  
The AR-67 carboxylate prepared in Vit E-TPGS (28:1, E/D) yielded similar 
bioavailability as the lactone formulation prepared in Vit E-TPGS (28:1, E/D) and SBE-
β-CD (200:1, E/D) ratio. This was considered as a potential formulation for preparing 
solutions which could be spray dried. At this point, based on literature evidence, 
supersaturation was considered an important factor for increased bioavailability and the 
Vit E-TPGS was considered as a viable excipient to formulate AR-67carboxylate because 
of its capacity to maintain supersaturation of AR-67 at a lower excipient to drug ratio 
than SBE-β-CD. 
In consultation with Arno Therapeutics we concluded that parallel studies in mice 
should also be considered because preliminary results from mouse pharmacokinetic 
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studies with cyclodextrin and cremophor/EL based formulations had indicated greater 
bioavailability. We concluded that mice could be used to establish IV/IV correlations and 
once we identify an optimum formulation, it could be tested in capsule form using the rat 
model. 
C. Pharmacokinetic experiments to establish vitro/in-vivo correlations (IVIVC) 
in mice. 
Formulations prepared in the laboratory of Dr. Anderson were tested for oral 
bioavailability in female C57BL/6 mice.  
C1. Experimental design 
The descriptions of the experiments are listed in Table 11. The experiment 
number can be used as a reference for experimental details and raw data. Several 
formulations were prepared in order to achieve AR-67 supersaturation and maintain a 
solution.  The extent of precipitation was to be compared with the bioavailability of each 
formulation.  
For animal experiments, the excipients were dissolved in simulated gastric fluid. 
Based on the results of the in-vitro studies the excipient concentrations were chosen to be 
28:1 (E:D) as though to minimize the excipient that may be required to prepare capsules. 
Initial studies established baseline pharmacokinetics for the vitamin E-TPGS and SBE-β-
CD formulations.  
Excipients were chosen based on their capacity to maintain (Vit E-TPGS) or not 
(PEG-6000) supersaturation in-vitro. A propylene glycol/Vit E-TPGS (PG/TPGS) 
formulation was also tested due to its increased capacity to solubilize the lactone form. 
The effect of the excipient to drug ratio (Vit E-TPGS) on the bioavailability of AR-67 
lactone was also studied.  
C2. Summary of animal experiments and sample analysis  
All experiments were carried out in female C57BL/6 mice weighing 
approximately 20-30 grams. Animals received a dose of 2.5 mg/kg or 5mg/kg AR-67 
lactone by oral gavage. Please refer to section A2 for additional details. 
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C3. Data Analysis 
Data were analyzed using non-compartmental analysis methods with WinNonlin 
v5.2 and GraphPad Prism 5.02. The area under the time-concentration curve was used to 
compare different formulations. Statistical analyses using t-test or ANOVA were carried 
out when appropriate. 
Table 11. Description of pharmacokinetic studies in mice intended for in-vitro/in-vivo 
correlation (IVIVC) analysis. 
Exp
# Title/Objective Notes 
159 Pharmacokinetics of SBE-β-CD based lactone (200:1, E:D) 5 mg/kg IV in female C57BL/6 mice 9 
Baseline IV 
studies to 
establish oral 
bioavailability in 
mice 
160 Pharmacokinetics of Vitamin E-TPGS based lactone (28:1, E:D) 5 mg/kg IV in female C57BL/6 mice 
158 Bioavailability of PG-TPGS based AR-67 lactone (3.2:28:1, E:D) 5 mg/kg PO in female C57BL/6 mice  
157 Bioavailability of PEG-6000 based AR-67 lactone (28:1, E:D)     5 mg/kg PO in female C57BL/6 mice  
162 Bioavailability of PEG-6000 based AR-67 lactone (28:1, E:D)  2.5 mg/kg PO in female C57BL/6 mice  
163 Bioavailability of Vit E-TPGS based AR-67 lactone (28:1, E:D) 2.5 mg/kg PO in female C57BL/6 mice  
The effect 
of E:D (VitE-
TPGS:AR-67) 
167 Bioavailability of Vit E-TPGS based AR-67 lactone (56:1, E:D) 2.5 mg/kg PO in female C57BL/6 mice 
166 Bioavailability of Vit E-TPGS based AR-67 lactone (200:1, E:D) 2.5 mg/kg PO in female C57BL/6 mice 
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C4. Results (IVIVC) 
Intravenous administration of AR-67 lactone in mice yielded the typical biphasic 
pharmacokinetic profile of distribution/elimination that was also observed in rats. As 
shown in Figure 4, this was true for both the cyclodextrin and vitamin E based 
formulations, which yielded very similar AUCs (Table 12). Figure 4 also demonstrates 
that regardless of the formulation, the lactone was the major form in plasma. Overall the 
total AR-67 concentrations were similar between the two formulations and the % lactone 
was 85-90% across all time points (Figure 5). 
The oral bioavailability of the different formulations ranged between 9.7-15.7%. 
Detailed results are presented in Table 12. The oral bioavailability was estimated using 
the intravenous AUC obtained from the SBE-β-CD formulation (exp 159). This was 
decided because Vit E-TPGS yielded a slightly higher AUC, but that could be due to 
interaction between the excipient and efflux transporters in the kidney and liver (i.e., P-
glycoprotein). As with the oral studies in rats, the lactone was the major species observed 
in plasma (refer to individual experiment reports. The pharmacokinetic profiles of total 
AR-67 resulting from administration of the PEG-6000 and Vit E-TPGS formulations 
(each 2.5 mg/kg, 28:1, E/D) are depicted in Figure 6 and no apparent difference was 
observed between the two formulations, despite their significantly different capacity to 
maintain supersaturation.  
There was an increase in the bioavailability of AR-67 formulated in Vit E-TPGS 
from ~11.5% in the 28:1 formulation to ~15.5% in the 56:1 and 200:1 E/D formulations 
(One-way ANOVA, with Bonferroni post-hoc correction for multiple comparisons). 
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Table 12. Results of pharmacokinetic studies designed to establish in-vitro/in-vivo correlations in mice administered AR-67 
lactone in various formulations.  
 
Exp# Excipient E:D Route/Dose (mg/kg) 
Average 
AUC            
(hr-ng/mL) 
SE F SE 
F 
estimated 
using 
exp# 
         
159 SBE-β-CD 200:1 IV / 5.0 1325.08 104.25      
160 Vit E-TPGS 28:1 IV / 5.0 1500.97 22.25      
           
158 PG-TPGS 3.2:28:1 PO / 5.0 128.01 7.12 9.66% 0.93% 
15
9 
162 PEG-6000 28:1 PO / 2.5 70.39 9.22 10.62% 1.62% 
157 PEG-6000 28:1 PO / 5.0 194.83 25.02 14.70% 2.21% 
163 Vit E-TPGS 28:1 PO / 2.5 76.48 3.73 11.54% 1.07% 
167 Vit E-TPGS 56:1 PO / 2.5 103.91 5.62 15.68% 1.50% 
166 Vit E-TPGS 200:1 PO / 2.5 103.00 8.55 15.55% 1.78% 
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Figure 4. Pharmacokinetic profiles of AR-67 in mice following intravenous 
administration of AR-67 lactone formulated in (A) SBE-β-CD (200:1, E/D) and (B) 
Vitamin E-TPGS (28:1, E/D). 
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Figure 5. Comparative (A) total AR-67 pharmacokinetics and (B) lactone fraction of the 
SBE-β-CD and Vit E-TPGS formulations. 
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Figure 6. Pharmacokinetic profiles of AR-67 lactone administered orally (2.5 mg/kg) in 
PEG-6000 and Vit E-TPGS formulations (28:1, E/D). 
C5. Conclusions  
The Vitamin E-TPGS intravenous formulation appears to be equivalent to the 
SBE-β-CD formulation, but at a lower excipient to drug ratio. Additional studies to assess 
pharmacokinetic linearity must be done to ensure that the excipient does not influence 
AR-67 clearance at higher doses due to potential interactions between Vit E-TPGS and P-
glycoprotein. 
There was no obvious correlation between the in-vitro results (capacity to 
maintain supersaturation) and the oral bioavailability or AR-67 observed in mice. 
However, the bioavailability was 3 to 5-fold higher than that observed in rats (see section 
B). There was a significant increase in the oral bioavailability of AR-67 with the two 
formulations that had the higher E/D ratio of Vit E-TPGS:AR-67. However, additional 
studies will have to be done to verify these results given the importance of reducing the 
excipient in the formulation. 
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At this point, in consultation with Arno Therapeutics, we concluded that a vitamin 
E-TPGS based formulation, most likely based on carboxylate, was the formulation that 
we would pursue further.  
Given the high lipophilicity of AR-67, we also considered the development of 
formulations that would facilitate the lymphatic transport and possibly increase oral 
bioavailability (see section D). 
D. Pharmacokinetic experiments designed to assess bioavailability of 
formulations containing excipients that enhance lymphatic transport. 
Several preliminary studies were carried out in mice using formulation prepared 
in Dr. Leggas’ lab. Based on published evidence, the effects of oleic acid were tested in 
several experiments to assess its capacity to increase oral bioavailability through 
increased lymphatic transport of AR-67. However, in order to use this excipient with AR-
67 carboxylate the sodium oleate had to be prepared. These latter formulations were 
prepared in the laboratory of Dr. Anderson. All formulations were tested for oral 
bioavailability in female C57BL/6 mice.  
D1. Experimental design 
The experiment number can be used as a reference for experimental details and 
raw data. 
Baseline studies to assess the effect of food were carried out. Several lipid 
formulations were also prepared to test the effect of pretreatment and co-treatment on 
AR-67 carboxylate bioavailability. Finally, the effect of increasing amount of sodium 
oleate in Vit E-TPGS based formulations was tested using formulations that incorporated 
both excipients.  
D2. Summary of animal experiments and sample analysis  
All experiments were carried out in female C57/BL6 mice weighing 
approximately 20-30 grams. Animals received 2.5 or 5 mg/kg AR-67. Please refer to 
section A2 and to the experimental reports for additional details. 
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D3. Data Analysis 
Data were analyzed using non-compartmental analysis methods with WinNonlin 
v5.2 and GraphPad Prism v5.02. The area under the time-concentration curve was used to 
compare different formulations. Statistical analyses using t-test or ANOVA were carried 
out when appropriate. 
Table 13. Description of pharmacokinetic experiments designed to assess the effect of 
lipid excipients on the oral bioavailability of AR-67 in mice. 
Exp
# 
Title/Objective N Notes 
164 
Bioavailability of SBE-β-CD based AR-67 lactone (200:1, 
E:D) 2.5 mg/kg PO in the absence of food during the 
experiment in female C57BL/6 mice 
9 
Determine food 
effects 
165 
Bioavailability of SBE-β-CD based AR-67 lactone (200:1, 
E:D) 2.5 mg/kg PO in the presence of food during the 
experiment in female C57BL/6 mice 
9 
168 
Study the effect of safflower oil pretreatment PO (5 mL/kg) 
on the absorption of E-TPGS based AR-67 lactone (2.5 
mL/kg, 2.5 mg/kg) PO 
9 
Mr. Adane’s 
formulations 
169 
Study the effect of oleic acid co-treatment PO (5 mL/kg) on 
the absorption of E-TPGS based AR-67 lactone (2.5 mL/kg, 
2.5 mg/kg) PO 
9 
170 
(Control pretreatment) Study the effect of control (D5W) co-
treatment PO (5 ml/kg) on the absorption of TPGS based AR-
67 carboxylate (2.5ml/kg, 5 mg/kg) PO. 
9 
171 
Study the effect of oleic acid co-treatment PO (5 ml/kg) on 
the absorption of TPGS based AR-67 carboxylate (2.5ml/kg, 
5 mg/kg) PO 
9 
172 (Control pretreatment) Study the effect of control (D5W) co- 9 
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treatment PO (5 mL/kg) on the absorption of TPGS based 
AR-67 lactone (2.5 mL/kg, 5 mg/kg) PO 
173 
Study the effect of oleic acid co-treatment PO (5 mL/kg) on 
the absorption of TPGS based AR-67 lactone (2.5mL/kg, 5 
mg/kg) PO 
9 
174 
Study on the bioavailability of mixture of TPGS based AR-67 
carboxylate (E:D ratio 56:1) premixed with oleic acid at 1:5, 
v/v (0.5 X) at dose of 5 mg/kg PO. 
9 
175 
Study the bioavailability of a mixture of TPGS based AR-67 
carboxylate (E:D ratio 56:1) premixed with oleic acid at 2:1, 
v/v ratios (5X)  at dose of 5mg/kg PO 
9 
176 
Study the absorption of 1:4 oleic acid:TPGS ratio (AR-67 
carboxylate, 5 mg/kg) PO. [Formulation TX17-16-3] 
9 
Dr. Xiang's 
formulations 
177 
Study the absorption of 1:7 oleic acid:TPGS ratio (AR-67 
carboxylate 5 mg/kg) PO. [Formulation TX17-15-2] 
9 
180 
Study the absorption of oleic acid:TPGS (1:7) based AR-67 
carboxylate (5 mg/kg) PO. [Formulation TX17-16-2] 
9 
181 
Study the absorption of oleic acid:TPGS (1:10) based AR-67 
carboxylate (5 mg/kg) PO [Formulation TX17-15-1] 
9 
 
D4. Results (Sodium oleate / Vit E-TPGS) 
As with the oral studies in rats, the lactone was the major species observed in 
mouse plasma. As shown in Figure 7, the effect of food was noticeable at the later time 
points, during which plasma concentrations were higher. However, the bioavailability 
was not significantly higher at 17.98% (±1.81%) in the fed group vs. 15.32% (±1.32%) in 
the fasted group. 
For results of the preliminary experiments using oleic acid and safflower oil (168, 
169, 170, 171, 172, 173, 174, 175).  Although these data indicated that oleic acid had an 
effect on the oral bioavailability, the results from the preliminary experiments listed 
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above should be interpreted carefully because oleic acid was influencing the pH and 
perhaps altering the lactone/carboxylate ratio of AR-67 in the dosing solutions. 
To overcome this limitation, formulations of carboxylate were prepared with 
various amounts of sodium oleate and Vit E-TPGS (50:1, E/D). The carboxylate was 
considered because of its higher solubility. These formulations yielded oral 
bioavailability in the order of ~20%. Although the amount of oleate varied from 9% 
(1:10, exp 181) to 20% (1:4, exp 176) of the total excipient weight the bioavailability was 
not significantly different among the four formulations tested. The pharmacokinetic 
profiles of these formulations are shown in  
Figure 8. 
 
Figure 7. Pharmacokinetic profiles of AR-67 lactone administered orally to mice that 
were fasted or were allowed to feed throughout the experiment. 
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Table 14. Results of pharmacokinetic studies designed to establish the effect of food on 
the AUC of AR-67 lactone (SBE-β-CD, 200:1, E/D) administered orally to mice. 
 
Table 15. Results of pharmacokinetic studies designed to establish the effect of sodium 
oleate (formulated along with Vit E-TPGS, 50:1, E/D) on the bioavailability of AR-67 
carboxylate administered orally to mice. 
 
Exp# Food 
Average AUC  
(hr-ng/mL) 
SE F SE 
F estimated 
using exp# 
      
164 No 101.48 3.56 15.32% 1.32% 159 
165 Yes 119.13 7.43 17.98% 1.81% 159 
       
Exp# Sodium Oleate: Vit E-TPGS 
Average AUC  
(hr-ng/mL) SE F SE 
F estimated 
using exp# 
     
176 1:4 285.00 15.90 21.51% 2.07% 
159 
77 1:7 269.20 56.30 20.32% 4.54% 
80 1:7 238.74 21.69 18.02% 2.17% 
81 1:10 270.44 18.62 20.41% 2.13% 
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Figure 8. Pharmacokinetic studies in mice depicting plasma concentration profiles of total 
AR-67 after oral administration of AR-67 carboxylate formulated with sodium oleate and 
Vit E-TPGS. 
D5. Conclusions 
The effect of food has minimal contribution to the oral bioavailability of AR-67. 
Preliminary experiments indicated that oleic acid may facilitate increase in oral 
bioavailability. The carboxylate formulation was chosen because of its increased 
solubility. Sodium oleate increased the oral bioavailability, but there was not dose 
dependent effect. Although lipid excipients have been used to increase oral 
bioavailability via enhanced lymphatic transport, the mechanism by which oleate 
increased absorption is not clear. If the results were due to increased lymphatic transport 
we would have expected a low Cmax and delayed Tmax. However, in the oleate 
experiments the values of Tmax and Cmax were very similar to the formulations 
prepared without sodium oleate. Further studies will have to be undertaken to better 
understand this mechanism of increased absorption.  
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E. Pharmacokinetic experiments to assess bioavailability of amorphous solid 
and other miscellaneous formulations. 
 
E1. Experimental design 
Two amorphous solid formulations were provided to the University of Kentucky 
by Arno Therapeutics for assessment of bioavailability. These were coded as PMFD/1 
and PMFD/2. Additional studies were undertaken to assess the bioavailability of 
formulations that contained either the exact composition of PMFD/1, but prepared at the 
University of Kentucky, or only select excipients found in PMFD/1. In addition, 
experiments to assess the bioavailability of AR-67 lactone, which was administered as a 
precipitate of carboxylate spiked into SGF or as suspended particles of different size were 
undertaken. The above experiments were carried out in mice. 
A final set of experiments was done in rats to assess the bioavailability of 
PMFD/1 in capsules or as a suspension in SGF. 
 Summary of animal experiments and sample analysis  
Experiments were carried out in female C57BL/6 mice weighing approximately 
20-30 grams. Please refer to section A2 and to the experimental reports for additional 
details. Experiments in rats were carried out as described in section A2. 
E2. Data Analysis 
Data were analyzed using non-compartmental analysis methods with WinNonlin 
v5.2 and GraphPad Prism v5.02. The area under the time-concentration curve was used to 
compare different formulations. Statistical analyses using t-test or ANOVA were carried 
out when appropriate. 
 190 
 
Table 16. Description of experiments designed to assess the bioavailability of amorphous 
solid formulations in mice. 
Exp
# Title/Objective N Notes 
178 Study the oral bioavailability of PMFD 576/1 suspended in ddH2O  9 
Fine precipitate 
was observed 
after mixing with 
water 
179 Study the oral bioavailability of PMFD 576/2 suspended in ddH2O 9 
Fine precipitate 
was observed 
after mixing with 
water 
182 Study the oral bioavailability of PMFD 576/1 suspended in water (pH 4.85) 9 
Repeated exp 
178 
183 Study the oral bioavailability of PMFD 576/1 suspended in S.G.F. (pH 1.2) 9 
Repeated exp 
178/182 
(different diluent) 
Fine precipitate 
was observed 
after mixing with 
SGF. 
184 
Study the absorption of 5 mg/kg PO AR-67 in PVP 
K30:Tween-80:AR-67 (71:6:23) spiked in SGF 
(precipitate formed) 
9 
Prepared 
PVP/Tween80 
formulation at 
UK. Fine 
precipitate was 
observed after 
mixing with 
SGF. 
185 
Study the absorption of 5 mg/kg PO AR-67 in Vit E-
TPGS:Tween-80:AR-67 (71:6:23) in simulated gastric 
fluid (pH 1.2) (remained in solution) 
9 
Substituted Vit 
E-TPGS for PVP. 
Remained in 
solution. 
187 Study the absorption of AR-67 lactone in SGF containing PVP (K30) (E/D 3:1)  9 
PVP only 
 prepared at UK 
(precipitate) 
196 Study the absorption of freshly prepared AR-67 lactone in SGF containing 0.065% Tween-80  9 
Tween-80 only 
prepared at UK 
(precipitate) 
197 
Study the absorption of AR-67 lactone in SGF 
containing 0.065% Tween-80 (administer 2 hr after 
mixing with SGF) at 5 mg/kg PO  
9 
Tween-80 only 
prepared at UK 
(allow more 
extensive 
precipitation) 
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Table 17. Description of experiments designed to assess the effect of drug particle size on 
oral bioavailability (suspensions of AR-67). 
Exp# Title/Objective Notes 
186 Study the absorption of AR-67 lactone in SGF at 5 mg/kg PO. 
Car
boxylate 
spiked into 
pH 1.2 SGF 
(PO) 
194 Study the absorption of AR-67 lactone (particle size between 45 µm and 75 µm) in SGF (5 mg/kg, 2.5 ml/kg) PO 9  
195 Study the absorption of AR-67 lactone (particle size between 75 µm and 150 µm) in SGF (5 mg/kg, 2.5 ml/kg) PO 9  
 
Table 18. Description of experiments designed to assess the bioavailability of amorphous 
solid formulations administered as a suspension to rats. 
Exp# Title/Objective N  Notes 
192 
Study on the oral bioavailability of PMFD 576/1 AR-67 
lactone suspension at the dose of 5.0 mg/kg PO in rats  
Dissolved 
in SGF. 
193 
Study on the oral bioavailability of capsule filled with PMFD 
576/1 AR-67 lactone at the dose of 5.0 mg/kg PO in rats 
3   
 
E3. Results 
The oral bioavailability of the PMFD 576/1 formulation (exp 178) dissolved in 
ddH20 was among the highest observed yet (31.40±3.91%). The PMFD 576/2 
formulation (exp 179) also displayed relatively good bioavailability (24.65±6.49%). 
These results of the PMFD 576/1 formulation were confirmed by a second experiment 
with bioavailability of 30.01±5.87% (exp 182). Subsequently, we sought to determine the 
bioavailability of a formulation that was prepared at the University of Kentucky using the 
exact composition of PMFD 576/1, but given as a solution in SGF (exp 184). As a control 
experiment we dissolved the amorphous solid (PMFD 576/1) in SGF (exp 183). The 
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results were practically identical with a biovailability of 28.22±2.88% for the University 
of Kentucky prepared formulation vs. 30.28±3.17% for the PMFD 576/1 dissolved in 
SGF. 
To assess the importance of PVP, which in vitro had demonstrated poor capacity 
to maintain supersaturation, we substituted it with Vit E-TPGS in the PMFD/1 
formulation (exp 185). The bioavailability of this formulation was 24.92±2.71%. 
Subsequently, we tested formulations that only contained PVP (3:1, E/D) or Tween-80 
(0.065%). The PVP formulation gave a bioavailability of 22.83±2.37% (exp187). The 
Tween-80 formulation gave a bioavailability of 13.21±2.81% when administered 
immediately after mixing with SGF (exp 196) and 11.71±1.87% when allowed to stand 
for 2-hrs after mixing with SGF (exp 197). These results along with the AUC from each 
experiment are presented in Table 19. 
The increased bioavailability results of formulations that formed a precipitate 
upon mixing with SGF prompted us to assess the bioavailability of lactone without any 
excipients. The lactone was prepared from a carboxylate solution, which was spiked into 
SGF and rapidly precipitated (exp 186). Interestingly, this formulation yielded a 
bioavailability of 24.38±2.89%. We also evaluated the bioavailability of solid AR-67 
lactone particles, which were sieved from bulk drug available at the University of 
Kentucky. In these experiments we tested the bioavailability of particles that were 45-75 
µm and 75-150 µm. The bioavailability of both of these suspensions (in SGF) was low (~ 
5-6%). These results along with the AUC from each experiment are presented in 
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Table 20.  
A final set of experiments were undertaken in rats to assess the bioavailability of 
PMFD/1 prepared as a suspension in SGF (exp 192) or filled into capsules (exp 193). 
Unfortunately, the bioavailability of both formulations was low (3.52±1.02% for the 
suspension and 4.72±2.35% for the capsules).  
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Table 19. Results of experiments designed to assess the bioavailability of amorphous 
solids formulations in mice. 
Table 20. Results of experiments designed to assess the effect of drug particle size on oral 
bioavailability (suspensions of AR-67). 
Exp# Excipient  Dose (mg/kg) 
Average  
AUC             
(hr-ng/mL) 
SE F SE NOTES 
      
178 PMFD 576/1 – (5) 416.14 40.17 31.40% 3.91% dd H2O 
179 PMFD 576/2 – (5) 326.60 82.12 24.65% 6.49% dd H2O 
182 PMFD 576/1 – (5)  397.68 71.22 30.01% 5.87% dd H2O 
183 PMFD 576/1 – (5)  401.20 27.72 30.28% 3.17% 
S.G.F.  
(pH 1.2) 
184 
PVP 
K30:Tween-
80:AR-67 
(71:6:23) – (5) 
373.92 24.31 28.22% 2.88% S.G.F.  (pH 1.2) 
         
185 
Vit E-
TPGS:Tween-
80:AR-67 
(71:6:23) – (5) 
330.25 24.77 24.92% 2.71% S.G.F.  (pH 1.2) 
187 PVP (K30) (E/D 3:1)  – (5) 302.53 20.44 22.83% 2.37% 
S.G.F.  
(pH 1.2) 
196 0.065% Tween-80  – (5) 175.10 34.62 13.21% 2.81% 
S.G.F. 
(pH 1.2) 
197 0.065% Tween-80  – (5) 155.17 21.63 11.71% 1.87% 
S.G.F.  
(pH 1.2) 
       
Exp
# 
Excipient / 
AR-67 Form 
Average  
AUC             
(hr-ng/mL) 
SE F SE NOTES 
      
186 
None / 
[Carboxylate 
spiked into 
SGF (pH 1.2)] 
(5mg/kg) 
323.06 28.57 24.38% 2.89% Precipitates as lactone 
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194 
None / 45 - 75 
µm particles 
Lactone (5 
mg/kg) 
65.55 13.47 4.95% 1.09% Sieved bulk material 
195 
None / 75 - 
150 µm 
particles 
Lactone (5 
mg/kg) 
83.67 14.08 6.31% 1.17% Sieved bulk material 
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Table 21. Results of experiments designed to assess the bioavailability of amorphous 
solid formulations administered as a suspension to rats. 
 
E4. Conclusions 
The experiments demonstrate that there is no obvious in-vitro/in-vivo correlation 
in terms of the degree of supersaturation and bioavailability. The PMFD/1 formulation 
provided the highest bioavailability although it precipitated after mixing with pH 1.2 
SGF. The combination of PVP and Tween-80 yielded the highest bioavailability. Studies 
with the carboxylate alone, which immediately precipitates to lactone in simulated gastric 
fluid, demonstrated that the bioavailability is in the order of 24%. Similarly studies with 
PVP alone demonstrated bioavailability of ~23%, while formulation of AR-67 with 
Tween-80 alone decreased the biovailability to ~12-13%. This suggests that PVP alone 
has no effect, whereas Tween-80 alone suppresses bioavailability.  
Together these results suggest that the nature of the precipitate formed in the 
formulation that contains PVP/Tween-80 allows the highest bioavailability possibly due 
to the slow dissolution and a steady state availability of the lactone. The precipitate 
formed from the carboxylate spiked into SGF behaves similarly. Probably the lactone 
particles that precipitate provide a continuous source of lactone.Whereas when excipients 
are included to support supersaturation, the lactone may convert to the carboxylate, which 
is not likely to be absorbed due to its negative charge.  
 
Exp# Formulation 
Average 
AUC           
(hr-
ng/mL) 
SE F SE NOTES 
     
192 PMFD 576/1 130.02 35.42 3.52% 1.02% Suspension in SGF (pH 1.2) 
193 PMFD 576/1 174.20 85.28 4.72% 2.35% Capsule 
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Objective 
To determine the effects of vehicle (40% PEG-300, 10% Tween-80 in D5W) 
pretreatment on oral bioavailability and PK profile of SBE-β-CD based AR-67 lactone 
PO in female SD rats. This will serve as a control for GF120918 pretreatment group. 
Expt 100: Study the effects of vehicle (40% PEG-300, 10% Tween-80 in D5W) PO 
pretreatment on bioavailability of SBE-β-CD (200:1 E/D ratio) based AR-67 lactone PO 
(2.5 mg/kg) in female SD rats. 
 
Method 
Animal treatment and sample processing 
Expt 100, Rats (#100-#105, n=6) were dosed with 2.5 mg/kg SBE-β-CD (200:1 E/D 
ratio) based AR-67 lactone PO 5 min after vehicle administration at 7.5 ml/kg PO. 
Dosing solution: 
AR-67 lactone = 1.0 mg/mL 
Vehicle (used to solubilizer GF):  
           40% PEG-300, 10% Tween-80 in D5W 
Blood was collected from the saphenous vein at 5 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h and 
12 h with heparinized hematocrit tubes and transferred into heparinized microcentrifuge 
tubes. Plasma was collected by centrifugation of blood and then extracted 1:4 (v/v) with 
cold MeOH     (-80oC). Samples were kept at -80oC until analysis.  
 
HPLC analysis  
Before injection into the HPLC, samples were diluted with an equal volume of mobile 
phase buffer (40 µL:40 µL) and were analyzed. For samples needing dilution (5min, 
30min, 1h & 2h after  intravenous doses), a 1:10 dilution was carried out using 1:4 extract 
of blank rat plasma.  
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Expt 100 
Sequence name: 20AC-030708-Rat PK Expt 100 Reprocessing with 10AD method.seq 
Method: 10AD-121807-Rat plasma curve.met 
Data were exported and saved in Leggas Lab/Experimental Results/AR-67 Oral PK 
folder. (A backup copy of HPLC data was also saved in Leggas Lab/Jamie’s project/AR-
67/Rat PK). Plots were made with Prism while nocompartmental analysis was made 
using Winnonlin v5.2. 
Results 
Table. Pharmacokinetic parameters estimated using the noncompartmental method 
in Winnonlin v5.2. 
Expt 
ID Parameter Units Estimate 
Average/ 
Median1  SD2/range 
100 100 AUCall h*ng/mL 118.0916 126.91 33.22
100 101 AUCall h*ng/mL 85.6844     
100 102 AUCall h*ng/mL 184.1765     
100 103 AUCall h*ng/mL 114.0443     
100 104 AUCall h*ng/mL 141.552     
100 105 AUCall h*ng/mL 117.8906     
100 100 Cmax ng/mL 37.59 27.09 7.34
100 101 Cmax ng/mL 15.76     
100 102 Cmax ng/mL 29.11     
100 103 Cmax ng/mL 24.83     
100 104 Cmax ng/mL 30.89     
100 105 Cmax ng/mL 24.38     
100 100 Tmax h 2 2       1--4 
100 101 Tmax h 4     
100 102 Tmax h 2     
100 103 Tmax h 2     
100 104 Tmax h 1     
100 105 Tmax h 2     
      
                                                 
1 Median was used for Tmax. All other parameters use the arithmetic mean. 
2 Standard deviation. 
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Figures 
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Fig. 1a. Plasma total DB-67 levels in SD rats treated with vehicle
(PEG, tween80, D5W) PO 5 min before 2.5 mg/kg DB-67 lactone PO
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Fig. 1b. Semi-log plot of plasma total DB-67 levels in SD rats treated with
vehicle (PEG, tween80, D5W) PO 5 min before 2.5 mg/kg DB-67 lactone PO
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Fig. 1c. Semi-log plot of plasma total DB-67 levels in SD rats treated with
vehicle (PEG, tween80, D5W) PO 5 min before 2.5 mg/kg DB-67 lactone PO
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Fig. 1d. Semi-log plot of plasma total DB-67 levels in SD rats treated with
vehicle (PEG, tween80, D5W) PO 5 min before 2.5 mg/kg DB-67 lactone PO
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Fig. 2. AUCs of lactone and carboxylate forms of DB-67 in SD rats
following PO administrtation of DB-67 lactone at 2.5 mg/kg 5 after
vehicle pretreatment (7.5 ml/kg) PO
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Raw Data 
Expt # Rat # Time (h) 
Carboxylate 
(ng/mL) Lactone(ng/mL)
Total AR-67 
(ng/mL) 
100 100 0.083 0 3.24 3.24
100 100 0.5 0.6 6.71 7.31
100 100 1 2.13 16.41 18.54
100 100 2 6.62 30.97 37.59
100 100 4 2.22 10.75 12.97
100 100 6 0.76 5.7 6.46
100 100 8 0.31 0.09 0.4
100 100 12 0.01 1.78 1.79
100 101 0.083 0 0.7 0.7
100 101 0.5 0.03 3.78 3.81
100 101 1 0.68 6.55 7.23
100 101 2 1.75 11.75 13.5
100 101 4 2.43 13.33 15.76
100 101 6 0.97 6.3 7.27
100 101 8 0.21 2.54 2.75
100 101 12 0 1.89 1.89
100 102 0.083 0 1.52 1.52
100 102 0.5 0.7 8.24 8.94
100 102 1 2.98 21.77 24.75
100 102 2 3.08 26.03 29.11
100 102 4 3.51 18.25 21.76
100 102 6 2.63 12.95 15.58
100 102 8 1.67 7.54 9.21
100 102 12 0.89 6.69 7.58
100 103 0.083 0 0 0
100 103 0.5 0 3.51 3.51
100 103 1 1.23 10.37 11.6
100 103 2 3.77 21.06 24.83
100 103 4 3.81 14 17.81
100 103 6 0.9 4.2 5.1
100 103 8 0.51 3.8 4.31
100 103 12 0.34 3.53 3.87
100 104 0.083 0 0.71 0.71
100 104 0.5 3.26 21.51 24.77
100 104 1 5.06 25.83 30.89
100 104 2 4.38 18.34 22.72
100 104 4 2.8 12.09 14.89
100 104 6 1.02 5.41 6.43
100 104 8 1.06 5.67 6.73
100 104 12 0.69 4.28 4.97
100 105 0.083 0 0.96 0.96
100 105 0.5 0 3.72 3.72
100 105 1 1.12 9.5 10.62
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100 105 2 3.4 20.98 24.38
100 105 4 2.82 13.5 16.32
100 105 6 1.41 8.07 9.48
100 105 8 0.63 3.9 4.53
100 105 12 0.25 2.86 3.11
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Effects of oral GF120918 on oral bioavailability of SBE-β-CD based AR-67 lactone in 
rats 
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Objective 
To determine oral GF120918 pretreatment on oral bioavailability of SBE-β-CD based 
AR-67 lactone in female SD rats. The vehicle pretreatment group will serve as a control 
for GF120918 pretreatment to study the effects of vehicle on AR-67 oral absorption. The 
vehicle pretreatment group is also a repeat of experiment 100 to see the reproducibility of 
the system.   
Expt 101a: Study the effects of vehicle (7.5 mL/kg) PO on oral bioavailability of SBE-β-
CD (200:1 E/D ratio) based AR-67 lactone (2.5 mg/kg) PO in rats  
Expt 101b: Study the effects of GF120918 (2.5 mg/kg) PO on oral bioavailability of 
SBE-β-CD (200:1 E/D ratio) based AR-67 lactone (2.5 mg/kg) PO in rats  
Method 
Animal treatment and sample processing 
Expt 101a, Rats (#121-#123, n=3) were dosed with 2.5 mg/kg SBE-β-CD (200:1 E/D 
ratio) based AR-67 lactone PO 5 min after vehicle pretreatment at 7.5 ml/kg PO. 
Expt 101b, Rats (#124-#126, n=3) were dosed with 2.5 mg/kg SBE-β-CD (200:1 E/D 
ratio) based AR-67 lactone PO 5 min after GF pretreatment at 2.5 mg/kg PO. 
Dosing solution: 
AR-67 lactone = 1.0 mg/mL 
GF120918 solution: 
           GF120918 was dissolved in vehicle (40% PEG-300, 10% Tween 80 in D5W) 
within 1 hour before experiment. 
Blood was collected from the saphenous vein at 5 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h and 
12 h with heparinized hematocrit tubes and transferred into heparinized microcentrifuge 
tubes. Plasma was collected by centrifugation of blood and then extracted 1:4 (v/v) with 
cold MeOH     (-80oC). Samples were kept at -80oC until analysis.  
HPLC analysis  
Before injection into the HPLC, samples were diluted with an equal volume of mobile 
phase buffer (40 µL:40 µL) and were analyzed. For samples needing dilution (5min, 
30min, 1h & 2h after  intravenous doses), a 1:10 dilution was carried out using 1:4 extract 
of blank rat plasma.  
Expt 101a and 101b 
Sequence name: 20AC-031408-Rat PK Expt 101 Reprocessing with 20AC method.seq 
Method: 10AD-121807-Rat plasma curve.met 
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Data were exported and saved in Leggas Lab/Experimental Results/AR-67 Oral PK 
folder. (A backup copy of HPLC data was also saved in Leggas Lab/Jamie’s project/AR-
67/Rat PK). Plots were made with Prism while nocompartmental analysis was made 
using WinNonlin v5.2. 
Results 
Tables: Pharmacokinetic parameters estimated using the noncompartmental 
method in Winnonlin v5.2 
Expt 101 
Expt 
ID Parameter Units Estimate 
Average/ 
Median3  SD4/range 
101a 121 AUCall h*ng/mL 91.7871 128.77 55.51
101a 122 AUCall h*ng/mL 192.6     
101a 123 AUCall h*ng/mL 101.9193     
101a 121 Cmax ng/mL 13.67 27.37 25.89
101a 122 Cmax ng/mL 57.23     
101a 123 Cmax ng/mL 11.21     
101a 121 Tmax h 2 2 2--4 
101a 122 Tmax h 2     
101a 123 Tmax h 4     
             
101b 124 AUCall h*ng/mL 713.7297 738.63 68.21
101b 125 AUCall h*ng/mL 686.3804     
101b 126 AUCall h*ng/mL 815.7946     
101b 124 Cmax ng/mL 136.02 139.20 9.35
101b 125 Cmax ng/mL 131.86     
101b 126 Cmax ng/mL 149.73     
101b 124 Tmax h 2 2 2
101b 125 Tmax h 2     
101b 126 Tmax h 2     
 
 
Figures 
                                                 
3 Median was used for Tmax. All other parameters used the arithmetic mean. 
4 Standard deviation. 
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Fig. 1a. Plasma total DB-67 levels in SD rats treated with vehicle
(PEG, tween80, D5W) PO 5 min before 2.5 mg/kg DB-67 lactone PO
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Fig. 1b. Semi-log plot of plasma total DB-67 levels in SD rats treated with
vehicle (PEG, tween80, D5W) PO 5 min before 2.5 mg/kg DB-67 lactone PO
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Fig. 2a. Plasma total DB-67 levels in SD rats treated with GF
(2.5 mg/kg) PO 5 min before 2.5 mg/kg DB-67 lactone PO
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Fig. 2b. Semi-log plot of plasma total DB-67 levels in SD rats treated
with GF (2.5 mg/kg) PO 5 min before 2.5 mg/kg DB-67 lactone PO
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Fig. 3. AUCs of lactone and carboxylate forms of DB-67 in SD rats
following PO administrtation of DB-67 lactone 5 min after administration of
vehicle PO (expt 101a)  and GF PO (expt 101b) at 2.5 mg/kg
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Raw Data 
Expt 
# 
Rat 
# 
Time 
(h) 
Carboxylate 
(ng/mL) 
Lactone 
(ng/mL) 
Total AR-67 
(ng/mL) 
101 121 0.083 0 0.99 0.99
101 121 0.5 0.16 2.14 2.3
101 121 1 0.91 8.81 9.72
101 121 2 2.15 11.52 13.67
101 121 4 1.74 8.2 9.94
101 121 6 1.25 6.34 7.59
101 121 8 0.68 4.27 4.95
101 121 12 1.11 5.28 6.39
101 122 0.083 5.49 Null Null 
101 122 0.5 0 3.19 3.19
101 122 1 0 26.44 26.44
101 122 2 7.92 49.31 57.23
101 122 4 3.44 21.42 24.86
101 122 6 0.96 6.09 7.05
101 122 8 0.71 4.3 5.01
101 122 12 0.35 2.89 3.24
101 123 0.083 0.06 3.15 3.21
101 123 0.5 0.25 2.78 3.03
101 123 1 0.81 4.64 5.45
101 123 2 1.27 7.95 9.22
101 123 4 1.56 9.65 11.21
101 123 6 1.72 9.31 11.03
101 123 8 1.31 7.62 8.93
101 123 12 0.46 4.81 5.27
101 124 0.083 0.44 4.05 4.49
101 124 0.5 2.65 17.9 20.55
101 124 1 9 67.82 76.82
101 124 2 20.35 115.67 136.02
101 124 4 20.39 75.4 95.79
101 124 6 8.72 36.66 45.38
101 124 8 6.79 30.85 37.64
101 124 12 3.22 19.92 23.14
101 125 0.083 0.08 1.95 2.03
101 125 0.5 2.17 18 20.17
101 125 1 6.31 45.63 51.94
101 125 2 17.39 114.47 131.86
101 125 4 17.02 75.29 92.31
101 125 6 8.8 39.33 48.13
101 125 8 6.13 28.71 34.84
101 125 12 3.19 24.05 27.24
101 126 0.083 1.04 9.45 10.49
101 126 0.5 4.05 33.67 37.72
101 126 1 9 60.91 69.91
 208 
 
101 126 2 19.6 130.13 149.73
101 126 4 18.16 87.24 105.4
101 126 6 10.39 48.46 58.85
101 126 8 7.98 37.09 45.07
101 126 12 4.34 23.23 27.57
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12/02/2008 
 
 
 
 
 210 
 
Objective 
To determine effects of D5W pretreatment on oral bioavailability of SBE-β-CD based 
AR-67 lactone in rats. This will serve as a control for GF120918 and vehicle pretreatment 
group. 
Expt 102: Study the effects of D5W (7.5 mL/kg) PO on oral bioavailability of SBE-β-CD 
(200:1 E/D ratio) based AR-67 lactone (2.5 mg/kg) PO in female SD rats  
Method 
Animal treatment and sample processing 
Expt 102, Rats (#131-#136, n=6) were dosed with 2.5 mg/kg SBE-β-CD (200:1 E/D 
ratio) based AR-67 lactone PO 5 min after administration of D5W at 7.5 ml/kg PO. 
Dosing solution: 
AR-67 lactone = 1.0 mg/mL 
Blood was collected from the saphenous vein at 5 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h and 
12 h with heparinized hematocrit tubes and transferred into heparinized microcentrifuge 
tubes. Plasma was collected by centrifugation of blood and then extracted 1:4 (v/v) with 
cold MeOH     (-80oC). Samples were kept at -80oC until analysis.  
 
HPLC analysis  
Before injection into the HPLC, samples were diluted with an equal volume of mobile 
phase buffer (40 µL:40 µL) and were analyzed. For samples needing dilution (5min, 
30min, 1h & 2h after  intravenous doses), a 1:10 dilution was carried out using 1:4 extract 
of blank rat plasma.  
Expt 102 
Sequence name: 20AC-031408-Rat PK Expt 102.seq 
Method: 20AC-031208-reinjection of 121807 rat plasma curve.met 
Data were exported and saved in Leggas Lab/Experimental Results/DB-67 Oral PK 
folder. (A backup copy of HPLC data was also saved in Leggas Lab/Jamie’s project/DB-
67/Rat PK). Plots were made with Prism while nocompartmental analysis was made 
using WinNonlin v5.2. 
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Results 
Tables 
Expt 102 
ID Parameter Units Estimate
Average/ 
Median5  SD6/range 
131 AUCall h*ng/mL 88.1589 68.643 21.609 
132 AUCall h*ng/mL 76.0564     
133 AUCall h*ng/mL 47.5229     
134 AUCall h*ng/mL 40.205     
135 AUCall h*ng/mL 93.8877     
136 AUCall h*ng/mL 66.0274     
131 Cmax ng/mL 25.75 22.218 12.913 
132 Cmax ng/mL 15.93     
133 Cmax ng/mL 8.74     
134 Cmax ng/mL 17.53     
135 Cmax ng/mL 46.08     
136 Cmax ng/mL 19.28     
131 Tmax h 0.5 0.5 0.5-1 
132 Tmax h 0.5     
133 Tmax h 1     
134 Tmax h 0.5     
135 Tmax h 0.5     
136 Tmax h 0.5     
 
 
 
 
 
 
                                                 
5 Median was used for Tmax. All other parameters use the arithmetic mean. 
6 Standard deviation 
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Figures 
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Fig. 1a. Plasma total DB-67 levels in SD rats treated with D5W PO
5 min before 2.5 mg/kg DB-67 lactone PO
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Fig. 1b. Semi-log plot of plasma total DB-67 levels in SD rats
treated with D5W PO 5 min before 2.5 mg/kg DB-67 lactone PO
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Fig. 2a. Plasma total DB-67 levels in SD rats treated with D5W PO
5 min before 2.5 mg/kg DB-67 lactone PO
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Fig. 2b. Semi-log plot of plasma total DB-67 levels in SD rats
treated with D5W PO 5 min before 2.5 mg/kg DB-67 lactone PO
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Fig. 3. AUCs of lactone and carboxylate forms of DB-67 in SD rats
following PO administrtation of DB-67 lactone at 2.5 mg/kg 5 min
after PO administration of D5W at 7.5 ml/kg
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Raw Data 
Expt # Rat # Time (h) 
Carboxylate 
(ng/mL) 
Lactone  
(ng/mL) 
Total AR-67  
(ng/mL) 
102 131 0.083 0.75 6.76 7.51
102 131 0.5 2.84 22.91 25.75
102 131 1 2.66 18.38 21.04
102 131 2 2.28 10.45 12.73
102 131 4 0.89 4.15 5.04
102 131 6 0.47 2.83 3.3
102 131 8 0.51 3.11 3.62
102 131 12 0.83 5.2 6.03
102 132 0.083 0.74 4.86 5.6
102 132 0.5 1.97 13.96 15.93
102 132 1 1.97 10.92 12.89
102 132 2 1.73 9.62 11.35
102 132 4 0.46 2.46 2.92
102 132 6 0.82 4.97 5.79
102 132 8 0.91 5.21 6.12
102 132 12 0.36 2.08 2.44
102 133 0.083 0.1 1.47 1.57
102 133 0.5 0.92 6.42 7.34
102 133 1 1.87 6.87 8.74
102 133 2 0.62 3.54 4.16
102 133 4 1.06 6.09 7.15
102 133 6 0.39 1.85 2.24
102 133 8 0.34 1.89 2.23
102 133 12 0.39 2.36 2.75
102 134 0.083 0.69 4.98 5.67
102 134 0.5 2.43 15.1 17.53
102 134 1 1.41 7.17 8.58
102 134 2 0.99 4.64 5.63
102 134 4 0.4 2.43 2.83
102 134 6 0.26 1.38 1.64
102 134 8 0.1 1.27 1.37
102 134 12 0.06 1.35 1.41
102 135 0.083 0.4 3.9 4.3
102 135 0.5 6.34 39.74 46.08
102 135 1 4.46 25.92 30.38
102 135 2 2.47 11.29 13.76
102 135 4 0.79 3.72 4.51
102 135 6 0.24 2.03 2.27
102 135 8 0.22 2.1 2.32
102 135 12 0.45 3.42 3.87
102 136 0.083 0.04 0.92 0.96
102 136 0.5 2.14 17.14 19.28
102 136 1 2.39 15.08 17.47
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102 136 2 1.77 9.96 11.73
102 136 4 0.54 2.88 3.42
102 136 6 0.37 2.48 2.85
102 136 8 0.44 1.89 2.33
102 136 12 0.44 2.92 3.36
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Dose dependence of GF120918 effect on oral bioavailability of SBE-β-CD based AR-67 
lactone in rats 
 
 
 
 
Expt # 103 
 
 
 
 
 
 
 
 
 
 
12/02/2008 
 
 
  
Objective 
To determine the effects of GF120918 (GF) doses on oral bioavailability of SBE-β-CD 
based AR-67 lactone in female SD rats. This is a part of GF dose-response experiments.   
Expt 103a: Study the effects of GF (2.5 mg/kg) PO on oral bioavailability of SBE-β-CD 
(200:1 E/D ratio) based AR-67 lactone (2.5 mg/kg) in rats PO  
Expt 103b: Study the effects of GF (20.0 mg/kg) PO on oral bioavailability of SBE-β-CD 
(200:1 E/D ratio) based AR-67 lactone (20 mg/kg) in rats PO 
Method 
Animal treatment and sample processing 
Expt 103a, Rats (#141-#143, n=3) were dosed with 2.5 mg/kg SBE-β-CD (200:1 E/D 
ratio) based AR-67 lactone PO 5 min after GF (2.5 mg/kg) PO. 
Expt 103b, Rats (#144-#146, n=3) were dosed with 2.5 mg/kg SBE-β-CD (200:1 E/D 
ratio) based AR-67 lactone PO 5 min after GF (20 mg/kg) PO.  
Dosing solution: 
AR-67 lactone = 1.0 mg/mL 
Blood was collected from the saphenous vein at 5 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h and 
12 h with heparinized hematocrit tubes and transferred into heparinized microcentrifuge 
tubes. Plasma was collected by centrifugation of blood and then extracted 1:4 (v/v) with 
cold MeOH     (-80oC). Samples were kept at -80oC until analysis.  
HPLC analysis  
Before injection into the HPLC, samples were diluted with an equal volume of mobile 
phase buffer (40 µL:40 µL) and were analyzed. For samples needing dilution (5min, 
30min, 1h & 2h after  intravenous doses), a 1:10 dilution was carried out using 1:4 extract 
of blank rat plasma.  
Expt 103a & 103b 
Sequence name: 20AC-031808-Rat PK Expt 103.seq 
Method: 20AC-031208-reinjection of 121807 rat plasma curve.met 
Data were exported and saved in Leggas Lab/Experimental Results/DB-67 Oral PK 
folder. (A backup copy of HPLC data was also saved in Leggas Lab/Jamie’s project/DB-
67/Rat PK). Plots were made with Prism while nocompartmental analysis was made 
using WinNonlin v5.2. 
  
Results 
Tables 
Expt 103a & 103b 
ID Parameter Units Estimate 
Average/ 
Median7  SD/range 
141 AUCall h*ng/mL 883.5052 1034.812 304.354 
142 AUCall h*ng/mL 906.0303     
143 AUCall h*ng/mL 367.9726     
141 Cmax ng/mL 146.85 786.781 59.637 
142 Cmax ng/mL 164.28     
143 Cmax ng/mL 53.38     
141 Tmax h 4 2.000 2--4 
142 Tmax h 2     
143 Tmax h 2     
            
            
144 AUCall h*ng/mL 739.3806 1149.130 202.195 
145 AUCall h*ng/mL 377.4737     
146 AUCall h*ng/mL 402.1725     
144 Cmax ng/mL 121.72 48.837 27.659 
145 Cmax ng/mL 66.8     
146 Cmax ng/mL 100     
144 Tmax h 2 2.000 0.5-2 
145 Tmax h 2     
146 Tmax h 0.5     
 
 
 
 
 
 
                                                 
7 Median was used for Tmax. All other parameters use the arithmetic mean. 
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Fig. 1a. Plasma total DB-67 levels in SD rats treated with 2.5 mg/kg
DB-67 PO 5 min after GF (2.5 mg/kg) PO
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Fig. 1b. Semi-log plot of plasma total DB-67 levels in SD rats
treated with 2.5 mg/kg DB-67 PO 5 min after GF (2.5 mg/kg) PO
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Fig. 2a. Plasma total DB-67 levels in SD rats treated with 2.5
mg/kg DB-67 PO 5 min after GF (20 mg/kg) PO
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Fig. 2b. Semi-log plot of plasma total DB-67 levels in SD rats
treated with 2.5 mg/kg DB-67 PO 5 min after GF (20 mg/kg) PO
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File path: \\pharm\public\PS\Leggas Lab\EXPERIMENTAL RESULTS\DB67 Oral 
PK\REPORTS\Prism data Files\ AUC Rat PK Expt 103 
  
Raw Data 
Expt # Rat # 
Time 
 (h) 
Carboxylate 
 (ng/mL) 
Lactone 
(ng/mL) 
Total AR-67  
(ng/mL) 
103 141 0.083 0 1.46 1.46
103 141 0.5 2.06 14.2 16.26
103 141 1 5.66 48.26 53.92
103 141 2 15.83 112.22 128.05
103 141 4 21.56 125.29 146.85
103 141 6 11.51 60.64 72.15
103 141 8 8.58 40.17 48.75
103 141 12 5.73 23.73 29.46
103 142 0.083 0 1.37 1.37
103 142 0.5 4.86 46.88 51.74
103 142 1 14.88 132.58 147.46
103 142 2 20.98 143.3 164.28
103 142 4 17.56 76.3 93.86
103 142 6 10.85 54.07 64.92
103 142 8 8.18 42.77 50.95
103 142 12 4.79 22.48 27.27
103 143 0.083 0.69 4.14 4.83
103 143 0.5 3.6 29.77 33.37
103 143 1 4.61 33.73 38.34
103 143 2 7.54 45.84 53.38
103 143 4 7.14 30.44 37.58
103 143 6 4.8 24.78 29.58
103 143 8 3.11 17.45 20.56
103 143 12 3.95 19.37 23.32
103 144 0.083 0 0.86 0.86
103 144 0.5 9.46 66.43 75.89
103 144 1 13.89 107.23 121.12
103 144 2 19.18 102.54 121.72
103 144 4 8.82 51.8 60.62
103 144 6 10.61 50.43 61.04
103 144 8 6.53 38.04 44.57
103 144 12 4.12 22.84 26.96
103 145 0.083 0 0.21 0.21
103 145 0.5 0 7.2 7.2
103 145 1 6.32 46.84 53.16
103 145 2 10.5 56.3 66.8
103 145 4 5.53 24.03 29.56
103 145 6 4.62 19.71 24.33
103 145 8 5.11 23.64 28.75
103 145 12 3.71 16.3 20.01
103 146 0.083 1.58 10.08 11.66
103 146 0.5 11.75 88.25 100
103 146 1 14.57 75.94 90.51
  
103 146 2 12.72 53.03 65.75
103 146 4 5.15 22.96 28.11
103 146 6 4.07 15.06 19.13
103 146 8 3.26 16.86 20.12
103 146 12 2.85 13.18 16.03
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Effects of D5W, vehicle and GF120918 PO on PK profiles of SBE-β-CD based AR-67 lactone 
IV in rats 
 
 
Expt # 104, Expt # 107 and Expt # 108 
 
 
 
 
 
 
 
 
 
 
11/25/2008 
 
 
  
Objective 
To determine the effects of D5W, vehicle and GF120918 PO on PK profile of SBE-β-CD 
based AR-67 lactone IV in female SD rats. This experiment will determine the systemic 
effects of GF120918 and allow us to calculate absolute bioavailability of SBE-β-CD 
(200:1 E/D ratio) based AR-67 lactone following PO administration.  
 
Expt 104, 107: Study the effects of vehicle and GF120918 PO on PK profile following IV 
administration of SBE-β-CD (200:1 E/D ratio) based AR-67 lactone (2.5 mg/kg) in 
female SD rats  
Expt 108: Study the effects of D5W PO on PK profile following IV administration of 
SBE-β-CD (200:1 E/D ratio) based AR-67 lactone (2.5 mg/kg) in female SD rats  
 
Method 
Animal treatment and sample processing 
Expt 104a, 107a, Rats (#151-#153, #171-#173, n=6) were dosed with SBE-β-CD (200:1 
E/D ratio) based AR-67 lactone (2.5 mg/kg) PO 5 min after vehicle administration at 7.5 
mL/kg PO. 
Expt 104b, 107b, Rats (#155-#156, #174-#176, n=6) were dosed with SBE-β-CD (200:1 
E/D ratio) based AR-67 lactone (2.5 mg/kg) PO 5 min after GF administration at  2.5 
mg/kg PO. 
Expt 108, Rats (#181-#186, n=3) were dosed with 2.5 mg/kg SBE-β-CD (200:1 E/D 
ratio) based AR-67 lactone PO 5 min after D5W administration at 7.5 mL/kg PO.  
Dosing solution: 
AR-67 lactone = 1.0 mg/mL 
GF120918 was dissolved in vehicle (40% PEG300, 10% Teween-80 in D5W) 
within 1 hour before experiments. 
Blood was collected from the saphenous vein at 5 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h and 
12 h with heparinized hematocrit tubes and transferred into heparinized microcentrifuge 
tubes. Plasma was collected by centrifugation of blood and then extracted 1:4 (v/v) with 
cold MeOH     (-80oC). Samples were kept at -80oC until analysis.  
 
 
  
HPLC analysis  
Before injection into the HPLC, samples were diluted with an equal volume of mobile 
phase buffer (40 µL:40 µL) and were analyzed. For samples needing dilution (5min, 
30min, 1h & 2h after  intravenous doses), a 1:10 dilution was carried out using 1:4 extract 
of blank rat plasma.  
Expt 104, 107 & 108 
Sequence name: 20AC-032008-Rat PK Expt 104.seq 
                             20AC-040208-Rat PK Expt 107.seq 
                 20AC-040308-Rat PK Expt 108.seq 
Method: 20AC-031208-reinjection of 121807 rat plasma curve.met 
Data were exported and saved in Leggas Lab/Experimental Results/DB-67 Oral PK 
folder. (A backup copy of HPLC data was also saved in Leggas Lab/Jamie’s project/DB-
67/Rat PK). Plots were made with Prism while nocompartmental analysis was made 
using WinNonlin v5.2. 
 
  
Results 
Table 1.  Pharmacokinetic parameters estimated using the noncompartmental 
method in Winnonlin v5.2 
Expt 104a & 107a 
Expt 
ID Parameter Units Estimate 
Average/ 
Median8  SD9/range 
104a 151 AUCall h*ng/mL 1516.369 1736.020 288.804
104a 152 AUCall h*ng/mL 1417.991     
104a 153 AUCall h*ng/mL 1806.815     
107a 171 AUCall h*ng/mL 2234.413     
107a 172 AUCall h*ng/mL 1637.368     
107a 173 AUCall h*ng/mL 1803.167     
104a 151 Cmax ng/mL 1486.65 1848.380 385.513
104a 152 Cmax ng/mL 1504.68     
104a 153 Cmax ng/mL 2244.65     
107a 171 Cmax ng/mL 2363.4     
107a 172 Cmax ng/mL 1904.6     
107a 173 Cmax ng/mL 1586.3     
104a 151 Tmax h 0.083 0.083 0.000
104a 152 Tmax h 0.083     
104a 153 Tmax h 0.083     
107a 171 Tmax h 0.083     
107a 172 Tmax h 0.083     
107a 173 Tmax h 0.083     
104a 151 Cl_obs mL/h/kg 1646.418 1467.898 228.548
104a 152 Cl_obs mL/h/kg 1759.938     
104a 153 Cl_obs mL/h/kg 1381.384     
107a 171 Cl_obs mL/h/kg 1112.829     
107a 172 Cl_obs mL/h/kg 1524.243     
107a 173 Cl_obs mL/h/kg 1382.576     
104a 151 Vss_obs mL/kg 1677.758 1552.289 320.571
104a 152 Vss_obs mL/kg 1993.347     
104a 153 Vss_obs mL/kg 1075.022     
                                                 
8 Median was used for Tmax. All other parameters use the arithmetic mean. 
9 Standard deviation. 
  
107a 171 Vss_obs mL/kg 1361.343     
107a 172 Vss_obs mL/kg 1472.479     
107a 173 Vss_obs mL/kg 1733.785     
 
Expt 104b & 107b 
Expt 
ID Parameter Units Estimate
Average/ 
Median  SD/range
104b 155 AUCall h*ng/mL 2514.237 2732.880 566.527
104b 156 AUCall h*ng/mL 3362.908     
107b 174 AUCall h*ng/mL 2121.467     
107b 175 AUCall h*ng/mL 2361.07     
107b 176 AUCall h*ng/mL 3304.72     
104b 155 Cmax ng/mL 1284.89 1859.448 478.310
104b 156 Cmax ng/mL 2599.91     
107b 174 Cmax ng/mL 1700.74     
107b 175 Cmax ng/mL 1931.7     
107b 176 Cmax ng/mL 1780     
104b 155 Tmax h 0.083 0.083 0.000
104b 156 Tmax h 0.083     
107b 174 Tmax h 0.083     
107b 175 Tmax h 0.083     
107b 176 Tmax h 0.083     
104b 155 Vss_obs mL/kg 2287.725 2160.307 431.934
104b 156 Vss_obs mL/kg 1440.141     
107b 174 Vss_obs mL/kg 2511.762     
107b 175 Vss_obs mL/kg 2109.548     
107b 176 Vss_obs mL/kg 2452.36     
104b 155 Cl_obs mL/h/kg 971.643 920.354 190.222
104b 156 Cl_obs mL/h/kg 728.1299     
107b 174 Cl_obs mL/h/kg 1144.657     
107b 175 Cl_obs mL/h/kg 1038.936     
107b 176 Cl_obs mL/h/kg 718.4048     
 
 
 
 
  
Expt 108 
Expt 
ID Parameter Units Estimate
Average/ 
Median  SD/range
108 181 AUCall h*ng/mL 1755.983 1845.774 177.787
108 182 AUCall h*ng/mL 1946.697    
108 183 AUCall h*ng/mL 1785.454    
108 184 AUCall h*ng/mL 1742.127    
108 185 AUCall h*ng/mL 2160.657    
108 186 AUCall h*ng/mL 1683.724    
108 181 Cmax ng/mL 2349.6 2153.300 301.833
108 182 Cmax ng/mL 2448.4    
108 183 Cmax ng/mL 1923.7    
108 184 Cmax ng/mL 2146.1    
108 185 Cmax ng/mL 2375.8    
108 186 Cmax ng/mL 1676.2    
108 181 Cl_obs mL/h/kg 1422.477 1362.323 121.090
108 182 Cl_obs mL/h/kg 1283.192    
108 183 Cl_obs mL/h/kg 1398.782    
108 184 Cl_obs mL/h/kg 1434.112    
108 185 Cl_obs mL/h/kg 1154.951    
108 186 Cl_obs mL/h/kg 1480.425    
108 181 Tmax h 0.08 0.080 0.000
108 182 Tmax h 0.08    
108 183 Tmax h 0.08    
108 184 Tmax h 0.08    
108 185 Tmax h 0.08    
108 186 Tmax h 0.08    
108 181 Vss_pred mL/kg 1107.45 1290.360 224.124
108 182 Vss_pred mL/kg 1197.219    
108 183 Vss_pred mL/kg 1502.552    
108 184 Vss_pred mL/kg 1125.87    
108 185 Vss_pred mL/kg 1169.085    
108 186 Vss_pred mL/kg 1639.984    
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Fig. 1a. Plasma total DB-67 levels in SD rats treated with 2.5
mg/kg DB-67 IV 5 min after vehicle (PEG, tween80, D5W) PO
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Fig. 1b. Plasma total DB-67 levels in SD rats treated with vehicle
(PEG, tween80, D5W) PO 5 min before 2.5mg/kg DB-67 IV
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Fig. 2a. Plasma total DB-67 levels in SD rats treated with 2.5
mg/kg DB-67 IV  5 min after GF (2.5 mg/kg) PO
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Fig. 2b. Plasma total DB-67 levels in SD rats treated 2.5
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Fig. 1a. Plasma total DB-67 levels in SD rats treated with
2.5mg/kg DB-67 lactone IV 7 min after vehicle administration
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Fig. 1b. Semi-log plot of plasma total DB-67 levels in SD rats treated
with 2.5mg/kg DB-67 lactone IV 7 min after vehicle administration
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Fig. 2a. Plasma total DB-67 levels in SD rats treated with 2.5
mg/kg DB-67 IV 5 min after GF (2.5 mg/kg) PO
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Fig. 2b. Semi-log plot of plasma total DB-67 levels in SD rats
treated with 2.5 mg/kg DB-67 IV 5 min after GF (2.5 mg/kg) PO
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Fig. 1a. Plasma total DB-67 levels in SD rats treated with 2.5
mg/kg DB-67 IV 5 min after D5W PO
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Fig. 1b. Semi-log plot of plasma total DB-67 levels in SD rats
treated with 2.5 mg/kg DB-67 IV 5 min after D5W PO
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Fig. 2b. Semi-log plot of plasma total DB-67 levels in SD rats
treated with 2.5mg/kg DB-67 IV 5 min after D5W PO
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Raw Data 
Expt Rat 
Time 
(h) 
Carboxylate 
(ng/mL) Lactone(ng/mL)
Total AR-67 
(ng/mL) 
104 151 0.083 292.53 1194.12 1486.65
104 151 0.5 125.69 598.02 723.72
104 151 1 115.15 464.50 579.64
104 151 2 32.82 111.76 144.58
104 151 4 7.88 21.59 29.47
104 151 6 2.85 7.48 10.33
104 151 8 0.46 2.18 2.64
104 151 12 0.18 1.10 1.28
104 152 0.083 268.85 1235.83 1504.68
104 152 0.5 131.40 557.01 688.41
104 152 1 71.49 330.45 401.94
104 152 2 31.40 112.36 143.76
104 152 4 13.23 33.97 47.20
104 152 6 2.06 7.36 9.42
104 152 8 Null Null Null 
104 152 12 0.14 1.21 1.35
104 153 0.083 373.01 1871.63 2244.65
104 153 0.5 221.21 908.97 1130.19
104 153 1 85.75 409.58 495.34
104 153 2 27.81 97.65 125.46
104 153 4 5.73 15.49 21.22
104 153 6 1.14 3.49 4.63
104 153 8 0.39 1.45 1.84
104 153 12 0.78 1.10 1.88
104 155 0.083 105.98 1178.91 1284.89
104 155 0.5 162.69 930.92 1093.61
104 155 1 115.84 576.51 692.35
104 155 2 57.71 309.91 367.62
104 155 4 25.25 116.06 141.31
104 155 6 11.93 59.67 71.60
104 155 8 5.90 30.16 36.06
104 155 12 2.37 13.55 15.92
104 156 0.083 162.17 2437.74 2599.91
104 156 0.5 205.39 1133.00 1338.40
104 156 1 197.10 919.81 1116.91
104 156 2 63.11 307.55 370.66
104 156 4 23.71 116.31 140.02
104 156 6 13.95 64.30 78.25
104 156 8 6.40 28.68 35.08
104 156 12 2.62 17.72 20.34
 
 
 
  
Expt Rat Time (h) Caboxylate Lactone Total AR-67 
107 171 0.083 143.51 1557.23 1700.74 
107 171 0.5 114 732.4 846.40 
107 171 1 100.6 502.6 603.20 
107 171 2 45.6 195 240.60 
107 171 4 24.84 83.52 108.36 
107 171 6 7.39 32.63 40.02 
107 171 8 4.18 19.45 23.63 
107 171 12 5.31 17.77 23.08 
107 172 0.083 148.5 1783.2 1931.70 
107 172 0.5 141.7 755.6 897.30 
107 172 1 105.9 538.1 644.00 
107 172 2 57.5 238.1 295.60 
107 172 4 25.3 89.67 114.97 
107 172 6 8.39 41.6 49.99 
107 172 8 5.55 25.94 31.49 
107 172 12 1.92 9.36 11.28 
107 173 0.083 119.5 1660.5 1780.00 
107 173 0.5 137.5 875 1012.50 
107 173 1 107.8 575.8 683.60 
107 173 2 78.1 363.4 441.50 
107 173 4 51.13 204.16 255.29 
107 173 6 21.87 90.05 111.92 
107 173 8 16.3 89.47 105.77 
107 173 12 5.98 37.1 43.08 
107 174 0.083 105.98 1178.91 1284.89 
107 174 0.5 162.69 930.92 1093.61 
107 174 1 115.84 576.51 692.35 
107 174 2 57.71 309.91 367.62 
107 174 4 25.25 116.06 141.31 
107 174 6 11.93 59.67 71.60 
107 174 8 5.90 30.16 36.06 
107 174 12 2.37 13.55 15.92 
107 175 0.083 162.17 2437.74 2599.91 
107 175 0.5 205.39 1133.00 1338.40 
107 175 1 197.10 919.81 1116.91 
107 175 2 63.11 307.55 370.66 
107 175 4 23.71 116.31 140.02 
107 175 6 13.95 64.30 78.25 
107 175 8 6.40 28.68 35.08 
107 175 12 2.62 17.72 20.34 
 
 
 
 
 
  
Expt Rat Time (h) Carboxylate Lactone Total AR-67 
108 181 0.083 227.20 2122.40 2349.60 
108 181 0.5 116.50 733.80 850.30 
108 181 1 97.40 420.70 518.10 
108 181 2 30.00 108.80 138.80 
108 181 4 6.99 19.55 26.54 
108 181 6 0.82 2.62 3.44 
108 181 8 0.20 1.07 1.27 
108 181 12 0 1.42 1.42 
108 182 0.083 236.20 2212.20 2448.40 
108 182 0.5 132.30 754.10 886.40 
108 182 1 98.50 462.20 560.70 
108 182 2 37.90 133.30 171.20 
108 182 4 11.95 36.31 48.26 
108 182 6 2.32 8.42 10.74 
108 182 8 0.67 2.73 3.40 
108 182 12.00 0.1 1.14 1.24 
108 183 0.083 215.20 1708.50 1923.70 
108 183 0.5 126.90 661.80 788.70 
108 183 1 95.30 395.00 490.30 
108 183 2 48.70 187.30 236.00 
108 183 4 10.90 36.89 47.79 
108 183 6 2.51 7.67 10.18 
108 183 8 0.71 2.64 3.35 
108 183 12.00 0.15 1.26 1.41 
108 184 0.08 170.20 1975.90 2146.10 
108 184 0.50 116.30 681.20 797.50 
108 184 1.00 - - - 
108 184 2.00 30.30 109.20 139.50 
108 184 4.00 8.17 25.37 33.54 
108 184 6.00 1.37 4.85 6.22 
108 184 8.00 0.45 3.19 3.64 
108 184 12.00 0.02 0.87 0.89 
108 185 0.08 227.10 2148.70 2375.80 
108 185 0.50 173.90 771.70 945.60 
108 185 1.00 - - - 
108 185 2.00 44.20 157.60 201.80 
108 185 4.00 15.05 49.54 64.59 
108 185 6.00 6.29 12.46 18.75 
108 185 8.00 1.75 5.01 6.76 
108 185 12.00 0.40 2.38 2.78 
108 186 0.08 139.50 1536.70 1676.20 
108 186 0.50 131.90 615.90 747.80 
108 186 1.00 - - - 
108 186 2.00 29.60 141.10 170.70 
108 186 4.00 13.97 44.48 58.45 
  
108 186 6.00 3.93 9.46 13.39 
108 186 8.00 1.40 5.05 6.45 
108 186 12.00 0.44 2.98 3.42 
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Objective 
To determine the effects of different doses of GF120918 (GF) on oral bioavailability of 
SBE-β-CD based AR-67 lactone in female SD rats. This is a part of GF (0.25, 1.0, 2.5, 20 
mg/kg) dose-response experiments. 
Expt 105: Study on the effects of GF (1.0 mg/kg) on the oral bioavailability of SBE-β-
CD (200:1 E/D ratio) based AR-67 lactone in rats (2.5 mg/kg) PO  
Expt 106: Study on the effects of GF (0.25 mg/kg) on the oral bioavailability of SBE-β-
CD (200:1 E/D ratio) based AR-67 lactone in rats (2.5 mg/kg) PO 
Method 
Animal treatment and sample processing 
Expt 105, Rats (#161-#163, n=3) were dosed with 2.5 mg/kg SBE-β-CD (200:1 E/D 
ratio) based AR-67 lactone PO 5 min after administration of GF (1.0 mg/kg) PO. 
Expt 106, Rats (#164-#166, n=3) were dosed with 2.5 mg/kg SBE-β-CD (200:1 E/D 
ratio) based AR-67 lactone PO 5 min after administration of GF (0.25 mg/kg) PO.  
Dosing solution: 
AR-67 lactone = 1.0 mg/mL 
GF120918 solution: 
            GF120918 was dissolved in vehicle (40% PEG-300, 10% Tween-80 in D5W) 
within 1 hour before experiments. 
Blood was collected from the saphenous vein at 5 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h and 
12 h with heparinized hematocrit tubes and transferred into heparinized microcentrifuge 
tubes. Plasma was collected by centrifugation of blood and then extracted 1:4 (v/v) with 
cold MeOH     (-80oC). Samples were kept at -80oC until analysis.  
HPLC analysis  
Before injection into the HPLC, samples were diluted with an equal volume of mobile 
phase buffer (40 µL:40 µL) and were analyzed. For samples needing dilution (5min, 
30min, 1h & 2h after  intravenous doses), a 1:10 dilution was carried out using 1:4 extract 
of blank rat plasma.  
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Expt 105 & 106 
Sequence name: 20AC-040108-Rat PK Expt 105 & 106.seq 
Method: 20AC-031208-reinjection of 121807 rat plasma curve.met 
Data were exported and saved in Leggas Lab/Experimental Results/DB-67 Oral PK 
folder. (A backup copy of HPLC data was also saved in Leggas Lab/Jamie’s project/DB-
67/Rat PK). Plots were made with Prism while noncompartmental analysis was made 
using WinNonlin v5.2. 
Results 
Tables.  Pharmacokinetic parameters estimated using the noncompartmental 
method in Winnonlin v5.2 
Expt 105 & 106 
ID Parameter Units Estimate 
Average/ 
Median 10 SD11/range 
161 AUCall h*ng/mL 578.184 646.933 105.608 
162 AUCall h*ng/mL 768.5319     
163 AUCall h*ng/mL 594.0823     
161 Cmax ng/mL 71.02 95.053 38.006 
162 Cmax ng/mL 138.87     
163 Cmax ng/mL 75.27     
161 Tmax h 6 2 2--6 
162 Tmax h 2     
163 Tmax h 2     
            
164 AUCall h*ng/mL 368.834 278.517 127.728 
165 AUCall h*ng/mL 188.1992     
164 Cmax ng/mL 36.28 31.860 6.251 
165 Cmax ng/mL 27.44     
164 Tmax h 2 2 2 
165 Tmax h 2     
 
                                                 
10 Median was used for Tmax. All other parameters use the arithmetic mean. 
11 Standard deviation 
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Fig. 1a. Plasma total DB-67 levels in SD rats treated with 2.5
mg/kg DB-67 PO 5 min after GF (1.0 mg/kg) PO
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Fig. 1b. Semi-log plot of plasma total DB-67 levels in SD rats treated
with 2.5 mg/kg DB-67 PO 5 min after GF (1.0 mg/kg) PO
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Fig. 2a. Plasma total DB-67 levels in SD rats treated with
2.5 mg/kg DB-67 PO 5 min after GF (0.25 mg/kg) PO
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Fig. 2b. Semi-log plot of plasma total DB-67 levels in SD rats treated
with 2.5 mg/kg DB-67 PO 5 min after GF (0.25 mg/kg) PO
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Fig. 3. AUCs of lactone and carboxylate forms of DB-67 in SD rats
following PO administrtation of DB-67 lactone (2.5 mg/kg) 5 min after
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File path: \\pharm\public\PS\Leggas Lab\EXPERIMENTAL RESULTS\DB67 Oral 
PK\REPORTS\Prism data Files\ AUC Rat PK Expt 105 & 106 
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Raw Data 
Expt # Rat Time (h)
Caboxylate  
(ng/mL) 
Lactone 
(ng/mL)
Total 
 (ng/mL) 
105 161 0.083 0.00 0.90 0.90 
105 161 0.5 1.27 7.43 8.70 
105 161 1 1.73 9.45 11.18 
105 161 2 3.91 32.84 36.75 
105 161 4 12.28 56.79 69.07 
105 161 6 16.09 54.93 71.02 
105 161 8 14.78 51.18 65.96 
105 161 12 3.41 12.79 16.20 
105 162 0.083 0.00 0.57 0.57 
105 162 0.5 2.99 31.06 34.05 
105 162 1 8.96 74.87 83.83 
105 162 2 19.06 119.81 138.87 
105 162 4 12.20 66.92 79.12 
105 162 6 12.84 55.00 67.84 
105 162 8 9.36 40.49 49.84 
105 162 12 3.35 15.73 19.08 
105 163 0.083 0.00 0.16 0.16 
105 163 0.5 3.64 22.45 26.09 
105 163 1 5.96 39.95 45.90 
105 163 2 11.07 64.20 75.27 
105 163 4 12.62 59.44 72.06 
105 163 6 9.70 44.96 54.66 
105 163 8 9.11 42.98 52.09 
105 163 12 2.20 10.32 12.52 
106 164 0.083 1.13 6.54 7.67 
106 164 0.5 4.76 26.77 31.53 
106 164 1 5.01 27.67 32.68 
106 164 2 5.53 30.75 36.28 
106 164 4 6.50 28.21 34.71 
106 164 6 4.88 22.70 27.58 
106 164 8 5.14 27.65 32.79 
106 164 12 4.29 21.00 25.29 
106 165 0.083 0.40 4.30 4.70 
106 165 0.5 1.37 11.42 12.79 
106 165 1 2.05 13.99 16.04 
106 165 2 4.01 23.43 27.44 
106 165 4 3.36 16.98 20.34 
106 165 6 2.48 11.50 13.98 
106 165 8 2.09 9.90 11.99 
106 165 12 1.70 9.98 11.68 
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Objective 
To compare the oral bioavailability of different excipients PEG, HP-CD, SBE-β-CD and 
vitamin E-TPGS based (E/D ratio 28:1) AR-67 lactone formulations in female SD rats 
and try to establish the correlation between in vivo bioavailability and in vitro solubility 
and precipitation data.  
Expt 109: Study the oral bioavailability of PEG based AR-67 lactone at 2.5 mg/kg 
Expt 110: Study the oral bioavailability of HP-CD based AR-67 lactone at 2.5 mg/kg 
Expt 111: Study the oral bioavailability of SBE-β-CD based AR-67 lactone at 2.5 mg/kg  
Expt 112: Study the oral bioavailability of vitamin E-TPGS based AR-67 lactone at 2.5 
mg/kg 
 
Method 
Animal treatment and sample processing 
Expt 109, Rats (#191-#193, n=3) were dosed with 2.5 mg/kg PEG based (28:1 E/D ratio) 
AR-67 lactone PO. 
Expt 110, Rats (#194-#196, n=3) were dosed with 2.5 mg/kg HP-CD based (28:1 E/D 
ratio) AR-67 lactone PO.  
Expt 111, Rats (#201-#203, n=3) were dosed with 2.5 mg/kg SBE-β-CD based (28:1 E/D 
ratio) AR-67 lactone PO. 
Expt 116, Rats (#204-#206, n=3) were dosed with 2.5 mg/kg vitamin E-TPGS (28:1 E/D 
ratio) AR-67 lactone PO.  
Dosing solution: Stock AR-67 solution was mixed with excipients solution immediately 
before dosing to mimic the in vitro precipitation studies done in Dr. Anderson’s lab. The 
AR-67 lactone in the dosing solution is 0.53 mg/mL.   
Blood was collected from the saphenous vein at 5 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h and 
12 h with heparinized hematocrit tubes and transferred into heparinized microcentrifuge 
tubes. Plasma was collected by centrifugation of blood and then extracted 1:4 (v/v) with 
cold MeOH     (-80oC). Samples were kept at -80oC until analysis.  
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HPLC analysis  
Expt 109 & 110 
Sequence: 20AC-040908-Rat PK Expt 109 & 110.seq 
Method: 20AC-031208-reinjection of 121807 rat plasma curve.met 
Expt 111 & 112 
Sequence: 20AC-041108-Rat PK Expt 111 & 112.seq 
Method: 20AC-031208-reinjection of 121807 rat plasma curve.met 
Data were exported and saved in Leggas Lab/Experimental Results/DB-67 Oral PK 
folder. (A backup copy of HPLC data was also saved in Leggas Lab/Jamie’s project/DB-
67/Rat PK). Plots were made with Prism while noncompartmental analysis was made 
using WinNonlin v5.2.  
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Results 
Tables:  
 
                                                 
12 Median was used for Tmax. All other parameters use the arithmetic mean. 
13 Standard deviation 
Expt  ID Parameter Units Estimate
Average/ 
Median12  SD13/range
109 191 AUCall h*ng/mL 35.4258 43.93 8.34
109 192 AUCall h*ng/mL 44.2584     
109 193 AUCall h*ng/mL 52.0954     
109 191 Cmax ng/mL 4.74 7.57 2.67
109 192 Cmax ng/mL 7.93     
109 193 Cmax ng/mL 10.05     
109 191 Tmax h 0.5 0.50 0.50
109 192 Tmax h 0.5     
109 193 Tmax h 0.5     
110 194 AUCall h*ng/mL 48.845 46.34 6.42
110 195 AUCall h*ng/mL 39.0459     
110 196 AUCall h*ng/mL 51.1408     
110 194 Cmax ng/mL 10 13.50 3.06
110 195 Cmax ng/mL 15.64     
110 196 Cmax ng/mL 14.86     
110 194 Tmax h 0.5 0.50 0.50
110 195 Tmax h 0.5     
110 196 Tmax h 0.5     
111 201 AUCall h*ng/mL 39.6901 52.46 11.11
111 202 AUCall h*ng/mL 59.9055     
111 203 AUCall h*ng/mL 57.7961     
111 201 Cmax ng/mL 5.66 10.17 3.96
111 202 Cmax ng/mL 13.06     
111 203 Cmax ng/mL 11.78     
111 201 Tmax h 0.5 0.50 0.50
111 202 Tmax h 0.5     
111 203 Tmax h 0.5     
112 204 AUCall h*ng/mL 65.7057 71.69 7.47
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112 205 AUCall h*ng/mL 80.0592     
112 206 AUCall h*ng/mL 69.296     
112 204 Cmax ng/mL 29.02 30.92 3.93
112 205 Cmax ng/mL 35.44     
112 206 Cmax ng/mL 28.29     
112 204 Tmax h 0.5 0.50 0.50
112 205 Tmax h 0.5     
112 206 Tmax h 0.5     
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Fig. 1a. Plasma total DB-67 levels in SD rats dosed with 2.5 mg/kg
PEG based  (28:1 E/D ratio) DB-67 lactone PO
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Fig. 1b. Semilog plot of plasma total DB-67 levels in SD rats dosed
with 2.5 mg/kg PEG based  (28:1 E/D ratio) DB-67 lactone PO
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Expt 110
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Fig. 2a. Plasma total DB-67 levels in SD rats dosed with 2.5 mg/kg
HP-CD based  (28:1 E/D ratio) DB-67 lactone PO
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Fig. 2b. Semilog plot of plasma total DB-67 levels in SD rats dosed
with 2.5 mg/kg HP-CD based  (28:1 E/D ratio) DB-67 lactone PO
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Figures 
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Fig. 3a. Plasma total DB-67 levels in SD rats dosed with 2.5 mg/kg
SBE-b-CD based (28:1 E/D ratio) DB-67 lactone PO
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Fig. 3b. Semilog plot of plasma total DB-67 levels in SD rats dosed
with 2.5 mg/kg SBE-b-CD based (28:1 E/D ratio) DB-67 lactone PO
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Fig. 4a. Plasma total DB-67 levels in SD rats dosed with 2.5 mg/kg
E-TPGS based (28:1 E/D ratio) DB-67 lactone PO
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Fig. 4b. Semilog plot of plasma total DB-67 levels in SD rats dosed
with 2.5 mg/kg E-TPGS based (28:1 E/D ratio) DB-67 lactone PO
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Fig. 5. AUCs of lactone and carboxylate forms of DB-67 in SD rats
following PO administrtation of PEG (expt 109), HP-CD (expt
110), SBE-b-CD (expt 111) and E-TPGS (expt 112) based (28:1
E/D ratio) DB-67 lactone at 2.5 mg/kg
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File path: \\pharm\public\PS\Leggas Lab\EXPERIMENTAL RESULTS\DB67 Oral 
PK\REPORTS\Prism data Files\ AUC Rat PK Expt 109 & 110  
File path: \\pharm\public\PS\Leggas Lab\EXPERIMENTAL RESULTS\DB67 Oral 
PK\REPORTS\Prism data Files\ AUC Rat PK Expt 111 & 11 
Raw Data 
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Expt Rat ID Time (h) Carboxylate  Lactone Total AR-67 (ng/mL) 
109 191 0.08333 0 0.69 0.69
109 191 0.5 0.47 4.27 4.74
109 191 1 0.57 3.13 3.7
109 191 2 0.39 2.86 3.25
109 191 4 0.87 3.56 4.43
109 191 6 0.63 2.97 3.6
109 191 8 0.13 1.2 1.33
109 191 12 0.34 2.35 2.69
109 192 0.08333 0.16 0.53 0.69
109 192 0.5 0.8 7.13 7.93
109 192 1 0.76 3.42 4.18
109 192 2 0.52 3.21 3.73
109 192 4 0.34 2.12 2.46
109 192 6 0.49 3.09 3.58
109 192 8 0.64 3.5 4.14
109 192 12 0.34 3.27 3.61
109 193 0.08333 0 0.91 0.91
109 193 0.5 0.98 9.07 10.05
109 193 1 0.95 4.39 5.34
109 193 2 0.88 5.05 5.93
109 193 4 0.93 4.88 5.81
109 193 6 0.65 3.18 3.83
109 193 8 0.34 2.06 2.4
109 193 12 0.55 3.39 3.94
110 194 0.08333 0 0.66 0.66
110 194 0.5 1.24 8.76 10
110 194 1 0.75 4.91 5.66
110 194 2 0.89 5.65 6.54
110 194 4 0.36 2.05 2.41
110 194 6 0.15 1.57 1.72
110 194 8 0.37 3.25 3.62
110 194 12 0.58 4.88 5.46
110 195 0.08333 0.11 2.9 3.01
110 195 0.5 1.89 13.75 15.64
110 195 1 0.73 4.6 5.33
110 195 2 0.61 3.72 4.33
110 195 4 0.68 3.41 4.09
110 195 6 0.3 2.04 2.34
110 195 8 0.03 1.06 1.09
110 195 12 0.15 2.1 2.25
110 196 0.08333 0.05 1.54 1.59
110 196 0.5 1.76 13.1 14.86
110 196 1 1.25 6.89 8.14
110 196 2 0.83 5.04 5.87
110 196 4 0.29 2.24 2.53
 246 
 
110 196 6 0.16 1.79 1.95
110 196 8 0.26 2.1 2.36
110 196 12 0.72 5.77 6.49
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Expt  Rat ID Time (h) 
AR-67  
Carboxylate 
AR-67 
 Lactone 
Total AR-67  
(ng/mL) 
111 201 0.083333 0.29 2.14 2.14 
111 201 0.5 0.72 5.66 5.66 
111 201 1 0.94 5.2 5.2 
111 201 2 0.75 4.36 4.36 
111 201 4 0.61 3.4 3.4 
111 201 6 0.44 2.93 2.93 
111 201 8 0.68 3.1 3.1 
111 201 12 0.31 2.08 2.08 
111 202 0.083333 0.08 2.29 2.29 
111 202 0.5 1.45 11.61 13.06 
111 202 1 1.3 7.84 9.14 
111 202 2 1.01 7.15 8.16 
111 202 4 1.07 6.62 7.69 
111 202 6 0.37 2.49 2.49 
111 202 8 0.39 2.47 2.47 
111 202 12 0.38 3.24 3.24 
111 203 0.083333 0.2 2.22 2.22 
111 203 0.5 1.29 10.49 11.78 
111 203 1 1.27 7.43 8.7 
111 203 2 1.2 6.51 7.71 
111 203 4 1.24 5.97 7.21 
111 203 6 0.71 3.07 3.07 
111 203 8 0.57 3.17 3.17 
111 203 12 0.17 1.84 1.84 
112 204 0.083333 0.53 3.42 3.42 
112 204 0.5 3.89 25.13 29.02 
112 204 1 2.25 13.19 15.44 
112 204 2 1.75 7.4 9.15 
112 204 4 2.16 - - 
112 204 6 0.26 2.14 2.14 
112 204 8 0.15 1.61 1.61 
112 204 12 0.47 2.92 2.92 
112 205 0.083333 0.1 1.67 1.67 
112 205 0.5 4.32 31.12 35.44 
112 205 1 3.88 19.91 23.79 
112 205 2 2.13 10.69 12.82 
112 205 4 0.81 4.02 4.02 
112 205 6 0.44 2.67 2.67 
112 205 8 0.34 2.12 2.12 
112 205 12 0.44 3.29 3.29 
112 206 0.083333 0.36 2.67 2.67 
112 206 0.5 3.96 24.33 28.29 
112 206 1 2.25 11.78 14.03 
112 206 2 1.72 8.97 10.69 
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112 206 4 1.13 6.15 7.28 
112 206 6 0.62 3.32 3.32 
112 206 8 0.23 1.54 1.54 
112 206 12 0.12 1.64 1.64 
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Objective 
To compare the relative oral bioavailability of buffered/unbuffered SBE-β-CD and 
Vitamin E –TPGS based AR-67 carboxylate formulations in female SD rats  
Expt 113: Study on oral bioavailability of buffered SBE-β-CD based AR-67 carboxylate 
(2.5 mg/kg) 
Expt 114: Study on oral bioavailability of unbuffered SBE-β-CD based AR-67 
carboxylate (2.5 mg/kg) 
Expt 115: Study on oral bioavailability of buffered Vitamin E-TPGS based AR-67 
carboxylate (2.5 mg/kg) 
Expt 116: Study on oral bioavailability of unbuffered Vitamin E-TPGS based AR-67 
carboxylate (2.5mg/kg) 
 
Method 
Animal treatment and sample processing 
Buffered/unbuffered SBE-β-CD / Vitamin E-TPGS based AR-67 carboxylate was 
prepared by Dr. Xiang (pH ≈10). The buffer was made with 0.5M Na2CO3 
Expt 113, Rats (#211-#213, n=3) were dosed with 2.5 mg/kg SBE-β-CD based (200:1 
E/D ratio) buffered AR-67 carboxylate at 7mL/kg PO. 
Expt 114, Rats (#214-#216, n=3) were dosed with 2.5mg/kg SBE-β-CD based (200:1 E/D 
ratio) buffered AR-67 unbuffered carboxylate at 7 mL/kg PO.  
Expt 115, Rats (#221-#223, n=3) were dosed with 2.5mg/kg Vitamin E-TPGS based 
(28:1 E/D ratio) AR-67 buffered carboxylate at 7 mL/kg PO. 
Expt 116, Rats (#224-#226, n=3) were dosed with 2.5mg/kg Vitamin E-TPGS based 
(28:1 E/D ratio) AR-67 unbuffered carboxylate at 7 mL/kg PO.  
Dosing solution = 0.36 mg/mL.   
Blood was collected from the saphenous vein at 5 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h and 
12 h with heparinized hematocrit tubes and transferred into heparinized microcentrifuge 
tubes. Plasma was collected by centrifugation of blood and then extracted 1:4 (v/v) with 
cold MeOH     (-80oC). Samples were kept at -80oC until analysis.  
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HPLC analysis  
Before injection into the HPLC, samples were diluted with an equal volume of mobile 
phase buffer (40 µL:40 µL) and were analyzed. 
Expt 113 & Expt 114:   
Sequence: 20AC-041108-Rat PK Expt 113 & 114.seq 
Method: 20AC-031208-reinjection of 121807 rat plasma curve.met 
Expt 115 & Expt 116:   
Sequence: 20AC-041708-Rat PK Experiment 115 &116.seq 
Method: 20AC-031208-reinjection of 121807 rat plasma curve.met 
 
Data were exported and saved in Leggas Lab/Experimental Results/DB-67 Oral PK 
folder. (A backup copy of HPLC data was also saved in Leggas Lab/Jamie’s project/DB-
67/Rat PK). 
 
Results 
Tables.  Pharmacokinetic parameters estimated using the noncompartmental method in 
Winnonlin v5.2 
Expt #113 PK Parameters 
PK 
Parameters Rat #211 Rat #212 Rat #213 Mean/Median
14 SD15/Range 
Tmax (h) 2.00 2.00 1.00 2.00 1.00-2.00 
Cmax 
(ng/mL) 12.05 28.62 20.81 20.49 8.29 
AUC0t 
(ng*h/mL) 39.28 77.68 62.04 59.67 19.31 
                                                 
14 Median was used for Tmax. All other parameters use the arithmetic mean. 
15 Standard deviation. 
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Expt #114 PK Parameters 
PK 
Parameters Rat #214 Rat #215 Rat #216 Mean/Median SD/Range 
Tmax (h) 0.50 0.50 0.50 0.50 0.50-0.50 
Cmax 
(ng/mL) 39.12 17.50 31.68 39.12 17.5 
AUC0t 
(ng*h/mL) 92.86 53.8 93.01 79.89 22.59 
 
 
Expt #115 PK Parameters 
PK 
Parameters Rat #221 Rat #222 Rat #223 Mean/Median SD/Range 
Tmax (h) 2.00 2.00 2.00 2.00 2.00-2.00 
Cmax 
(ng/mL) 21.51 25.75 13.68 20.31 6.12 
AUC0t 
(ng*h/mL) 66.71 97.25 59.42 74.46 20.07 
 
Expt #116 PK Parameters 
PK 
Parameters Rat #224 Rat #225 Rat #226 Mean/Median SD/Range 
Tmax (h) 0.50 0.50 1.00 0.50 0.50-1.00 
Cmax 
(ng/mL) 24.29 17.16 32.73 24.29 17.16 
AUC0t 
(ng*h/mL) 59.68 76.65 64.75 67.03 8.71 
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Figures 
 
File path: \\pharm\public\PS\Leggas Lab\EXPERIMENTAL RESULTS\DB67 Oral 
PK\REPORTS\Prism data Files\AUC Rat PK Expt 113, 114,115 & 116 (041708) 
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File path: \\pharm\public\PS\Leggas Lab\EXPERIMENTAL RESULTS\DB67 Oral 
PK\REPORTS\Prism data Files\AUC Rat PK Expt 113, 114,115 & 116 (041708) 
 
File path: \\pharm\public\PS\Leggas Lab\EXPERIMENTAL RESULTS\DB67 Oral 
PK\REPORTS\Prism data Files\AUC Rat PK Expt 113, 114,115 & 116 (041708) 
Raw Data 
Expt # Rat ID Time (h) 
Carboxylate  
(ng/mL) 
Lactone  
(ng/mL) Total (ng/mL) 
113 211 0.083 0.04 0.61 0.65 
113 211 0.5 0.47 1.93 2.4 
113 211 1 1.36 8.44 9.8 
113 211 2 1.79 10.26 12.05 
113 211 4 0.61 3.14 3.75 
113 211 6 0.02 0.97 0.99 
113 211 8 0 0.56 0.56 
113 211 12 0 0.73 0.73 
113 212 0.083 0.1 0.26 0.36 
113 212 0.5 0.59 2.91 3.5 
113 212 1 2.06 13 15.06 
113 212 2 4.35 24.27 28.62 
113 212 4 0.81 4.13 4.94 
113 212 6 0.2 1.67 1.87 
113 212 8 0.1 1.36 1.46 
113 212 12 0.21 1.68 1.89 
113 213 0.083 0.34 0.33 0.67 
113 213 0.5 0.8 3.46 4.26 
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113 213 1 2.49 18.32 20.81 
113 213 2 2.87 14.28 17.15 
113 213 4 0.63 2.78 3.41 
113 213 6 0.18 1.56 1.74 
113 213 8 0.05 1.27 1.32 
113 213 12 0.26 1.92 2.18 
114 214 0.083 0.16 3.5 3.66 
114 214 0.5 5.59 33.53 39.12 
114 214 1 3.35 23.44 26.79 
114 214 2 2.38 10.43 12.81 
114 214 4 1.25 4.57 5.82 
114 214 6 0.67 3.06 3.73 
114 214 8 0.43 2.41 2.84 
114 214 12 0.52 3.1 3.62 
114 215 0.083 0 0.95 0.95 
114 215 0.5 2.4 15.1 17.5 
114 215 1 1.59 9.95 11.54 
114 215 2 1.19 6.25 7.44 
114 215 4 0.86 3.73 4.59 
114 215 6 0.22 1.69 1.91 
114 215 8 0.19 2.08 2.27 
114 215 12 0.43 2.55 2.98 
114 216 0.083 0.17 1.66 1.83 
114 216 0.5 4.86 26.82 31.68 
114 216 1 4.01 23.94 27.95 
114 216 2 2.25 10.59 12.84 
114 216 4 0.74 3.96 4.7 
114 216 6 0.59 3.3 3.89 
114 216 8 0.6 3.39 3.99 
114 216 12 0.66 3.71 4.37 
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Expt# 115 & Expt# 116 
 
Expt # Rat ID 
Time 
(h) 
Carboxylate
(ng/mL) 
Lactone 
(ng/mL) 
Total 
(ng/mL) 
115 221 0.083 1.43 0.35 1.78 
115 221 0.5 1.17 3.88 5.05 
115 221 1 2.39 12.78 15.17 
115 221 2 3.46 18.05 21.51 
115 221 4 1.08 4.8 5.88 
115 221 6 0.2 1.7 1.9 
115 221 8 0.01 1.01 1.02 
115 221 12 0.06 0.82 0.88 
115 222 0.083 1.69 0.4 2.09 
115 222 0.5 1.07 4.86 5.93 
115 222 1 2.94 14.43 17.37 
115 222 2 4.35 21.4 25.75 
115 222 4 2.79 9.32 12.11 
115 222 6 0.63 2.92 3.55 
115 222 8 0.43 2.13 2.56 
115 222 12 0.08 1.64 1.72 
115 223 0.083 0.83 0.36 1.19 
115 223 0.5 0.58 3.4 3.98 
115 223 1 1.18 6.28 7.46 
115 223 2 2.05 11.63 13.68 
115 223 4 1.35 5.48 6.83 
115 223 6 0.57 2.55 3.12 
115 223 8 0.23 1.54 1.77 
115 223 12 0.45 2.56 3.01 
116 224 0.083 0.34 4.59 4.93 
116 224 0.5 3.34 20.95 24.29 
116 224 1 2.18 10.73 12.91 
116 224 2 1.2 5.72 6.92 
116 224 4 0.49 2.88 3.37 
116 224 6 0.35 2.59 2.94 
116 224 8 0.35 2.07 2.42 
116 224 12 0.5 3.29 3.79 
116 225 0.083 0.01 1.62 1.63 
116 225 0.5 2.09 15.07 17.16 
116 225 1 1.85 8.75 10.6 
116 225 2 1.47 7.33 8.8 
116 225 4 0.54 3.19 3.73 
116 225 6 0.5 3.16 3.66 
116 225 8 0.39 2.89 3.28 
116 225 12 1.61 9.73 11.34 
116 226 0.083 0.06 1.01 1.07 
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116 226 0.5 1.72 9.1 10.82 
116 226 1 1.74 30.99 32.73 
116 226 2 1.45 0.21 1.66 
116 226 4 0.64 2.94 3.58 
116 226 6 0.64 2.96 3.6 
116 226 8 0.56 2.71 3.27 
116 226 12 0.57 3.61 4.18 
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Objective 
To determine oral bioavailability of SBE-β-CD based (200:1 E/D ratio) AR-67 
carboxylate and effect of GF120918 (GF) on oral bioavailability of AR-67 carboxylate in 
female SD rats  
Expt 117: Study on the effect of GF (2.5 mg/kg) PO on bioavailability of SBE-β-CD 
based AR-67 carboxylate (2.5 mg/kg) PO 
Expt 118: Study on the effect of GF (2.5 mg/kg) PO on SBE-β-CD based AR-67 
carboxylate (2.5 mg/kg) IV 
Expt 119: Study on oral bioavailability of SBE-β-CD based AR-67 carboxylate (2.5 
mg/kg) PO 
Expt 120: Study on PK profile of SBE-β-CD based AR-67 carboxylate (2.5 mg/kg) IV 
 
Method 
Animal treatment and sample processing 
Expt 117, Rats (#231-#233, n=3) were dosed with 2.5 mg/kg SBE-β-CD based (200:1 
E/D ratio) AR-67 carboxylate PO 5 min after GF (2.5 mg/kg) at 7.5 mL/kg PO. 
Expt 118, Rats (#234-#236, n=3) were dosed with 2.5 mg/kg SBE-β-CD based (200:1 
E/D ratio) AR-67 carboxylate IV 5 min after GF (2.5 mg/kg) at 7.5 mL/kg PO.  
Expt 119, Rats (#241-#243, n=3) were dosed with 2.5 mg/kg SBE-β-CD based (200:1 
E/D ratio) AR-67 carboxylate PO 5 min after vehicle (40% PEG, 10% Tween 80, D5W) 
at 7.5 mL/kg PO. 
Expt 120, Rats (#244-#246, n=3) were dosed with 2.5 mg/kg SBE-β-CD based (200:1 
E/D ratio) AR-67 carboxylate IV 5 min after vehicle (40% PEG, 10% Tween 80, D5W) 
at 7.5 mL/kg PO.  
Dosing solution = 1.0 mg/mL. 
Blood was collected from the saphenous vein at 5 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h and 
12 h with heparinized hematocrit capillary tubes and transferred into heparinized 
microcentrifuge tubes. Plasma was collected by centrifugation of blood and then 
extracted 1:4 (v/v) with cold MeOH     (-80oC). Samples were kept at -80oC until 
analysis.  
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HPLC analysis  
Before injection into the HPLC, samples were diluted with an equal volume of mobile 
phase buffer (40 µL:40 µL) and were analyzed. 
Expt 117 & Expt 118:   
Sequence: 20AC-042308-Rat PK Expt 117 & 118.seq 
Method: 20AC-031208-reinjection of 121807 rat plasma curve.met 
Expt 119 & Expt 120:   
20AC-042408-Rat PK Expt 119 & 120.seq 
Method: 20AC-031208-reinjection of 121807 rat plasma curve.met 
                 
Data were exported and saved in Leggas Lab/Experimental Results/DB-67 Oral PK 
folder. (A backup copy of HPLC data was also saved in Leggas Lab/Jamie’s project/DB-
67/Rat PK). 
 
Results 
Tables.  Pharmacokinetic parameters estimated using the noncompartmental 
method in Winnonlin v5.2 
Expt #  ID PK Parameter Units Estimate 
Average/ 
 
Median16  SD/range 
117 231 AUCall hr*ng/mL 372.5378 480.632 94.618
117 232 AUCall hr*ng/mL 520.9203     
117 233 AUCall hr*ng/mL 548.4368     
117 231 
AUC 
inf_pred hr*ng/mL 444.7429 595.625 143.451
117 232 
AUC 
inf_pred hr*ng/mL 611.8705     
117 233 
AUC 
inf_pred hr*ng/mL 730.2615     
117 231 Cmax ng/mL 50 74.807 21.778 
                                                 
16 Median was used for Tmax. All other parameters use the arithmetic mean. 
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117 232 Cmax ng/mL 83.64     
117 233 Cmax ng/mL 90.78     
117 231 Tmax hr 4 4.000 4-4 
117 232 Tmax hr 4     
117 233 Tmax hr 4     
119 241 AUCall hr*ng/mL 94.56 94.974 11.823 
119 242 AUCall hr*ng/mL 106.9984     
119 243 AUCall hr*ng/mL 83.3629     
119 241 
AUC 
inf_pred hr*ng/mL 110.356 117.933 12.823 
119 242 
AUC 
inf_pred hr*ng/mL 132.7386     
119 243 
AUC 
inf_pred hr*ng/mL 110.7037     
119 241 Cmax ng/mL 13.77 13.467 1.547 
119 242 Cmax ng/mL 14.84     
119 243 Cmax ng/mL 11.79     
119 241 Tmax hr 2 2 2-4 
119 242 Tmax hr 2     
119 243 Tmax hr 4     
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Expt #  ID PK Parameter Units Estimate 
Average/  
Median  
SD/ 
range 
118 234 AUCall h*ng/mL 1206.524     
118 235 AUCall h*ng/mL 1360.368 1283.446 108.784 
118 234 AUCINF_pred h*ng/mL 1228.367     
118 235 AUCINF_pred h*ng/mL 1378.094 1303.230 105.873 
118 234 Cmax ng/mL 1160.2     
118 235 Cmax ng/mL 1244.4 1202.300 59.538 
118 234 Tmax h 0.083     
118 235 Tmax h 0.083 0.083 
0.083-
0.083 
118 234 Vss_obs mL/kg 6279.421     
118 235 Vss_obs mL/kg 5279.921 5779.671 706.753 
120 244 AUCall h*ng/mL 621.6544     
120 245 AUCall h*ng/mL 798.4906     
120 246 AUCall h*ng/mL 1075.162 831.769 228.578 
120 244 AUCINF_pred h*ng/mL 621.7071     
120 245 AUCINF_pred h*ng/mL 798.7154     
120 246 AUCINF_pred h*ng/mL 1075.208 831.877 228.562 
120 244 Cmax ng/mL 1245.7     
120 245 Cmax ng/mL 1203.1     
120 246 Cmax ng/mL 2282.4 1577.067 611.208 
120 244 Tmax h 0.083     
120 245 Tmax h 0.083     
120 246 Tmax h 0.083 0.083 
0.083-
0.083 
120 244 Vss_obs mL/kg 3316.46     
120 245 Vss_obs mL/kg 5823.333     
120 246 Vss_obs mL/kg 5169.809 4769.868 1300.411
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Figures 
Expt 117
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Fig. 1a. Plasma total DB-67 levels in SD rats dose with 2.5 mg/kg GF PO 5
min before 2.5 mg/kg DB-67 carboxylate PO
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Fig. 1b. Plasma total DB-67 concentration in SD rats treated with 2.5 mg/kg GF
PO 5 min before 2.5 mg/kg DB-67 carboxylate PO
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Fig. 2a. Plasma total DB-67 concentration in SD rats GF 2.5 mg/kg PO 5
min before DB-67 carboxylate (2.5 mg/kg) IV
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Fig. 2b. Plasma total DB-67 concentration in SD rats GF 2.5 mg/kg PO 5
min before DB-67 carboxylate (2.5 mg/kg) IV
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Fig. 3a. Plasma total DB-67 concentration in SD rats treated with vehicle (40%
PEG, 10% Tween 80) PO 5 min before 2.5 mg/kg DB-67 carboxylate PO
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Fig. 3b. Plasma total DB-67 concentration in SD rats treated with vehicle (40%
PEG, 10% Tween 80) PO 5 min before 2.5 mg/kg DB-67 carboxylate PO
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Fig. 4a. Plasma total DB-67 concentration in SD rats treated with vehicle (40%
PEG, 10% Tween 80) PO 5 min before 2.5 mg/kg DB-67 carboxylate IV
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Fig. 4b. Plasma total DB-67 concentration in SD rats treated with vehicle (40%
PEG, 10% Tween 80) PO 5 min before 2.5 mg/kg DB-67 carboxylate IV
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Expt 117 & 119
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Fig. 5a. Plasma total DB-67 levels in SD rats dosed with 2.5 mg/kg DB-67
carboxylate PO 5 min before GF PO (Expt 117) and vehicle PO (expt 119)
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Fig. 5b. Semilog plot of plasma total DB-67 levels in SD rats dosed
with 2.5 mg/kg DB-67 carboxylate PO 5 min before GF PO (Expt
117) and vehicle PO (expt 119)
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Fig. 6a. Plasma total DB-67 levels in SD rats dosed with 2.5 mg/kg DB-67
carboxylate IV 5 min before GF PO (Expt 118) and vehicle PO (expt 120)
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Fig. 6b. Semilog plot of plasma total DB-67 levels in SD rats dosed with
2.5 mg/kg DB-67 carboxylate IV 5 min before GF PO (Expt 118) and
vehicle PO (expt 120)
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Fig. 7. AUCs of lactone and carboxylate forms of DB-67 in SD rats
following PO administrtation of DB-67 carboxylate at 2.5 mg/kg 5 min
after GF PO at 2.5 mg/kg (expt 117) and  vehicle PO (expt 119)
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Fig. 8. AUCs of lactone and carboxylate forms of DB-67 in SD rats
following IV administrtation of DB-67 carboxylate at 2.5 mg/kg 5
min after GFat 2.5 mg/kg PO (expt 118) and vehicle PO (expt 120)
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File path: \\pharm\public\PS\Leggas Lab\EXPERIMENTAL RESULTS\DB67 Oral 
PK\REPORTS\Prism data Files\ AUC Rat PK Expt 117,118,119 & 120 (042408) 
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Raw Data 
Expt # Rat # 
Time 
(h) 
Carboxylate 
(ng/mL) 
Lactone 
(ng/mL) 
Total 
(ng/mL) 
117 231 0.083 0 0.24 0.24 
117 231 0.5 1.8 15 16.8 
117 231 1 4.15 32.11 36.26 
117 231 2 7.7 40.64 48.34 
117 231 4 7.24 42.76 50 
117 231 6 5.83 25.91 31.74 
117 231 8 4.62 21.07 25.69 
117 231 12 1.88 10.38 12.26 
117 232 0.083 0.13 0.4 0.53 
117 232 0.5 1.88 14.86 16.74 
117 232 1 2.85 23.34 26.19 
117 232 2 9.5 65.62 75.12 
117 232 4 14.38 69.26 83.64 
117 232 6 7.95 37.13 45.08 
117 232 8 5.02 25.53 30.55 
117 232 12 3.66 12.19 15.85 
117 233 0.083 0 0.33 0.33 
117 233 0.5 0.69 4.99 5.68 
117 233 1 1.67 14.45 16.12 
117 233 2 9.72 61.54 71.26 
117 233 4 12.85 77.93 90.78 
117 233 6 9.41 39.96 49.37 
117 233 8 5.97 27.54 33.51 
117 233 12 3.28 19.69 22.97 
118 234 0.083 1068.3 91.9 1160.2 
118 234 0.5 64.89 60.29 125.18 
118 234 1 31.48 93.5 124.98 
118 234 2 35.65 170.58 206.23 
118 234 4 14.44 64.28 78.72 
118 234 6 9.77 40.14 49.91 
118 234 8 5.17 23.53 28.7 
118 234 12 2.83 15.99 18.82 
118 235 0.083 1126.4 118 1244.4 
118 235 0.5 114.94 99.49 214.43 
118 235 1 44.75 134.32 179.07 
118 235 2 32.63 176.66 209.29 
118 235 4 18.33 83.84 102.17 
118 235 6 7.39 36.62 44.01 
118 235 8 6.24 26.87 33.11 
118 235 12 2.07 16.8 18.87 
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Expt # Rat Time 
(h) 
AR-67 
Carboxylate
AR-67 
Lactone 
Total 
119 241 0.083  outlier  outlier  outlier 
119 241 0.5 1.09 5.39 6.48
119 241 1 1.36 7.38 8.74
119 241 2 2.31 11.46 13.77
119 241 4 1.88 8.99 10.87
119 241 6 4.53 7.01 11.54
119 241 8 0.63 4.04 4.67
119 241 12 0.32 2.32 2.64
119 242 0.083 0.24 1.97 2.21
119 242 0.5 2.31 10.74 13.05
119 242 1 2.12 9.47 11.59
119 242 2 2.56 12.28 14.84
119 242 4 2.41 10.96 13.37
119 242 6 1.91 7.62 9.53
119 242 8 0.74 4.47 5.21
119 242 12 0.47 3.57 4.04
119 243 0.083 0 0.5 0.5
119 243 0.5 0.28 2.36 2.64
119 243 1 0.74 3.69 4.43
119 243 2 1.16 7.99 9.15
119 243 4 1.88 9.91 11.79
119 243 6 1.46 7.07 8.53
119 243 8 0.78 4.66 5.44
119 243 12 0.36 3.65 4.01
120 244 0.083 1150.5 95.2 1245.7
120 244 0.5 89.71 48.24 137.95
120 244 1 28.24 46.74 74.98
120 244 2 16.66 35.89 52.55
120 244 4 2.41 5.98 8.39
120 244 6 0.5 2.07 2.57
120 244 8 0.22 1.27 1.49
120 244 12 0.27 2.44 2.71
120 245 0.083 1107.6 95.5 1203.1
120 245 0.5 183.12 51.81 234.93
120 245 1 81.66 40.58 122.24
120 245 2 33.88 50.3 84.18
120 245 4 6.32 14.58 20.9
120 245 6 1.68 5.07 6.75
120 245 8 0.6 2.58 3.18
120 245 12 4.81 14.24 19.05
120 246 0.083 2106.7 175.7 2282.4
120 246 0.5 114.95 50.83 165.78
120 246 1 37.46 44.78 82.24
120 246 2 10.19 31.53 41.72
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120 246 4 2.79 9.06 11.85
120 246 6 0.35 2.44 2.79
120 246 8 0.07 1.47 1.54
120 246 12 11.53 43.85 55.38
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Objective 
To determine the effects of selective P-gp and BCRP inhibition on oral bioavailability of 
SBE-β-CD based AR-67 lactone in rats  
Expt 121: Study the effect of the selective P-gp inhibitor zosuquidar (20 mg/kg) PO on 
bioavailability of SBE-β-CD based AR-67 lactone (2.5 mg/kg) PO 
Expt 122: Study the effect of the selective P-gp inhibitor zosuquidar (20 mg/kg) PO on 
the kinetics of SBE-β-CD based AR-67 lactone (2.5 mg/kg) IV 
Expt 123: Study the effect of the selective Bcrp inhibitor novobiocin (50 mg/kg) PO on 
bioavailability of SBE-β-CD based AR-67 lactone (2.5 mg/kg) PO  
Expt 124: Study the effect of the selective Bcrp inhibitor novobiocin (50 mg/kg) PO on 
the kinetics of SBE-β-CD based AR-67 lactone (2.5 mg/kg) IV 
 
Method 
Animal treatment and sample processing 
Expt 121, Rats (#251-#253, n=3) were dosed with 2.5 mg/kg SBE-β-CD based (200:1 
E/D ratio) AR-67 lactone PO 5 min after zosuquidar (20 mg/kg)  at 7.5 mL/kg PO. 
Expt 122, Rats (#254-#256, n=3) were dosed with 2.5 mg/kg SBE-β-CD based (200:1 
E/D ratio) AR-67 lactone IV 5 min after zosuquidar(20 mg/kg) at 7.5 mL/kg PO.  
Expt 123, Rats (#261-#263, n=3) were dosed with 2.5 mg/kg SBE-β-CD based (200:1 
E/D ratio) AR-67 lactone PO 5 min after novobiocin (50 mg/kg) at 7.5 mL/kg PO. 
Expt 124, Rats (#264-#266, n=3) were dosed with 2.5 mg/kg SBE-β-CD based (200:1 
E/D ratio) AR-67 lactone IV 5 min after novobiocin (50 mg/kg)  at 7.5 mL/kg PO.  
Dosing solution concentrations 
AR-67 lactone = 1.0 mg/mL.   
Zosuquidar17= 2.67 mg/ml 
Novobiocin18= 6.67 mg/ml 
                                                 
17 5g of SBE‐b‐CD was dissolved in D5W to a final volume of 25ml (20% solution). 66.7mg of 
zosuquidar was dissolved in 25ml of the SBE‐b‐CD solution. 
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Blood was collected from the saphenous vein at 5 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h and 
12 h with heparinized hematocrit tubes and transferred into heparinized microcentrifuge 
tubes. Plasma was collected by centrifugation of blood and then extracted 1:4 (v/v) with 
cold MeOH     (-80oC). Samples were kept at -80oC until analysis.  
 
HPLC analysis  
Before injection into the HPLC, samples were diluted with an equal volume of mobile 
phase buffer (40 µL:40 µL) and were analyzed. For samples needing dilution (5min, 
30min, 1h & 2h after  intravenous doses), a 1:10 dilution was carried out using 1:4 extract 
of blank plasma.  
Expt 121 & Expt 122:   
Sequence name:20AC-050108-Rat PK Expt 121 & 122.seq 
Method: 20AC-031208-reinjection of 121807 rat plasma curve.met 
Expt 123 & Expt 124:   
Sequence name: 20AC-050208-Rat PK Expt 122 & 124.seq 
Method: 20AC-031208-reinjection of 121807 rat plasma curve.met 
Data were exported and saved in Leggas Lab/Experimental Results/DB-67 Oral PK 
folder. (A backup copy of HPLC data was also saved in Leggas Lab/Jamie’s project/DB-
67/Rat PK). Plots were made with Prism while noncompartmental analysis was made 
using WinNonlin v5.2. 
 
 
 
 
                                                                                                                                                 
18166.7 mg of novobiocin sodium was dissolved in 25ml D5W. 
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Results 
Tables.  Pharmacokinetic parameters estimated using the noncompartmental 
method in Winnonlin v5.2 
(Expt 121 & 123) 
 
 
Expt ID Parameter Unit Estimate 
Average/ 
Median 19 
SD20/ 
range 
123 261 AUCall hr*ng/mL 99.7921 65.71 
  
  31.84 
123 262 AUCall hr*ng/mL 36.7306
123 263 AUCall hr*ng/mL 60.5979
123 261 AUCINF_pred hr*ng/mL 106.1287 77.81 
  
  
28.72 
  
  
123 262 AUCINF_pred hr*ng/mL 48.7064
123 263 AUCINF_pred hr*ng/mL 78.5944
123 261 Cmax ng/mL 35.37 21.20 
  
  
12.30 
  
  
123 262 Cmax ng/mL 13.31
123 263 Cmax ng/mL 14.93
123 261 Tmax hr 0.5 0.50 
  
  
0.5-1 
  
  
123 262 Tmax hr 1
123 263 Tmax hr 0.5
121 251 AUCall hr*ng/mL 121.9123 155.68 
  
  
55.95 
  
  
121 252 AUCall hr*ng/mL 124.8569
121 253 AUCall hr*ng/mL 220.2647
121 251 AUCINF_pred hr*ng/mL 126.9403 180.14 
  
  
85.35 
  
  
121 252 AUCINF_pred hr*ng/mL 134.89
121 253 AUCINF_pred hr*ng/mL 278.5849
121 251 Cmax ng/mL 71.03 71.01 
  
  
9.91 
  
  
121 252 Cmax ng/mL 61.1
121 253 Cmax ng/mL 80.91
121 251 Tmax hr 0.5
0.5 
  
  
  
 Same 
Tmax 
  
121 252 Tmax hr 0.5
121 
253 Tmax hr 0.5
 
 
                                                 
19 Median was used for Tmax. All other parameters use the arithmetic mean. 
20 SD: standard deviation 
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Expt 122 & 124 
Expt 
ID Parameter Units Estimate 
Average/  
Median  
SD 
/range 
124 264 AUCall hr*ng/mL 1566.039 1784.770 
  
  
373.854 
  
  
124 265 AUCall hr*ng/mL 2216.446
124 266 AUCall hr*ng/mL 1571.823
124 264 Cmax ng/mL 1936.700 2153.900 
  
  
499.566 
  
  
124 265 Cmax ng/mL 2725.300
124 266 Cmax ng/mL 1799.700
124 264 Tmax hr 0.083 0.083 
  
  
  
  
 Same Tmax 
124 265 Tmax hr 0.083 
124 266 Tmax hr 0.083 
124 264 Vss_obs mL/kg 1134.692 1208.065 
  
  
291.935 
  
  
124 265 Vss_obs mL/kg 959.817 
124 266 Vss_obs mL/kg 1529.687
125 254 AUCall hr*ng/mL 2357.721 2323.415 
  
  
49.040 
  
  
125 255 AUCall hr*ng/mL 2267.245
125 256 AUCall hr*ng/mL 2345.278
125 254 Cmax ng/mL 2013.800 2061.233 
  
  
47.104 
  
  
125 255 Cmax ng/mL 2061.900
125 256 Cmax ng/mL 2108.000
125 254 Tmax hr 0.083 0.083 
  
  
  
 Same Tmax 
  
125 255 Tmax hr 0.083 
125 256 Tmax hr 0.083 
125 254 Vss_obs mL/kg 1484.891 1535.702 
  
  
55.156 
  
  
125 255 Vss_obs mL/kg 1594.362
125 256 Vss_obs mL/kg 1527.854
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Figures 
Expt 121
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Fig. 1a. Plasma total DB-67 concentration in SD rats treated with 20 mg/kg
Zosuquidar PO 5 min before 2.5 mg/kg DB-67 lactone PO
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Fig. 1b. Plasma total DB-67 concentration in SD rats treated with 20 mg/kg
Zosuquidar PO 5 min before 2.5 mg/kg DB-67 lactone PO
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Fig. 2a. Plasma total DB-67 concentration in SD rats treated with 20 mg/kg
Zosuquidar PO 5 min before 2.5 mg/kg DB-67 lactone IV
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Fig. 2b. Plasma total DB-67 concentration in SD rats treated with 20 mg/kg
Zosuquidar PO 5 min before 2.5 mg/kg DB-67 lactone IV
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Expt 123
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Fig. 3a. Plasma total DB-67 concentration in SD rats treated with 50 mg/kg
Novobiocin PO 5 min before 2.5 mg/kg DB-67 lactone PO
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Fig. 3b. Plasma total DB-67 concentration in SD rats treated with 50 mg/kg
Novobiocin PO 5 min before 2.5 mg/kg DB-67 lactone PO
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Fig. 4a. Plasma total DB-67 concentration in SD rats treated with 50 mg/kg
Novobiocin PO 5 min before 2.5 mg/kg DB-67 lactone IV
Time (h)
C
on
c 
(n
g/
m
L)
Expt 124
0 5 10 15
1
10
100
1000
10000
Rat #264
Rat #265
Rat #266
Fig. 4b. Plasma total DB-67 concentration in SD rats treated with 50 mg/kg
Novobiocin PO 5 min before 2.5 mg/kg DB-67 lactone IV
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File path: \\pharm\public\PS\Leggas Lab\EXPERIMENTAL RESULTS\DB67 Oral 
PK\REPORTS\Prism data Files\AUC Rat PK Expt 121, 122,123 & 124(050208) 
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Raw Data 
Sample ID Expt # Rat # Time (h) 
AR-67  
Carboxylate 
AR-67  
Lactone 
Total  
AR-67 
L251-5min 121 251 0.083 0.05 2.32 2.37 
L251-30min 121 251 0.5 11.74 59.29 71.03 
L251-1h 121 251 1 7.69 34.3 41.99 
L251-2h 121 251 2 4.31 16.11 20.42 
L251-4h 121 251 4 1.51 6.69 8.2 
L251-6h 121 251 6 0.55 2.95 3.5 
L251-8h 121 251 8 0.45 2.78 3.23 
L251-12h 121 251 12 0.46 2.55 3.01 
L252-5min 121 252 0.083 0.09 1.19 1.28 
L252-30min 121 252 0.5 9.27 51.83 61.1 
L252-1h 121 252 1 7.4 32.19 39.59 
L252-2h 121 252 2 4.54 16.74 21.28 
L252-4h 121 252 4 1.89 7.47 9.36 
L252-6h 121 252 6 1.24 5.35 6.59 
L252-8h 121 252 8 0.49 2.52 3.01 
L252-12h 121 252 12 0.4 2.4 2.8 
L253-5min 121 253 0.083 0.32 3.75 4.07 
L253-30min 121 253 0.5 12.17 68.74 80.91 
L253-1h 121 253 1 14.4 63.02 77.42 
L253-2h 121 253 2 10.28 30.15 40.43 
L253-4h 121 253 4 2.62 8.81 11.43 
L253-6h 121 253 6 1.35 5.39 6.74 
L253-8h 121 253 8 1.28 4.86 6.14 
L253-12h 121 253 12 0.87 3.47 4.34 
L254-5 min 
Dilu (1:10) 122 254 0.083 169.4 1844.4 2013.8 
L254-30 min 
Dilu (1:10) 122 254 0.5 198.6 855.4 1054 
L254-1 h 
Dilu (1:10) 122 254 1 129 445 574 
L254-2 h 
Dilu (1:10) 122 254 2 63.3 239.8 303.1 
L254-4h 122 254 4 14.41 46.74 61.15 
L254-6h 122 254 6 6.93 21.39 28.32 
L254-8h 122 254 8 3.16 11.63 14.79 
L254-12h 122 254 12 1.89 6.89 8.78 
L255-5 min 
Dilu (1:10) 122 255 0.083 181.5 1880.4 2061.9 
L255-30 min 
Dilu (1:10) 122 255 0.5 169.6 793.8 963.4 
L255-1 h 122 255 1 111.2 476.8 588 
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Dilu (1:10) 
L255-2 h 
Dilu (1:10) 122 255 2 83.3 278.9 362.2 
L255-4h 122 255 4 15.71 51.61 67.32 
L255-6h 122 255 6 4.41 15.41 19.82 
L255-8h 122 255 8 2.35 8.72 11.07 
L255-12h 122 255 12 2.24 7.11 9.35 
L256-5 min 
Dilu (1:10) 122 256 0.083 273.3 1834.7 2108 
L256-30 min 
Dilu (1:10) 122 256 0.5 206.8 738.9 945.7 
L256-1 h 
Dilu (1:10) 122 256 1 183.2 535.8 719 
L256-2 h 
Dilu (1:10) 122 256 2 82.2 251.1 333.3 
L256-4h 122 256 4 20.48 53.45 73.93 
L256-6h 122 256 6 12.16 26.79 38.95 
L256-8h 122 256 8 4.41 12.69 17.1 
L256-12h 122 256 12  Will be reanalyzed  
L261-5min 123 261 0.083 0.07 1.7 1.77 
L261-30min 123 261 0.5 3.98 31.39 35.37 
L261-1h 123 261 1 5.47 26.28 31.75 
L261-2h 123 261 2 4.17 19.03 23.2 
L261-4h 123 261 4 0.99 5.24 6.23 
L261-6h 123 261 6 0.87 3.79 4.66 
L261-8h 123 261 8 0.35 2.39 2.74 
L261-12h 123 261 12 0.68 4.46 5.14 
L262-5min 123 262 0.083 0 0.66 0.66 
L262-30min 123 262 0.5 1.92 9.45 11.37 
L262-1h 123 262 1 2.47 10.84 13.31 
L262-2h 123 262 2 1.34 4.72 6.06 
L262-4h 123 262 4 0.28 1.68 1.96 
L262-6h 123 262 6 0.41 1.91 2.32 
L262-8h 123 262 8 0.68 3.04 3.72 
L262-12h 123 262 12 1.75 9.27 11.02 
L263-5min 123 263 0.083 0.17 2.37 2.54 
L263-30min 123 263 0.5 1.72 13.21 14.93 
L263-1h 123 263 1 1.91 12.06 13.97 
L263-2h 123 263 2 1.89 8.85 10.74 
L263-4h 123 263 4 1.04 4.96 6 
L263-6h 123 263 6 0.88 4.61 5.49 
L263-8h 123 263 8 0.52 3.03 3.55 
L263-12h 123 263 12 0.7 3.83 4.53 
L264-5 min 124 264 0.083 160.7 1776 1936.7 
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Dilu (1:10) 
L264-30 min 
Dilu (1:10) 124 264 0.5 124.8 549.1 673.9 
L264-1 h 
Dilu (1:10) 124 264 1 69.8 289 358.8 
L264-2 h 
Dilu (1:10) 124 264 2 
Run stopped. 
Sample will be renalyzed 
L264-4h 124 264 4 3.65 9.26 12.91 
L264-6h 124 264 6 0.76 2.09 2.85 
L264-8h 124 264 8 0.24 0.82 1.06 
L264-12h 124 264 12 0.38 1.95 2.33 
L265-5 min 
Dilu (1:10) 124 265 0.083 235.5 2489.8 2725.3 
L265-30 min 
Dilu (1:10) 124 265 0.5 186.1 960.5 1146.6 
L265-1 h 
Dilu (1:10) 124 265 1 131.1 547 678.1 
L265-2 h 
Dilu (1:10) 124 265 2 37 145.5 182.5 
L265-4h 124 265 4 7.31 24.4 31.71 
L265-6h 124 265 6 2.21 6.71 8.92 
L265-8h 124 265 8 0.36 2.01 2.37 
L265-12h 124 265 12 0.3 1.87 2.17 
L266-5 min 
Dilu (1:10) 124 266 0.083 169.1 1630.6 1799.7 
L266-30 min 
Dilu (1:10) 124 266 0.5 155.6 646.6 802.2 
L266-1 h 
Dilu (1:10) 124 266 1 92.6 354.8 447.4 
L266-2 h 
Dilu (1:10) 124 266 2 34.3 125.7 160 
L266-4h 124 266 4 9.54 23.16 32.7 
L266-6h 124 266 6 2.32 5.68 8 
L266-8h 124 266 8 0.41 1.69 2.1 
L266-12h 124 266 12 0.23 1.33 1.56 
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Objective 
To determine the oral bioavailability of SBE-β-CD based DB-67 carboxylate in female 
SD rats. 
Expt 125: Study on PK of SBE-β-CD based (200:1 E/D ratio) DB-67 carboxylate (2.5 
mg/kg) PO  
Expt 126: Study on PK of SBE-β-CD based (200:1 E/D ratio) DB-67 carboxylate (2.5 
mg/kg ) IV 
Method 
Animal treatment and sample processing 
Expt 125, Rats (#271-#273, n=3) were dosed with 2.5 mg/kg SBE-β-CD based (200:1 
E/D ratio) DB-67 carboxylate PO 5 min after vehicle administration at 7.5 mL/kg PO. 
Expt 126, Rats (#274-#276, n=3) were dosed with 2.5 mg/kg SBE-β-CD based (200:1 
E/D ratio) DB-67 carboxylate IV 5 min after vehicle administration at 7.5 mL/kg PO.  
DB-67 dosing solution: 
DB-67 carboxylate = 1.0 mg/mL.  \ 
Vehicle:  
           40% PEG-300, 10% Tween-80 in D5W 
Blood was collected from the saphenous vein at 5 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h and 
12 h with heparinized hematocrit tubes and transferred into heparinized microcentrifuge 
tubes. Plasma was collected by centrifugation of blood and then extracted 1:4 (v/v) with 
cold MeOH     (-80oC). Samples were kept at -80oC until analysis.  
HPLC analysis 
Before injection into the HPLC, samples were diluted with an equal volume of mobile 
phase buffer (40 µL:40 µL) and were analyzed. For samples needing dilution (5min, 
30min, 1h & 2h after  intravenous doses), a 1:10 dilution was carried out using 1:4 extract 
of blank rat plasma.  
Expt 125 & Expt 126:   
Sequence name: 20AC-050808-Rat PK Expt 125 & 126.seq 
Method:  20AC-052108-reinjection of 051208 calibration curve.met  
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Data were exported and saved in Leggas Lab/Experimental Results/DB-67 Oral PK 
folder. (A backup copy of HPLC data was also saved in Leggas Lab/Jamie’s project/DB-
67/Rat PK). Plots were made with Prism while noncompartmental analysis was made 
using WinNonlin v5.2. 
Results 
Table 1.  Pharmacokinetic parameters estimated using the noncompartmental 
method in Winnonlin v5.2 -- Expt 125 & 126 
Expt 
# 
Rat 
ID Parameter Units Estimate 
Average/ 
Median21 
SD/ 
Range22 
125 271 AUCall hr*ng/mL 89.7
113.3 21.6 
125 272 AUCall hr*ng/mL 132.1
125 273 AUCall hr*ng/mL 118.1
125 271 Cmax ng/mL 14.8
16.9 2.0 
125 272 Cmax ng/mL 18.7
125 273 Cmax ng/mL 17.3
125 271 Tmax Hr 6
2 2-6 
125 272 Tmax Hr 2
125 273 Tmax Hr 2
126 274 AUCall hr*ng/mL 752.0
835.2 76.0 
126 275 AUCall hr*ng/mL 900.9
126 276 AUCall hr*ng/mL 852.6
126 274 Cmax ng/mL 1478.6
1691.2 184.8 
126 275 Cmax ng/mL 1813.0
126 276 Cmax ng/mL 1781.9
126 274 Tmax hr 0.083
0.083 
Same as  
Tmax 
126 275 Tmax hr 0.083
126 276 Tmax hr 0.083
126 274 Vss_pred mL/kg 2872.3
2566.1 700.6 
126 275 Vss_pred mL/kg 3061.5
126 276 Vss_pred mL/kg 1764.5
 
 
 
                                                 
21 Median was used for Tmax. All other parameters use the arithmetic mean 
22 SD: standard deviation 
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Figures 
0 2 4 6 8 10 12 14
0
5
10
15
20
Fig. 1a. Plasma total DB-67 levels in SD rats treated with 200
mg/kg valproic acid PO 5 min before 2.5mg/kg DB-67 PO
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Fig. 1b. Semilog plot of plasma total DB-67 levels in SD rats
treated with valproic acid (200 mg/kg) PO 5 min before
2.5mg/kg DB-67 PO
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Fig. 2a. Plasma total DB-67 levels in SD rats treated with 2.5
mg/kg GF IV 5 min before 2.5mg/kg DB-67 PO
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Fig. 2b. Plasma total DB-67 levels in SD rats treated with 2.5
mg/kg GF IV 5 min before 2.5mg/kg DB-67 PO
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File path: \\pharm\public\PS\Leggas Lab\EXPERIMENTAL RESULTS\DB67 Oral 
PK\REPORTS\Prism data Files\ AUC Rat PK Expt 125 & 126 
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Raw Data 
 
Sample ID Expt # Rat # Time (h) 
AR-67 
Carboxylate 
(ng/mL) 
AR-67 
Lactone 
(ng/mL) 
Total  
AR-67 
(ng/mL) 
L271-5min-
050708 125 271 0.083 0 0.61 0.61 
L271-30min-
050708 125 271 0.5 0.08 1.23 1.31 
L271-1h-
050708 125 271 1 0.18 1.32 1.5 
L271-2h-
050708 125 271 2 0.48 4.14 4.62 
L271-4h-
050708 125 271 4 1.97 12.56 14.53 
L271-6h-
050708 125 271 6 2.66 12.11 14.77 
L271-8h-
050708 125 271 8 1.13 5.9 7.03 
L271-12h-
050708 125 271 12 0.57 3.84 4.41 
L272-5min-
050708 125 272 0.083 0.09 1.08 1.17 
L272-30min-
050708 125 272 0.5 1.68 14.26 15.94 
L272-1h-
050708 125 272 1 1.79 11.65 13.44 
L272-2h-
050708 125 272 2 2.62 16.12 18.74 
272-4h-
125 272 4 2.67 8.44 11.11 
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050808 
272-6h-
050808 125 272 6 2.9 11.27 14.17 
272-8h-
050808 125 272 8 2.32 8.01 10.33 
272-12h-
050808 125 272 12 1 4.43 5.43 
273-5min-
050808 125 273 0.083 0.32 0.86 1.18 
273-30min-
050808 125 273 0.5 9.68 3.54 13.22 
273-1h-
050808 125 273 1 1.03 4.79 5.82 
273-2h-
050808 125 273 2 6.18 11.15 17.33 
273-4h-
050808 125 273 4 2.91 12.54 15.45 
273-6h-
050808 125 273 6 2.39 9.33 11.72 
273-8h-
050808 125 273 8 1.77 5.99 7.76 
273-12h-
050808 125 273 12 1.14 4.32 5.46 
274-5min-
050808  126 274 0.083 1325.111 153.4848 1478.595 
274-30min-
050808 126 274 0.5 126.64 60.64 187.28 
274-1h-
050808 126 274 1 42.93 65.3 108.23 
274-2h-
126 274 2 14.12 36.08 50.2 
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050808 
274-4h-
050808 126 274 4 5.75 8.3 14.05 
274-6h-
050808 126 274 6 1.39 3.36 4.75 
274-8h-
050808 126 274 8 0.85 2.55 3.4 
274-12h-
050808 126 274 12 0.61 1.94 2.55 
275-5min-
050808  126 275 0.083 1631.592 181.44 1813.032 
275-30min-
050808 126 275 0.5 98.53 66.31 164.84 
275-1h-
050808 126 275 1 31.39 52.71 84.1 
275-2h-
050808 126 275 2 3.77 10.04 13.81 
275-4h-
050808 126 275 4 15.04 57.29 72.33 
275-6h-
050808 126 275 6 1.54 4.35 5.89 
275-8h-
050808 126 275 8 0.9 2.9 3.8 
275-12h-
050808 126 275 12 0.7 2.38 3.08 
276-5min-
050808  126 276 0.083 1588.487 193.4016 1781.888 
276-30min-
050808 126 276 0.5 172.45 72.89 245.34 
276-1h-
126 276 1 35.52 65.81 101.33 
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050808 
276-2h-
050808 126 276 2 13.2 37.37 50.57 
276-4h-
050808 126 276 4 2.83 7.23 10.06 
276-6h-
050808 126 276 6 1.09 3.36 4.45 
276-8h-
050808 126 276 8 0.78 2.36 3.14 
276-12h-
050808 126 276 12 0.54 1.75 2.29 
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Objective 
To determine the effects of GF120918 at low dose of 0.25 mg/kg on oral bioavailability 
of SBE-β-CD based DB-67 lactone in female SD rats  
To determine the effects of GF120918 at 2.5 mg/kg on oral bioavailability of SBE-β-CD 
based DB-67 carboxylate in female SD rats  
Expt 127: Study on effects of GF120918 (0.25 mg/kg) on PK of SBE-β-CD based (200:1 
E/D ratio) DB-67 lactone (2.5 mg/kg) PO  
Expt 128: Study on effects of GF120918 (2.5 mg/kg) on PK of SBE-β-CD based (200:1 
E/D ratio) DB-67 carboxylate (2.5 mg/kg) PO  
Expt 129: Study on effects of GF120918 (2.5 mg/kg) on PK of SBE-β-CD based (200:1 
E/D ratio) DB-67 carboxylate (2.5 mg/kg) IV 
 
Method 
Animal treatment and sample processing 
Expt 127, Rats (#281-#282, n=2) were dosed with 2.5 mg/kg SBE-β-CD based (200:1 
E/D ratio) DB-67 lactone PO 5 min after GF120918 (2.5 mg/kg) administration at 7.5 
mL/kg PO.  
Expt 128, Rats (#283-#285, n=3) were dosed with 2.5 mg/kg SBE-β-CD based (200:1 
E/D ratio) DB-67 carboxylate PO 5 min after GF120918 (2.5 mg/kg) administration at 
7.5 mL/kg PO. 
Expt 129, Rats (#286-#288, n=3) were dosed with 2.5 mg/kg SBE-β-CD based (200:1 
E/D ratio) DB-67 carboxylate IV 5 min after GF120918 (2.5 mg/kg) administration at 7.5 
mL/kg IV.  
Dosing solution: 
DB-67 lactone = 1.0 mg/mL.   
DB-67 carboxylate = 1.0 mg/mL.   
GF120918 solution: 
           GF120918 was dissolved in vehicle (40% PEG-300, 10% Tween-80 in D5W) 
within 1 hour before experiment.  
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Blood was collected from the saphenous vein at 5 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h and 
12 h with heparinized hematocrit tubes and transferred into heparinized microcentrifuge 
tubes. Plasma was collected by centrifugation of blood and then extracted 1:4 (v/v) with 
cold MeOH     (-80oC). Samples were kept at -80oC until analysis.  
 
HPLC analysis 
Before injection into the HPLC, samples were diluted with an equal volume of mobile 
phase buffer (40 µL:40 µL) and were analyzed. For samples needing dilution (5min, 
30min, 1h & 2h after  intravenous doses), a 1:10 dilution was carried out using 1:4 extract 
of blank rat plasma.  
Expt 126, Expt 127 & Expt 128   
Sequence name: 20AC-052108-Rat PK Expt 127, 128 & 129.seq 
Method: 20AC-052108-reinjection of 051208 calibration curve.met 
Data were exported and saved in Leggas Lab/Experimental Results/DB-67 Oral PK 
folder. (A backup copy of HPLC data was also saved in Leggas Lab/Jamie’s project/DB-
67/Rat PK). Plots were made with Prism while noncompartmental analysis was made 
using WinNonlin v5.2. 
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Results 
Tables 
Expt 127, 128 & 129 
Expt 
ID Parameter Units Estimate 
Average/ 
Median  SD/range 
127 281 AUCall h*ng/mL 214.548 218.813 6.031
127 282 AUCall h*ng/mL 223.0773     
127 281 Cmax ng/mL 32.18 32.850 0.948
127 282 Cmax ng/mL 33.52     
127 281 Tmax h 2 3.000 1.414
127 282 Tmax h 4     
127 281 Cl_F_obs mL/h/kg 10322.21 9771.833 778.358
127 282 Cl_F_obs mL/h/kg 9221.451     
128 283 AUCall h*ng/mL 430.8436 416.591 12.345
128 284 AUCall h*ng/mL 409.2437     
128 285 AUCall h*ng/mL 409.6845     
128 283 Cmax ng/mL 71.95 68.443 5.363
128 284 Cmax ng/mL 62.27     
128 285 Cmax ng/mL 71.11     
128 283 Tmax h 2 2.667 1.155
128 284 Tmax h 4     
128 285 Tmax h 2     
128 283 Cl_F_obs mL/h/kg 4646.13 4888.916 216.822
128 284 Cl_F_obs mL/h/kg 5063.252     
128 285 Cl_F_obs mL/h/kg 4957.366     
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Expt 
ID Parameter Units Estimate 
Average/ 
Median  SD/range 
129 286 AUCall h*ng/mL 956.8197 1176.112 200.709
129 287 AUCall h*ng/mL 1220.817     
129 288 AUCall h*ng/mL 1350.699     
129 286 Cmax ng/mL 1217.005 1226.252 280.125
129 287 Cmax ng/mL 1510.886     
129 288 Cmax ng/mL 950.8644     
129 286 Tmax h 0.083 0.083 0.000
129 287 Tmax h 0.083     
129 288 Tmax h 0.083     
129 286 Vss_obs mL/kg 6893.898 6584.311 870.879
129 287 Vss_obs mL/kg 5600.936     
129 288 Vss_obs mL/kg 7258.099     
129 286 Cl_obs mL/h/kg 2489.785 2044.452 405.593
129 287 Cl_obs mL/h/kg 1947.344     
129 288 Cl_obs mL/h/kg 1696.228     
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Figures 
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Fig. 1a. Plasma total DB-67 levels in SD rats dosed with 2.5 mg/kg
DB-67 lactone PO 5 min after GF (0.25 mg/kg) PO administration
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Fig. 1b. Semilog plot of plasma total DB-67 levels in SD rats dosed with 2.5
mg/kg DB-67 lactone PO 5 min after GF (0.25 mg/kg) PO administration
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Fig. 2a. Plasma total DB-67 levels in SD rats dosed with 2.5 mg/kg
DB-67 carboxylate PO 5 min after GF (2.5 mg/kg) PO administration
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Fig. 2b. Semilog plot of plasma total DB-67 levels in SD rats dosed with 2.5
mg/kg DB-67 carboxylate PO 5 min after GF (2.5 mg/kg) PO administration
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Fig. 3a. Plasma total DB-67 levels in SD rats dosed with 2.5 mg/kg
DB-67 carboxylate PO 5 min after GF (2.5 mg/kg) PO administration
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Fig. 3b. Semilog plot of plasma total DB-67 levels in SD rats dosed with 2.5
mg/kg DB-67 carboxylate PO 5 min after GF (2.5 mg/kg) PO administration
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Fig. 7. AUCs of lactone and carboxylate forms of DB-67 in SD rats
following PO administrtation of DB-67 lactone at 2.5 mg/kg 5 min
after GF PO at 0.25 mg/kg (expt 127), PO (expt 128) and IV (expt
129) administration of DB-67 carboxylate at 2.5 mg/kg 5 min after
GF PO at 2.5 mg/kg
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Raw Data 
Expt # Rat # 
Time 
(h) 
DB-67 
Carboxylate
DB-67 
Lactone 
Total 
DB-67 
(ng/mL) 
127 281 0.083 0.43 3.53 3.96 
127 281 0.5 2.49 10.63 13.12 
127 281 1 3.59 15.52 19.11 
127 281 2 6.02 26.16 32.18 
127 281 4 6.12 24.58 30.7 
127 281 6 3.86 15.36 19.22 
127 281 8 2.78 8.4 11.18 
127 281 12 1.22 4.56 5.78 
127 282 0.083 0.36 0.99 1.35 
127 282 0.5 2 9.45 11.45 
127 282 1 3.03 11.25 14.28 
127 282 2 4.46 15.64 20.1 
127 282 4 6.61 26.91 33.52 
127 282 6 6.05 19.46 25.51 
127 282 8 3.27 10.58 13.85 
127 282 12 1.65 6.86 8.51 
128 283 0.083 0.42 2.08 2.5 
128 283 0.5 7.56 41.63 49.19 
128 283 1 12.02 54.46 66.48 
128 283 2 13.39 58.56 71.95 
128 283 4 11.36 41.16 52.52 
128 283 6 5.55 22.06 27.61 
128 283 8 4.05 17.05 21.1 
128 283 12 2.65 10.51 13.16 
128 284 0.083 0.49 0.77 1.26 
128 284 0.5 1.15 5.81 6.96 
128 284 1 3.22 13.89 17.11 
128 284 2 8.93 36.4 45.33 
128 284 4 12.41 49.86 62.27 
128 284 6 9.75 29.71 39.46 
128 284 8 7.17 23.44 30.61 
128 284 12 3.04 11.77 14.81 
128 285 0.083 1.38 1.21 2.59 
128 285 0.5 6.2 33.15 39.35 
128 285 1 7.38 36.1 43.48 
128 285 2 14.95 56.16 71.11 
128 285 4 9.47 35.53 45 
128 285 6 7.18 25.03 32.21 
128 285 8 4.98 18.42 23.4 
128 285 12 2.31 11.24 13.55 
129 286 0.083 1123.019 93.9862 1217.006 
129 286 0.5 100.68 48.21 148.89 
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129 286 1 45.61 78.61 124.22 
129 286 2 25.66 92.8 118.46 
129 286 4 10.69 35.44 46.13 
129 286 6 7.65 25.18 32.83 
129 286 8 4.22 15.72 19.94 
129 286 12 1.99 7.5 9.49 
129 287 0.083 1398.05 112.8358 1510.886 
129 287 0.5 96.77 62.14 158.91 
129 287 1 44.99 86.33 131.32 
129 287 2 32.35 128.75 161.1 
129 287 4 15.82 56.84 72.66 
129 287 6 8.9 35.79 44.69 
129 287 8 4.66 18.21 22.87 
129 287 12 3.12 11.19 14.31 
129 288 0.083 864.994 85.8704 950.8644 
129 288 0.5 128.39 62 190.39 
129 288 1 66.68 99.9 166.58 
129 288 2 48.37 148.66 197.03 
129 288 4 22.6 82.22 104.82 
129 288 6 17.36 63.48 80.84 
129 288 8 9.17 33.91 43.08 
129 288 12 4.58 20.57 25.15 
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Objective 
To determine the effects of GF (in 10% PEG-300) on oral bioavailability of SBE-β-CD 
based DB-67 lactone in rats  
To determine the effects of grapefruit juice on oral bioavailability of SBE-β-CD based 
DB-67 lactone in rats  
Expt 131: Study on effects of GF in 10% PEG-300 (2.5 mg/kg) on PK of SBE-β-CD 
based (200:1 E/D ratio) DB-67 lactone (2.5 mg/kg) PO  
Expt 132: Study on effects of grapefruit juice double strength (10 mL/kg) on PK of SBE-
β-CD based (200:1 E/D ratio) DB-67 lactone (2.5 mg/kg) PO  
 
Method 
Animal treatment and sample processing 
Expt 131, Rats (#291-#293, n=3) were dosed with 2.5 mg/kg SBE-β-CD based (200:1 
E/D ratio) DB-67 lactone PO 5 min after GF120918 (2.5 mg/kg) administration at 7.5 
mL/kg PO. 
Expt 132, Rats (#294-#296, n=3) were dosed with 2.5 mg/kg SBE-β-CD based (200:1 
E/D ratio) DB-67 lactone PO 1 hour after grapefruit juice (double strength) 
administration at 10 mL/kg PO.  
Dosing solution: 
DB-67 lactone = 1.0 mg/mL 
GF120918 solution: 
           GF120918 was dissolved in 10% PEG-300 in D5W, prepared freshly before using.  
Grapefruit juice: 
           Double strength, Kroger brand, thawed right before using. 
Blood was collected from the saphenous vein at 5 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h and 
12 h with heparinized hematocrit tubes and transferred into heparinized microcentrifuge 
tubes. Plasma was collected by centrifugation of blood and then extracted 1:4 (v/v) with 
cold MeOH     (-80oC). Samples were kept at -80oC until analysis.  
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HPLC analysis 
Before injection into the HPLC, samples were diluted with an equal volume of mobile 
phase buffer (40 µL:40 µL) and were analyzed. For samples needing dilution (5min, 
30min, 1h & 2h after  intravenous doses), a 1:10 dilution was carried out using 1:4 extract 
of blank rat plasma.  
Expt 131 & 132   
Sequence name: 20AC-051908-Rat PK Expt 131 & 132.seq 
Method: 20AC-052108-reinjection of 051208 calibration curve.met 
Data were exported and saved in Leggas Lab/Experimental Results/DB-67 Oral PK 
folder. (A backup copy of HPLC data was also saved in Leggas Lab/Jamie’s project/DB-
67/Rat PK). Plots were made with Prism while nocompartmental analysis was made 
using Winnonlin v5.2. 
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Results 
Tables 
Expt 131 & 132 
ID Parameter Units Estimate 
Average/ 
Median  SD/range 
291 AUCall h*ng/mL 278.4716 289.007 28.669 
292 AUCall h*ng/mL 267.0952     
293 AUCall h*ng/mL 321.4531     
291 Cl_F_obs mL/h/kg 3573.39 5555.672 2541.509 
292 Cl_F_obs mL/h/kg 8420.896     
293 Cl_F_obs mL/h/kg 4672.73     
291 Cmax ng/mL 35.18 39.490 10.866 
292 Cmax ng/mL 51.85     
293 Cmax ng/mL 31.44     
291 Tmax h 2 2.000 2--6 
292 Tmax h 2     
293 Tmax h 6     
            
294 AUCall h*ng/mL 106.3305 112.595 15.086 
295 AUCall h*ng/mL 101.6499     
296 AUCall h*ng/mL 129.8031     
294 Cl_F_obs mL/h/kg 16673.44 16545.277 1352.975 
295 Cl_F_obs mL/h/kg 17829.61     
296 Cl_F_obs mL/h/kg 15132.78     
294 Cmax ng/mL 30.47 29.450 4.920 
295 Cmax ng/mL 24.1     
296 Cmax ng/mL 33.78     
294 Tmax h 0.5 0.500 0.500 
295 Tmax h 0.5     
296 Tmax h 0.5     
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Figures 
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Fig. 1a. Plasma total DB-67 levels in SD rats treated with 2.5 mg/mL GF in 10% PEG300 5
min before 2.5 mg/kg DB-67 lactone PO
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Fig. 1b. Semilog plot of plasma total DB-67 levels in SD rats treated with 2.5 mg/kg GF in
10% PEG300 5 min before 2.5 mg/kg DB-67 lactone PO
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Fig. 2a. Plasma total DB-67 levels in SD rats pretreated with double strengh grapefruit
juice (10 mL/kg) twice for 2 days and once 1 h before of 2.5 mg/kg DB-67 lactone PO
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Fig. 2b. Semilog plot of plasma total DB-67 levels in SD rats pretreated with double
strengh grapefruit juice (10 mL/kg) twice for 2 days and once 1 h before 2.5 mg/kg
DB-67 lactone PO
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Raw Data 
Sample ID Expt # Rat # Time (h) Carboxylate Lactone 
Total 
AR-67 
L291-5min-
051908 131 291 0.083 0.07 3.61 3.68 
L291-30min-
051908 131 291 0.5 1.52 13.14 14.66 
L291-1h-051908 131 291 1 4.18 28.9 33.08 
L291-2h-051908 131 291 2 5.6 29.58 35.18 
L291-4h-051908 131 291 4 4.58 25.12 29.7 
L291-6h-051908 131 291 6 3.22 16.13 19.35 
L291-8h-051908 131 291 8 2.92 14.03 16.95 
L291-12h-
051908 131 291 12 2.41 19.74 22.15 
L292-5min-
051908 131 292 0.083 0.83 7.06 7.89 
L292-30min-
051908 131 292 0.5 5.33 28.28 33.61 
L292-1h-051908 131 292 1 7.1 42.11 49.21 
L292-2h-051908 131 292 2 9.03 42.82 51.85 
L292-4h-051908 131 292 4 5.17 22.42 27.59 
L292-6h-051908 131 292 6 3.09 15.29 18.38 
L292-8h-051908 131 292 8 1.59 8.88 10.47 
L292-12h-
051908 131 292 12 0.61 5.23 5.84 
L293-5min-
051908 131 293 0.083 1.4 11.1 12.5 
L293-30min-
051908 131 293 0.5 4.48 19.24 23.72 
L293-1h-051908 131 293 1 3.94 19.59 23.53 
L293-2h-051908 131 293 2 6.41 24.56 30.97 
L293-4h-051908 131 293 4 6.05 21.9 27.95 
L293-6h-051908 131 293 6 6.06 25.38 31.44 
L293-8h-051908 131 293 8 5.2 23.75 28.95 
L293-12h-
051908 131 293 12 2.9 15.96 18.86 
L294-5min-
051908 132 294 0.083 0.22 4.2 4.42 
L294-30 min-
051908 132 294 0.5 3.6 26.87 30.47 
L294-1 h-051908 132 294 1 3.58 20.58 24.16 
L294-2 h-051908 132 294 2 1.8 10.35 12.15 
L294-4 h-051908 132 294 4 0.94 6.66 7.6 
L294-6h-051908 132 294 6 0.6 5.21 5.81 
L294-8h-051908 132 294 8 0.48 4.81 5.29 
 300 
 
L294-12h-
051908 132 294 12 0.64 5.47 6.11 
L295- 5min-
051908 132 295 0.083 0.28 4.46 4.74 
L295-30 min-
051908 132 295 0.5 2.76 21.34 24.1 
L295- 1h-051908 132 295 1 3.96 17.48 21.44 
L295-2 h-051908 132 295 2 2.98 12.53 15.51 
L295-4 h-051908 132 295 4 1.15 6.15 7.3 
L295-6h-051908 132 295 6 0.64 4.73 5.37 
L295-8h-051908 132 295 8 0.37 4.16 4.53 
L295-12h-
051908 132 295 12 0.6 4.97 5.57 
L296-5min-
051908 132 296 0.083 0.17 4.02 4.19 
L296-30min-
051908 132 296 0.5 3.45 30.33 33.78 
L296- 1h-051908 132 296 1 4.63 27.5 32.13 
L296-2 h-051908 132 296 2 2.65 14.29 16.94 
L296-4 h-051908 132 296 4 1.94 10 11.94 
L296-6h-051908 132 296 6 0.63 5.38 6.01 
L296-8h-051908 132 296 8 0.49 4.83 5.32 
L296-12h-
051908 132 296 12 0.57 5.38 5.95 
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DEPARTMENT OF PHARMACEUTICAL SCIENCES, COLLEGE OF 
PHARMACY 
UNIVERSITY OF KENTUCKY (LEGGAS LAB) 
Report on DB-67 Lactone Rat PK Study  
 
(May 22nd, 08) 
 
Effects of valproic acid (PO) and  GF120918 (IV) on bioavailability of SBE-β-CD based  
DB-67 Lactone (PO) 
 
 
Expt # 134 and Expt # 135 
 
 
 
 
 
 
 
 
 
 
11/21/2008 
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Objective 
To determine the effects of UGT inhibition by valproic acid on oral bioavailability of 
SBE-β-CD based DB-67 lactone in rats  
To determine the effects of GF IV on oral bioavailability of SBE-β-CD based DB-67 
lactone in rats  
Expt 134: Study on effects of UGT inhibition by valproic acid (200 mg/kg) on PK of 
SBE-β-CD based (200:1 E/D ratio) DB-67 lactone (2.5 mg/kg) PO  
Expt 135: Study on effects of GF (2.5 mg/kg) IV on PK of SBE-β-CD based (200:1 E/D 
ratio) DB-67 lactone (2.5 mg/kg) PO  
 
Method 
 
Animal treatment and sample processing 
Expt 134, Rats (#301-#303, n=3) were dosed with 2.5 mg/kg SBE-β-CD based (200:1 
E/D ratio) DB-67 lactone PO 5 min after valproic acid (200 mg/kg) administration at 7.5 
mL/kg PO. 
Expt 135, Rats (#304-#306, n=3) were dosed with 2.5 mg/kg SBE-β-CD based (200:1 
E/D ratio) DB-67 lactone PO 5 min after GF (2.5 mg/kg) at 7.5 mL/kg IV.  
Dosing solution: 
DB-67 lactone = 1.0 mg/mL 
Blood was collected from the saphenous vein at 5 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h and 
12 h with heparinized hematocrit tubes and transferred into heparinized microcentrifuge 
tubes. Plasma was collected by centrifugation of blood and then extracted 1:4 (v/v) with 
cold MeOH     (-80oC). Samples were kept at -80oC until analysis.  
 
HPLC analysis  
Before injection into the HPLC, samples were diluted with an equal volume of mobile 
phase buffer (40 µL:40 µL) and were analyzed. For samples needing dilution (5min, 
30min, 1h & 2h after  intravenous doses), a 1:10 dilution was carried out using 1:4 extract 
of blank rat plasma.  
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Expt 134 & 135 
Sequence name: 20AC-050308-Rat PK Expt 134 & 135.seq 
Method: 20AC-052108-reinjection of 051208 calibration curve.met 
Data were exported and saved in Leggas Lab/Experimental Results/DB-67 Oral PK 
folder. (A backup copy of HPLC data was also saved in Leggas Lab/Jamie’s project/DB-
67/Rat PK). Plots were made with Prism while nocompartmental analysis was made 
using Winnonlin v5.2. 
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Results 
Tables 
Expt 131 & 132 
ID Parameter Units Estimate 
Average/ 
Median  SD/range 
301 AUCall h*ng/mL 94.1298 90.701 5.154 
302 AUCall h*ng/mL 84.7738     
303 AUCall h*ng/mL 93.1988     
301 Cmax ng/mL 18.86 21.460 3.554 
302 Cmax ng/mL 25.51     
303 Cmax ng/mL 20.01     
301 Cl_F_obs mL/h/kg 13984.2 12710.256 5616.915 
302 Cl_F_obs mL/h/kg 6565.784     
303 Cl_F_obs mL/h/kg 17580.78     
301 Tmax h 0.5 0.500 0.5--1 
302 Tmax h 0.5     
303 Tmax h 1     
            
            
304 AUCall h*ng/mL 192.3323 244.139 57.989 
305 AUCall h*ng/mL 306.7813     
306 AUCall h*ng/mL 233.3036     
304 Cmax ng/mL 26.21 40.703 25.607 
305 Cmax ng/mL 70.27     
306 Cmax ng/mL 25.63     
304 Cl_F_obs mL/h/kg 8207.239 6118.561 1808.882 
305 Cl_F_obs mL/h/kg 5063.222     
306 Cl_F_obs mL/h/kg 5085.221     
304 Tmax h 0.5 0.500 0.5--2 
305 Tmax h 0.5     
306 Tmax h 2     
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Figures 
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Fig. 1a. Plasma total DB-67 levels in SD rats treated with 200
mg/kg valproic acid PO 5 min before 2.5mg/kg DB-67 PO
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Fig. 1b. Semilog plot of plasma total DB-67 levels in SD rats
treated with valproic acid (200 mg/kg) PO 5 min before
2.5mg/kg DB-67 PO
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Fig. 2a. Plasma total DB-67 levels in SD rats treated with 2.5
mg/kg GF IV 5 min before 2.5mg/kg DB-67 PO
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Fig. 2b. Plasma total DB-67 levels in SD rats treated with 2.5
mg/kg GF IV 5 min before 2.5mg/kg DB-67 PO
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Raw Data 
Sample ID Expt # Rat # Time (h) Carb. Lact 
Total 
AR-67 
L301-5min-
052308 134 301 0.083 0.63 8.51 9.14 
L301-30min-
052308 134 301 0.5 2.35 16.51 18.86 
L301-1h-052308 134 301 1 1.91 10.26 12.17 
L301-2h-052308 134 301 2 1.76 9.08 10.84 
L301-4h-052308 134 301 4 1.28 7.17 8.45 
L301-6h-052308 134 301 6 0.51 5.87 6.38 
L301-8h-052308 134 301 8 0.53 4.82 5.35 
L301-12h-
052308 134 301 12 0.58 5.47 6.05 
L302-5min-
052308 134 302 0.083 0.33 6.23 6.56 
L302-30min-
052308 134 302 0.5 3.41 22.1 25.51 
L302-1h-052308 134 302 1 1.03 6.68 7.71 
L302-2h-052308 134 302 2 0.65 5.2 5.85 
L302-4h-052308 134 302 4 0.58 4.58 5.16 
L302-6h-052308 134 302 6 0.34 4.21 4.55 
L302-8h-052308 134 302 8 0.57 5.09 5.66 
L302-12h-
052308 134 302 12 1.38 8.86 10.24 
L303-5min-
052308 134 303 0.083 1.09 10.99 12.08 
L303-30min-
052308 134 303 0.5 1.45 9 10.45 
L303-1h-052308 134 303 1 3.13 16.88 20.01 
L303-2h-052308 134 303 2 2.03 10.35 12.38 
L303-4h-052308 134 303 4 0.69 5.62 6.31 
L303-6h-052308 134 303 6 0.7 5.82 6.52 
L303-8h-052308 134 303 8 0.41 4.74 5.15 
L303-12h-
052308 134 303 12 0.44 4.91 5.35 
L304-5min-
052308 135 304 0.083 0.18 4 4.18 
L304-30min-
052308 135 304 0.5 2.59 23.62 26.21 
L304-1h-052308 135 304 1 2.63 19.55 22.18 
L304-2h-052308 135 304 2 3.6 22.47 26.07 
L304-4h-052308 135 304 4 2.88 16.08 18.96 
L304-6h-052308 135 304 6 1.89 13.26 15.15 
L304-8h-052308 135 304 8 1.27 11.04 12.31 
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L304-12h-
052308 135 304 12 1.05 8.14 9.19 
L305-5min-
052308 135 305 0.083 2.45 11.31 13.76 
L305-30min-
052308 135 305 0.5 7.24 63.03 70.27 
L305-1h-052308 135 305 1 7.01 41.8 48.81 
L305-2h-052308 135 305 2 7.21 42.76 49.97 
L305-4h-052308 135 305 4 3.69 19.32 23.01 
L305-6h-052308 135 305 6 1.92 11.89 13.81 
L305-8h-052308 135 305 8 1.58 12.4 13.98 
L305-12h-
052308 135 305 12 2.55 19.44 21.99 
L306-5min-
052308 135 306 0.083 0.72 6.37 7.09 
L306-30min-
052308 135 306 0.5 3.41 20.72 24.13 
L306-1h-052308 135 306 1 4.33 20.58 24.91 
L306-2h-052308 135 306 2 4.21 21.42 25.63 
L306-4h-052308 135 306 4 3.6 20.17 23.77 
L306-6h-052308 135 306 6 3.2 15.91 19.11 
L306-8h-052308 135 306 8 2.61 13.21 15.82 
L306-12h-
052308 135 306 12 1.92 13.14 15.06 
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OF PHARMACEUTICAL SCIENCES, COLLEGE OF PHARMACY 
UNIVERSITY OF KENTUCKY (LEGGAS LAB) 
Report on DB-67 Rat PK Study  
 
(May 29th, 08) 
 
Bioavailability of SBE-β-CD based DB-67 lactone and carboxylate (10 mg/kg) 
administered PO 
 
 
Expt # 137 and Expt # 138 
 
 
 
 
 
 
 
 
 
 
11/22/2008 
 
 
 
 
Objective 
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To determine the oral bioavailability of SBE-β-CD based DB-67 in lactone and 
carboxylate forms at 10 mg/kg in rats. This is a part of dose-dependent experiments (2.5, 
5.0 10.0 mg/kg) to determine the linear range between DB-67 dose and AUC of plasma 
total DB-67 levels. To keep the total dosing volume consistent in all 3 groups at 10.0 
mL/kg, the rats in 10 mg/kg groups were co-treated with no D5W.  
Expt 137: Study on the oral bioavailability of SBE-β-CD based DB-67 lactone 10 mg/kg 
in SD female rats PO  
Expt 138: Study on the oral bioavailability of SBE-β-CD based DB-67 carboxylate at 10 
mg/kg in SD female rats PO  
 
Method 
 
Animal treatment and sample processing 
Expt 137, Rats (#311-#313, n=3) were dosed with 10 mg/kg SBE-β-CD based (200:1 E/D 
ratio) DB-67 lactone PO. 
Expt 138, Rats (#314-#316, n=3) were dosed with 2.5 mg/kg SBE-β-CD based (200:1 
E/D ratio) DB-67 carboxylate PO.  
Dosing solution: 
DB-67 lactone = 1.0 mg/mL 
DB-67 carboxylate = 1.0 mg/mL 
Blood was collected from the saphenous vein at 5 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h and 
12 h with heparinized hematocrit tubes and transferred into heparinized microcentrifuge 
tubes. Plasma was collected by centrifugation of blood and then extracted 1:4 (v/v) with 
cold MeOH     (-80oC). Samples were kept at -80oC until analysis.  
 
HPLC analysis  
Before injection into the HPLC, samples were diluted with an equal volume of mobile 
phase buffer (40 µL:40 µL) and were analyzed. For samples needing dilution (5min, 
30min, 1h & 2h after  intravenous doses), a 1:10 dilution was carried out using 1:4 extract 
of blank rat plasma.  
Expt 137 & 138 
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Sequence name: 20AC-060908-Expt 137 & 138.seq 
Method: 20AC-052108-reinjection of 051208 calibration curve.met 
Data were exported and saved in Leggas Lab/Experimental Results/DB-67 Oral PK 
folder. (A backup copy of HPLC data was also saved in Leggas Lab/Jamie’s project/DB-
67/Rat PK). Plots were made with Prism while nocompartmental analysis was made 
using Winnonlin v5.2. 
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Results 
Tables 
Expt 137 & 138 
ID Parameter Units Estimate 
Average/ 
Median  SD/range 
311 AUCall h*ng/mL 391.9731 358.374 50.234 
312 AUCall h*ng/mL 382.5226     
313 AUCall h*ng/mL 300.6262     
311 Cmax ng/mL 123.54 138.700 13.748 
312 Cmax ng/mL 150.36     
313 Cmax ng/mL 142.2     
311 Cl_F_obs mL/h/kg 4482.995 5028.643 531.551 
312 Cl_F_obs mL/h/kg 5544.876     
313 Cl_F_obs mL/h/kg 5058.058     
311 Tmax h 0.5 0.500 0.500 
312 Tmax h 0.5     
313 Tmax h 0.5     
            
            
314 AUCall h*ng/mL 319.2915 323.105 39.685 
315 AUCall h*ng/mL 364.5588     
316 AUCall h*ng/mL 285.4643     
314 Cmax ng/mL 146.59 135.163 21.060 
315 Cmax ng/mL 148.04     
316 Cmax ng/mL 110.86     
314 Cl_F_obs mL/h/kg 6988.664 6813.151 531.318 
315 Cl_F_obs mL/h/kg 6216.282     
316 Cl_F_obs mL/h/kg 7234.507     
314 Tmax h 0.5 0.500 0.500 
315 Tmax h 0.5     
316 Tmax h 0.5     
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Fig. 1a. Plasma total DB-67 levels in SD rats treated with 10
mg/kg DB-67 lactone PO
Expt 137
Rat #311
Rat #312
Rat #313
Time (h)
C
on
c(
ng
/m
L)
0 2 4 6 8 10 12
1
10
100
1000
Fig. 1b. Semilog plot of plasma total DB-67 levels in SD rats
treated with 10 mg/kg DB-67 lactone PO
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Fig. 2a. Plasma total DB-67 levels in SD rats treated with 10
mg/kg DB-67 carboxylate PO
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Fig. 2b. Plasma total DB-67 levels in SD rats treated with 10
mg/kg DB-67 carboxylate PO
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PK\REPORTS\Prism data Files\ AUC Rat PK Expt 137 & 138 
 313 
 
Raw Data 
Sample ID Expt # Rat # Time (h) 
Carboxylate  
(ng/mL) 
Lactone  
(ng/mL) Total (ng/ml)
L311-5 min 137 311 0.083 2.16 14.33 16.49 
L311-30 min 137 311 0.5 15.42 108.12 123.54 
L311- 1 h 137 311 1 11.49 74.9 86.39 
L311- 2 h 137 311 2 7.61 36.1 43.71 
L311- 4 h 137 311 4 3.5 15.59 19.09 
L311- 6 h 137 311 6 4.5 22.48 26.98 
L311- 8 h 137 311 8 3.66 17.71 21.37 
L311- 12 h 137 311 12 3.68 18.62 22.3 
L312-5 min 137 312 0.083 1.99 8.98 10.97 
L312-30 min 137 312 0.5 18.06 132.3 150.36 
L312- 1 h 137 312 1 19.9 105.74 125.64 
L312- 2 h 137 312 2 11.81 42.87 54.68 
L312- 4 h 137 312 4 3.99 11.83 15.82 
L312- 6 h 137 312 6 2.38 10.15 12.53 
L312- 8 h 137 312 8 3.01 13.46 16.47 
L312- 12 h 137 312 12 3.04 11.2 14.24 
L313-5 min 137 313 0.083 2.19 11.76 13.95 
L313-30 min 137 313 0.5 20 122.2 142.2 
L313- 1 h 137 313 1 17.96 84.56 102.52 
L313- 2 h 137 313 2 8.3 33.94 42.24 
L313- 4 h 137 313 4 3.91 11.92 15.83 
L313- 6 h 137 313 6 1.83 7.78 9.61 
L313- 8 h 137 313 8 1.55 7.02 8.57 
L313- 12 h 137 313 12 1.86 5.69 7.55 
L314-5 min 138 314 0.083 0.95 5.24 6.19 
L314-30 min 138 314 0.5 18.78 127.81 146.59 
L314- 1 h 138 314 1 21.8 99.15 120.95 
L314- 2 h 138 314 2 9.81 40.61 50.42 
L314- 4 h 138 314 4 3.03 11.43 14.46 
L314- 6 h 138 314 6 1.64 6.65 8.29 
L314- 8 h 138 314 8 1.04 5.15 6.19 
L314- 12 h 138 314 12 2.21 7.85 10.06 
L315-5 min 138 315 0.083 0.54 3.54 4.08 
L315-30 min 138 315 0.5 19.96 128.08 148.04 
L315- 1 h 138 315 1 17.27 98.38 115.65 
L315- 2 h 138 315 2 10.53 43.3 53.83 
L315- 4 h 138 315 4 2.49 10.02 12.51 
L315- 6 h 138 315 6 1.48 6.67 8.15 
L315- 8 h 138 315 8 4.57 18.59 23.16 
L315- 12 h 138 315 12 2.27 6.42 8.69 
L316-5 min 138 316 0.083 1.49 5.78 7.27 
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L316-30 min 138 316 0.5 17.91 92.95 110.86 
L316- 1 h 138 316 1 15.92 71.71 87.63 
L316- 2 h 138 316 2 9.76 31.45 41.21 
L316- 4 h 138 316 4 3.19 10.47 13.66 
L316- 6 h 138 316 6 miss miss miss 
L316- 8 h 138 316 8 2.44 7.76 10.2 
L316- 12 h 138 316 12 3.54 8.21 11.75 
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DEPARTMENT OF PHARMACEUTICAL SCIENCES, COLLEGE OF PHARMACY 
UNIVERSITY OF KENTUCKY (LEGGAS LAB) 
Report on DB-67 Rat PK Study  
 
(June 10th, 08) 
 
Bioavailability of SBE-β-CD based DB-67 lactone and carboxylate (10 mg/kg) administered PO 
 
 
 
 
Expt # 140 and Expt # 141 
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Objective 
To determine the oral bioavailability of SBE-β-CD based DB-67 in lactone and 
carboxylate form at 5.0 mg/kg in rats. This is a part of dose-dependent experiments (2.5, 
5.0 10.0 mg/kg) to determine the linear range between DB-67 dose and AUC of plasma 
total DB-67 levels. To keep the total dosing volume consistent in all 3 groups at 10.0 
mL/kg, the rats in 5.0 mg/kg groups were co-treated with 5.0 mL/kg D5W.  
Expt 140: Study on the oral bioavailability of SBE-β-CD based DB-67 lactone in rats at 5 
mg/kg PO  
Expt 141: Study on the oral bioavailability of SBE-β-CD based DB-67 carboxylate in rats 
at 5 mg/kg PO  
 
Method 
 
Animal treatment and sample processing 
Expt 140, Rats (#321-#323, n=3) were dosed with 5.0 mg/kg SBE-β-CD based (200:1 
E/D ratio) DB-67 lactone PO. 
Expt 141, Rats (#324-#326, n=3) were dosed with 5.0 mg/kg SBE-β-CD based (200:1 
E/D ratio) DB-67 carboxylate PO.  
Dosing solution: 
DB-67 lactone = 1.0 mg/mL 
DB-67 carboxylate = 1.0 mg/mL 
Blood was collected from the saphenous vein at 5 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h and 
12 h with heparinized hematocrit tubes and transferred into heparinized microcentrifuge 
tubes. Plasma was collected by centrifugation of blood and then extracted 1:4 (v/v) with 
cold MeOH     (-80oC). Samples were kept at -80oC until analysis.  
 
HPLC analysis  
Before injection into the HPLC, samples were diluted with an equal volume of mobile 
phase buffer (40 µL:40 µL) and were analyzed. For samples needing dilution (5min, 
30min, 1h & 2h after  intravenous doses), a 1:10 dilution was carried out using 1:4 extract 
of blank rat plasma.  
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Expt 137 & 138 
Sequence name: 20AC-061108 Rat PK Exp 140 &141.seq 
Method: 20AC-052108-reinjection of 051208 calibration curve.met 
Data were exported and saved in Leggas Lab/Experimental Results/DB-67 Oral PK 
folder. (A backup copy of HPLC data was also saved in Leggas Lab/Jamie’s project/DB-
67/Rat PK). Plots were made with Prism while nocompartmental analysis was made 
using Winnonlin v5.2. 
Results 
Tables 
Expt 140 & 141 
Expt 
ID Parameter Units Estimate 
Average/  
Median  SD/range 
140 321 AUCall h*ng/mL 159.8737 183.97 41.78 
140 322 AUCall h*ng/mL 232.2123     
140 323 AUCall h*ng/mL 159.8232     
140 321 Cmax ng/mL 72.26 93.52 37.13 
140 322 Cmax ng/mL 136.39     
140 323 Cmax ng/mL 71.91     
140 321 Tmax h 0.5 0.50 0.50 
140 322 Tmax h 0.5     
140 323 Tmax h 0.5     
140 321 HL_Lambda_z h 2.7774 2.36 0.38 
140 322 HL_Lambda_z h 2.0383     
140 323 HL_Lambda_z h 2.2683     
             
141 324 AUCall h*ng/mL 199.7589 146.48 46.26 
141 325 AUCall h*ng/mL 123.1403     
141 326 AUCall h*ng/mL 116.5495     
141 324 Cmax ng/mL 66.64 49.16 20.43 
141 325 Cmax ng/mL 54.15     
141 326 Cmax ng/mL 26.7     
141 324 Tmax h 1 0.500 0.5--1 
141 325 Tmax h 0.5     
141 326 Tmax h 0.5     
141 324 HL_Lambda_z h 4.0737 4.65 0.79 
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141 325 HL_Lambda_z h 4.3081     
141 326 HL_Lambda_z h 5.5547     
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Fig. 1a. Plasma total DB-67 levels in SD rats treated
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Fig. 1b. Semilog plot of plasma total DB-67 levels in SD rats
treated with  5 mg/kg DB-67 lactone PO
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File path: \\pharm\public\PS\Leggas Lab\EXPERIMENTAL RESULTS\DB67 Oral 
PK\REPORTS\Prism data Files\ AUC Rat PK Expt 140 & 141 
Raw Data 
Sample ID Expt # Rat # Time (h) Carboxylate Lactone 
Total DB-67 
 (ng/mL) 
L321-5 min 140 321 0.083 0.92 6.56 7.48 
L321-30 min 140 321 0.5 10.7 61.56 72.26 
L321-1 h 140 321 1 10.81 35.96 46.77 
L321-2 h 140 321 2 7.16 22.93 30.09 
L321-4 h 140 321 4 1.87 6.87 8.74 
L321-6 h 140 321 6 0.88 2.37 3.25 
L321-8 h 140 321 8 0.56 2.12 2.68 
L321-12 h 140 321 12 1.55 4.77 6.32 
L322-5 min 140 322 0.083 0.96 5.15 6.11 
L322-30 min 140 322 0.5 20.38 116.01 136.39 
L322-1 h 140 322 1 18.91 68.31 87.22 
L322-2 h 140 322 2 9.41 28.98 38.39 
L322-4 h 140 322 4 2.23 6.45 8.68 
L322-6 h 140 322 6 1.66 4.49 6.15 
L322-8 h 140 322 8 0.68 2.35 3.03 
L322-12 h 140 322 12 0.58 2.62 3.2 
L323-5 min 140 323 0.083 0.63 3.19 3.82 
L323-30 min 140 323 0.5 12.41 59.5 71.91 
L323-1 h 140 323 1 11.55 43.52 55.07 
L323-2 h 140 323 2 6.61 25.22 31.83 
L323-4 h 140 323 4 1.67 6.43 8.1 
L323-6 h 140 323 6 0.91 2.8 3.71 
 320 
 
L323-8 h 140 323 8 0.39 1.84 2.23 
L323-12 h 140 323 12 0.58 2.69 3.27 
L324-5 min 141 324 0.083 0.44 2.22 2.66 
L324-30 min 141 324 0.5 7.97 48.08 56.05 
L324-1 h 141 324 1 13.61 53.03 66.64 
L324-2 h 141 324 2 6.62 22.19 28.81 
L324-4 h 141 324 4 2.53 8.04 10.57 
L324-6 h 141 324 6 2.05 7.52 9.57 
L324-8 h 141 324 8 1.46 6.34 7.8 
L324-12 h 141 324 12 1.47 6.79 8.26 
L325-5 min 141 325 0.083 0.43 2.79 3.22 
L325-30 min 141 325 0.5 9.21 44.94 54.15 
L325-1 h 141 325 1 6.46 25.37 31.83 
L325-2 h 141 325 2 3.69 11.22 14.91 
L325-4 h 141 325 4 1.22 4.64 5.86 
L325-6 h 141 325 6 0.9 3.71 4.61 
L325-8 h 141 325 8 0.72 3.41 4.13 
L325-12 h 141 325 12 1.95 7.02 8.97 
L326-5 min 141 326 0.083 0.59 3.2 3.79 
L326-30 min 141 326 0.5 4.89 21.81 26.7 
L326-1 h 141 326 1 5.89 20.33 26.22 
L326-2 h 141 326 2 3.19 12.08 15.27 
L326-4 h 141 326 4 2.3 5.75 8.05 
L326-6 h 141 326 6 1.08 4.75 5.83 
L326-8 h 141 326 8 1.22 4.63 5.85 
L326-12 h 141 326 12 1.75 5.99 7.74 
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Bioavailability of E-TPGS and PEG-6000 based DB-67 lactone in male SD rats 
 
 
 
Expt # 146 and Expt # 147 
 
 
 
 
 
 
 
 
 
 
 
11/24/2008 
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Objective 
To determine the oral bioavailability of E-TPGS (28:1 E/D ratio) and PEG-6000 (28:1 
E/D ratio) based DB-67 lactone in male SD rats 
To determine whether there is gender-difference in the oral bioavailability of DB-67 oral 
formulations 
Expt 146: Study on the oral bioavailability of E-TPGS (28:1 E/D ratio) based DB-67 
lactone in male SD rats (2.5 mg/kg) PO  
Expt 147: Study on the oral bioavailability of PEG-6000 (28:1 E/D ratio) based DB-67 
lactone in male SD rats (2.5 mg/kg) PO 
Method 
 
Animal treatment and sample processing 
Expt 146, Rats (#361-#363, n=3) were dosed with 2.5 mg/kg E-TPGS (28:1 E/D ratio) 
based DB-67 lactone PO. 
Expt 147, Rats (#364-#366, n=3) were dosed with 2.5 mg/kg PEG-6000 (28:1 E/D ratio) 
based DB-67 lactone PO.  
Dosing solution: 
DB-67 lactone = 0.53 mg/mL 
Blood was collected from the saphenous vein at 5 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h and 
12 h with heparinized hematocrit tubes and transferred into heparinized microcentrifuge 
tubes. Plasma was collected by centrifugation of blood and then extracted 1:4 (v/v) with 
cold MeOH     (-80oC). Samples were kept at -80oC until analysis.  
 
HPLC analysis  
Before injection into the HPLC, samples were diluted with an equal volume of mobile 
phase buffer (40 µL:40 µL) and were analyzed. For samples needing dilution (5min, 
30min, 1h & 2h after  intravenous doses), a 1:10 dilution was carried out using 1:4 extract 
of blank rat plasma.  
Expt 146 & 147 
Sequence name: 20AC-062508-Rat PK expt146.seq 
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Method: 20AC-052108-reinjection of 051208 calibration curve.met 
Data were exported and saved in Leggas Lab/Experimental Results/DB-67 Oral PK 
folder. (A backup copy of HPLC data was also saved in Leggas Lab/Jamie’s project/DB-
67/Rat PK). Plots were made with Prism while nocompartmental analysis was made 
using Winnonlin v5.2. 
Results 
Tables 
Expt 146 & 147 
Expt 
ID Parameter Units Estimate 
Average/ 
Median  SD/range 
146 361 AUCall h*ng/mL 67.557 64.911 5.582
146 362 AUCall h*ng/mL 58.4979     
146 363 AUCall h*ng/mL 68.679     
146 361 Cl_F_obs mL/h/kg 6940.735 12098.437 5249.082
146 362 Cl_F_obs mL/h/kg 17434.36     
146 363 Cl_F_obs mL/h/kg 11920.22     
146 361 Cmax ng/mL 11.7 11.957 1.928
146 362 Cmax ng/mL 10.17     
146 363 Cmax ng/mL 14     
146 361 Tmax h 0.5 0.500 0.000
146 362 Tmax h 0.5     
146 363 Tmax h 0.5     
             
             
147 364 AUCall h*ng/mL 58.6448 56.090 3.712
147 365 AUCall h*ng/mL 51.8324     
147 366 AUCall h*ng/mL 57.7942     
147 364 Cl_F_obs mL/h/kg 13239.37 15094.742 2623.887
147 365 Cl_F_obs mL/h/kg Missing     
147 366 Cl_F_obs mL/h/kg 16950.11     
147 364 Cmax ng/mL 8.56 7.810 2.607
147 365 Cmax ng/mL 4.91     
147 366 Cmax ng/mL 9.96     
147 364 Tmax h 0.5 1.833 1.893
147 365 Tmax h 4     
147 366 Tmax h 1     
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Fig. 1b. Semilog plot of plasma total DB-67 levels in male
SD rats treated 2.5 mg/kg DB-67 PO
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File path: \\pharm\public\PS\Leggas Lab\EXPERIMENTAL RESULTS\DB67 Oral 
PK\REPORTS\Prism data Files\ AUC Rat PK Expt 146 & 147 
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Raw Data 
Expt # Rat # Time  Carboxylate Lactone
Total DB-67 
(ng/mL) 
146 361 0.083 0.14 3.81 3.95 
146 361 0.5 1.07 10.63 11.7 
146 361 1 0.94 7.5 8.44 
146 361 2 0.35 4.64 4.99 
146 361 4 0.27 4.33 4.6 
146 361 6 0.25 4.49 4.74 
146 361 8 0.22 4.11 4.33 
146 361 12 0.2 7.66 7.86 
146 362 0.083 0.16 3.69 3.85 
146 362 0.5 1 9.17 10.17 
146 362 1 0.79 6.4 7.19 
146 362 2 0.39 4.69 5.08 
146 362 4 0.34 4.4 4.74 
146 362 6 0.27 4.15 4.42 
146 362 8 0.26 3.82 4.08 
146 362 12 0.13 4.52 4.65 
146 363 0.083 0.56 5.22 5.78 
146 363 0.5 1.86 12.14 14 
146 363 1 1.5 8.12 9.62 
146 363 2 0.61 5.43 6.04 
146 363 4 0.33 4.29 4.62 
146 363 6 0.27 3.9 4.17 
146 363 8 0.25 3.85 4.1 
146 363 12 0.21 7.12 7.33 
147 364 0.083 1.78 5.61 7.39 
147 364 0.5 1.53 7.03 8.56 
147 364 1 0.87 5.78 6.65 
147 364 2 0.32 4.23 4.55 
147 364 4 0.41 4.4 4.81 
147 364 6 0.34 4.43 4.77 
147 364 8 0.17 3.85 4.02 
147 364 12 0.23 4.69 4.92 
147 365 0.083 0.17 3.88 4.05 
147 365 0.5 0.23 4.11 4.34 
147 365 1 0.37 3.95 4.32 
147 365 2 0.25 3.89 4.14 
147 365 4 0.39 4.52 4.91 
147 365 6 0.24 3.67 3.91 
147 365 8 0.19 3.83 4.02 
147 365 12 0.16 4.68 4.84 
147 366 0.083 0.43 5.33 5.76 
147 366 0.5 0.41 4.91 5.32 
147 366 1 0.78 9.18 9.96 
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147 366 2 0.48 5.21 5.69 
147 366 4 0.37 4.26 4.63 
147 366 6 0.18 3.76 3.94 
147 366 8 0.12 3.57 3.69 
147 366 12 0.23 4.62 4.85 
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Bioavailability of SBE-β-CD based AR-67 carboxylate in rats & 
effect of GF120918 IV on bioavailability of SBE-β-CD based AR-67 lactone (PO) in rats 
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Objective 
To determine the oral bioavailability of SBE-β-CD based AR-67 carboxylate in female 
SD rats  
To determine the effects of GF IV on the oral bioavailability of SBE-β-CD based AR-67 
lactone in female SD rats.  
Expt 151: Study on the oral bioavailability of SBE-β-CD (200:1 E/D ratio) based AR-67 
carboxylate in rats (2.5 mg/kg) PO  
Expt 152: Study on the effects of GF (8.25 mg/kg) IV on oral bioavailability of SBE-β-
CD (200:1 E/D ratio) based AR-67 lactone (2.5 mg/kg) in rats PO 
 
Method 
 
Animal treatment and sample processing 
Expt 151, Rats (#401-#403, n=3) were dosed with SBE-β-CD (200:1 E/D ratio) based 
AR-67 carboxylate PO. 
Expt 152, Rats (#404-#406, n=3) were dosed with 2.5 mg/kg SBE-β-CD (200:1 E/D 
ratio) based AR-67 lactone PO 5 min after GF (8.25mg/kg) IV.  
Dosing solution: 
AR-67 lactone = 1.0 mg/mL 
Blood was collected from the saphenous vein at 5 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h and 
12 h with heparinized hematocrit tubes and transferred into heparinized microcentrifuge 
tubes. Plasma was collected by centrifugation of blood and then extracted 1:4 (v/v) with 
cold MeOH     (-80oC). Samples were kept at -80oC until analysis.  
 
HPLC analysis  
Before injection into the HPLC, samples were diluted with an equal volume of mobile 
phase buffer (40 µL:40 µL) and were analyzed. For samples needing dilution (5min, 
30min, 1h & 2h after  intravenous doses), a 1:10 dilution was carried out using 1:4 extract 
of blank rat plasma.  
Expt 146 & 147 
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Sequence name: 20AC-070208-Rat PK animal 401-406.seq 
Method: 20AC-052108-reinjection of 051208 calibration curve.met 
Data were exported and saved in Leggas Lab/Experimental Results/AR-67 Oral PK 
folder. (A backup copy of HPLC data was also saved in Leggas Lab/Jamie’s project/AR-
67/Rat PK). Plots were made with Prism while noncompartmental analysis was made 
using WinNonlin v5.2. 
 
Results 
Tables.  Pharmacokinetic parameters estimated using the noncompartmental 
method in Winnonlin v5.2 
Expt 151 & 152 
ID Parameter Units Estimate 
Average/ 
 Median23  SD/range 
401 AUCall h*ng/mL 180.7498 135.569 39.491 
402 AUCall h*ng/mL 107.6384     
403 AUCall h*ng/mL 118.3181     
401 Cl_F_obs mL/h/kg 11525.04 15405.491 3642.343 
402 Cl_F_obs mL/h/kg 18750.43     
403 Cl_F_obs mL/h/kg 15941.01     
401 Cmax ng/mL 73.62 48.283 22.396 
402 Cmax ng/mL 40.1     
403 Cmax ng/mL 31.13     
401 Tmax h 0.5 0.500 0.500 
402 Tmax h 0.5     
403 Tmax h 0.5     
401 HL_Lambda_z h 3.1535 3.852 0.659 
402 HL_Lambda_z h 3.9399     
403 HL_Lambda_z h 4.4637     
404 AUCall h*ng/mL 355.4199 324.850 63.324 
405 AUCall h*ng/mL 252.04     
406 AUCall h*ng/mL 367.089     
404 Cl_F_obs mL/h/kg 5561.148 5395.049 702.121 
                                                 
23 Median was used for Tmax. All other parameters use the arithmetic mean 
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405 Cl_F_obs mL/h/kg 5999.228     
406 Cl_F_obs mL/h/kg 4624.772     
404 Cmax ng/mL 61.23 42.973 16.308 
405 Cmax ng/mL 29.85     
406 Cmax ng/mL 37.84     
404 Tmax h 2 2.000 1-6 
405 Tmax h 6     
406 Tmax h 1     
404 HL_Lambda_z h 5.8779 6.423 0.525 
405 HL_Lambda_z h 6.9264     
406 HL_Lambda_z h 6.4648     
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Fig. 1b. Semilog plot of plasma total DB-67 levels in SD rats
treated with 2.5 mg/kg DB-67 carboxylate PO
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Fig. 2a. Plasma total DB-67 levels in SD rats treated with
8.25 mg/kg GF IV 5 min before 2.5mg/kg DB-67 PO
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File path: \\pharm\public\PS\Leggas Lab\EXPERIMENTAL RESULTS\DB67 Oral 
PK\REPORTS\Prism data Files\ AUC Rat PK Expt 151 & 152 
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Raw Data 
Data ID Expt # Rat ID Time (h)
 Carboxylate 
(ng/ml) 
Lactone  
(ng/ml) 
Total AR-67 
 (ng/ml) 
401 5 min 151 401 0.083 0 4.7 4.7 
401 30 min 151 401 0.5 8.36 65.26 73.62 
401 1 hour 151 401 1 9.89 45.63 55.52 
401 2 hour 151 401 2 5.02 21.34 26.36 
401 4 hour 151 401 4 2.56 9.9 12.46 
401 6 hour 151 401 6 0.6 5.01 5.61 
401 8 hour 151 401 8 0 4.2 4.2 
401 12 hour 151 401 12 1 6.95 7.95 
402 5 min 151 402 0.083 0.87 8.57 9.44 
402 30 min 151 402 0.5 6.23 33.87 40.1 
402 1 hour 151 402 1 5.54 24.79 30.33 
402 2 hour 151 402 2 1.58 9.01 10.59 
402 4 hour 151 402 4 0.72 5.79 6.51 
402 6 hour 151 402 6 0 4.49 4.49 
402 8 hour 151 402 8 0.52 5.22 5.74 
402 12 hour 151 402 12 0.34 4.18 4.52 
403 5 min 151 403 0.083 0.53 5.36 5.89 
403 30 min 151 403 0.5 4.05 27.08 31.13 
403 1 hour 151 403 1 4.29 19.58 23.87 
403 2 hour 151 403 2 3.45 15.23 18.68 
403 4 hour 151 403 4 1.24 7.45 8.69 
403 6 hour 151 403 6 0.64 5.41 6.05 
403 8 hour 151 403 8 0.37 4.7 5.07 
403 12 hour 151 403 12 0.53 5.45 5.98 
404 5 min 152 404 0.083 0 4.17 4.17 
404 30 min 152 404 0.5 3.78 38.15 41.93 
404 1 hour 152 404 1 5.8 41.53 47.33 
404 2 hour 152 404 2 7.33 53.9 61.23 
404 4 hour 152 404 4 5.57 36.93 42.5 
404 6 hour 152 404 6 3.15 19.09 22.24 
404 8 hour 152 404 8 2.53 16.18 18.71 
404 12 hour 152 404 12 1.28 9.82 11.1 
405 5 min 152 405 0.083 0 3.34 3.34 
405 30 min 152 405 0.5 0 7.53 7.53 
405 1 hour 152 405 1 0 8.53 8.53 
405 2 hour 152 405 2 0 9.51 9.51 
405 4 hour 152 405 4 2.04 27.33 29.37 
405 6 hour 152 405 6 4.36 25.49 29.85 
405 8 hour 152 405 8 3.6 21.63 25.23 
405 12 hour 152 405 12 2.52 13.96 16.48
406 5 min 152 406 0.083 0 4.78 4.78
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406 30 min 152 406 0.5 4.14 27.33 31.47
406 1 hour 152 406 1 5.81 32.03 37.84
406 2 hour 152 406 2 5.18 27.35 32.53
406 4 hour 152 406 4 5.46 31.41 36.87
406 6 hour 152 406 6 6.21 28.35 34.56
406 8 hour 152 406 8 5.3 26.11 31.41
406 12 hour 152 406 12 3.21 15.39 18.6
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Bioavailability of amorphous PMFD576/1 suspension and capsule filled with  PMFD576/1 in 
female SD rats 
 
 
 
Expt # 192 and Expt # 193 
 
 
 
 
 
 
 
 
 
 
 
03/24/2009 
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Objective 
It has been showed that PMFD 576/1 (PVP (K30)-Tween-80-lactone) gave the highest 
oral bioavailability, which is about 2-fold in comparison with that given by 
supersaturated AR-67 lactone solution with excipients SBE-β-CD or E-TPGS in mice. 
We further examined the oral bioavailability of the same formulation and capsules filled 
with PMFD 576/1 in female SD rats in the following 2 experiments: 
Expt 192: Study on the oral bioavailability of PMFD 576/1 AR-67 lactone suspension in 
SGF (pH1.2) at a dose of 2.5 mg/kg PO in rats 
Expt 193: Study on the oral bioavailability of capsule filled with PMFD 576/1 AR-67 
lactone at a dose of 2.5 mg/kg PO in rats 
 
Method 
 
Formulation 
The PMFD 576/1 powder was weighted in glass vial by Dr. Xiang and reconstituted in 
SGF (pH 1.2) to make 2 mg/mL AR-67 suspension, and the capsule were filled with 
PMFD 576/1 powder using filling apparatus by Dr. Xiang. 
 
Animal treatment and sample processing 
Expt 192, Rats ((#801-#803, n=3) were dosed with PMFD 576/1 suspension in SGF (pH 
1.2) PO at the dose of 5 mg/kg. 
Expt 193, Rats (#804-#806, n=3) were dosed with capsules filled with PMFD 576/1 at 
the dose of 5 mg/kg. 
Blood was collected from the saphenous vein at 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 12 
h and 24 h with heparinized hematocrit tubes and transferred into heparinized 
microcentrifuge tubes. Plasma was collected by centrifugation of blood and then 
extracted 1:4 (v/v) with cold MeOH (-80oC). Samples were kept at -80oC until analysis.  
HPLC analysis  
Before injection into the HPLC, samples were diluted with an equal volume of mobile 
phase buffer (40 µL:40 µL) and were analyzed.   
Expt 192 & 193 
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Sequence name: 20AC-022109-rat plasma PK Expt 192 & 193.seq 
Method: 20AC-022209-reinjection of rat plasma curve prep 062008.met 
Data were exported and saved in Leggas Lab/Experimental Results/AR-67 Oral PK 
folder. (A backup copy of HPLC data was also saved in Leggas Lab/Jamie’s project/AR-
67/Rat PK). Plots were made with Prism while noncompartmental analysis was made 
using WinNonlin v5.2. 
Results 
1. Prism file: ..\Prism data Files\AUC Rat PK Expt 192 & 193.pzf 
2. Tables  
Table 1. Summary of pharmacokinetic parameters 
Expt #192 5 mg/mL AR-67 lactone PMFD 576/1 suspension   
AUC 
(ng·h/mL) Mean SD Tmax (h) Median 
Cmax 
(ng/mL) Mean SD 
Carb 26.40 8.56 Car   Car     
Lactone 103.65 27.39 Lactone   Lactone     
Total  130.02 35.42 Total  0.50 Total  19.36 9.40
                
Expt #193 5 mg/mL AR-67 lactone PMFD 576/1 in capsule  
AUC 
(ng·h/mL) Mean SD Tmax (h) Median 
Cmax 
(ng/mL) Mean SD 
Carb 33.65 11.47 Car   Car     
Lactone 140.57 73.86 Lactone   Lactone     
Total  174.20 85.28 Total  2 Total  38.80 3.36
                
Expt #140 5 mg/mL AR-67 lactone in SBE-β-CD 200:1  
AUC 
(ng·h/mL) Mean SD Tmax (h) Median 
Cmax 
(ng/mL) Mean SD 
Carb 38.31 9.17 Car   Car     
Lactone 145.40 32.67 Lactone   Lactone     
Total  183.77 41.77 Total  0.5 Total  93.52 37.13
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3. Figures  
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Raw Data 
Carboxylate Lactone Total 
Expt  Rat ID 
Time 
(h) (ng/mL) (ng/mL) (ng/mL)
192 801 0.25 0.39 1.7 2.09
192 801 0.5 0.69 4.62 5.31
192 801 1 1.09 4.87 5.96
192 801 2 1.14 4 5.14
192 801 4 1.39 6.33 7.72
192 801 6 1.22 3.93 5.15
192 801 8 1.7 7.6 9.3
192 801 12 2.13 8.56 10.69
192 801 24 0.26 1.07 1.33
192 802 0.25 2.48 18.09 20.57
192 802 0.5 4.15 25.2 29.35
192 802 1 3.83 16.5 20.33
192 802 2 4.03 20.1 24.13
192 802 4 2.64 9.51 12.15
192 802 6 3.22 12.68 15.9
192 802 8 1.2 4.7 5.9
192 802 12 0.6 2.91 3.51
192 802 24 0 0.4 0.4
192 803 0.25 2.07 15.96 18.03
192 803 0.5 2.46 14.85 17.31
192 803 1 2.47 9.59 12.06
192 803 2 2.09 7.24 9.33
192 803 4 4.86 7.33 12.19
192 803 6 2.79 12.79 15.58
192 803 8 3.5 14.45 17.95
192 803 12 1.25 5.6 6.85
192 803 24 0.24 1.52 1.76
194 804 0.25 0.06 0.6 0.66
194 804 0.5 0.79 6.67 7.46
194 804 1 3.46 23.54 27
194 804 2 5.83 30.7 36.53
194 804 4 8.11 33.06 41.17
194 804 6 2.98 12.15 15.13
194 804 8 1.76 8.18 9.94
194 804 12 1.33 5.76 7.09
194 804 24 0.33 1.6 1.93
194 805 0.25 0.05 0.2 0.25
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194 805 0.5 0.06 0.46 0.52
194 805 1 12.93 58.83 71.76
194 805 2 0.11 0.26 0.37
194 805 4 0.08 0.26 0.34
194 805 6 0.14 0.38 0.52
194 805 8 0.17 0.96 1.13
194 805 12 2.44 9.52 11.96
194 805 24 2.47 9.55 12.02
194 806 0.25 0.07 5.87 5.94
194 806 0.5 4.94 31.36 36.3
194 806 1 0.13 0.51 0.64
194 806 2 7.67 28.75 36.42
194 806 4 3.61 8.83 12.44
194 806 6 1.16 3.45 4.61
194 806 8 0.56 1.74 2.3
194 806 12 0.43 1.28 1.71
194 806 24 1.14 5.27 6.41
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DEPARTMENT OF PHARMACEUTICAL SCIENCES, COLLEGE OF 
PHARMACY 
UNIVERSITY OF KENTUCKY (LEGGAS LAB) 
 
 
 
REPORT ON THE EFFECTS OF PEG-6000 AND PG-TPGS ON THE ORAL 
ABSORPTION OF AR-67 LACTONE IN MICE  
(PERFORMED 7/16/2008-7/17/2008) 
BIOAVAILABILITY PEG-6000 AND PG-TPGS BASED AR-67 LACTONE 
FORMULATIONS IN FEMALE C57BL/6 MICE 
EXPT # 157 AND EXPT # 158 
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Objective 
Two excipients or mixtures of excipients were separately assessed for their effects on the 
oral bioavailability of AR-67. These experiments were done following in vitro solubility 
studies that showed that PEG-6000 was unable to maintain AR-67 lactone in solution at 
an excipient to drug ratio of 28:1 while the presence of propylene glycol (PG) improved 
the solubilzing capacity of vitamin E-TPGS. We therefore, assessed the relationship 
between in vitro dissolution and oral bioavailability.   
Expt 157: Study the absorption of PEG-6000 based AR-67 lactone (5 mg/kg, 9.43 ml/kg) 
PO.  
Expt 158: Study the absorption of PG-TPGS based AR-67 lactone (5 mg/kg, 9.43 ml/kg) 
PO.  
 
Method 
Formulation  
a) SGF (pH 1.2) containing PEG-6000 was spiked with carboxylate stock solution to 
prepare 0.53 mg/mL dosing solution (28:1, E:D) and was dosed immediately after 
mixing. 
b) SGF (pH 1.2) containing PG-TPGS was spiked with carboxylate stock solution to 
prepare 0.53 mg/mL dosing solution (3.2:28:1, E:D) and was dosed immediately after 
mixing  
AR-67 carboxylate stock solution was prepared by Dr. Xiang. 
 
Animal treatment and sample processing 
Expt 157: Mouse# 451-459 were treated with AR-67 lactone suspension in PEG-6000 
containing simulated gastric fluid (pH 1.2) right after mixing. 
Expt 158: Mouse# 461-469 were treated with AR-67 suspension in PG-TPGS containing 
simulated gastric fluid (pH 1.2) right after mixing. 
Groups of three mice were sampled at 15 min, 30 min, 45 min, 1 h, 1.5 h, 3 h, 6 h, 8 h 
and 12 h. Each animal was sampled at 3-4 different time points. The blood sample of 
about 50 µL was collected from the saphenous vein with heparinized hematocrit tubes 
and transferred into heparinized microcentrifuge tubes. Plasma of 25 µL was collected by 
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centrifugation of blood and then extracted 1:4 (v/v) with cold MeOH (100 µL,-80oC). 
Samples were kept at -80oC until analysis.  
  
HPLC analysis  
Before injection into the HPLC, samples were diluted with an equal volume of mobile 
phase buffer (40 µL:40 µL) and were analyzed. 
 
Sequence name:  
20AC-071808-Mouse PK ext (PEG vs PG-TPGS).seq 
20AC-071708-mouse PK expt.seq 
 
Method:  
20AC-070307-Mouse plasma curve.met 
 
Data were exported and saved in Leggas Lab/Experimental Results/AR-67 Oral PK / 
Mouse oral PK folder. Areas under the curve were estimated with Prism v5 and 
WinNonlin v5.2 (sparse sampling noncompartmental analysis). Plasma concentration 
versus time plots were made with Prism v5. 
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Results 
4. Prism file:..\ ..\Prism files\Mouse PK 5mg PO Expt 157 & 158.pzf 
5.  WinNonlin file: ....\Winnonlin files\Mouse PK Expt 157 & 158.wsp 
6. Tables 
 
Table 1. Basic pharmacokinetic parameters 
Expt #157 
AUC(ng*h/mL)  
Mean (SE) 
Tmax (h)  
Median 
Cmax (ng/mL) 
Mean (SE) 
Carboxylate 19.10 (2.43) 0.50 6.06 (1.24) 
Lactone 175.72 (22.68) 0.50 58.38 (9.96) 
Total  194.83 (25.02) 0.50 64.44 (11.20) 
 
Expt #158  
AUC (ng*h/mL)  
Mean (SE) 
Tmax (h) 
 Median 
Cmax (ng/mL) 
Mean (SE) 
Carboxylate 13.55 (0.75) 0.75 6.89 (0.72) 
Lactone 114.47 (0.17) 0.17 55.86 
Total  128.01 (0.17) 0.17 60.66 
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7. Figures 
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Figure 1a. Plasma concentration of AR-67
carboxylate and lactone and  AR-67 in C57BL/6
mice treated with 5mg/kg PEG-6000 based AR-67
lactone PO.
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Figure 1b. Plasma concentration of AR-67
carboxylate and lactone in C57BL/6 mice
treated with 5mg/kg PG-TPGS based AR-67
lactone PO.
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Figure 1c. Comparison of plasma concentration of
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File path: \\Pharm\public\PS\Leggas Lab\Experimental Results\DB67 Oral 
PK\Mouse oral PK\Prism files\Mouse PK 5mg PO Expt 157 & 158. 
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Raw Data 
Sample ID Expt Time (h) Carb. (ng/mL) 
 Lact. 
 (ng/mL) 
Total 
(ng/mL) 
451-10min 157 0.167 5.24 63.93 69.17 
452-10min 157 0.167 3.72 36.91 40.63 
453-10min 157 0.167 6.56 73.29 79.85 
454-30min 157 0.5 3.82 40.68 44.5 
455-30min 157 0.5 8.1 75.14 83.24 
456-30min 157 0.5 6.26 59.33 65.59 
457-45min 157 0.75 2.93 21.11 24.04 
458-45min 157 0.75 5.43 58.57 64 
459-45min 157 0.75 4.91 36.39 41.3 
451-1h 157 1 3.74 41.45 45.19 
452-1h 157 1 2.49 23.58 26.07 
453-1h 157 1 4.4 37.65 42.05 
454-1.5h 157 1.5 3.02 24.99 28.01 
4551.5h 157 1.5 2.96 25.84 28.8 
456-1.5h 157 1.5 3.09 26.02 29.11 
454-3h 157 3 1.23 7.15 8.38 
455-3h 157 3 2.94 19.07 22.01 
456-3h 157 3 1.81 13.51 15.32 
451-6h 157 6 0.29 5.11 5.4 
452-6h 157 6 0.41 3.84 4.25 
453-6h 157 6 1.28 10.9 12.18 
457-8h 157 8 0.15 1.31 1.46 
458-8h 157 8 1.09 12.35 13.44 
459-8h 157 8 0.47 5.19 5.66 
457-12h 157 12 0.6 7.54 8.14 
458-12h 157 12 1.14 13.71 14.85 
459-12h 157 12 2.37 25.07 27.44 
461-10min 158 0.167 4.8 55.86 60.66 
464-30min 158 0.5 7.35 66.65 74 
465-30min 158 0.5 6.38 51.51 57.89 
466-30min 158 0.5 3.88 33.06 36.94 
467-45min 158 0.75 8.02 57.85 65.87 
468-45min 158 0.75 7.1 48.19 55.29 
469-45min 158 0.75 5.55 30.25 35.8 
461-1h 158 1 5.74 50.47 56.21 
464-1.5h 158 1.5 2.75 22.31 25.06 
465 1.5h 158 1.5 2.2 20.38 22.58 
466-1.5h 158 1.5 1.84 17.9 19.74 
464-3h 158 3 0.95 7.07 8.02 
465-3h 158 3 0.75 3.93 4.68 
466-3h 158 3 0.95 5.41 6.36 
461-6h 158 6 0.35 2.81 3.16 
467-8h 158 8 0.13 1.97 2.1 
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468-8h 158 8 0.19 1.52 1.71 
469-8h 158 8 0.38 2.94 3.32 
467-12h 158 12 0.37 3.91 4.28 
468-12h 158 12 0.79 8.32 9.11 
469-12h 158 12 0.24 2.12 2.36 
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DEPARTMENT OF PHARMACEUTICAL SCIENCES, COLLEGE OF 
PHARMACY 
UNIVERSITY OF KENTUCKY (LEGGAS LAB) 
REPORT ON PHARMACOKINETICS OF SBE-β-CD AND VITAMIN E-TPGS 
BASED AR-67 LACTONE 
 
(PERFORMED 3/10/2009-3/13/2009) 
 
PHARMACOKINETICS OF AR-67 LACTONE (SBE-Β-CD, 200:1, E:D;TPGS, 
200:1, E:D) IN FEMALE C57BL/6 MICE 
 
EXPT # 159 AND EXPT # 160 
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Objective 
We performed pharmacokinetic studies on the SBE-β-CD (200:1, E/D) and TPGS based 
AR-67 lactone formulations. The data generated will be used as references for estimation 
of oral bioavailability of AR-67. 
Expt 159: Pharmacokinetics of IV SBE-β-CD based AR-67 lactone (200:1, E:D) at a 
dose of 5 mg/kg. 
Expt 160: Pharmacokinetics of IV TPGS based AR-67 lactone (200:1, E:D) at a dose of 5 
mg/kg. 
 
Method 
Formulation  
a) A dosing solution of 1 mg/mL AR-67 containing SBE-β-CD was prepared (200:1, 
E:D) by reconstituting lyophilized powder. 
b) A dosing solution of 0.53 mg/mL AR-67 containing TPGS was prepared (200:1, E:D) 
from 5.3 mg/mL of carboxylate stock solution. 
AR-67 carboxylate stock solution as well as the excipient solution was prepared by Dr. 
Xiang. 
 
Animal treatment and sample processing 
(Refer to \\Pharm\public\PS\Leggas Lab\Experimental Results\DB67 Oral PK\Mouse 
oral PK\sampling time for details) 
Expt 159: mouse#471-479 were treated IV SBE-β-CD based AR-67 lactone (200:1, E:D) 
at a dose of 5 mg/kg. 
Expt 160: mouse#481-489 were treated IV TPGS based AR-67 lactone (28:1, E:D) at a 
dose of 5 mg/kg. (The stock AR-67 carboxylate solution precipitated when stored at 4°C 
overnight. 
Groups of three mice were sampled at 5 min, 30 min, 45 min, 1 h, 1.5 h, 3 h, 6 h, 8 h and 
12 h. Each animal was sampled at 3-4 different time points.  
The blood sample of about 50 µL was collected from the saphenous vein with 
heparinized hematocrit tubes and transferred into heparinized microcentrifuge tubes. 
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Plasma of 25 µL was collected by centrifugation of blood and then extracted 1:4 (v/v) 
with cold MeOH (100 µL,-80oC). Samples were kept at -80oC until analysis.  
 
HPLC analysis  
Before injection into the HPLC, samples were diluted with an equal volume of mobile 
phase buffer (40 µL:40 µL) and were analyzed.  
Sequence name: 20AC-072708-Mouse PK Expt SBE-β-CD vs TPGS IV.seq AND 20AC-
072508-Mouse PK expt SBE-CD vs TPGS IV.seq 
Method: 20AC-070307-Mouse plasma curve.met 
Data were exported and saved in Leggas Lab/Experimental Results/DB-67 Oral PK / 
Mouse oral PK folder. Areas under the curve were estimated with Prism v5 and 
WinNonlin v5.2 (sparse sampling noncompartmental analysis). Plasma concentration 
versus time plots were made with Prism v5. 
 
Results 
1. Prism file..\Prism files\Mouse PK 5mg-kg IV SBE-CD vs TPGS (Expt 159 & 
160).pzf  
2. WinNonlin file: ..\Winnonlin files\Mouse PK Expt 159 & 160.wsp 
3. Tables 
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Table 1. Basic pharmacokinetic parameters 
Expt 159: 5.0 mg/kg Lactone (SBE-β-CD,200:1, E:D) IV 
AUC 
AUC (ng*hr/mL) 
Mean (SE) 
Tmax (h) 
Median 
Cmax (ng/mL) 
Mean (SE) 
Carb 137.47 (6.69) 0.08 187.44 (23.42) 
Lactone 1187.63 (94.97) 0.08 1836.64 (305.12) 
Total 1325.08 (104.25) 0.08 2024.08 (328.54) 
 
Expt 160: 5.0 mg/kg Lactone (TPGS, 28:1, E:D) IV 
AUC (ng*hr/mL) 
Mean (SE) 
Tmax (h) 
Median 
Cmax (ng/mL) 
Mean * 
Carb 180.84 (2.17) 0.08 301.36 
Lactone 1320.19 (20.44) 0.08 2355.84 
Total 1500.97 (22.25) 0.08 2657.20 
*single point 
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4. Figures 
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Expt 159: Plasma concentration of carboxylate and lactone
in female C57BL/6 mice treated intravenously with 5 mg/kg
SBE--CD based AR-67 lactone (E:D ratio 200:1)
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Expt 160: Plasma concentration of carboxylate and lactone
in female C57BL/6 mice treated intravenously with 5 mg/kg
TPGS based AR-67  (E:D ratio 28:1)
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File path: \\pharm\public\PS\Leggas Lab\Experimental Results\DB67 Oral 
PK\Mouse oral PK\Prism files. 
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Raw Data 
Expt Sample ID Time (h) 
Carb. 
(ng/mL) 
Lact. 
(ng/mL) 
Total 
(ng/mL) 
159 471 0.083 147.12 1306.32 1453.44 
159 472 0.083 186.96 1840.32 2027.28 
159 473 0.083 228.24 2363.28 2591.52 
159 474 0.5 75.68 666.4 742.08 
159 475 0.5 115.44 952.56 1068 
159 476 0.5 91.6 716.8 808.4 
159 471 1 44.8 364.8 409.6 
159 472 1 49.28 378.16 427.44 
159 473 1 49.28 394.56 443.84 
159 474 1.5 5.73 39.12 44.85 
159 475 1.5 12.51 92.13 104.64 
159 476 1.5 13.57 85.71 99.28 
159 474 3 1.91 9.14 11.05 
159 475 3 1.8 1.41 3.21 
159 476 3 0.37 2.76 3.13 
159 471 6 0.25 1.39 1.64 
159 472 6 0.39 2.6 2.99 
159 473 6 0.29 2.41 2.7 
159 477 8 0 0.09 0.09 
159 478 8 0 0.8 0.8 
159 479 8 0.1 0.62 0.72 
159 477 12 0 2.17 2.17 
159 478 12 0 0.56 0.56 
159 479 12 0.08 0.78 0.86 
160 483 0.083 301.36 2355.84 2657.2 
160 484 0.5 82.56 578.08 660.64 
160 485 0.5 103.36 669.52 772.88 
160 486 0.5 87.52 533.28 620.8 
160 481 1 47.6 342.56 390.16 
160 482 1 48.4 339.68 388.08 
160 483 1 54.64 403.52 458.16 
160 484 1.5 18.72 130.05 148.77 
160 485 1.5 13.14 100.78 113.92 
160 486 1.5 16.46 110.34 126.8 
160 484 3 2.26 12.77 15.03 
160 485 3 1.98 10.88 12.86 
160 486 3 1.97 10.84 12.81 
160 481 6 0.26 1.95 2.21 
160 482 6 1.65 9.32 10.97 
160 483 6 2.03 8.48 10.51 
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DEPARTMENT OF PHARMACEUTICAL SCIENCES, COLLEGE OF 
PHARMACY 
UNIVERSITY OF KENTUCKY (LEGGAS LAB) 
 
 
REPORT ON THE BIOAVAILABILITY OF PEG-6000 (28:1, E:D) AND 
VITAMIN E-TPGS BASED AR-67 LACTONE (28:1, E:D) IN MICE 
(PERFORMED 7/30/2008-7/31/2008) 
BIOAVAILABILITY OF PEG-6000 (28:1, E:D) AND VITAMIN E-TPGS BASED 
AR-67 LACTONE (28:1, E:D) IN FEMALE C57BL/6 MICE 
EXPT # 162 AND EXPT # 163 
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Objective 
The oral bioavailability of PEG-6000 based AR-67 lactone (28:1, E:D) and Vitamin E-
TPGs based AR-67 lactone (28:1, E:D) were determined in the following experiments, 
which is a series of studies to screen excipients for better formulations with higher 
bioavailability.    
 
Expt 162: Study the bioavailability of PEG-6000 based AR-67 lactone (28:1, E:D) at 2.5 
mg/kg PO in female C57BL/6 mice. 
 
Expt 163: Study the bioavailability of Vitamin E-TPGs based AR-67 lactone (28:1, E:D) 
at 2.5 mg/kg PO in female C57BL/6 mice. 
 
Method 
Formulation  
The 2 formulations were prepared at 1 mg/mL by Dr. Xiang.   
Animal treatment and sample processing 
(Refer to \\Pharm\public\PS\Leggas Lab\Experimental Results\DB67 Oral PK\Mouse 
oral PK\sampling time for details) 
Expt 162: mice (#501-509) were orally treated with PEG-6000 based AR-67 lactone 
(28:1, E:D) at 2.5 mg/kg PO in female C57BL/6 mice. 
Expt 163: mice (#511-519) were orally treated with Vitamin E-TPGs based AR-67 
lactone (28:1, E:D) at 2.5 mg/kg PO in female C57BL/6 mice. 
Groups of three mice were sampled at 15 min, 30 min, 45 min, 1 h, 1.5 h, 3 h, 6 h, 8 h 
and 12 h. Each animal was sampled at 3 different time points.  
The blood sample of about 50 µL was collected from the saphenous vein with 
heparinized hematocrit tubes and transferred into heparinized microcentrifuge tubes. 
Plasma of 25 µL was collected by centrifugation of blood and then extracted 1:4 (v/v) 
with cold MeOH (100 µL,-80oC). Samples were kept at -80oC until analysis.  
 
 
 
 355 
 
HPLC analysis  
Before injection into the HPLC, samples were diluted with an equal volume of mobile 
phase buffer (40 µL:40 µL) and were analyzed.  
 
Sequence name: 20AC-080108-Mouse plasma curve & QCs prep 073108.seq  
  20AC-080408-Mouse PK Expt 162 & 163 ctd from 080108.seq         
Method:  
20AC-080108 mouse plasma curve.met 
Data were exported and saved in Leggas Lab/Experimental Results/AR-67 Oral PK / 
Mouse oral PK folder. Areas under the curve were estimated with Prism v5 and 
WinNonlin v5.2 (sparse sampling noncompartmental analysis). Plasma concentration 
versus time plots were made with Prism v5. 
 
Results 
1. Prism file: .\Prism files\Mouse PK 2.5 mg PO Expt 162 & 163.pzf  
2. WinNonlin file: .\Winnonlin files\Mouse PK Expt 162 & 163.wsp 
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3. Tables 
 
Table 1. Basic pharmacokinetic parameters 
Expt #162: 2.5 mg/kg Lactone (PEG-6000, 28:1, E:D) PO 
AUC (ng*h/mL) 
Mean (SE) 
Tmax (h) 
Median Mean (SE) 
Carboxylate 7.69 (1.17) 0.75 3.05 (1.72) 
Lactone 62.70 (8.09) 0.75 23.94 (11.64) 
Total  70.39 (9.22) 0.75 26.99 (13.36) 
 
 
Expt #163: 2.5 mg/kg Lactone (TPGS, 28:1, E:D ) PO 
AUC (ng*h/mL) 
Mean (SE) 
Tmax (h) 
Median 
Cmax (ng/mL) 
Mean 
Carboxylate 9.21 (1.74) 0.08 9.78 (5.95) 
Lactone 67.27 (2.63) 0.50 31.49 (5.97) 
Total  76.48 (3.73) 0.50 35.39 (6.89) 
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4. Figures 
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Raw Data 
Expt Mouse ID Time (h) 
Carb.  
(ng/mL) 
Lact. 
( ng/mL) 
Total 
(ng/mL) 
162 501 0.083 0.78 7.2 7.98 
162 502 0.083 0.14 1.89 2.03 
162 503 0.083 0.22 1.57 1.79 
162 504 0.5 3.27 21.18 24.45 
162 505 0.5 1.79 12.86 14.65 
162 506 0.5 0.76 6.36 7.12 
162 507 0.75 2 18.06 20.06 
162 508 0.75 6.41 46.4 52.81 
162 509 0.75 0.74 7.37 8.11 
162 501 1 2.61 20.79 23.4 
162 502 1 2.84 22.47 25.31 
162 503 1 2.04 16.95 18.99 
162 504 1.5 2.36 17.69 20.05 
162 505 1.5 1.63 10.23 11.86 
162 506 1.5 0.77 4.86 5.63 
162 504 3 1.32 8.84 10.16 
162 505 3 0.86 5.38 6.24 
162 506 3 0.67 4.99 5.66 
162 501 6 0.3 2.78 3.08 
162 502 6 0.37 3.64 4.01 
162 503 6 0.36 2.58 2.94 
162 507 8 0.44 4.57 5.01 
162 508 8 0 0.65 0.65 
162 509 8 0 1.48 1.48 
162 507 12 0 0.97 0.97 
162 508 12 0 0.84 0.84 
162 509 12 0.34 4.6 4.94 
163 511 0.083 21.67 9.21 30.88 
163 512 0.083 3.91 6.95 10.86 
163 513 0.083 3.75 16 19.75 
163 514 0.5 2.24 20.61 22.85 
163 515 0.5 5.42 41.18 46.6 
163 516 0.5 4.06 32.67 36.73 
163 517 0.75 1.93 16.95 18.88 
163 518 0.75 1.74 16.47 18.21 
163 519 0.75 3.82 30.35 34.17 
163 511 1 2.84 18.11 20.95 
163 512 1 2.61 19.64 22.25 
163 513 1 2.01 14.35 16.36 
163 514 1.5 1.71 14.29 16 
163 515 1.5 1.74 13.44 15.18 
163 516 1.5 1.21 11.24 12.45 
163 514 3 0.49 5.66 6.15 
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163 515 3 0.55 4.3 4.85 
163 516 3 0 3.28 3.28 
163 511 6 0.44 4.11 4.55 
163 512 6 0.44 4.37 4.81 
163 513 6 0.36 3.52 3.88 
163 517 8 0.29 3.46 3.75 
163 518 8 0.12 1.9 2.02 
163 519 8 0 1.07 1.07 
163 517 12 0.19 1.46 1.65 
163 518 12 0 1.59 1.59 
163 519 12 0 1.32 1.32 
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DEPARTMENT OF PHARMACEUTICAL SCIENCES, COLLEGE OF 
PHARMACY 
UNIVERSITY OF KENTUCKY (LEGGAS LAB) 
 
 
 
REPORT ON THE EFFECTS OF FEEDING DURING EXPERIMENT ON 
BIOAVAILABILITY OF AR-67 LACTONE IN MICE 
(PERFORMED 8/7/2008-8/8/2008) 
EFFECTS OF FEEDING DURING EXPERIMENT ON THE  BIOAVAILABILITY 
AR-67 LACTONE IN FEMALE C57BL/6 MICE 
EXPT # 164 AND EXPT # 165 
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Objective 
Because AR-67 lactone is highly lipophilic, we tested the effects of presence of food 
during experiment on bioavailability of AR-67 lactone PO.    
 
Expt 164: Study the bioavailability of SBE-β-CD based AR-67 lactone (200:1, E:D) at 
2.5 mg/kg PO WITHOUT food during experiment.  
 
Expt 165: Study the bioavailability of SBE-β-CD based AR-67 lactone (200:1, E:D) at 
2.5 mg/kg PO WITH food during experiment. 
 
Method 
Formulation  
The lyophilized powder SBE-β-CD based AR-67 lactone (200:1, E:D) was reconstituted 
in D5W to make 1 mg/mL dosing solution.   
 
Animal treatment and sample processing 
(Refer to \\Pharm\public\PS\Leggas Lab\Experimental Results\DB67 Oral PK\Mouse 
oral PK\sampling time for details) 
Expt 164: mice (#521-529) were orally treated SBE-β-CD based AR-67 lactone (200:1, 
E:D) at the dose of 2.5 mg/kg WITHOUT food during experiment 
Expt 165: mice (#531-539) were orally treated SBE-β-CD based AR-67 lactone (200:1, 
E:D) at the dose of 2.5 mg/kg WITH food during experiment 
Groups of three mice were sampled at 15 min, 30 min, 45 min, 1 h, 1.5 h, 3 h, 6 h, 8 h 
and 12 h. Each animal was sampled at 3-4 different time points.  
The blood sample of about 50 µL was collected from the saphenous vein with 
heparinized hematocrit tubes and transferred into heparinized microcentrifuge tubes. 
Plasma of 25 µL was collected by centrifugation of blood and then extracted 1:4 (v/v) 
with cold MeOH (100 µL,-80oC). Samples were kept at -80oC until analysis.  
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HPLC analysis  
Before injection into the HPLC, samples were diluted with an equal volume of mobile 
phase buffer (40 µL:40 µL) and were analyzed.  
 
Sequence name:  
20AC-080808-Mouse PK Expt 164 & 165 (SBE-β-CD fed vs non-fed).seq 
 
Method:  
20AC-080808-mouse plasma curve.met  
Data were exported and saved in Leggas Lab/Experimental Results/DB-67 Oral PK / 
Mouse oral PK folder. Areas under the curve were estimated with Prism v5 and 
WinNonlin v5.2 (sparse sampling noncompartmental analysis). Plasma concentration 
versus time plots were made with Prism v5. 
 
Results 
1. Prism file: ..\Prism files\Mouse PK 2.5 mg PO Expt 164 & 165 food effect.pzf 
2. WinNonlin file: ..\Winnonlin files\Mouse PK Expt 164 & 165.wsp 
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3. Tables 
 
Table 1. Basic pharmacokinetic parameters 
Expt 164: 2.5 mg/kg Lactone (SBE-β-CD 200:1) PO without food during expt 
 
AUC (ng*h/mL) 
Mean (SE) 
Tmax (h) 
Median 
Cmax (ng/mL) 
Mean (SE) 
Carboxylate 19.42 (4.22) 1.00 5.22 (0.31) 
Lactone 82.06 (5.11) 0.75 36.99 (4.14) 
Total  101.48 (3.56) 0.75 42.11 (4.91) 
 
Expt 165: 2.5 mg/kg Lactone (SBE-β-CD 200:1) PO with food during expt 
AUC (ng·h/mL) 
Mean (SE) 
Tmax (h) 
Median 
Cmax (ng/mL) 
Mean (SE) 
Carboxylate 23.85 (5.68) 0.75 6.11 (1.09) 
Lactone 95.28 (4.75) 0.75 40.04 (7.25) 
Total  119.13 (7.43) 0.75 46.15 (8.31) 
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4. Figures 
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Raw Data 
 
Expt Animal # Time (h) 
Carb. 
ng/mL 
Lact. 
(ng/mL) 
Total 
(ng/mL) 
164 521 0.083 3.35 22.63 25.98 
164 522 0.083 1.36 9.57 10.93 
164 523 0.083 1.25 9.17 10.42 
164 524 0.5 3.83 26.04 29.87 
164 525 0.5 3.95 29.74 33.69 
164 526 0.5 Missing Missing Missing 
164 527 0.75 4.26 33.61 37.87 
164 528 0.75 4.41 32.14 36.55 
164 529 0.75 6.67 45.23 51.9 
164 521 1 5.12 31.35 36.47 
164 522 1 4.74 33.94 38.68 
164 523 1 5.79 32.05 37.84 
164 524 1.5 4.07 16.27 20.34 
164 525 1.5 3.56 25.56 29.12 
164 526 1.5 Missing Missing Missing 
164 524 3 4.13 6.87 11 
164 525 3 1.02 6.25 7.27 
164 526 3 Missing Missing Missing 
164 521 6 2.29 2.1 4.39 
164 522 6 0.35 1.51 1.86 
164 523 6 0.45 2.73 3.18 
164 527 8 0.88 1.05 1.93 
164 528 8 0.16 1.04 1.2 
164 529 8 0.33 1.76 2.09 
164 527 12 0.73 1.18 1.91 
164 528 12 0.16 1.63 1.79 
164 529 12 0.36 1.82 2.18 
165 531 0.083 2.34 21.16 23.5 
165 532 0.083 2.16 16.63 18.79 
165 533 0.083 2.04 13.92 15.96 
165 534 0.5 7.74 34.6 42.34 
165 535 0.5 5.95 24.07 30.02 
165 536 0.5 1.63 11.41 13.04 
165 537 0.75 4.57 32.87 37.44 
165 538 0.75 5.55 32.7 38.25 
165 539 0.75 8.22 54.54 62.76 
165 531 1 5.05 33.79 38.84 
165 532 1 3.22 28.51 31.73 
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165 533 1 5.53 35.53 41.06 
165 534 1.5 4.48 16.49 20.97 
165 535 1.5 3.5 22 25.5 
165 536 1.5 1.54 13.5 15.04 
165 534 3 4.16 5.7 9.86 
165 535 3 0.97 6.27 7.24 
165 536 3 1.92 15.28 17.2 
165 531 6 6.26 6.06 12.32 
165 532 6 0.73 4.21 4.94 
165 533 6 1.06 6.44 7.5 
165 537 8 1.1 3.05 4.15 
165 538 8 0.3 0.85 1.15 
165 539 8 0.36 1.66 2.02 
165 537 12 0.98 2.04 3.02 
165 538 12 Missing Missing Missing 
165 539 12 0.44 1.65 2.09 
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DEPARTMENT OF PHARMACEUTICAL SCIENCES, COLLEGE OF 
PHARMACY 
UNIVERSITY OF KENTUCKY (LEGGAS LAB) 
REPORT ON THE EFFECT OF EXCIPIENT TO DRUG RATIO ON THE 
BIOAVAILABILITY OF E-TPGS BASED AR-67 LACTONE IN MICE 
 
(PERFORMED 8/19/2008-8/20/2008) 
 
COMPARISON OF E:D RATIOS OF 56:1 AND 200:1 ON THE 
BIOAVAILABILITY OF E-TPGS-BASED AR-67 LACTONE IN C57BL/6 MICE 
EXPT # 166 AND EXPT # 167 
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Objective 
Expt 166: Study the E:D ratio of 200:1 on the absorption of E-TPGS based AR-67 
lactone (2.5ml/kg, 2.5 mg/kg) PO.  
 
Expt 167: Study the E:D ratio of 56:1 on the absorption of E-TPGS based AR-67 lactone 
(2.5ml/kg, 2.5 mg/kg) PO.  
 
Method 
Formulation 
The excipient solution and AR-67 carboxylate stock solution (20 mg/mL) were prepared 
by Dr. Xiang, the excipient solution were spiked with carboxylate stock solution to make 
2 mg/mL dosing solution. The dosing solutions were made freshly before dosing.  
 
Animal treatment and sample processing 
(Refer to \\Pharm\public\PS\Leggas Lab\Experimental Results\DB67 Oral PK\Mouse 
oral PK\sampling time for details) 
Expt 166, mice  (#541-# 549, n=9, three per time point) were dosed with 2.5 mg/kg 
TPGS based AR-67 lactone (E:D ratio 200:1) PO. 
Expt 167, mice (#551-# 559, n=9, three per time point) were dosed with 2.5 mg/kg TPGS 
based AR-67 lactone (E:D ratio 56:1) PO. 
Dosing solution was prepared by Sagar Rane to give a solution concentration of 1 mg/mL 
lactone after mixing 1 part of AR-67 stock solution (10 mg/mL carboxylate) with 9 parts 
of simulated gastric fluid containing TPGS.  
Groups of three mice were sampled at 15 min, 30 min, 45 min, 1 h, 1.5 h, 4 h, 6 h, 8 h 
and 12 h. Each animal was sampled at three different time points.  
Blood (about 50 µL) was collected from the saphenous vein with heparinized hematocrit 
tubes and transferred into heparinized microcentrifuge tubes. Plasma (about 25 uL) was 
collected by centrifugation of blood and then extracted 1:4 (v/v) with cold MeOH (100 
uL,-80oC). Samples were kept at -80oC until analysis.  
 
HPLC analysis  
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Before injection into the HPLC, samples were diluted with an equal volume of mobile 
phase buffer (40 µL:40 µL) and were analyzed.  
 
Sequence name:  
20AC-082008-Mouse Expt 166 & 167.seq &  
20AC-082108-mouse Exp 166 & 167.seq 
 
Method:  
20AC-082208-mousecurve.met 
 
Data were exported and saved in Leggas Lab/Experimental Results/AR-67 Oral PK / 
Mouse oral PK folder. Areas under the curve were estimated with Prism v5 and 
Winnonlin v5.2 (sparse sampling noncompartmental analysis). Plasma concentration 
versus time plots were made with Prism v5. 
 
Results 
1. Prism files: \Prism files\Mouse PK Expt 166 & 167.pzf 
2. Winnonlin files: \Winnonlin files\Mouse PK Expt 166 & 167.wsp 
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3. Tables  
 
Table 1. Summary of basic pharmacokinetic parameters 
Expt #166: 2.5 mg/kg Lactone (TPGS 200:1) PO 
AUC(ng*h/mL) 
Mean 
Tmax (h) 
Median 
Cmax (ng/mL) 
Mean (SE) 
Carboxylate 10.16 (0.93) 1.00 4.94 (1.2) 
Lactone 92.84 (7.7) 1.00 49.90 (6.10) 
Total  103.0 (8.55) 1.00 54.83 (7.29) 
 
 
Expt # 167: 2.5 mg/kg Lactone (TPGS 56:1) PO 
AUC  
(ng*h/mL) Mean SE Tmax (h) Median 
Cmax 
 (ng/mL) Mean SE 
Carb 9.92 0.56 Carb 0.75 Carb 4.11 0.30 
Lactone 93.99 5.15 Lactone 1.00 Lactone 40.43 5.35 
Total  103.91 5.62 Total 1.00 Total 44.29 5.66 
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4. Figures 
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Raw Data 
Sample ID Expt Animal # Time (h) 
Carb. 
(ng/mL) 
Lact. 
(ng/mL) 
Total 
(ng/mL) 
541-5min 166 541 0.083 0.85 9.38 10.23 
543-5min 166 543 0.083 0.86 8.21 9.07 
544-30min 166 544 0.5 3.71 29.34 33.05 
545-30min 166 545 0.5 6.26 57.97 64.23 
546-30min 166 546 0.5 4.14 32.63 36.77 
547-45min 166 547 0.75 2.36 25.15 27.51 
548-45min 166 548 0.75 3.67 32.34 36.01 
549-45min 166 549 0.75 1.73 15.05 16.78 
541-1h 166 541 1 3.74 43.8 47.54 
543-1h 166 543 1 6.13 55.99 62.12 
544-1.5h 166 544 1.5 4.03 33.77 37.8 
545-1.5h 166 545 1.5 3.16 27.07 30.23 
546-1.5h 166 546 1.5 1.54 15.15 16.69 
544-3h 166 544 3 0.42 3.23 3.65 
545-3h 166 545 3 0.97 8.67 9.64 
546-3h 166 546 3 0.68 7.26 7.94 
541-6h 166 541 6 0.21 1.64 1.85 
543-6h 166 543 6 0.1 1.11 1.21 
547-8 h 166 547 8 0.43 4.28 4.71 
548-8 h 166 548 8 0.14 0.54 0.68 
549-8 h 166 549 8 0.16 1.4 1.56 
547-12 h 166 547 12 0 1.2 1.2 
548-12 h 166 548 12 0.12 0.79 0.91 
549-12 h 166 549 12 0.33 2.8 3.13 
551-5 min 167 551 0.083 1.1 13.45 14.55 
552-5 min 167 552 0.083 1.94 17.95 19.89 
553-5 min 167 553 0.083 1.83 17.65 19.48 
554-30 min 167 554 0.5 1.66 16.9 18.56 
555-30 min 167 555 0.5 1.01 11.49 12.5 
556-30 min 167 556 0.5 1.51 12.3 13.81 
557-45 min 167 557 0.75 4.36 36.71 41.07 
558-45 min 167 558 0.75 4.45 44.64 49.09 
559-45 min 167 559 0.75 3.51 18.38 21.89 
551-1 h 167 551 1 4.31 48.93 53.24 
552-1 h 167 552 1 4.01 41.8 45.81 
553-1 h 167 553 1 3.26 30.55 33.81 
554-1.5 h 167 554 1.5 1.33 12.43 13.76 
555-1.5 h 167 555 1.5 2.29 22.24 24.53 
556-1.5 h 167 556 1.5 1.99 19.42 21.41 
554-3 h 167 554 3 0.84 8.08 8.92 
555-3 h 167 555 3 1.16 11.58 12.74 
556-3 h 167 556 3 0.91 7.1 8.01 
551-6 h 167 551 6 0.16 1.94 2.1 
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552-6 h 167 552 6 0.19 1.81 2 
553-6 h 167 553 6 0.49 5.72 6.21 
557-8 h 167 557 8 0.22 2.13 2.35 
558-8 h 167 558 8 0.21 2.1 2.31 
559-8 h 167 559 8 0.57 4.18 4.75 
557-12 h 167 557 12 0.42 4.06 4.48 
558-12 h 167 558 12 0.36 2.95 3.31 
559-12 h 167 559 12 0.45 4.25 4.7 
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DEPARTMENT OF PHARMACEUTICAL SCIENCES, COLLEGE OF 
PHARMACY 
UNIVERSITY OF KENTUCKY (LEGGAS LAB) 
REPORT ON THE EFFECT OF LIPID/FREE FATTY ACID PRETREATMENT 
ON THE BIOAVAILABILITY OF E-TPGS BASED AR-67 LACTONE IN MICE  
 
(PERFORMED 8/28/2008-8/29/2008) 
 
EFFECT OF PRETREATMENT WITH SAFFLOWER OIL AND CO-
TREATMENT WITH OLEIC ACID ON THE BIOAVAILABILITY OF TPGS-
BASED AR-67 LACTONE (E:D 200:1) IN FEMALE C57BL/6 MICE 
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Objective 
Long chain unsaturated free fatty acids and lipids composed of long chain unsaturated 
fatty acids facilitate the lymphatic transport of lipophilic drugs administered by the oral 
route. In order for lipids to enhance lymphatic transport, however, they first need to be 
digested into the corresponding free fatty acid. The purpose of these mouse PK studies 
was to facilitate the lymphatic transport of AR-67 lactone by pretreatment with a lipid 
(safflower oil, containing triglycerides of linoleic acid) and by co-treatment with oleic 
acid.  
 
Expt 168: Study the effect of safflower oil pretreatment PO (5 mL/kg) on the absorption 
of E-TPGS based AR-67 lactone (2.5 mL/kg, 2.5 mg/kg) PO.  
 
Expt 169: Study the effect of oleic acid co-treatment PO (5 mL/kg) on the absorption of 
E-TPGS based AR-67 lactone (2.5 mL/kg, 2.5 mg/kg) PO 
 
Method 
Animal treatment and sample processing 
(Refer to \\Pharm\public\PS\Leggas Lab\Experimental Results\DB67 Oral PK\Mouse 
oral PK\sampling time for details) 
Expt 168, Mice (#561-# 569, n=9, three per time point) were dosed with 2.5 mg/kg TPGS 
based AR-67 lactone (E:D ratio 200:1) PO 1 hour after safflower oil pretreatment (5 
mL/kg) PO. 
Expt 169, Mice (#561-# 569, n=9, three per time point) were dosed with 2.5 mg/kg TPGS 
based AR-67 lactone (E:D ratio 200:1) PO 5 minutes after oleic acid pretreatment (5 
mL/kg) PO. 
Dosing solution was prepared as described in Dr. Xiang’s protocol (Refer to L0050 page 
28 for protocol) to give a solution concentration of 1 mg/ml lactone after mixing 1 part of 
AR-67 stock solution (10 mg/mL carboxylate) with 9 parts of simulated gastric fluid 
containing TPGS.  
Groups of three animals were sampled at 5 min, 30 min, 45 min, 1 h, 1.5 h, 4 h, 6 h, 8 h 
and 12 h. Each animal was sampled at three different time points.  
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Blood of about 50 µL was collected from the saphenous vein with heparinized hematocrit 
tubes and transferred into heparinized microcentrifuge tubes. Plasma ( about 25 µL) was 
collected by centrifugation of blood and then extracted 1:4 (v/v) with cold MeOH (100 
µL,-80oC). Samples were kept at -80oC until analysis.  
 
HPLC analysis  
 
Before injection into the HPLC, samples were diluted with an equal volume of mobile 
phase buffer (40 µL:40 µL) and were analyzed.  
 
Sequence name: 
20AC-090208-Mouse PK Expt 168 & 169.seq 
Method:  
20AC-082208-mousecurve.met 
Data were exported and saved in Leggas Lab/Experimental Results/AR-67 Oral PK / 
Mouse oral PK folder. Areas under the curve were estimated with Prism v5 and 
Winnonlin v5.2 (sparse sampling noncompartmental analysis). Plasma concentration 
versus time plots were made with Prism v5. 
 
Results 
1. Prism files: \Prism files\Mouse PK expt 168 & 169.pzf 
2. Winnonlin files: \Winnonlin files\Mouse PK expt 168 & 169a.wsp 
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3. Tables (from Prism) 
Table 1. Summary of basic pharmacokinetic parameters 
2.5 mg/kg Lactone (TPGS 200:1) PO Safflower seed oil pretreatment with 
food during expt 
Expt #168 
AUC 
(ng*h/mL) Tmax (h) Cmax (ng/mL) 
Carboxylate 14.93 3 2.633 
Lactone 95.29 1.5 21.05 
Total 110.2 1.5 23.04 
F (Bioavailability) 0.18     
 
2.5 mg/kg Lactone (TPGS 200:1) PO Oleic acid co-treatment with food 
during expt 
Expt #169 AUC (ng*h/mL) Tmax (h) Cmax (ng/mL) 
Carboxylate 15.04 8 2.053 
Lactone 125.4 8 17.3 
Total 140.4 8 19.36 
F (Bioavailability) 0.23     
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4. Figures 
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Fig.1.: Semi-logarithmic plot of the plasma concentration of total AR-67 (Mean±SD) in 
female C57BL/6 mice treated with 2.5 mg/kg AR-67 PO with or without co-
treatment/pretreatment with oleic acid or safflower seed oil (TPGS E:D 200:1) File path: 
\\Pharm\public\PS\Leggas Lab\Experimental Results\DB67 Oral PK\Mouse oral 
PK\Prism files\ Mouse PK expt 168 & 169. 
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Raw Data 
Expt Animal # Time (h) 
Carb. 
(ng/mL) 
 Lact. 
(ng/mL) 
Total 
(ng/mL) 
168 561 0.083 0.13 0.93 1.06 
168 561 1 1.23 9.71 10.94 
168 561 8 2.65 11.22 13.87 
168 562 0.083 0 0.19 0.19 
168 562 1 0.37 5.41 5.78 
168 563 0.083 0.23 1.8 2.03 
168 563 1 0.31 5.35 5.66 
168 563 8 0.24 2.84 3.08 
168 564 0.5 1 12.78 13.78 
168 564 1.5 2.77 19.22 21.99 
168 564 3 4.28 14.6 18.88 
168 565 0.5 0.81 13.28 14.09 
168 565 1.5 1.83 25.43 27.26 
168 565 3 2.69 5.85 8.54 
168 566 0.5 1.4 18.26 19.66 
168 566 1.5 1.37 18.51 19.88 
168 566 3 0.93 11.48 12.41 
168 567 0.75 1.06 12.87 13.93 
168 567 6 0.27 1.87 2.14 
168 567 12 0.24 1.73 1.97 
168 568 0.75 0.9 12.51 13.41 
168 568 6 0.26 2.67 2.93 
168 568 12 0.45 5.51 5.96 
168 569 0.75 1.46 19.76 21.22 
168 569 6 0.2 1.86 2.06 
168 569 12 1.06 11.38 12.44 
169 571 0.083 0.21 1.09 1.3 
169 571 1 1.23 11.09 12.32 
169 571 8 5.16 40.94 46.1 
169 572 0.083 0.71 1.06 1.77 
169 572 1 1.93 23.96 25.89 
169 572 8 0.64 6.23 6.87 
169 573 0.083 0 0.38 0.38 
169 573 1 1.1 12.63 13.73 
169 573 8 0.36 4.74 5.1 
169 574 0.5 1 7.7 8.7 
169 574 1.5 2.36 21.84 24.2 
169 574 3 3.08 16 19.08 
169 575 0.5 0.09 1.23 1.32 
169 575 1.5 0.44 5.95 6.39 
169 575 3 0.55 7.8 8.35 
169 576 0.5 0.1 1.09 1.19 
169 576 1.5 1 13.4 14.4 
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169 576 3 0.63 7.34 7.97 
169 577 0.75 0.23 3.21 3.44 
169 577 6 0.92 3.53 4.45 
169 577 12 2.5 14.28 16.78 
169 578 0.75 0.2 4.41 4.61 
169 578 6 0.72 9.81 10.53 
169 578 12 0.25 4.71 4.96 
169 579 0.75 1.87 26.8 28.67 
169 579 6 0.17 1.67 1.84 
169 579 12 0.23 1.69 1.92 
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DEPARTMENT OF PHARMACEUTICAL SCIENCES, COLLEGE OF 
PHARMACY 
UNIVERSITY OF KENTUCKY (LEGGAS LAB) 
REPORT ON THE EFFECT OF FREE FATTY ACID PRETREATMENT ON 
THE BIOAVAILABILITY OF TPGS BASED AR-67 CARBOXYLATE IN MICE  
 
(PERFORMED 9/11/2008-9/12/2008) 
 
EFFECT OF CO-TREATMENT WITH OLEIC ACID ON THE 
BIOAVAILABILITY OF TPGS-BASED AR-67 CARBOXYLATE (E:D 56:1) IN 
FEMALE C57BL/6 MICE 
 
EXPT # 170 AND EXPT # 171 
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Objective 
Long chain unsaturated free fatty acids facilitate the lymphatic transport of lipophilic 
drugs administered by the oral route. This is a continuation of similar experiments done 
previously (Expt 168 & 169) with the lactone. The purpose of these mouse PK studies 
was to facilitate the lymphatic transport of AR-67 carboxylate by co-treatment with oleic 
acid. The carboxylate was chosen for further studies because of its enhanced water 
solubility. 
 
Expt 170: (Control pretreatment) Study the effect of control (D5W) co-treatment PO (5 
ml/kg) on the absorption of TPGS based AR-67 carboxylate (2.5ml/kg, 5 mg/kg) PO.  
 
Expt 171: Study the effect of oleic acid co-treatment PO (5 ml/kg) on the absorption of 
TPGS based AR-67 carboxylate (2.5ml/kg, 5 mg/kg) PO. 
 
Method 
Formulation  
The formulation of AR-67 carboxylate in TPGS (E:D ratio 56:1) was prepared at 2 mg/ml 
by Sagar  Rane on 092308 and was analyzed by HPLC in Leggas lab on 09/23/08 and 
09/24/08 prior to use. The formulation had 0.01M sodium bicarbonate.  
 
Animal treatment and sample processing 
(Refer to \\Pharm\public\PS\Leggas Lab\Experimental Results\DB67 Oral PK\Mouse 
oral PK\sampling time for details) 
Expt 170, Mice (#581-# 589, n=9, three per time point) were dosed with 5 mg/kg TPGS 
based AR-67 carboxylate (E:D ratio 56:1) PO 5 min after D5W (5 ml/kg) PO. 
Expt 171, Mice (#591-# 599, n=9, three per time point) were dosed with 5 mg/kg TPGS 
based AR-67 carboxylate (E:D ratio 56:1) PO 5 minutes after oleic acid pretreatment (5 
ml/kg) PO. 
Groups of three mice were sampled at 5 min, 30 min, 45 min, 1 h, 1.5 h, 3 h, 6 h, 8 h and 
12 h, 18 h, 31 h and 51h. Each animal was sampled at three different time points.  
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Blood (about 50 uL) was collected from the saphenous vein with heparinized hematocrit 
tubes and transferred into heparinized microcentrifuge tubes. Plasma (about 25 uL) was 
collected by centrifugation of blood and then extracted 1:4 (v/v) with cold MeOH (100 
uL,-80oC). Samples were kept at -80oC until analysis.  
 
HPLC analysis  
Before injection into the HPLC, samples were diluted with an equal volume of mobile 
phase buffer (40 µL:40 µL) and were analyzed.  
 
Sequence name:  
20AC-092508.seq 
 
Method:  
20AC-082208-mousecurve.met 
 
Data were exported and saved in Leggas Lab/Experimental Results/DB-67 Oral PK / 
Mouse oral PK folder. Areas under the curve were estimated with Prism v5 and 
Winnonlin v5.2 (sparse sampling noncompartmental analysis). Plasma concentration 
versus time plots were made with Prism v5. 
 
Results 
1. Prism files:..\Prism files\Mouse PK Expt 170 & 171.pzf 
2. Winnonlin files:  ..\Winnonlin files\Mouse PK Expt 170 & 171.wsp 
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3. Tables (from Prism) 
 
Table 1. Summary of basic pharmacokinetic parameters 
 
Expt #170 5 mg/kg carboxylate (TPGS 56:1) PO + D5W co-treatment   
AUC (ng·h/mL) Mean SE Tmax (h) Median Cmax (ng/mL) Mean (SE) 
Total 176.48 7.48 Total 1.00 Total 99.72 (11.33)
 
Expt #171 5 mg/kg Carboxylate (TPGS 56:1) PO +  Oleic acid co-treatment  
AUC (ng·h/mL) Mean  SE Tmax (h) Median Cmax (ng/mL) Mean (SE) 
Total 202.29 68.33 Total 0.75 Total 47.54 (17.73)
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4. Figures 
0 5 10 15 20 25
0.1
1
10
100 D5W
Oleic acid
5 mg/kg oral E-TPGS based AR-67 carboxylate (56:1,E/D)
5 min after administration of D5W or oleic acid (5 mL/kg) PO
Time (h)
Pl
as
m
a 
To
ta
l A
R
-6
7
C
on
c 
(n
g/
m
L)
 
File path: \\Pharm\public\PS\Leggas Lab\Experimental Results\DB67 Oral PK\Mouse 
oral PK\Prism files\ Mouse PK expt 170 & 171 
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Raw Data 
Expt  ID Time (h) 
Carboxylate 
(ng/mL) 
Lactone 
(ng/mL) 
Total 
(ng/mL) 
170 581 0.083 3.72 12.55 16.27 
170 581 1 8.75 78.16 86.91 
170 581 8 0 4.83 4.83 
170 581 19 1.17 0 1.17 
170 582 0.083 1.85 23.37 25.22 
170 582 1 6.11 83.84 89.95 
170 582 8 0 2.99 2.99 
170 583 0.083 0 8.71 8.71 
170 583 1 11.9 110.41 122.31 
170 583 8 0 3.03 3.03 
170 584 0.5 3.84 56.53 60.37 
170 584 1.5 4.14 48.33 52.47 
170 584 3 0 7.78 7.78 
170 585 0.5 4.09 54.33 58.42 
170 585 1.5 3.73 45.77 49.5 
170 585 3 0 9.88 9.88 
170 586 0.5 2.98 41.96 44.94 
170 586 1.5 3 39.17 42.17 
170 586 3 0 6.52 6.52 
170 587 0.75 4.86 71.83 76.69 
170 587 6 0 2.58 2.58 
170 587 12 1.86 4.87 6.73 
170 588 0.75 7.09 95.15 102.24 
170 589 0.75 3.91 52.24 56.15 
170 589 6 0 2.71 2.71 
171 591 1 6.46 73.4 79.86 
171 591 8 0 7.52 7.52 
171 591 19 1.57 4.58 6.15 
171 592 1 1.16 11.66 12.82 
171 592 8 0 7.74 7.74 
171 592 19 0 2.64 2.64 
171 593 0.083 1.16 0 1.16 
171 593 1 4.64 41.47 46.11 
171 593 8 0 11.26 11.26 
171 593 19 1.79 7.32 9.11 
171 594 0.5 2.96 40.31 43.27 
171 594 1.5 6.97 81.51 88.48 
171 594 3 5.26 55.76 61.02 
171 594 24 1.06 0 1.06 
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171 595 1.5 0 5.94 5.94 
171 595 3 0 6.87 6.87 
171 595 24 0 9.81 9.81 
171 596 0.5 0 3.46 3.46 
171 596 1.5 0 8.28 8.28 
171 596 3 1.77 24.82 26.59 
171 596 24 0 6.7 6.7 
171 597 0.75 3.07 44.29 47.36 
171 597 6 0 4.41 4.41 
171 597 12 6.56 10.72 17.28 
171 598 0.75 5.98 72.35 78.33 
171 598 6 0 5.17 5.17 
171 598 12 0 5.19 5.19 
171 599 0.75 1.22 15.7 16.92 
171 599 6 0 4.22 4.22 
171 599 12 0 10.32 10.32 
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DEPARTMENT OF PHARMACEUTICAL SCIENCES, COLLEGE OF 
PHARMACY 
UNIVERSITY OF KENTUCKY (LEGGAS LAB) 
REPORT ON THE EFFECT OF FREE FATTY ACID PRETREATMENT ON 
THE BIOAVAILABILITY OF TPGS BASED AR-67 LACTONE IN MICE  
 
(PERFORMED 9/11/2008-9/12/2008) 
 
EFFECT OF CO-TREATMENT WITH OLEIC ACID ON THE 
BIOAVAILABILITY OF TPGS-BASED AR-67 LACTONE (E:D 56:1) IN 
FEMALE C57BL/6 MICE 
 
EXPT # 172 AND EXPT # 173 
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Objective 
Long chain unsaturated free fatty acids facilitate the lymphatic transport of lipophilic 
drugs administered by the oral route. This is a continuation of similar experiments done 
previously (Expt 168, 169, 170, 171) with the lactone (2.5 mg/kg) & carboxylate (5 
mg/kg). The purpose of these mouse PK studies was to facilitate the lymphatic transport 
of AR-67 lactone by co-treatment with oleic acid and to compare with results obtained 
from carboxylate (Expts 170 & 171). 
 
Expt 172: (Control pretreatment) Study the effect of control (D5W) co-treatment PO (5 
mL/kg) on the absorption of TPGS based AR-67 lactone (2.5 mL/kg, 5 mg/kg) PO.  
 
Expt 173: Study the effect of oleic acid co-treatment PO (5 mL/kg) on the absorption of 
TPGS based AR-67 lactone (2.5mL/kg, 5 mg/kg) PO. 
 
Method 
Formulation  
The formulation of AR-67 lactone in TPGS (E:D ratio 56:1) was prepared at 2 mg/ml by 
E. Adane on 100208 and was analyzed by HPLC in Leggas lab on 10/06/08 prior to use. 
The formulation concentration was 1.72 mg/ml.  
 
Animal treatment and sample processing 
(Refer to \\Pharm\public\PS\Leggas Lab\Experimental Results\DB67 Oral PK\Mouse 
oral PK\sampling time for details) 
Expt 172, Mice (#601-# 609, n=9, three per time point) were dosed with 5 mg/kg TPGS 
based AR-67 lactone (E:D ratio 56:1) PO 5 min after D5W (5 mL/kg) PO. 
Expt 173, Mice (#6111-# 619, n=9, three per time point) were dosed with 5 mg/kg TPGS 
based AR-67 lactone (E:D ratio 56:1) PO 5 minutes after oleic acid pretreatment (5 
mL/kg) PO. 
Groups of three mice were sampled at 5 min, 30 min, 45 min, 1 h, 1.5 h, 3 h, 6 h, 8 h and 
12 h, 18 h, 31 h and 51h. Each animal was sampled at three different time points.  
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Blood (about 50 µL) was collected from the saphenous vein with heparinized hematocrit 
tubes and transferred into heparinized microcentrifuge tubes. Plasma (about 25 µL) was 
collected by centrifugation of blood and then extracted 1:4 (v/v) with cold MeOH (100 
µL,-80oC). Samples were kept at -80oC until analysis.  
 
HPLC analysis  
 
Before injection into the HPLC, samples were diluted with an equal volume of mobile 
phase buffer (40 µL:40 µL) and were analyzed.  
 
Sequence name: 20AC-101008-Mouse PK expt 172 & 173.seq 
Method: 20AC-082208-mousecurve.met 
 
Data were exported and saved in Leggas Lab/Experimental Results/DB-67 Oral PK / 
Mouse oral PK folder. Areas under the curve were estimated with Prism v5 and 
Winnonlin v5.2 (sparse sampling noncompartmental analysis). Plasma concentration 
versus time plots were made with Prism v5. 
Results 
1. Prism files:..\Prism files\Mouse PK Expt 172 & 173.pzf 
2. Winnonlin files:  ..\Winnonlin files\Mouse PK Expt 172 & 173.wsp 
3. Tables 
Table 1. Summary of basic pharmacokinetic parameters 
Expt #172 5 mg/kg Lactone (TPGS 56:1) PO: D5W retreatment 
AUC (ng·h/mL) Mean SE Tmax (h) Median Cmax (ng/mL) Mean (SE) 
Total  230.24 18.62 Total 0.75 Total 100.67 (16.09)
              
Expt #173 5 mg/kg Lactone (TPGS 56:1) PO: Oleic acid pretreatment 
AUC (ng·h/mL) Mean  SE Tmax (h) Median Cmax (ng/mL) Mean (SE) 
Total 256.47  30.45 Total 0.75 Total 121. 57 (8.34) 
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4. Figures 
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File path: \\Pharm\public\PS\Leggas Lab\Experimental Results\DB67 Oral PK\Mouse 
oral PK\Prism files\ Mouse PK expt 172 & 173. 
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Raw Data 
Expt Time (h) ID 
Carboxylate 
(ng/mL) 
Lactone 
(ng/mL) 
Total 
 (ng/mL) 
172 0.083 601 4.81 68.49 73.3 
172 0.083 602 4.1 50.5 54.6 
172 0.083 603 3.98 44.54 48.52 
172 0.5 604 2.83 29.51 32.34 
172 0.5 605 1.79 26.54 28.33 
172 0.75 607 9.5 75.22 84.72 
172 0.75 608 11.86 120.99 132.85 
172 0.75 609 7.43 77.02 84.45 
172 1 601 6.69 69.27 75.96 
172 1 602 7.33 79.59 86.92 
172 1 603 5.25 47.83 53.08 
172 1.5 604 6.22 57.94 64.16 
172 1.5 605 5.83 68.31 74.14 
172 1.5 606 4.09 45.18 49.27 
172 3 604 5.28 19.18 24.46 
172 3 605 2.25 21.76 24.01 
172 3 606 1.09 8.34 9.43 
172 6 607 8.3 2.22 8.3 
172 6 608 0.46 2.63 2.63 
172 6 609 0.43 2.92 2.92 
172 8 601 4.46 3.73 8.19 
172 8 602 1.18 9.6 10.78 
172 8 603 1.2 10.44 11.64 
172 12 607 9.35 2.58 11.93 
172 12 608 0.52 1.21 1.73 
172 12 609 0.33 1.43 1.76 
172 14 604 5.05 2.87 7.92 
172 14 605 0.53 1.11 1.64 
172 14 606 0.33 1.56 1.89 
173 0.25 611 1.18 15.2 16.38 
173 0.25 612 1.41 19.2 20.61 
173 0.25 613 3.64 39.86 43.5 
173 0.5 615 13.17 127.36 140.53 
173 0.5 616 8.62 74.98 83.6 
173 0.75 617 10.87 119.02 129.89 
173 0.75 619 9.22 104.02 113.24 
173 1 612 5.66 50.4 56.06 
173 1 613 9.1 89.83 98.93 
173 1.5 614 2.12 20.05 22.17 
173 1.5 615 8.14 66.05 74.19 
173 1.5 616 4.89 50.23 55.12 
173 3 615 1.87 14.17 16.04 
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173 3 616 1.47 12.46 13.93 
173 6 617 2.97 8.97 11.94 
173 6 618 2.45 24.04 26.49 
173 6 619 0.63 4.62 4.62 
173 8 611 1.34 6.59 7.93 
173 8 612 1.14 9.95 11.09 
173 8 613 0.82 7.12 7.12 
173 12 617 4.66 4.95 9.61 
173 12 618 1.03 9.79 10.82 
173 12 619 0.49 3.67 3.67 
173 14 614 9 10.6 19.6 
173 14 615 0.68 2.65 2.65 
173 14 616 0.61 14.46 14.46 
173 24 611 1 4.8 5.8 
173 24 612 0.2 1.66 1.86 
173 24 613 0.13 1.11 1.24 
173 28 617 2.68 0.77 3.45 
173 28 618 0.42 0.61 1.03 
173 28 619 0.53 0.48 1.01 
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DEPARTMENT OF PHARMACEUTICAL SCIENCES, COLLEGE OF 
PHARMACY 
UNIVERSITY OF KENTUCKY (LEGGAS LAB) 
REPORT ON THE EFFECT OF FREE FATTY ACID ON THE 
BIOAVAILABILITY OF TPGS BASED AR-67 CARBOXYLATE IN MICE  
 
(PERFORMED 10/16/2008-10/17/2008) 
 
EFFECT OF OLEIC ACID AMOUNT IN THE FORMULATION ON THE ORAL 
BIOAVAILABILITY OF TPGS-BASED AR-67 CARBOXYLATE (E:D, 56:1) IN 
FEMALE C57BL/6 MICE 
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Objective 
Long chain unsaturated free fatty acids facilitate the lymphatic transport of lipophilic 
drugs administered by the oral route. The previous experiments have shown that 
pretreatment and co-treatment with oleic acid increased the oral bioavailability of AR-67 
by about 1.5 fold, and this is a continuation of this set of experiments to incorporate the 
oleic acid in the final formulation. The purpose of these mouse PK studies was to 
determine the bioavailability of mixture of E-TPGS based formulation premix with oleic 
acid. 
 
Expt 174: Study on the bioavailability of mixture of TPGS based AR-67 carboxylate 
(E:D ratio 56:1) premixed with oleic acid at 1:5, v/v (0.5 X) at dose of 5 mg/kg PO. 
 
Expt 175: Study the bioavailability of a mixture of TPGS based AR-67 carboxylate (E:D 
ratio 56:1)  premixed with oleic acid at 2:1, v/v ratios (5X)  at dose of 5mg/kg PO. 
 
Method 
Formulation  
The formulation of AR-67 carboxylate in TPGS (E:D ratio 56:1) was prepared at 2 mg/ml 
by E. Adane and was analyzed by HPLC in Leggas laboratory.   
 
Animal treatment and sample processing 
Expt 174: mice (#621-629) were treated with mixture of TPGS based AR-67 carboxylate 
(E:D ratio 56:1) premixed with oleic acid at 1:5, v/v (0.5 X) at dose of 5 mg/kg PO 
Expt 175: mice (#631-639) were treated orally with a mixture TPGS based AR-67 
carboxylate (E:D ratio 56:1)  premixed with oleic acid at 2:1, v/v ratios (5X)  at dose of 
5mg/kg PO. 
Groups of three mice were sampled at 15 min, 30 min, 45 min, 1 h, 1.5 h, 3 h, 6 h, 8 h, 12 
h and 24 h. Each animal was sampled at three different time points.  
Blood (about 50 µL) was collected from the saphenous vein with heparinized hematocrit 
tubes and transferred into heparinized microcentrifuge tubes. Plasma (about 25 uL) was 
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collected by centrifugation of blood and then extracted 1:4 (v/v) with cold MeOH (100 
uL,-80oC). Samples were kept at -80oC until analysis.  
 
HPLC analysis  
 
Before injection into the HPLC, samples were diluted with an equal volume of mobile 
phase buffer (40 µL:40 µL) and were analyzed.  
 
Sequence name: 20AC-102008-Mouse PK expt 174 & 175.seq 
 
Method: 20AC-070307-Mouse plasma curve.met    
Data were exported and saved in Leggas Lab/Experimental Results/DB-67 Oral PK / 
Mouse oral PK folder. Areas under the curve were estimated with Prism v5 and 
Winnonlin v5.2 (sparse sampling noncompartmental analysis). Plasma concentration 
versus time plots were made with Prism v5. 
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Results 
1. Prism files: ..\Prism files\Mouse PK Expt 174 & 175.pzf 
2. Winnonlin files: ..\Winnonlin files\Mouse PK Expt 174 & 175.wsp 
3. Tables 
Table 1. Summary of basic pharmacokinetic parameters 
Expt #174 5 mg/kg Lactone (TPGS 56:1) PO:Winnonlin Oleic acid 0.5x 
AUC (ng·h/mL) Mean SE Tmax (h) Median Cmax (ng/mL) Mean (SE) 
Total  198.24 11.32 Total 0.75 Total 85.92 (8.34) 
              
Expt #175 
AUC (ng·h/mL) Mean  SE Tmax (h) Median Cmax (ng/mL) Mean (SE) 
Total 158.54 11.41 Total 0.50 Total 42.03 (12.16)
 
4. Figures 
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File path: \\Pharm\public\PS\Leggas Lab\Experimental Results\DB67 Oral 
PK\Mouse oral PK\Prism files\ Mouse PK expt 174 & 175. 
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Raw data 
Filter  
>=1 
Filter  
>=2.5 Filter 
Expt 
Time  
(h) ID 
Carb.  
(ng/ml) 
Lact. 
(ng/ml) 
Tot. 
(ng/ml) 
Carb. 
(ng/ml) 
Lact. 
(ng/ml) Total 
174 0.25 621 3.03 46.81 49.84 3.03 46.81 49.84 
174 0.25 622 5.33 80.5 85.83 5.33 80.5 85.83 
174 0.25 623 1.48 18.63 20.11 1.48 18.63 20.11 
174 0.5 624 5.41 73.93 79.34 5.41 73.93 79.34 
174 0.5 625 6.89 91.34 98.23 6.89 91.34 98.23 
174 0.5 626 8.45 53.47 61.92 8.45 53.47 61.92 
174 0.75 627 8.2 89.64 97.84 8.2 89.64 97.84 
174 0.75 628 8.28 81.8 90.08 8.28 81.8 90.08 
174 0.75 629 7.13 62.72 69.85 7.13 62.72 69.85 
174 1 621 6.29 66.6 72.89 6.29 66.6 72.89 
174 1 622 9.04 62.29 71.33 9.04 62.29 71.33 
174 1.5 624 5.06 49 54.06 5.06 49 54.06 
174 1.5 625 6.35 59.97 66.32 6.35 59.97 66.32 
174 1.5 626 4.84 43.87 48.71 4.84 43.87 48.71 
174 3 627 4.53 12.03 16.56 4.53 12.03 16.56 
174 3 628 0.65 7.71 8.36 0.5 7.71 8.21 
174 3 629 1.4 12.26 13.66 1.4 12.26 13.66 
174 6 624 0.34 3.93 4.27 0.5 3.93 4.43 
174 6 625 0.56 7.35 7.91 0.5 7.35 7.85 
174 6 626 0.52 5.91 6.43 0.5 5.91 6.41 
174 8 627 1.71 0.17 1.88 1.71 1.25 2.96 
174 8 628 0.24 2.53 2.77 0.5 2.53 3.03 
174 8 629 0.51 4.77 5.28 0.5 4.77 5.27 
174 12 621 0.27 3.67 3.94 0.5 3.67 4.17 
174 12 622 0.16 0.82 0.98 0.5 1.25 1.75 
174 12 623 0 4.14 4.14 0 4.14 4.14 
174 24 624 5.13 0.21 5.34 5.13 1.25 6.38 
174 24 625 0 0.4 0.4 0 1.25 1.25 
174 24 626 7.24 0.59 7.83 7.24 1.25 8.49 
175 0.25 631 0.64 7.65 8.29 0.5 7.65 8.15 
175 0.25 632 0.98 15.13 16.11 0.5 15.13 15.63 
175 0.25 633 0.62 7.65 8.27 0.5 7.65 8.15 
175 0.5 634 5.18 57.45 62.63 5.18 57.45 62.63 
175 0.5 635 2.01 18.51 20.52 2.01 18.51 20.52 
175 0.5 636 3.39 39.55 42.94 3.39 39.55 42.94 
175 0.75 637 1.32 15.66 16.98 1.32 15.66 16.98 
175 0.75 638 2.48 27.8 30.28 2.48 27.8 30.28 
175 0.75 639 1.64 15.72 17.36 1.64 15.72 17.36 
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175 1 631 3.02 21.03 24.05 3.02 21.03 24.05 
175 1 632 2.15 22.93 25.08 2.15 22.93 25.08 
175 1 633 3.06 23.18 26.24 3.06 23.18 26.24 
175 1.5 634 2.61 17.74 20.35 2.61 17.74 20.35 
175 1.5 635 3.91 30.47 34.38 3.91 30.47 34.38 
175 1.5 636 3.02 29.38 32.4 3.02 29.38 32.4 
175 3 637 0 9.42 9.43 0 9.42 9.42 
175 3 638 0.62 6.66 7.28 0.5 6.66 7.16 
175 3 639 1.29 14.77 16.06 1.29 14.77 16.06 
175 6 634 1.95 14.26 16.21 1.95 14.26 16.21 
175 6 635 0.84 5.42 6.26 0.5 5.42 5.92 
175 6 636 1.15 10.72 11.87 1.15 10.72 11.87 
175 8 637 0.72 9.09 9.81 0.5 9.09 9.59 
175 8 638 0.46 5.61 6.07 0.5 5.61 6.11 
175 8 639 0.95 8.96 9.91 0.5 8.96 9.46 
175 12 631 0.76 10.96 11.72 0.5 10.96 11.46 
175 12 632 1.06 13.54 14.6 1.06 13.54 14.6 
175 12 633 0.57 6.83 7.4 0.5 6.83 7.33 
175 24 634 0 0.97 0.97 0 1.25 1.25 
175 24 635 0.36 2.89 3.25 0.5 2.89 3.39 
175 24 636 0 2.22 2.22 0 1.25 1.25 
Note: LLOQ of carboxylate is 1.0 ng/mL; LLOQ of lactone  is 2.5 ng/mL; if the 
concentration is larger than 0 and smaller than LLOQ, half of LLOQ value was 
taken.    
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DEPARTMENT OF PHARMACEUTICAL SCIENCES, COLLEGE OF 
PHARMACY 
UNIVERSITY OF KENTUCKY (LEGGAS LAB) 
REPORT ON THE EFFECT OF OLEATE TO TPGS RATIO ON THE 
ABSORPTION OF TPGS BASED AR-67 CARBOXYLATE IN MICE  
 
(PERFORMED 12/9/2008-12/10/2008) 
 
COMPARISON OF 1:4 AND 1:7 OLEATE TO TPGS RATIOS ON THE 
ABSORPTION OF TPGS-BASED AR-67 CARBOXYLATE (E:D~50:1) IN 
FEMALE C57BL/6 MICE 
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Objective 
Long chain unsaturated free fatty acids facilitate the lymphatic transport of 
lipophilic drugs administered by the oral route. Prior experiments that assessed 
lymphatic transport were done by either by pretreating animals with oleic acid 
before administration of AR-67 or mixing oleic acid with AR-67 formulation 
right before dosing. We thought efficient mixing will be a problem when animals 
were pretreated with the oil before AR-67 administration; hence the reason for 
premixing oleic acid and AR-67 formulation prior to dosing. However, the latter 
approach was observed to decrease the pH drastically because of the oleic acid. 
Thus a series of studies were conducted to incorporate oleic acid in the 
formulation as the oleate. The purpose of the current mouse PK studies was to 
compare the absorption of AR-67 carboxylate formulations containing 1:4 and 1:7 
oleate to TPGS ratios.  
 
Expt 176: Study the absorption of 1:4 oleate:TPGS ratio (AR-67 carboxylate, 
2.5ml/kg, 5 mg/kg) PO. [Formulation TX17-16-3] 
 
Expt 177: Study the absorption of 1:7 oleate:TPGS ratio (AR-67 
carboxylate,2.5ml/kg, 5 mg/kg) PO. [Formulation TX17-15-2] 
 
N.B. The formulations were kept frozen at-20 for a week before use and were 
thawed overnight. 
 
Method 
Formulation  
The formulations were prepared at 2 mg/ml by Dr. Xiang on --- (as the 
carboxylate)  
Animal treatment and sample processing 
(Refer to \\Pharm\public\PS\Leggas Lab\Experimental Results\DB67 Oral 
PK\Mouse oral PK\sampling time for details) 
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Expt 176, Mice (#641-# 649, n=9, three per time point) were dosed with 1:4 ratio 
of oleate to TPGS (5 mg/kg PO, 2.5 ml/kg). 
Expt 177, Mice (#651-# 659, n=9, three per time point) were dosed with 1:7 ratio 
of oleate to TPGS (5 mg/kg PO, 2.5 ml/kg). 
Groups of three mice were sampled at 15 min, 30 min, 45 min, 1 h, 1.5 h, 3 h, 6 h, 
8 h, 12 h and 24 h. Each animal was sampled at 3-4 different time points.  
Blood (about 50 uL) was collected from the saphenous vein with heparinized 
hematocrit tubes and transferred into heparinized microcentrifuge tubes. Plasma 
(about 25 uL) was collected by centrifugation of blood and then extracted 1:4 
(v/v) with cold MeOH (100 uL,-80oC). Samples were kept at -80oC until 
analysis.  
 
HPLC analysis 
Before injection into the HPLC, samples were diluted with an equal volume of 
mobile phase buffer (40 µL:40 µL) and were analyzed.  
Sequence name:  
20AC-121208-Mouse Plasma PK Expt 176 & 177.seq 
Method:  
20AC-082208-mousecurve.met 
Data were exported and saved in Leggas Lab/Experimental Results/DB-67 Oral 
PK / Mouse oral PK folder. Areas under the curve were estimated with Prism v5 
and Winnonlin v5.2 (sparse sampling noncompartmental analysis). Plasma 
concentration versus time plots were made with Prism v5. 
Results 
1. Prism files:..\Prism files\Mouse PK 5mg PO exps 176 & 177.pzf 
2. Winnonlin files: ..\Winnonlin files\Mouse PK Expt 176.wsp 
                             ..\Winnonlin files\Mouse PK Expt 177.wsp
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3. Tables 
Table 1. Summary of basic pharmacokinetics parameters  
Expt #176 5.0 mg/kg Carboxylate PO Oleate:TPGS 1:4,  
AUC(ng·h/mL) Mean SE Tmax (h) Median Cmax (ng/mL) Mean 
Carb 22.81 Carb 1.00 Carb 5.55 
Lactone 267.90 Lactone 1.00 Lactone 83.08 
Total  285.00 15.90 Total 1.00 Total 88.62 
  
Expt #177 5.0 mg/kg Carboxylate PO Oleate:TPGS 1:7 
AUC (ng·h/mL) Mean SE Tmax (h) Median Cmax (ng/mL) Mean 
Carb 19.46 Carb 1.50 Carb 6.80 
Lactone 250.50 Lactone 1.50 Lactone 83.58 
Total 269.20 56.30 Total 1.50 Total 90.38 
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4. Figures 
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File path: \\Pharm\public\PS\Leggas Lab\Experimental Results\DB67 Oral 
PK\Mouse oral PK\Prism files\ Mouse PK expt 176 & 177. 
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Appendix 
Raw Data 
Sample ID Expt Mouse # 
Time  
(h) 
Carb. 
 (ng/ml) 
Lact. 
(ng/ml) 
Total 
(ng/ml) 
641-15min 176 641 0.25 1.73 27.19 28.92 
642-15min 176 642 0.25 1.18 15.15 16.33 
643-15min 176 643 0.25 2.08 28.17 30.25 
644-30min 176 644 0.5 3.17 41.18 44.35 
645-30min 176 645 0.5 2.16 35.33 37.49 
646-30min 176 646 0.5 1.64 22.95 24.59 
647-45 min 176 647 0.75 3.89 61.04 64.93 
648-45 min 176 648 0.75 1.72 25.71 27.43 
649-45 min 176 649 0.75 3.04 44.97 48.01 
641-1h 176 641 1 3.94 55.22 59.16 
642-1h 176 642 1 7.56 105.14 112.7 
643-1h 176 643 1 5.14 88.87 94.01 
644-1.5h 176 644 1.5 5.19 76.53 81.72 
645-1.5h 176 645 1.5 4 63.01 67.01 
646-1.5h 176 646 1.5 3.11 43.25 46.36 
644-3h 176 644 3 3.9 45.86 49.76 
645-3h 176 645 3 3.4 54.41 57.81 
646-3h 176 646 3 3.4 44.42 47.82 
641-6h 176 641 6 0.77 8.32 8.32 
642-6h 176 642 6 0.72 7.19 7.19 
643-6h 176 643 6 0.83 7.04 7.04 
647-8 h 176 647 8 0.53 5.22 5.22 
648-8 h 176 648 8 0.73 7.36 7.36 
649-8 h 176 649 8 1.41 5.16 6.57 
647-12 h 176 647 12 0.48 2.39 2.87 
648-12 h 176 648 12 0.53 5.22 5.75 
649-12 h 176 649 12 0.41 3.31 3.72 
641-24h 176 641 24 0.36 1.14 1.5 
642-24h 176 642 24 0.4 0.74 1.14 
643-24h 176 643 24 0.21 0.7 0.91 
651-15min 177 651 0.25 0.91 13.16 14.07 
652-15min 177 652 0.25 1.85 24.77 26.62 
653-15min 177 653 0.25 1.48 17.22 18.7 
654-30min 177 654 0.5 1.73 24.03 25.76 
655-30min 177 655 0.5 3.07 25.06 28.13 
656-30min 177 656 0.5 4.25 54.3 58.55 
657-45 min 177 657 0.75 4.43 68.12 72.55 
658-45 min 177 658 0.75 2.81 35.58 38.39 
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659-45 min 177 659 0.75 7.39 100.05 107.44 
651-1h 177 651 1 3.94 68.12 72.06 
652-1h 177 652 1 4.09 66.85 70.94 
653-1h 177 653 1 4.69 72.24 76.93 
654-1.5h 177 654 1.5 8.79 119.61 128.4 
655-1.5h 177 655 1.5 5.69 66.22 71.91 
656-1.5h 177 656 1.5 5.91 64.91 70.82 
654-3h 177 654 3 5.29 70.3 75.59 
655-3h 177 655 3 1.84 19.55 21.39 
656-3h 177 656 3 2.65 28 30.65 
651-6h 177 651 6 1.04 15.47 16.51 
652-6h 177 652 6 0.57 6.09 6.66 
653-6h 177 653 6 0.57 4.2 4.77 
657-8 h 177 657 8 0.45 3.8 4.25 
658-8 h 177 658 8 0.46 0.17 0.63 
659-8 h 177 659 8 0.45 2.83 3.28 
657-12 h 177 657 12 0.74 6.78 7.52 
658-12 h 177 658 12 0.38 2.34 2.72 
659-12 h 177 659 12 0.31 1.86 2.17 
651-24h 177 651 24 0.52 4.28 4.8 
652-24h 177 652 24 0.21 0.65 0.86 
653-24h 177 653 24 0.42 0.9 1.32 
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DEPARTMENT OF PHARMACEUTICAL SCIENCES, COLLEGE OF 
PHARMACY 
UNIVERSITY OF KENTUCKY (LEGGAS LAB) 
REPORT ON THE BIOAVAILABILITY OF AMORPHOUS FORMULATIONS 
PMFD 576/1 AND PMFD 576/2 SUSPENDED IN DDH2O IN MICE 
 
(PERFORMED 1/17/2009-1/18/2009) 
 
THE BIOAVAILABILITY OF AMORPHOUS FORMULATIONS PMFD 576/1 
AND PMFD 576/2 DISSOLVED IN DDH2O IN FEMALE C57BL/6 MICE 
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Objective 
The oral bioavailability of 2 amorphous formulations PMFD 576/1 and PMFD 576/2 
provided by Arno was determined.  
PMFD 576/1: PVP K30: Tween-80: AR-67 (71:6:23), spray dry power 
PMFD 576/2: PVP K90: Tween-80: AR-67 (71:6:23), spray dry power 
The purpose of the current mouse PK studies was to determine the bioavailability of 
amorphous formulations PMFD 576/1 and PMFD 576/2 suspended in water. 
Expt  178: Study the oral bioavailability of PMFD 576/1 in ddH2O (pH 4.85) 
Expt 179: Study the oral bioavailability of PMFD 576/2 in ddH2O (pH 6.00) 
The amorphous powders were kept at -20 oC. The dosing suspensions were prepared 
freshly at 2 mg/mL AR-67 andwere used within 1 hour after preparation. They were 
vortexed vigoursly before gavage.  
 
Method 
Formulation  
The powder was weighed by Dr. Xiang and certain volume of ddH2O was added to make 
2 mg/mL AR-67 suspension.  
 
Animal treatment and sample processing 
(Refer to \\Pharm\public\PS\Leggas Lab\Experimental Results\DB67 Oral PK\Mouse 
oral PK\sampling time for details) 
Expt 178, Mice #661-# 669 were dosed with PMFD 576/1 in ddH2O (pH 4.85) at 5 
mg/kg PO. 
Expt 179, Mice #671-# 679 were dosed with PMFD 576/2 in ddH2O (pH 1.2) at 5 mg/kg 
PO. 
Groups of three mice were sampled at 15 min, 30 min, 45 min, 1 h, 1.5 h, 3 h, 6 h, 8 h, 12 
h and 24h. Each animal was sampled at 3-4 different time points.  
At each sampling time point, blood samples of about 50 µL were collected from the 
saphenous vein with heparinized hematocrit tubes and transferred into heparinized 
microcentrifuge tubes. Plasma of 25 µL was collected by centrifugation of blood and then 
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extracted 1:4 (v/v) with cold MeOH (100 µL,-80oC). Samples were kept at -80oC until 
analysis.  
 
HPLC analysis  
 
Before injection into the HPLC, samples were diluted with an equal volume of mobile 
phase buffer (40 µL:40 µL) and were analyzed.  
 
Sequence name:  
20AC-121908-Mouse PK expt 178 & 179 real.seq 
Method:  
 
20AC-122408-Mouse curve.seq 
 
Data were exported and saved in Leggas Lab/Experimental Results/DB-67 Oral PK / 
Mouse oral PK folder. Areas under the curve were estimated with Prism v5 and 
WinNonlin v5.2 (sparse sampling noncompartmental analysis). Plasma concentration 
versus time plots were made with Prism v5. 
 
Results 
1. Prism file: ..\Prism files\Mouse PK 5mg PO exps 178 & 179.pzf 
2. WinNonlin file: ..\Winnonlin files\Mouse PK Expt 178 & 179.wsp
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3. Tables 
 
Table 1. Summary of basic pharmacokinetic parameters 
Expt #178 5.0 mg/kg lactone PO amorphous PMDF 576/1 dissolved in ddH2O 
AUC 
(ng·/mL) Mean SE Tmax (h) Median Cmax (ng/mL) Mean 
Carb 23.89   Carb 1.50 Carb 10.32 
Lactone 392.85   Lactone 1.50 Lactone 183.31 
Total  416.14 40.17 Total 1.50 Total 193.62 
Expt #179 5.0 mg/kg lactone PO amorphous PMFD 576/2  dissolved in ddH2O 
AUC 
(ng·/mL) Mean SE Tmax (h) Median Cmax (ng/mL) Mean 
Carb 16.35   Carb 1.50 Carb 4.59 
Lactone 312.54   Lactone 1.50 Lactone 98.46 
Total  326.60 82.12 Total 1.50 Total 103.08 
 
 
4. Figures 
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Raw Data 
Filter  
>=1 
Filter 
>=2.5 Filter 
Expt # Mouse # Time (h) 
Carb.  
(ng/ml) 
 
Lact. 
(ng/ml) 
Carb. 
(ng/ml) 
Lact. 
(ng/ml) 
Total 
(ng/ml)
178 661 0.25 2.58 60.06 2.58 60.06 62.64 
178 662 0.25 0.48 22.23 0.5 22.23 22.73 
178 663 0.25 0.14 12.59 0.5 12.59 13.09 
178 664 0.5 5.62 123.16 5.62 123.16 128.78 
178 665 0.5 4.09 93.9 4.09 93.9 97.99 
178 666 0.5 1.89 58.94 1.89 58.94 60.83 
178 667 0.75 11.02 162.62 11.02 162.62 173.64 
178 668 0.75 10.23 140.41 10.23 140.41 150.64 
178 669 0.75 6.62 88.97 6.62 88.97 95.59 
178 661 1 9.3 156.14 9.3 156.14 165.44 
178 662 1 7.17 152.62 7.17 152.62 159.79 
178 663 1 1.16 29.78 1.16 29.78 30.94 
178 664 1.5 18.04 249.25 18.04 249.25 267.29 
178 665 1.5 15.62 314.94 15.62 314.94 330.56 
178 666 1.5 6.59 150.74 6.59 150.74 157.33 
178 664 3 2.72 53.17 2.72 53.17 55.89 
178 665 3 3.9 68.27 3.9 68.27 72.17 
178 666 3 4.3 74.91 4.3 74.91 79.21 
178 661 6 0 4.57 0 4.57 4.57 
178 662 6 0.39 11.88 0.5 11.88 12.38 
178 663 6 0.2 7.78 0.5 7.78 8.28 
178 667 8 0 2.46 0 1.25 1.25 
178 668 8 0 3.16 0 3.16 3.16 
178 669 8 0 2.86 0 2.86 2.86 
178 667 12 0 1.12 0 1.25 1.25 
178 668 12 0 2.2 0 1.25 1.25 
178 669 12 0.92 19.5 0.5 19.5 20 
178 661 24 0 0.29 0 1.25 1.25 
178 662 24 0 0.67 0 1.25 1.25 
178 663 24 0 4.18 0 4.18 4.18 
179 671 0.25 2.66 61.55 2.66 61.55 64.21 
179 672 0.25 0.9 26.83 0.5 26.83 27.33 
179 673 0.25 1.39 38.05 1.39 38.05 39.44 
179 674 0.5 2.53 68.32 2.53 68.32 70.85 
179 675 0.5 2.55 72.47 2.55 72.47 75.02 
179 676 0.5 2 60.37 2 60.37 62.37 
179 677 0.75 3.09 56.12 3.09 56.12 59.21 
179 678 0.75 3.7 54.04 3.7 54.04 57.74 
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179 679 0.75 3.19 47.77 3.19 47.77 50.96 
179 671 1 5.97 107.78 5.97 107.78 113.75 
179 672 1 6.47 138.74 6.47 138.74 145.21 
179 673 1 3.7 89.36 3.7 89.36 93.06 
179 674 1.5 8.3 183.43 8.3 183.43 191.73 
179 675 1.5 5.95 131.51 5.95 131.51 137.46 
179 676 1.5 3.66 69.1 3.66 69.1 72.76 
179 674 3 8.97 138.46 8.97 138.46 147.43 
179 675 3 2.35 37.01 2.35 37.01 39.36 
179 676 3 4.14 47.39 4.14 47.39 51.53 
179 671 6 0.12 7.32 0.5 7.32 7.82 
179 672 6 0 6.68 0 6.68 6.68 
179 673 6 0 3.67 0 3.67 3.67 
179 677 8 0 2.73 0 2.73 2.73 
179 678 8 0 6.28 0 6.28 6.28 
179 679 8 0 2.04 0 1.25 1.25 
179 677 12 0 2.25 0 1.25 1.25 
179 678 12 0 2.85 0 2.85 2.85 
179 679 12 0 0.65 0 1.25 1.25 
179 671 24 0 0.49 0 1.25 1.25 
179 672 24 0 7.74 0 7.74 7.74 
179 673 24 0 0.58 0 1.25 1.25 
Note: LLOQ of carboxylate is 1.0 ng/mL; LLOQ of lactone  is 2.5 ng/mL; if the 
concentration is larger than 0 and smaller than LLOQ, half of LLOQ value was 
taken.    
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DEPARTMENT OF PHARMACEUTICAL SCIENCES, COLLEGE OF 
PHARMACY 
UNIVERSITY OF KENTUCKY (LEGGAS LAB) 
REPORT ON THE EFFECTS OF OLEIC ACID TO E-TPGS RATIOS ON 
ABSORPTION OF TPGS BASED AR-67 CARBOXYLATE IN MICE 
 
(PERFORMED 12/22/2008-12/23/2008) 
 
COMPARISON OF 1:7 AND 1:10 OLEATE TO TPGS RATIOS ON THE 
ABSORPTION OF TPGS-BASED AR-67 CARBOXYLATE (E:D~50:1) IN 
FEMALE C57BL/6 MICE 
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Objective 
Long chain unsaturated free fatty acids facilitate the lymphatic transport of lipophilic 
drugs administered orally. Previous experiments that assessed lymphatic transport were 
done by either pre-treating animals with oleic acid or mixing oleic acid with AR-67 
formulation right before dosing. We thought efficient mixing will be a problem when 
animals were pretreated with the oil before AR-67 administration; hence the reason for 
premixing oleic acid and AR-67 formulation prior to dosing. However, the latter 
approach was observed to decrease the pH drastically because of the oleic acid. Thus a 
series of studies were conducted to.  
a) Buffer the formulation to prevent pH change due to oleic acid. 
b) Incorporate oleic acid in the formulation as the oleate. 
The former approach was abandoned and the latter was studied further. The purpose of 
the current mouse PK studies was to compare the absorption of AR-67 carboxylate 
formulations containing 1:7 and 1:10 oleate to TPGS ratios.  
 
Expt 180: Study the absorption of oleate:TPGS (1:7) based AR-67 carboxylatemg/kg, 
2.5ml/kg) PO. [Formulation TX17-16-2] 
 
Expt 181: Study the absorption of oleate:TPGS (1:10) based AR-67 carboxylate (5 
mg/kg, 2.5ml/kg) PO [Formulation TX17-15-1] 
N.B. The formulations were kept frozen at -20oC for a week before use and were thawed 
overnight. 
Method 
Formulation  
The formulations were prepared at 2 mg/mL by Dr. Xiang on --- (as the carboxylate)  
Animal treatment and sample processing 
(Refer to \\Pharm\public\PS\Leggas Lab\Experimental Results\DB67 Oral PK\Mouse 
oral PK\sampling time for details) 
Expt 180: Mice (#681-# 689, n=9) were dosed with oleic acid:TPGS (1:7) based AR-67 
carboxylate at 5 mg/kg PO 
 415 
 
Expt 181, Mice (#691-# 699, n=9) were dosed with oleic acid:TPGS (1:10) based AR-67 
carboxylate at 5 mg/kg PO 
Groups of three mice were sampled at 15 min, 30 min, 45 min, 1 h, 1.5 h, 3 h, 6 h, 8 h 
and 12 h, 18 h, 24h. Each animal was sampled at 3-4 different time points.  
The blood sample of about 50 µL was collected from the saphenous vein with 
heparinized hematocrit tubes and transferred into heparinized microcentrifuge tubes. 
Plasma of 25 µL was collected by centrifugation of blood and then extracted 1:4 (v/v) 
with cold MeOH (100 uL,-80oC). Samples were kept at -80oC until analysis.  
 
 
HPLC analysis 
 
Before injection into the HPLC, samples were diluted with an equal volume of mobile 
phase buffer (40 µL:40 µL) and were analyzed.  
Sequence name:  
20AC-122708-Mouse Exp 180 & 181.seq 
   20AC-122408-mouse curve & Exp 180 & 181.seq 
Method:  
20AC-122408-mouse curve.met 
 
Data were exported and saved in Leggas Lab/Experimental Results/DB-67 Oral PK / 
Mouse oral PK folder. Areas under the curve were estimated with Prism v5 and 
WinNonlin v5.2 (sparse sampling noncompartmental analysis). Plasma concentration 
versus time plots were made with Prism v5. 
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Results 
1. Prism file:..\Prism files\Mouse PK 5mg PO exps 180 & 181.pzf 
2. WinNonlin file: ..\Winnonlin files\Mouse PK Expt 180 & 181.wsp 
3. Tables  
 
 
 
 
 
 
 
 
 
 
Table 1. Summary of basic pharmacokinetic 
parameters   
Expt #180 5.0 mg/kg Carboxylate PO  Oleate : TPGS 1:7 
AUC (ng·h/mL) Mean SE Tmax (h) Median 
Cmax 
(ng/mL) Mean 
Carb 12.22 Carb 1.50 Carb 5.16 
Lactone 229.40 Lactone 1.50 Lactone 87.86 
Total 238.74 21.69 Total 1.50 Total 93.02 
              
Expt #181 5.0 mg/kg Carboxylate PO Oleate :TPGS 1:10   
AUC (ng·h/mL) Mean SE Tmax (h) Median 
Cmax  
(ng/mL) Mean 
Carb 16.10   Carb 1.50 Carb 7.89 
Lactone 255.00   Lactone 1.50 Lactone 105.10
Total 270.44 18.62 Total 1.50 Total 112.90
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4. Figures 
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File path: \\Pharm\public\PS\Leggas Lab\Experimental Results\DB67 Oral 
PK\Mouse oral PK\Prism files\ Mouse PK expt 180 & 181. 
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Raw Data 
Filter >=1 
Filter 
>=2.5 Filter 
Expt 
Mouse 
# 
Time 
(h) 
AR-67 
Carboxylate
AR-67 
Lactone 
AR-67 
Carboxylate
AR-67 
Lactone total 
180 681 0.25 1.54 33.36 1.54 33.36 34.9 
180 682 0.25 0.66 11.42 0.5 11.42 11.92 
180 683 0.25 0.87 20.03 0.5 20.03 20.53 
180 684 0.5 3 63.12 3 63.12 66.12 
180 685 0.5 2.84 58.98 2.84 58.98 61.82 
180 686 0.5 2.79 63.7 2.79 63.7 66.49 
180 687 0.75 5.47 86.23 5.47 86.23 91.7 
180 688 0.75 8.14 67.35 8.14 67.35 75.49 
180 689 0.75 1.04 20.76 1.04 20.76 21.8 
180 681 1 5 76.24 5 76.24 81.24 
180 682 1 4.88 90.26 4.88 90.26 95.14 
180 683 1 3.79 60.36 3.79 60.36 64.15 
180 684 1.5 3.91 63.64 3.91 63.64 67.55 
180 685 1.5 5.35 89.69 5.35 89.69 95.04 
180 686 1.5 6.21 110.25 6.21 110.25 116.46 
180 684 3 1.01 18.63 1.01 18.63 19.64 
180 685 3 1.56 27.19 1.56 27.19 28.75 
180 686 3 1.73 26.96 1.73 26.96 28.69 
180 681 6 0 2.71 0 2.71 2.71 
180 682 6 0 4.41 0 4.41 4.41 
180 683 6 0 5.64 0 5.64 5.64 
180 687 8 0 2.27 0 1.25 1.25 
180 688 8 0 2.78 0 2.78 2.78 
180 689 8 0 2.19 0 1.25 1.25 
180 687 12 0 3.34 0 3.34 3.34 
180 688 12 0 3.93 0 3.93 3.93 
180 689 12 0 3.16 0 3.16 3.16 
180 681 24 0 0.34 0 1.25 1.25 
180 682 24 0 3.06 0 3.06 3.06 
180 683 24 0 0.23 0 1.25 1.25 
181 691 0.25 0.41 11.14 0.5 11.14 11.64 
181 692 0.25 0.82 22.25 0.5 22.25 22.75 
181 693 0.25 1.51 25.26 1.51 25.26 26.77 
181 694 0.5 7.4 150.19 7.4 150.19 157.59 
181 695 0.5 4.45 73.54 4.45 73.54 77.99 
181 696 0.5 1.92 33.73 1.92 33.73 35.65 
181 697 0.75 8.77 126.7 8.77 126.7 135.47 
181 698 0.75 8.73 113.27 8.73 113.27 122 
181 699 0.75 6.16 75.18 6.16 75.18 81.34 
181 691 1 5.73 84.01 5.73 84.01 89.74 
181 692 1 7.44 83.49 7.44 83.49 90.93 
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181 693 1 8.02 91.58 8.02 91.58 99.6 
181 694 1.5 7.7 118.98 7.7 118.98 126.68 
181 695 1.5 5.44 83.62 5.44 83.62 89.06 
181 696 1.5 5.54 86.05 5.54 86.05 91.59 
181 694 3 1.47 24.69 1.47 24.69 26.16 
181 695 3 1.57 22.79 1.57 22.79 24.36 
181 696 3 2.11 33.64 2.11 33.64 35.75 
181 691 6 0 4.26 0 4.26 4.26 
181 692 6 0 4.87 0 4.87 4.87 
181 693 6 0 3.99 0 3.99 3.99 
181 697 8 0 1.51 0 1.25 1.25 
181 698 8 0 2.18 0 1.25 1.25 
181 699 8 0 4.43 0 4.43 4.43 
181 697 12 0 1.83 0 1.25 1.25 
181 698 12 0 1.69 0 1.25 1.25 
181 699 12 0 0.14 0 1.25 1.25 
181 691 24 0 0.44 0 1.25 1.25 
181 692 24 0 0.24 0 1.25 1.25 
181 693 24 0 0.22 0 1.25 1.25 
Note: LLOQ of carboxylate is 1.0 ng/mL; LLOQ of lactone is 2.5 ng/mL; if the 
concentration is larger than 0 and smaller than LLOQ, half of LLOQ value was 
taken.    
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DEPARTMENT OF PHARMACEUTICAL SCIENCES, COLLEGE OF 
PHARMACY 
UNIVERSITY OF KENTUCKY (LEGGAS LAB) 
REPORT ON THE BIOAVAILABILITY OF AMORPHOUS 
FORMULATION OF AR-67 (PMFD 576/1) SUSPENDED IN DDH2O AND 
S.G.F.IN MICE 
 
(PERFORMED 1/14/2009-1/15/2009)) 
 
THE BIOAVAILABILITY OF AMORPHOUS FORMULATION OF AR-67 
(PMFD 576/1) SUSPENDED IN DDH2O AND S.G.F. IN FEMALE C57BL/6 
MICE 
 
EXPT # 182 AND EXPT # 183 
 
 
 
 
 
 
421 
 
Objective 
The previous studies have shown that Arno’s amorphous formulation PMFD 576/1 
(suspended in ddH2O) gave the best bioavailability among all the formulations we tested 
so far. The following studies were conducted to assess the reproducibility of our results 
and examine the effect of the suspending medium pH on oral bioavailability of PMFD 
576/1.    
PMFD 576/1: PVP K30: Tween-80: AR-67 (71:6:23), spray-dried power. 
 
Expt 182: Study the oral bioavailability of PMFD 576/1 suspension in ddwater (pH 4.85) 
Expt 183: Study the oral bioavailability of PMFD 576/1 suspension in S.G.F. (pH 1.2) 
 
The amorphous powders were kept at -20oC. The dosing suspensions were prepared 
freshly and used within 1 hour of preparation and vortexed vigorously before gavage.  
 
Method 
Formulation  
The powder was weighed by Dr. Xiang. Water or SGF was added to make 2 mg/mL AR-
67 dosing suspensions.  
 
Animal treatment and sample processing 
(Refer to \\Pharm\public\PS\Leggas Lab\Experimental Results\DB67 Oral PK\Mouse 
oral PK\sampling time for details) 
Expt 182, Mice #701-# 709 were dosed with PMFD 576/1 in H2O (pH 4.85) at 5 mg/kg 
PO. 
Expt 183, Mice #711-# 719 were dosed with PMFD 576/1 in S.G.F. (pH 1.2) at 5 mg/kg 
PO. 
Groups of three mice were sampled at 15 min, 30 min, 45 min, 1 h, 1.5 h, 3 h, 6 h, 8 h, 12 
h, and 24h. Each animal was sampled at 3-4 different time points.  
At each sampling time point, blood samples of about 50 µL were collected from the 
saphenous vein with heparinized hematocrit tubes and transferred into heparinized 
microcentrifuge tubes. Plasma of 25 µL was collected by centrifugation of blood and then 
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extracted 1:4 (v/v) with cold MeOH (100 µL,-80oC). Samples were kept at -80oC until 
analysis.  
 
HPLC analysis 
Before injection into the HPLC, samples were diluted with an equal volume of mobile 
phase buffer (40 µL:40 µL) and were analyzed.  
 
Sequence name:  
20AC-0111609-mouse PK expt 182 & 183.seq 
 
Method:  
20AC-010909-mouse curve.met 
 
Data were exported and saved in Leggas Lab/Experimental Results/DB-67 Oral PK / 
Mouse oral PK folder. Areas under the curve were estimated with Prism v5 and 
WinNonlin v5.2 (sparse sampling noncompartmental analysis). Plasma concentration 
versus time plots were made with Prism v5. 
 
Results 
1. Prism file: ..\Prism files\Mouse PK 5 mg PO exps 182 & 183.pzf 
2. WinNonlin file:  ..\Winnonlin files\Mouse PK Expt 182 & 183.wsp 
3. Tables 
Table 1. Basic pharmacokinetic parameters 
Expt #182 5.0 mg/kg lactone PMFD 576/1 in ddH2O PO, a repeat of Expt 178 
AUC (ng·h/mL) Mean SE Tmax (h) Median Cmax (ng/mL) Mean 
Carb 11.71   Carb 1.00 Carb 13.38 
Lactone 384.83   Lactone 0.25 Lactone 256.62 
Total  397.68 71.22 Total 0.25 Total 270.08 
Expt #183 5.0 mg/kg lactone PO amorphous PMFD 576/1 in SGF   
AUC 
(ng·h/mL) Mean SE Tmax (h) Median Cmax (ng/mL) Mean 
Carb 13.57   Carb 1.00 Carb 9.58 
Lactone 386.12   Lactone 0.25 Lactone 219.23 
Total  401.20 27.72 Total 0.25 Total 227.62 
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4. Figures 
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 Raw Data 
Filter 
 >=1 
Filter 
 >=2.5 Filter 
Expt 
Mouse 
# 
Time 
(h) 
Carb. 
(ng/ml) 
Lact. 
(ng/ml) 
Carb. 
(ng/ml) 
Lact. 
(ng/ml) 
Total 
(ng/ml) 
182 701 0.25 0 8.45 0 8.45 8.45 
182 702 0.25 0 7.36 0 7.36 7.36 
182 703 0.25 3.01 87.14 3.01 87.14 90.15 
182 704 0.5 28.12 576.96 28.12 576.96 605.08 
182 705 0.5 19.31 304.61 19.31 304.61 323.92 
182 706 0.5 4.78 119.37 4.78 119.37 124.15 
182 707 0.75 16.19 353.87 16.19 353.87 370.06 
182 708 0.75 14.39 273.61 14.39 273.61 288 
182 709 0.75 3.47 96.15 3.47 96.15 99.62 
182 701 1 1.32 52.73 1.32 52.73 54.05 
182 702 1 2.29 73.34 2.29 73.34 75.63 
182 703 1 1.32 53.02 1.32 53.02 54.34 
182 704 1.5 9.65 205.11 9.65 205.11 214.76 
182 705 1.5 6.74 178.3 6.74 178.3 185.04 
182 706 1.5 2.87 92.4 2.87 92.4 95.27 
182 704 3 1.78 56.09 1.78 56.09 57.87 
182 705 3 1.19 68.7 1.19 68.7 69.89 
182 706 3 0 35.17 0 35.17 35.17 
182 701 6 0 17.97 0 17.97 17.97 
182 702 6 0 3.99 0 3.99 3.99 
182 703 6 0 7.73 0 7.73 7.73 
182 707 8 0 12.43 0 12.43 12.43 
182 708 8 0 2.31 0 1.25 1.25 
182 709 8 0 3.6 0 3.6 3.6 
182 707 12 0 5 0 5 5 
182 708 12 0 2.46 0 1.25 1.25 
182 709 12 0 2.22 0 1.25 1.25 
182 704 24 0 35.42 0 35.42 35.42 
182 705 24 0 1.35 0 1.25 1.25 
182 706 24 0 3.68 0 3.68 3.68 
183 711 0.25 15.6 425.72 15.6 425.72 441.32 
183 712 0.25 14.44 352.8 14.44 352.8 367.24 
183 713 0.25 2.58 76.43 2.58 76.43 79.01 
183 714 0.5 10.02 194.27 10.02 194.27 204.29 
183 715 0.5 4.13 119.93 4.13 119.93 124.06 
183 716 0.5 10.97 214.28 10.97 214.28 225.25 
183 717 0.75 7.89 170.88 7.89 170.88 178.77 
183 718 0.75 13.99 260.86 13.99 260.86 274.85 
183 719 0.75 6.99 144.66 6.99 144.66 151.65 
183 711 1 5.14 122.18 5.14 122.18 127.32 
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183 712 1 16.24 279.1 16.24 279.1 295.34 
183 713 1 15.98 247.17 15.98 247.17 263.15 
183 714 1.5 4.1 100.64 4.1 100.64 104.74 
183 715 1.5 3.5 92.5 3.5 92.5 96 
183 716 1.5 6.73 132.61 6.73 132.61 139.34 
183 714 3 2.11 59.07 2.11 59.07 61.18 
183 715 3 1.3 48.37 1.3 48.37 49.67 
183 716 3 0.49 37.82 0.5 37.82 38.32 
183 711 6 0 11.79 0 11.79 11.79 
183 712 6 0 11.25 0 11.25 11.25 
183 713 6 0 3.84 0 3.84 3.84 
183 717 8 0 2.95 0 2.95 2.95 
183 718 8 0 5.37 0 5.37 5.37 
183 719 8 0 2.37 0 1.25 1.25 
183 717 12 0 1.74 0 1.25 1.25 
183 718 12 0 3.29 0 3.29 3.29 
183 719 12 0 7.59 0 7.59 7.59 
183 714 24 0 2.74 0 2.74 2.74 
183 715 24 0 17.28 0 17.28 17.28 
183 716 24 0 1.39 0 1.25 1.25 
Note: LLOQ of carboxylate is 1.0 ng/mL; LLOQ of lactone  is 2.5 ng/mL; if the 
concentration is larger than 0 and smaller than LLOQ, half of LLOQ value was 
taken.    
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REPORT ON THE BIOAVAILABILITY OF PVP K30 AND E-TPGS 
BASED AR-67 LACTONE IN MICE 
 
(PERFORMED 1/29/2009) 
 
THE BIOAVAILABILITY OF PVP K30:TWEEN-80:AR-67 (71:6:23) 
AND E-TPGS:TWEEN-80:AR-67 (71:6:23) BASED FORMULATIONS IN 
FEMALE C57BL/6 MICE 
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Objective 
In previous mouse PK studies using Arno’s amorphous formulations, we demonstrated 
that the amorphous formulation PMFD 576/1 had the highest AUC and gave an oral 
bioavailability of 33%. It suggested that keeping the drug in solution at supersaturated 
condition (at least as tested in vitro) might not be as important as keeping it in the 
amorphous form for absorption of AR-67 from GI tract. The amorphous form, and/or the 
combination of PVP K30 with Tween-80 might contribute to higher oral bioavailability 
by preventing crystallization of AR-67. To test this hypothesis, we designed two 
formulations to see the effects of excipients on oral bioavailability of AR-67.  
a) PVP K30: Tween-80: AR-67 (71:6:23) in simulated gastric fluid (pH 1.2): lactone was 
made by spiking stock carboxylate solution with simulated gastric acid fluid containing 
PVP and Tween 80.  
b) E-TPGS: Tween-80: AR-67 (71:6:23) in simulated gastric fluid (pH 1.2): lactone was 
made by mixing stock carboxylate solution with simulated gastric acid fluid containing 
E-TPGS and Tween 80. 
The purpose of the current mouse PK studies was to compare the bioavailability AR-67 
lactone formulations containing PVP K30: Tween-80: AR-67 (71:6:23) and E-TPGS: 
Tween-80: AR-67 (71:6:23).  
 
 Expt 184: Study the absorption of 5 mg/kg PO AR-67 in PVP K30: Tween-80: AR-67 
(71:6:23) in simulated gastric fluid (pH 1.2) 
 
Expt 185: Study the absorption of % mg/kg PO AR-67 in E-TPGS: Tween-80: AR-67 
(71:6:23) in simulated gastric fluid (pH 1.2)  
Excipients were mixed with simulated gastric fluid and stock AR-67 carboxylate solution 
before dosing. Because of lack of stability of TPGS at acidic pH all dosing suspensions 
were freshly prepared used within 1 hour after preparation. Suspension were vortexed 
every time before gavage.  
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Method 
Formulation  
Each solution was prepared by Dr. Xiang, and the final dosing solution was made by 
mixing them as sequence described. 
Sequence Solution Volume (µL) 
1 PVP K30 (or E-TPGS) with Tween-80   250  
2 Simulated gastric fluid (pH 1.2) 2000  
3 Carboxylate (20 mg/kg) 250  
 
Animal treatment and sample processing 
(Refer to \\Pharm\public\PS\Leggas Lab\Experimental Results\DB67 Oral PK\Mouse 
oral PK\sampling time for details) 
Expt 184, Mice (#721-# 729) were dosed with AR-67 in PVP K30: Tween-80: AR-67 
(71:6:23) in SGF (pH 1.2) at 5 mg/kg PO. 
Expt 185, Mice (#731-# 739) were dosed with AR-67 in E-TPGS: Tween-80: AR-67 
(71:6:23) in SGF (pH 1.2) at 5 mg/kg PO. 
Groups of three mice were sampled at 15 min, 30 min, 45 min, 1 h, 1.5 h, 3 h, 6 h, 8 h, 12 
h and 24h. Each animal was sampled at 3-4 different time points.  
At each sampling time point, blood samples of about 50 µL were collected from the 
saphenous vein with heparinized hematocrit tubes and transferred into heparinized 
microcentrifuge tubes. Plasma of 25 µL was collected by centrifugation of blood and then 
extracted 1:4 (v/v) with cold MeOH (100 µL,-80oC). Samples were kept at -80oC until 
analysis.  
HPLC analysis 
 
Before injection into the HPLC, samples were diluted with an equal volume of mobile 
phase buffer (40 µL:40 µL) and were analyzed.  
 
Sequence name:  
20AC-012309-Mouse Plasma PK Expt 184 & 185.seq 
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  20AC-012409-Mouse Plasma PK Expt 184 & 185.seq 
 
Method:  
20AC-010909-mouse curve.met 
Data were exported and saved in Leggas Lab/Experimental Results/AR-67 Oral PK / 
Mouse oral PK folder. Areas under the curve were estimated with Prism v5 and 
WinNonlin v5.2 (sparse sampling noncompartmental analysis). Plasma concentration 
versus time plots were made with Prism v5. 
 
Results 
1. Prism file: ..\Prism files\Mouse PK 5 mg PO exps 184 & 185.pzf 
2. WinNonlin file:  ..\Winnonlin files\Mouse PK Expt 184 & 185.wsp 
3. Tables 
 
 
 
Table 1. Summary of basic pharmacokinetic parameters 
Expt #184 5.0 mg/kg lactone PO (PVP K30:Tween-80:AR-67 (71:6:23) in SGF pH 1.2)
AUC (ng·h/mL) Mean SE Tmax (h) Median Cmax (ng/mL) Mean 
Carb 6.94 1.33 Carb 0.75 Carb 6.30 
Lactone 366.49 23.36 Lactone 0.75 Lactone 152.4 
Total  373.92 24.31 Total 0.75 Total 158.7 
 
              
Expt #185 5.0 mg/kg lactone PO (E-TPGS:Tween-80:AR-67 (71:6:23) in SGF pH 1.2) 
AUC  Mean  SE Tmax (h) Median Cmax (ng/mL) Mean 
(ng·h/mL) 
Carb 6.30 1.69 Carb 1 Carb 6.24 
Lactone 322.01 23.18 Lactone 0.5 Lactone 148.6 
Total 330.25 24.77 Total 0.5 Total 153.8 
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 Raw Data 
Filter >=1 Filter >=2.5 Filter 
Expt Mouse # 
Time 
(h) 
Carb. 
(ng/ml) 
Lact. 
(ng/ml) 
Carb. 
(ng/ml) 
Lact. 
(ng/ml) 
Total 
(ng/ml)
184 721 0.25 0 5.49 0 5.49 5.49 
184 722 0.25 0 54.46 0 54.46 54.46 
184 723 0.25 1.82 118.96 1.82 118.96 120.78 
184 724 0.5 13.04 262.16 13.04 262.16 275.2 
184 725 0.5 1.95 73.47 1.95 73.47 75.42 
184 726 0.5 2.38 99.02 2.38 99.02 101.4 
184 727 0.75 6.38 167.77 6.38 167.77 174.15 
184 728 0.75 11.2 220.57 11.2 220.57 231.77 
184 729 0.75 1.33 68.86 1.33 68.86 70.19 
184 721 1 0 26.63 0 26.63 26.63 
184 722 1 2.04 74.99 2.04 74.99 77.03 
184 723 1 2.39 72.28 2.39 72.28 74.67 
184 724 1.5 3.14 102.94 3.14 102.94 106.08 
184 725 1.5 1.89 75.12 1.89 75.12 77.01 
184 726 1.5 3.84 135.67 3.84 135.67 139.51 
184 724 3 0 40.77 0 40.77 40.77 
184 725 3 0.39 45.99 0.5 45.99 46.49 
184 726 3 0.46 45.95 0.5 45.95 46.45 
184 721 6 0 17.69 0 17.69 17.69 
184 722 6 0 4.16 0 4.16 4.16 
184 723 6 0 8.47 0 8.47 8.47 
184 727 8 0 2.32 0 1.25 1.25 
184 728 8 0 4.18 0 4.18 4.18 
184 729 8 0 3.46 0 3.46 3.46 
184 727 12 0 7.82 0 7.82 7.82 
184 728 12 0 1.89 0 1.25 1.25 
184 729 12 0 16.81 0 16.81 16.81 
184 724 24 0 1.27 0 1.25 1.25 
184 725 24 0 0.92 0 1.25 1.25 
184 726 24 0 0.7 0 1.25 1.25 
185 731 0.25 1.54 90.1 1.54 90.1 91.64 
185 732 0.25 0 38.88 0 38.88 38.88 
185 733 0.25 7.21 252.1 7.21 252.1 259.31 
185 734 0.5 3.65 132.03 3.65 132.03 135.68 
185 735 0.5 4.54 124.77 4.54 124.77 129.31 
185 736 0.5 7.58 188.9 7.58 188.9 196.48 
185 737 0.75 5.75 123.23 5.75 123.23 128.98 
185 738 0.75 5.38 144 5.38 144 149.38 
185 739 0.75 4.17 121.38 4.17 121.38 125.55 
185 731 1 4.86 148.82 4.86 148.82 153.68 
185 732 1 1.99 65.46 1.99 65.46 67.45 
185 733 1 11.86 124.36 11.86 124.36 136.22 
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185 734 1.5 2.62 85.34 2.62 85.34 87.96 
185 735 1.5 1.81 64.17 1.81 64.17 65.98 
185 736 1.5 3.32 89.8 3.32 89.8 93.12 
185 734 3 0 34.23 0 34.23 34.23 
185 735 3 0 36.28 0 36.28 36.28 
185 736 3 0 23.35 0 23.35 23.35 
185 731 6 0 4.39 0 4.39 4.39 
185 732 6 0 6.37 0 6.37 6.37 
185 733 6 0 6.44 0 6.44 6.44 
185 737 8 0 4.28 0 4.28 4.28 
185 738 8 0 2.63 0 2.63 2.63 
185 739 8 0 2.19 0 1.25 1.25 
185 737 12 0 2.23 0 1.25 1.25 
185 738 12 0 6.11 0 6.11 6.11 
185 739 12 0 1.72 0 1.25 1.25 
185 734 24 0 0.73 0 1.25 1.25 
185 735 24 0 1.12 0 1.25 1.25 
185 736 24 0 0.6 0 1.25 1.25 
Note: LLOQ of carboxylate is 1.0 ng/mL; LLOQ of lactone is 2.5 ng/mL; if the 
concentration is larger than 0 and smaller than LLOQ, half of LLOQ value was taken.    
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DEPARTMENT OF PHARMACEUTICAL SCIENCES, COLLEGE OF 
PHARMACY 
UNIVERSITY OF KENTUCKY (LEGGAS LAB) 
 
 
 
REPORT ON BIOAVAILABILITY OF EXCIPIENT FREE (BLANK) AND 
PVP (K30) CONTAINING AR-67 LACTONE SUSPENSIONS IN MICE 
(PERFORMED 2/3/2009-2/4/2009) 
COMPARISON OF THE BIOAVAILABILITY OF EXCIPIENT FREE 
(BLANK) AND PVP (K30) SUSPENSIONS OF AR-67 LACTONE IN 
FEMALE C57BL/6 MICE 
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Objective 
Previous experiments showed that the amorphous formulation of AR-67 (PMFD 576/1 
(PVP (30 K)-Tween 80-lactone) gave 2-fold increase in oral bioavailability compared to 
supersaturated solutions of AR-67 lactone (e.g. SBE-β-CD or E-TPGS). To delineate if 
this increase in bioavailability is due to PVP or tween 80, we studied the bioavailability 
of AR-67 suspension in the in presence or absence PVP using the following two 
formulations:   
a) Blank AR-67 lactone in SGF: simulated gastric fluid (SGF, pH 1.2) was spiked with 
carboxylate stock solution to make 2 mg/mL dosing suspension and dosed right after 
mixing. 
b) PVP + AR-67 lactone in SGF: simulated gastric fluid containing PVP (K30) (pH 1.2) 
(E: D, 3:1) was spiked with carboxylate stock solution to make 2 mg/mL, and dosed right 
after mixing. 
 
Expt 186: Study the bioavailability of blank AR-67 lactone suspension in SGF at 5 mg/kg 
(2.5 mL/kg) PO.  
 
Expt 187: Study the bioavailability of AR-67 lactone suspension in SGF containing PVP 
(K30) (E/D 3:1) at 5 mg/kg (2.5 mL/kg) PO  
 
Method 
Formulation  
The dosing solutions were prepared by mixing AR-67 carboxylate stock solution (20 
mg/mL) with SGF or SGF containing PVP K30 (E: D, 3:1); then dosed right after 
mixing.  
 
Animal treatment and sample processing 
(Refer to \\Pharm\public\PS\Leggas Lab\Experimental Results\DB67 Oral PK\Mouse 
oral PK\sampling time for details) 
Expt 186: Mouse# 741-749 were treated with blank AR-67 lactone suspension in 
simulated gastric fluid (pH 1.2) right after mixing. 
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Expt 187: Mouse# 751-759 were treated with AR-67 lactone suspension in simulated 
gastric fluid (pH 1.2) containing PVPK30 (E: D, 3:1) right after mixing. 
Groups of three mice were sampled at 15 min, 30 min, 45 min, 1 h, 1.5 h, 3 h, 6 h, 8 h, 12 
h, and 24 h. Each animal was sampled at 3-4 different time points.  
The blood sample of about 50 µL was collected from the saphenous vein with 
heparinized hematocrit tubes and transferred into heparinized microcentrifuge tubes. 
Plasma of 25 µL was collected by centrifugation of blood and then extracted 1:4 (v/v) 
with cold MeOH (100 µL,-80oC). Samples were kept at -80oC until analysis.  
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HPLC analysis  
Before injection into the HPLC, samples were diluted with an equal volume of mobile 
phase buffer (40 µL:40 µL) and were analyzed.  
 
Sequence name:  
20AC-020509-mouse PK expt 186 & 187.seq    
 
Method:      
20AC-010909-mouse plasma curve.met  
 
Data were exported and saved in Leggas Lab/Experimental Results/DB-67 Oral PK / 
Mouse oral PK folder. Areas under the curve were estimated with Prism v5 and 
WinNonlin v5.2 (sparse sampling noncompartmental analysis). Plasma concentration 
versus time plots were made with Prism v5. 
 
Results 
1. Prism file:..\Prism files\Mouse PK 5 mg PO exps 186 & 187.pzf 
2.  WinNonlin file: ..\Winnonlin files\Mouse PK Expt 186 & 187 0-8 h.wsp 
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3. Tables 
 
4. Figures 
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File path: \\Pharm\public\PS\Leggas Lab\Experimental Results\DB67 Oral 
PK\Mouse oral PK\Prism files\ Mouse PK 5 mg PO exps 186 & 187. 
Table 1. Basic pharmacokinetic parameters 
0-12 h 
Expt #186 5.0 mg/kg AR-67 lactone PO in SGF (pH 1.2) 
AUC 
(ng*h/mL) Mean SE Tmax (h) Median Cmax (ng/mL) Mean SE 
Carb 19.21 1.04 Carb 0.75 Carb 6.39 0.22 
Lactone 303.85 28.54 Lactone 0.75 Lactone 101.31 1.99 
Total  323.06 28.57 Total 0.75 Total 107.70 2.14 
0-12 h 
Expt #187 5.0 mg/kg AR-67 lactone PO (PVP K30:AR-67 (71:23)) in SGF (pH 1.2) 
AUC 
(ng*h/mL) Mean Tmax (h) Median Cmax (ng/mL) Mean SE 
Carb 18.99 0.76 Carb 0.50 Carb 7.92 0.86 
Lactone 283.53 19.73 Lactone 0.50 Lactone 138.38 12.38 
Total 302.53 20.44 Total 0.50 Total 146.29 13.23 
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 Raw Data 
Filter  
>=1 
Filter  
>=2.5 Filter 
Expt Mouse # 
Time 
(h) 
Carb. 
(ng/ml) 
Lact. 
(ng/ml) 
Carb. 
(ng/ml) 
Lact. 
(ng/ml) 
Total 
(ng/ml) 
186 741 0.25 2.31 50.5 2.31 50.5 52.81 
186 742 0.25 1.79 40.39 1.79 40.39 42.18 
186 743 0.25 2.34 45.62 2.34 45.62 47.96 
186 744 0.5 5.14 90.66 5.14 90.66 95.8 
186 745 0.5 3.33 64.38 3.33 64.38 67.71 
186 746 0.5 1.88 36.61 1.88 36.61 38.49 
186 747 0.75 6.48 104.75 6.48 104.75 111.23 
186 748 0.75 5.97 97.86 5.97 97.86 103.83 
186 749 0.75 6.72 101.32 6.72 101.32 108.04 
186 741 1 3.8 51.81 3.8 51.81 55.61 
186 742 1 5.86 90.65 5.86 90.65 96.51 
186 743 1 4.05 54.28 4.05 54.28 58.33 
186 744 1.5 4.03 61.52 4.03 61.52 65.55 
186 745 1.5 5.71 76.99 5.71 76.99 82.7 
186 746 1.5 4.08 70.85 4.08 70.85 74.93 
186 744 3 2.11 26.26 2.11 26.26 28.37 
186 745 3 2.48 32.83 2.48 32.83 35.31 
186 746 3 2.56 33.26 2.56 33.26 35.82 
186 741 6 0.63 6.26 0.5 6.26 6.76 
186 742 6 0.28 3.57 0.5 3.57 4.07 
186 743 6 0.44 5.95 0.5 5.95 6.45 
186 747 8 0.31 1.94 0.5 1.25 1.75 
186 748 8 0.47 5.4 0.5 5.4 5.9 
186 749 8 0.26 2.72 0.5 2.72 3.22 
186 747 12 1.67 31.48 1.67 31.48 33.15 
186 748 12 0.65 54.98 0.5 54.98 55.48 
186 749 12 0.66 11.06 0.5 11.06 11.56 
186 747 24 0 0.39 0 1.25 1.25 
186 748 24 0.11 0 0.5 0 0.5 
186 749 24 0.21 0.28 0.5 1.25 1.75 
187 751 0.25 1.2 21.5 1.2 21.5 22.7 
187 752 0.25 2.74 57.85 2.74 57.85 60.59 
187 753 0.25 4.41 71.59 4.41 71.59 76 
187 754 0.5 6.31 114.07 6.31 114.07 120.38 
187 755 0.5 8.19 146.46 8.19 146.46 154.65 
187 756 0.5 9.25 154.6 9.25 154.6 163.85 
187 757 0.75 7.75 107.7 7.75 107.7 115.45 
187 758 0.75 6.5 85.92 6.5 85.92 92.42 
187 759 0.75 4.41 66.72 4.41 66.72 71.13 
187 751 1 4.71 75.16 4.71 75.16 79.87 
187 752 1 4.63 78.45 4.63 78.45 83.08 
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187 753 1 4.37 63.99 4.37 63.99 68.36 
187 754 1.5 5.23 84.5 5.23 84.5 89.73 
187 755 1.5 3.58 54.21 3.58 54.21 57.79 
187 756 1.5 4.75 60.5 4.75 60.5 65.25 
187 754 3 2.77 45.34 2.77 45.34 48.11 
187 755 3 2.56 35.93 2.56 35.93 38.49 
187 756 3 1.71 23.85 1.71 23.85 25.56 
187 751 6 0.96 9.67 0.5 9.67 10.17 
187 752 6 0.66 8.67 0.5 8.67 9.17 
187 753 6 0.4 5.06 0.5 5.06 5.56 
187 757 8 0 2.39 0 1.25 1.25 
187 758 8 0.28 2.47 0.5 1.25 1.75 
187 759 8 0.26 2.63 0.5 2.63 3.13 
187 757 12 0.23 1.93 0.5 1.25 1.75 
187 758 12 0.91 14.83 0.5 14.83 15.33 
187 759 12 0.45 10.31 0.5 10.31 10.81 
187 757 24 0 0.47 0 1.25 1.25 
187 758 24 0.11 0.34 0.5 1.25 1.75 
187 759 24 0.14 0.72 0.5 1.25 1.75 
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Objective 
We studied the oral bioavailability and systemic and interconversion clearances of the 
lactone and carboxylate forms of AR-67 in SBE-β-CD (200:1, E/D). Data from this panel 
of experiments will be used to build a pharmacokinetic model of interconversion for AR-
67.  
 
Expt 188: Study the bioavailability of AR-67 lactone in SBE-β-CD (200:1, E/D) at dose 
of 10 mg/kg (10 mL/kg) PO 
 
Expt 189: Study the pharmacokinetics of AR-67 lactone in SBE-β-CD (200:1, E/D) at 
dose of 10 mg/kg (10 mL/kg) IV 
 
Expt 190: Study the pharmacokinetics of AR-67 carboxylate in SBE-β-CD (200:1, E/D) 
at dose of 10 mg/kg (10 mL/kg) PO 
 
Expt 191: Study the pharmacokinetics of AR-67 carboxylate in SBE-β-CD (200:1, E/D) 
at dose of 10 mg/kg (10 mL/kg) IV 
 
Method 
Formulation  
The AR-67 lactone and carboxylate SBE-β-CD (200:1, E/D) lyophile powder were 
prepared by Dr. Xiang, and reconstructed to 1 mg/mL using D5W.  
 
Animal treatment and sample processing 
(Refer to \\Pharm\public\PS\Leggas Lab\Experimental Results\DB67 Oral PK\Mouse 
oral PK\sampling time for details) 
Expt 188: mouse# 761-769 were treated with AR-67 lactone in SBE-β-CD (200:1,  
E/D) at dose of 10 mg/kg (10 mL/kg) PO 
Expt 189: mouse# 771-779 were treated with AR-67 lactone in SBE-β-CD (200:1,  
E/D) at dose of 10 mg/kg (10 mL/kg) IV 
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Expt 190: mouse# 781-789 were treated with AR-67 carboxylate in SBE-β-CD (200:1, 
E/D) at dose of 10 mg/kg (10 mL/kg) PO 
Expt 191: mouse# 791-799 were treated with AR-67 carboxylate in SBE-β-CD (200:1, 
E/D) at dose of 10 mg/kg (10 mL/kg) IV 
Groups of three mice were sampled at 5 min (IV)/15 min (PO), 30 min, 45 min, 1 h, 1.5 
h, 3 h, 6 h, 8 h, 12 h and 24 h. Each animal was sampled at 3-4 different time points.  
The blood sample of about 50 µL was collected from the saphenous vein with 
heparinized hematocrit tubes and transferred into heparinized microcentrifuge tubes. 
Plasma of 25 µL was collected by centrifugation of blood and then extracted 1:4 (v/v) 
with cold MeOH (100 µL,-80oC). Samples were kept at -80oC until analysis.  
HPLC analysis  
 
Before injection into the HPLC, samples were diluted with an equal volume of mobile 
phase buffer (40 µL:40 µL) and were analyzed.  
 
Sequence name:  
20ac-021109-Exp 188 & 189.seq 
              
Method:  
20ac-021109-0109 mouse plasma curve reinjected.met 
   
Sequence name:  
20ac-021109-Exp 188 & 189.seq 
 
Method:  
Carboxylate: 
20AC-061807-mouse plasma curve.met 
Lactone 
20ac-021109-0109 mouse plasma curve reinjected.met 
Sequence name:  
20ac-021109-Exp 188 & 189.seq 
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Method: 
 
Carboxylate: 
20AC-061807-mouse plasma curve.met 
Lactone 
20ac-021109-0109 mouse plasma curve reinjected.met 
Sequence name:  
20ac-021109-Exp 188 & 189.seq 
Method: 
20AC-021609-reinjection of 0109 mouse plasma curve.met 
Sequence name:  
20ac-021109-Exp 188 & 189.seq 
Method: 
20AC-021709-reinjection of 0109 mouse plasma curve.met 
 
Data were exported and saved in Leggas Lab/Experimental Results/DB-67 Oral PK / 
Mouse oral PK folder. Areas under the curve were estimated with Prism v5 and 
WinNonlin v5.2 (sparse sampling noncompartmental analysis). Plasma concentration 
versus time plots were made with Prism v5. 
Results 
1. Prism file: ..\Prism files\Mouse PK 10 mg PO exps 188 & 190.pzf 
                      ..\Prism files\Mouse PK 10 mg IV exps 189 & 191.pzf 
2.  WinNonlin file: ..\Winnonlin files\Mouse PK Expt 188 & 190.wsp 
                          ..\Winnonlin files\Mouse PK Expt 189 & 191.wsp 
3. Tables 
 
Table 1. Basic pharmacokinetic parameters 
Expt #188 10 mg/kg lactone PO (SBE-β-CD 200:1) 
AUC 
(ng·h/mL) Mean SE Tmax (h) Median Cmax (ng/mL) Mean SE 
Carb 34.49 0.88 Carb 0.75 Carb 16.83 4.67 
Lactone 323.95 13.00 Lactone 0.75 Lactone 160.52 40.38 
Total 358.44 13.54 Total 0.75 Total 177.35 45.02 
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Expt #190 10 mg/kg carboxylate PO (SBE- β -CD 200:1)
AUC 
(ng·h/mL) Mean Tmax (h) Median Cmax (ng/mL) Mean SE 
Carb 36.68 2.40 Carb 0.50 Carb 19.43 1.98 
Lactone 408.56 13.55 Lactone 0.50 Lactone 217.83 22.35
Total 445.24 14.74 Total 0.50 Total 237.25 24.08
Expt #189 10 mg/kg lactone IV (SBE- β -CD 200:1) 
AUC 
(ng·h/mL) Mean SE Tmax (h) Median
Cmax  
(ng/mL) Mean SE 
Carb 349.28 31.54 Carb 0.08 Carb 288.86 18.81 
tone 3066.89 118.14 Lactone 0.08 Lactone 4515.65 27.39 
Total 3414.43 130.27 Total 0.08 Total 4804.51 9.66 
Expt #191 
10 mg/kg carboxylate IV (SBE- β -CD 
200:1) 
AUC 
(ng·h/mL) Mean SE Tmax (h) Median 
Cmax  
(ng/mL) Mean SE 
Carb 1420.57 76.46 Carb 0.08 Carb 3926.42 292.29
Lactone 508.53 22.79 Lactone 0.08 Lactone 327.56 22.83 
Total 1891.70 93.68 Total 0.08 Total 4253.98 310.31
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4. Figures 
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File path: \\Pharm\public\PS\Leggas Lab\Experimental Results\DB67 Oral PK\Mouse 
oral PK\Prism files\ Mouse PK 10 mg PO exps 188 & 190 
File path: \\Pharm\public\PS\Leggas Lab\Experimental Results\DB67 Oral PK\Mouse 
oral PK\Prism files\ Mouse PK 10 mg IV exps 189 & 191 
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Raw Data 
Filter  
>=1 
Filter 
 >=2.5 Filter 
Expt 
Mouse 
# 
Time 
(h) 
Carb. 
(ng/mL) 
Lact.  
(ng/mL) 
Carb. 
(ng/mL) 
Lact. 
(ng/mL) Total 
188 761 0.167 14.48 153.22 14.48 153.22 167.7 
188 762 0.167 17.09 190.2 17.09 190.2 207.29 
188 763 0.167 12.56 131.54 12.56 131.54 144.1 
188 764 0.5 7.65 92.22 7.65 92.22 99.87 
188 765 0.5 10.9 112.63 10.9 112.63 123.53 
188 766 0.5 8.12 105.21 8.12 105.21 113.33 
188 767 0.75 9.22 89.56 9.22 89.56 98.78 
188 768 0.75 25.32 229.4 25.32 229.4 254.72 
188 769 0.75 15.96 162.59 15.96 162.59 178.55 
188 761 1 9.95 87.53 9.95 87.53 97.48 
188 762 1 15.25 133.48 15.25 133.48 148.73 
188 763 1 13.2 105.73 13.2 105.73 118.93 
188 764 1.5 8.01 80.7 8.01 80.7 88.71 
188 765 1.5 8.9 69.99 8.9 69.99 78.89 
188 766 1.5 8.92 85.08 8.92 85.08 94 
188 764 3 2.87 22.43 2.87 22.43 25.3 
188 765 3 2.1 16.54 2.1 16.54 18.64 
188 766 3 2.3 15.34 2.3 15.34 17.64 
188 761 6 1.16 8.62 1.16 8.62 9.78 
188 762 6 0.72 10.98 0.5 10.98 11.48 
188 763 6 0.75 5.91 0.5 5.91 6.41 
188 767 8 1.35 12.58 1.35 12.58 13.93 
188 768 8 0.6 4.08 0.5 4.08 4.58 
188 769 8 0.82 6.32 0.5 6.32 6.82 
188 767 12 29.75 387.71 29.75 387.71 417.46 
188 768 12 0.58 4.1 0.5 4.1 4.6 
188 769 12 0.53 5.61 0.5 5.61 6.11 
188 764 24 0.7 8.11 0.5 8.11 8.61 
188 765 24 0.76 5.03 0.5 5.03 5.53 
188 766 24 0.57 2.99 0.5 2.99 3.49 
190 781 0.167 170.98 425.08 170.98 425.08 596.06 
190 782 0.167 3.66 32.13 3.66 32.13 35.79 
190 783 0.167 8.04 86.26 8.04 86.26 94.3 
190 784 0.5 20.2 247.86 20.2 247.86 268.06 
190 785 0.5 15.67 174.13 15.67 174.13 189.8 
190 786 0.5 22.41 231.49 22.41 231.49 253.9 
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190 787 0.75 14.22 180.73 14.22 180.73 194.95 
190 788 0.75 9.44 116.57 9.44 116.57 126.01 
190 789 0.75 7.95 100.89 7.95 100.89 108.84 
190 781 1 188.18 372.81 188.18 372.81 560.99 
190 782 1 25.07 47.4 25.07 47.4 72.47 
190 783 1 48.47 100.99 48.47 100.99 149.46 
190 784 1 12.58 180.19 12.58 180.19 192.77 
190 785 1 11.04 152.8 11.04 152.8 163.84 
190 786 1 15.49 145.09 15.49 145.09 160.58 
190 784 1.5 8.24 96.22 8.24 96.22 104.46 
190 785 1.5 9.04 127.45 9.04 127.45 136.49 
190 786 1.5 9.36 95.24 9.36 95.24 104.6 
190 784 3 3.89 27.13 3.89 27.13 31.02 
190 785 3 2.12 18.22 2.12 18.22 20.34 
190 786 3 2.45 20.76 2.45 20.76 23.21 
190 781 6 2.46 12.56 2.46 12.56 15.02 
190 782 6 0.62 6.65 0.5 6.65 7.15 
190 783 6 0.76 7.74 0.5 7.74 8.24 
190 787 8 0.71 9.3 0.5 9.3 9.8 
190 788 8 0.72 8.04 0.5 8.04 8.54 
190 789 8 1.73 10.66 1.73 10.66 12.39 
190 787 12 0.96 12.87 0.5 12.87 13.37 
190 788 12 1.29 17.55 1.29 17.55 18.84 
190 789 12 0 16.04 0 16.04 16.04 
190 784 24 0.61 5.9 0.5 5.9 6.4 
190 785 24 0.62 5.85 0.5 5.85 6.35 
190 786 24 0.65 5.74 0.5 5.74 6.24 
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Filter 
 >=1 
Filter  
>=2.5 Filter 
Expt Mouse # Time 
Carb. 
(ng/mL) 
Lact 
(ng/mL) 
Carb. 
(ng/mL) 
Lact. 
(ng/mL) 
Total 
(ng/mL) 
189 771 0.083 251.394 4570.137 251.394 4570.137 4821.531
189 772 0.083 304.59 4483.479 304.59 4483.479 4788.069
189 773 0.083 310.596 4493.346 310.596 4493.346 4803.942
189 774 0.5 315.984 1657.1 315.984 1657.1 1973.084
189 775 0.5 296.689 1356.552 296.689 1356.552 1653.241
189 776 0.5 219.509 2127.671 219.509 2127.671 2347.18 
189 777 0.75 129.941 1129.968 129.941 1129.968 1259.909
189 778 0.75 119.168 989.254 119.168 989.254 1108.422
189 779 0.75 109.592 1031.947 109.592 1031.947 1141.539
189 771 1 82.194 593.446 82.194 593.446 675.64 
189 772 1 125.552 862.106 125.552 862.106 987.658 
189 773 1 81.662 682.423 81.662 682.423 764.085 
189 774 1.5 88.757 539.806 88.757 539.806 628.563 
189 775 1.5 85.806 395.434 85.806 395.434 481.24 
189 776 1.5 31.63 274.07 31.63 274.07 305.7 
189 774 3 22.47 98.64 22.47 98.64 121.11 
189 775 3 6.67 35.6 6.67 35.6 42.27 
189 776 3 15.81 93.92 15.81 93.92 109.73 
189 771 6 0.64 5.07 0.5 5.07 5.57 
189 772 6 1.15 6.99 1.15 6.99 8.14 
189 773 6 0.67 6 0.5 6 6.5 
189 777 8 0.5 3.21 0.5 3.21 3.71 
189 778 8 0.46 2.68 0.5 2.68 3.18 
189 779 8 0.39 3.05 0.5 3.05 3.55 
189 777 12 0 10.62 0 10.62 10.62 
189 778 12 0.44 2.87 0.5 2.87 3.37 
189 779 12 0.34 3.19 0.5 3.19 3.69 
189 774 24 5.34 7.04 5.34 7.04 12.38 
189 776 24 0.68 0.91 0.5 1.25 1.75 
191 793 0.083 3964.328 358.66 3964.328 358.66 4322.988
191 792 0.083 4412.653 340.954 4412.653 340.954 4753.607
191 791 0.083 3402.276 283.069 3402.276 283.069 3685.345
191 794 0.5 130.28 133.71 130.28 133.71 263.99 
191 795 0.5 94.53 139.47 94.53 139.47 234 
191 796 0.5 103.1 139.4 103.1 139.4 242.5 
 449 
 
191 797 0.75 60.8 147.57 60.8 147.57 208.37 
191 798 0.75 79.4 169.96 79.4 169.96 249.36 
191 799 0.75 54.8 129.78 54.8 129.78 184.58 
191 791 1 40.37 125.3 40.37 125.3 165.67 
191 792 1 71.25 195.88 71.25 195.88 267.13 
191 793 1 53.65 222.65 53.65 222.65 276.3 
191 794 1.5 14.44 125.12 14.44 125.12 139.56 
191 795 1.5 15.48 127.67 15.48 127.67 143.15 
191 796 1.5 13.66 125.05 13.66 125.05 138.71 
191 794 3 3.84 23.59 3.84 23.59 27.43 
191 795 3 5.61 36.7 5.61 36.7 42.31 
191 796 3 4.09 23 4.09 23 27.09 
191 791 6 1.5 12.59 1.5 12.59 14.09 
191 792 6 1.45 17.12 1.45 17.12 18.57 
191 793 6 2.04 15.16 2.04 15.16 17.2 
191 797 8 0.76 6.03 0.5 6.03 6.53 
191 798 8 1.1 8.92 1.1 8.92 10.02 
191 799 8 0.97 7.13 0.5 7.13 7.63 
191 797 12 1.28 3.17 1.28 3.17 4.45 
191 798 12 0.62 4.19 0.5 4.19 4.69 
191 799 12 1.66 9.85 1.66 9.85 11.51 
191 794 24 0.7 1.67 0.5 1.25 1.75 
191 795 24 0.2 0 0.5 0 0.5 
191 796 24 0.22 0 0.5 0 0.5 
Note: LLOQ of carboxylate is 1.0 ng/mL; LLOQ of lactone is 2.5 ng/mL; if the 
concentration is larger than 0 and smaller than LLOQ, half of LLOQ value was 
taken.    
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Objective 
Previous experiments showed that amorphous formulations such as PMFD 576/1 (PVP 
(30 K)-Tween 80-lactone) and blank AR-67 lactone (prepared by spiking simulated 
gastric fluid (SGF) with AR-67 carboxylate stock solution) gave higher oral 
bioavailability compared to  supersaturated solutions of AR-67 lactone (e.g. SBE-β-CD 
or E-TPGS). Since that charge on the carboxylate might reduce absorption by passive 
diffusion, we hypothesized that conversion of lactone into the carboxylate at the alkaline 
pH of the small intestine is likely to be rapid from solution formulations and slow from 
suspensions (amorphous formulations). We speculated that lactone particles in 
suspension can serve as a drug reservoir due to relatively lower dissolution and 
conversion rates. Thus particles with optimal combination of dissolution and conversion 
rates are likely to give enhanced oral bioavailability. To test this hypothesis, we prepared 
a series of particles of different sizes by serial sieving and tested the bioavailability of 
suspensions of two different particle size distributions in mice.  
 
Expt 194: Study the absorption of AR-67 lactone (particle size: 45 µm to 75 µm) in SGF 
(5 mg/kg, 2.5 ml/kg) PO.  
 
Expt 195: Study the absorption of AR-67 lactone (particle size:75 µm to 150 µm) in SGF 
(5 mg/kg, 2.5 ml/kg) PO. 
 
Method 
Formulation  
Dr. Xiang prepared AR-67 crystals in 5 different sizes by sieving:  
         Size 1: ≥600 µm  
         Size 2: 150 µm to 600 µm  
         Size 3: 75 µm to 150 µm 
         Size 4: 45 µm to 75 µm 
         Size 5: ≤ 45 µm 
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Due to the limited amount of size 5 and the difficulty of making homogenous suspensions 
with sizes 1 and 2, sizes 3 and 4 were used to make 2 mg/mL suspensions for mouse PK 
experiments.  
 
Animal treatment and sample processing 
(Refer to \\Pharm\public\PS\Leggas Lab\Experimental Results\DB67 Oral PK\Mouse 
oral PK\sampling time for details) 
Expt 194: mouse #811-819 were treated with AR-67 (particle size: 45 µm-75 µm) 
suspension in simulated gastric fluid (pH 1.2). The dosing solutions (2 mg/mL) were 
administered right after mixing. 
Expt 195: mouse#751-759 were treated with AR-67 (particle size:75 µm-150 µm)  
suspension in simulated gastric fluid (pH 1.2), the dosing solution (2 mg/mL) were 
administered right after mixing. 
Groups of three mice were sampled at 15 min, 30 min, 45 min, 1 h, 1.5 h, 3 h, 6 h, 8 h,12 
h, and 24 h. Each animal was sampled at 3-4 different time points.  
The blood sample of about 50 µL was collected from the saphenous vein with 
heparinized hematocrit tubes and transferred into heparinized microcentrifuge tubes. 
Plasma of 25 µL was collected by centrifugation of blood and then extracted 1:4 (v/v) 
with cold MeOH (100 µL,-80oC). Samples were kept at -80oC until analysis.  
 
HPLC analysis  
 
Before injection into the HPLC, samples were diluted with an equal volume of mobile 
phase buffer (40 µL:40 µL) and were analyzed.  
 
Sequence name:  
20AC-022709-mouse plasma PK expt 194 & 195.seq 
  20AC-030209-mouse plasma PK expt 194 &195.seq 
Method:  
20AC-022709 mouse plasma curve.met 
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Data were exported and saved in Leggas Lab/Experimental Results/DB-67 Oral PK / 
Mouse oral PK folder. Areas under the curve were estimated with Prism v5 and 
WinNonlin v5.2 (sparse sampling noncompartmental analysis). Plasma concentration 
versus time plots were made with Prism v5. 
 
Results 
1. Prism file: ..\Prism files\Mouse PK 5 mg PO exps 194 & 195.pzf 
2.  WinNonlin file: ..\Winnonlin files\Mouse PK Expt 194 & 195.wsp 
3. Tables 
 
 
 
Table 1. Basic PK parameters 
0-12 h 
Expt #194 
5 mg/kg AR-67 lactone PO (45 µm -75 µm 
crystals) 
AUC  
(ng*h/mL) Mean SE 
Tmax 
(h) 
Cmax 
(ng/mL) Mean SE 
Carb 6.86 1.73 0.50 Carb 1.93 0.22 
Lactone 58.68 11.93 1.00 Lactone 16.29 1.41 
Total 65.55 13.47 1.00 Total 17.73 1.50 
0-12 h 
Expt #195 
5 mg/kg AR-67 lactone PO (75 µm -150 
µm crystals) 
AUC 
(ng*h/mL) Mean SE 
Tmax 
(h) 
Cmax 
(ng/mL) Mean SE 
Carb 9.76 2.03 3.00 Carb 1.15 0.34 
Lactone 73.91 12.08 8.00 Lactone 8.23 4.16 
Total 83.67 14.08 8.00 Total 9.31 4.74 
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4. Figures 
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File path: \\Pharm\public\PS\Leggas Lab\Experimental Results\DB67 Oral PK\Mouse 
oral PK\Prism files\ Mouse PK 5 mg PO exps 194 & 195 
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Raw Data 
Filter 
>=1 
Filter  
>=2.5 Filter 
Expt Mouse # Time (h) 
Carb. 
(ng/mL) 
Lact.  
(ng/mL) 
Carb. 
(ng/mL) 
Lact. 
(ng/mL) 
Total 
(ng/mL)
194 811 0.25 0 1.04 0 1.25 1.25 
194 812 0.25 0 1.05 0 1.25 1.25 
194 813 0.25 0 0.82 0 1.25 1.25 
194 814 0.5 1.73 3.42 1.73 3.42 5.15 
194 815 0.5 2.38 3.74 2.38 3.74 6.12 
194 816 0.5 1.69 2.91 1.69 2.91 4.6 
194 817 0.75 0.87 5.03 0.5 5.03 5.53 
194 818 0.75 0.48 5.91 0.5 5.91 6.41 
194 819 0.75 0.23 1.8 0.5 1.25 1.75 
194 811 1 1.58 18.94 1.58 18.94 20.52 
194 812 1 1.47 15.81 1.47 15.81 17.28 
194 813 1 1.27 14.11 1.27 14.11 15.38 
194 814 1.5 0.73 8.22 0.5 8.22 8.72 
194 815 1.5 0.93 8.19 0.5 8.19 8.69 
194 816 1.5 1.87 20.82 1.87 20.82 22.69 
194 814 3 0.98 6.83 0.5 6.83 7.33 
194 815 3 0 2.66 0 2.66 2.66 
194 816 3 1.44 12.91 1.44 12.91 14.35 
194 811 6 0.55 4.53 0.5 4.53 5.03 
194 812 6 0.49 2.51 0.5 2.51 3.01 
194 813 6 0.55 5.15 0.5 5.15 5.65 
194 817 8 0 1.45 0 1.25 1.25 
194 818 8 0.81 2.88 0.5 2.88 3.38 
194 819 8 0.74 1.79 0.5 1.25 1.75 
194 817 12 0 0.48 0 1.25 1.25 
194 818 12 1.08 5.99 1.08 5.99 7.07 
194 819 12 0.52 2.09 0.5 1.25 1.75 
194 814 24 0 0.49 0 1.25 1.25 
194 815 24 0.18 0.47 0.5 1.25 1.75 
194 816 24 0 0.22 0 1.25 1.25 
195 821 0.25 0 0.37 0 1.25 1.25 
195 822 0.25 0 0.51 0 1.25 1.25 
195 823 0.25 0 0 0 0 0 
195 824 0.5 0.79 5.44 0.5 5.44 5.94 
195 825 0.5 0.53 2.55 0.5 2.55 3.05 
195 826 0.5 0.33 2.5 0.5 2.5 3 
195 827 0.75 0.2 2.06 0.5 1.25 1.75 
195 828 0.75 0.5 5.06 0.5 5.06 5.56 
195 829 0.75 0.39 5.87 0.5 5.87 6.37 
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195 821 1 0.91 8.93 0.5 8.93 9.43 
195 822 1 0.6 5.15 0.5 5.15 5.65 
195 823 1 0.41 2.96 0.5 2.96 3.46 
195 824 1.5 0.59 7.01 0.5 7.01 7.51 
195 825 1.5 0.74 8.57 0.5 8.57 9.07 
195 826 1.5 0.61 6.2 0.5 6.2 6.7 
195 824 3 1.65 10.95 1.65 10.95 12.6 
195 825 3 1.29 7.16 1.29 7.16 8.45 
195 826 3 0.59 3.67 0.5 3.67 4.17 
195 821 6 14.96 13.06 14.96 13.06 28.02 
195 822 6 0.33 1.1 0.5 1.25 1.75 
195 823 6 1.11 3.82 1.11 3.82 4.93 
195 827 8 0.83 4.07 0.5 4.07 4.57 
195 828 8 10.16 9.17 10.16 9.17 19.33 
195 829 8 1.65 12.39 1.65 12.39 14.04 
195 827 12 0.33 8.62 0.5 8.62 9.12 
195 828 12 0.62 8.99 0.5 8.99 9.49 
195 829 12 0.53 4.98 0.5 4.98 5.48 
195 824 24 0.15 0 0.5 0 0.5 
195 825 24 0 0 0 0 0 
195 826 24 0.63 17.77 0.5 17.77 18.27 
Note: LLOQ of carboxylate is 1.0 ng/mL; LLOQ of lactone is 2.5 ng/mL; if the 
concentration is larger than 0 and smaller than LLOQ, half of LLOQ value was taken.    
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Objective 
Previous experiments showed that amorphous formulations such as PMFD 576/1 (PVP 
(30 K)-Tween 80-lactone) and blank AR-67 lactone (prepared by spiking simulated 
gastric fluid (SGF) with AR-67 carboxylate stock solution) gave higher oral 
bioavailability compared to  supersaturated solutions of AR-67 lactone (e.g. SBE-β-CD 
or E-TPGS). Since that charge on the carboxylate might reduce absorption by passive 
diffusion, we hypothesized that conversion of lactone into the carboxylate at the alkaline 
pH of the small intestine is likely to be rapid from solution formulations and slow from 
suspensions (amorphous formulations). We speculated that lactone particles in 
suspension can serve as a drug reservoir due to relatively lower dissolution and 
conversion rates. Thus particles with optimal combination of dissolution and conversion 
rates are likely to give enhanced oral bioavailability. To test this hypothesis, we 
examined the effect of tween-80 and degree of crystallization on bioavailability of AR-67 
lactone.   
a) SGF (pH 1.2) containing Tween-80 (0.065%) was spiked with carboxylate stock 
solution to prepare 2 mg/mL dosing suspension and was dosed immediately after mixing. 
b) SGF (pH 1.2) containing Tween-80 (0.065%) was spiked with carboxylate stock 
solution and was dosed 2 hours after mixing (the suspension was incubated at 37oC for 2 
hours to allow crystal to grow).  
 
Expt 196: Study the bioavailability of freshly prepared AR-67 lactone in SGF containing 
0.065% Tween-80 (5 mg/kg, 2.5 ml/kg) PO.  
 
Expt 197: Study the bioavailability of AR-67 lactone in SGF containing 0.065% Tween-
80 (2 hr after preparation) (5 mg/kg, 2.5 ml/kg) PO  
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Method 
Formulation  
The dosing suspension with concentration of 2 mg/mL were prepared by spiking SGF 
containing Tween-80 (0.065%) with AR-67 carboxylate stock solution (20 mg/mL); AR-
67 carboxylate stock solution were prepared at 20 mg/ml by Dr. Xiang. 
Animal treatment and sample processing 
(Refer to \\Pharm\public\PS\Leggas Lab\Experimental Results\DB67 Oral PK\Mouse 
oral PK\sampling time for details) 
Expt 196: Mouse# 831-839 were treated with AR-67 lactone suspension in T-80 
containing simulated gastric fluid (pH 1.2) right after mixing. 
Expt 197: Mouse# 841-849 were treated with AR-67 suspension in T-80 containing 
simulated gastric fluid (pH 1.2) administered right 2 h after preparation. 
Groups of three mice were sampled at 15 min, 30 min, 45 min, 1 h, 1.5 h, 3 h, 6 h, 8 h 
and 12 h, 24h. Each animal was sampled at 3-4 different time points.  
The blood sample of about 50 µL was collected from the saphenous vein with 
heparinized hematocrit tubes and transferred into heparinized microcentrifuge tubes. 
Plasma of 25 µL was collected by centrifugation of blood and then extracted 1:4 (v/v) 
with cold MeOH (100 µL,-80oC). Samples were kept at -80oC until analysis.  
   
HPLC analysis Before injection into the HPLC, samples were diluted with an equal 
volume of mobile phase buffer (40 µL:40 µL) and were analyzed.  
Sequence name:  
20AC-030609-mouse plasma PK expt 196 & 197.seq 
20AC-030709-mouse plasma PK expt 196 & 197.seq 
Method: 20AC-022709-mouse plasma curve 
Data were exported and saved in Leggas Lab/Experimental Results/DB-67 Oral PK / 
Mouse oral PK folder. Areas under the curve were estimated with Prism v5 and 
WinNonlin v5.2 (sparse sampling noncompartmental analysis). Plasma concentration 
versus time plots were made with Prism v5. 
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Results 
1. Prism file:..\Prism files\Mouse PK 5 mg PO exps 196 & 197.pzf 
2.  WinNonlin file: ..\Winnonlin files\Mouse PK Expt 196 & 197.wsp 
3. Tables 
Table 1. Basic pharmacokinetic parameters 
Expt 
#196 
5 mg/kg lactone PO (T-80 + SGF dosed immediately after 
preparation) 
AUC  
(ng·h/m
L) Mean SE Tmax (h) 
Cmax  
(ng/mL) Mean SE 
Carb 14.11 5.22 0.50 Carb 5.92 3.63 
Lactone 160.99 29.71 0.50 Lactone 50.92 16.74 
Total 175.10 34.62 0.50 Total 56.84 20.20 
Expt 
#197 
5 mg/kg lactone PO (T-80 + SGF dosed 2 hours after 
preparation) 
AUC  
(ng·h/m
L) Mean SE Tmax (h) 
Cmax  
(ng/mL) Mean SE 
Carb 9.20 1.12 3.00 Carb 1.95 0.31 
Lactone 145.97 20.55 3.00 Lactone 36.01 6.72 
Total 155.17 21.63 3.00 Total 37.96 7.04 
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4. Figures 
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File path: \\Pharm\public\PS\Leggas Lab\Experimental Results\DB67 Oral PK\Mouse 
oral PK\Prism files\ Mouse PK 5 mg PO exps 196 & 197. 
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Raw Data 
Filter  
>=1 
Filter 
 >=2.5 Filter 
Expt Mouse ID Time (h)
Carb. 
(ng/mL)
Lact. 
(ng/mL) 
Carb.  
(ng/mL)
Lact. 
(ng/mL) 
Total 
(ng/mL)
196 831 0.25 0.88 19.3 0.5 19.3 19.8 
196 832 0.25 2.3 15.06 2.3 15.06 17.36 
196 833 0.25 1.57 15.23 1.57 15.23 16.8 
196 834 0.5 13.1 80.35 13.1 80.35 93.45 
196 835 0.5 3.29 50.02 3.29 50.02 53.31 
196 836 0.5 1.37 22.38 1.37 22.38 23.75 
196 837 0.75 1.47 30.82 1.47 30.82 32.29 
196 838 0.75 2.95 65.81 2.95 65.81 68.76 
196 839 0.75 2.67 50.17 2.67 50.17 52.84 
196 831 1 1.03 18.52 1.03 18.52 19.55 
196 832 1 3.94 30.91 3.94 30.91 34.85 
196 833 1 1.36 26.62 1.36 26.62 27.98 
196 834 1.5 8.55 74.54 8.55 74.54 83.09 
196 835 1.5 1.16 18.58 1.16 18.58 19.74 
196 836 1.5 1.92 30.49 1.92 30.49 32.41 
196 834 3 3.4 24.47 3.4 24.47 27.87 
196 835 3 1.08 14.14 1.08 14.14 15.22 
196 836 3 1.08 17.41 1.08 17.41 18.49 
196 831 6 0 2.1 0 1.25 1.25 
196 832 6 1.3 8.26 1.3 8.26 9.56 
196 833 6 0.31 5.17 0.5 5.17 5.67 
196 837 8 0.56 10.73 0.5 10.73 11.23 
196 838 8 0.19 2.08 0.5 1.25 1.75 
196 839 8 0 2.98 0 2.98 2.98 
196 837 12 0 9.76 0 9.76 9.76 
196 838 12 0.4 6.96 0.5 6.96 7.46 
196 839 12 0 1.82 0 1.25 1.25 
196 834 24 0 0.9 0 1.25 1.25 
196 835 24 0 0.5 0 1.25 1.25 
196 836 24 0 0.35 0 1.25 1.25 
197 841 0.25 0.79 1.34 0.5 1.25 1.75 
197 842 0.25 0.34 2.78 0.5 2.78 3.28 
197 843 0.25 1.33 1.62 1.33 1.25 2.58 
197 844 0.5 0.32 3.45 0.5 3.45 3.95 
197 845 0.5 0.14 2.74 0.5 2.74 3.24 
197 846 0.5 0.28 4.84 0.5 4.84 5.34 
197 847 0.75 0.82 16.09 0.5 16.09 16.59 
197 848 0.75 0.68 13.47 0.5 13.47 13.97 
197 849 0.75 0.53 7.92 0.5 7.92 8.42 
197 841 1 0.84 14.82 0.5 14.82 15.32 
197 842 1 1.04 25.28 1.04 25.28 26.32 
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197 843 1 1.33 23.95 1.33 23.95 25.28 
197 844 1.5 1.79 32.12 1.79 32.12 33.91 
197 845 1.5 0.78 13.38 0.5 13.38 13.88 
197 846 1.5 0.75 12.15 0.5 12.15 12.65 
197 844 3 2.39 45.39 2.39 45.39 47.78 
197 845 3 2.12 39.66 2.12 39.66 41.78 
197 846 3 1.34 22.98 1.34 22.98 24.32 
197 841 6 0.23 3.47 0.5 3.47 3.97 
197 842 6 0.27 3.25 0.5 3.25 3.75 
197 843 6 0.25 3.79 0.5 3.79 4.29 
197 847 8 0.25 4.91 0.5 4.91 5.41 
197 848 8 0.45 6.87 0.5 6.87 7.37 
197 849 8 0.44 5.56 0.5 5.56 6.06 
197 847 12 0 1.71 0 1.25 1.25 
197 848 12 0 2.94 0 2.94 2.94 
197 849 12 0.48 6.52 0.5 6.52 7.02 
197 844 24 0 0.35 0 1.25 1.25 
197 845 24 0 0.69 0 1.25 1.25 
197 846 24 0 1.07 0 1.25 1.25 
Note: LLOQ of carboxylate is 1.0 ng/mL; LLOQ of lactone is 2.5 ng/mL; if the 
concentration is larger than 0 and smaller than LLOQ, half of LLOQ value was 
taken.    
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